3117 lines
2.6 MiB
3117 lines
2.6 MiB
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK576848">
|
|
<meta name="ncbi_domain" content="niceng130er">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK576848/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2019/05">
|
|
<meta name="citation_pmid" content="35072992">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK576848/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2019/05">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK576848/">
|
|
<meta name="og:title" content="Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK576848/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng130er-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng130er/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK576848/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8CB07A7D7454310000000000240020.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK576848/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK576848/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK576848/&text=Evidence%20reviews%20for%20induction%20of%20remission%20in%20mild-to-moderate%20ulcerative%20colitis"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK576848/?report=classic">Switch to classic view</a><a href="/books/n/niceng130er/pdf/">PDF (5.1M)</a><a href="/books/n/niceng130er/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK576848%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8CB07A7D7454310000000000240020.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng130er-lrg.png" alt="Cover of Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis" /></a></div><div class="bkr_bib"><h1 id="_NBK576848_"><span itemprop="name">Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis</span></h1><div class="subtitle">Ulcerative colitis: management</div><p><b>Evidence review</b></p><p><i>NICE Guideline, No. 130</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2019 May</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3392-1</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2019.</div></div><div class="bkr_clear"></div></div><div id="niceng130er.s1"><h2 id="_niceng130er_s1_">Induction of remission in mild-to-moderate ulcerative colitis</h2><div id="niceng130er.s1.1"><h3>Review question</h3><p>In adults, children and young people with mild-to-moderate ulcerative colitis, what is the clinical and cost-effectiveness of corticosteroids, aminosalicylates, immunomodulators (methotrexate, mycophenolate and tacrolimus) for the induction of remission compared to themselves (different preparations and doses), each other, combinations of preparations (oral and topical) and placebo?</p></div><div id="niceng130er.s1.2"><h3>Introduction</h3><p>Ulcerative colitis is a chronic inflammatory disease of the rectum and colon characterised by mucosal inflammation, resulting in symptoms of diarrhoea (both soft stool and an increased frequency of defaecation), rectal bleeding, an urgent need to defaecate and abdominal pain.</p><p>The natural course of ulcerative colitis is characterised by periods where symptoms are present, interspersed with periods of clinical remission. The severity of the symptoms, when present, can vary from mild to severe. The most severe form was defined by Truelove and Witts as those with a high stool frequency associated with systemic features including fever, tachycardia, anaemia or a raised erythrocyte sedimentation rate (ESR). Mild attacks are defined as those where the stool frequency is less than four times per day, with only small amounts of blood. Moderate attacks are those where the severity is between mild and severe. Treatment of these exacerbations – induction of remission – may involve a range of different drug types, administered by different routes and at different doses.</p><p>In 2017, the NICE Surveillance team reviewed evidence on the induction of remission in people with mild-to-moderate ulcerative colitis. New evidence was found for the treatment options included in the review, including budesonide multimatrix (MMX), which was licensed in 2014 for inducing remission in mild-to-moderate ulcerative colitis in adults for whom aminosalicylate treatment is not sufficient. Additionally, new evidence was available on topical preparations. This review aims to consider aminosalicylates, corticosteroids and immunomodulators for the induction of remission in mild-to-moderate ulcerative colitis. Oral and topical preparations were considered, and subcutaneous was considered for methotrexate only. For full details of the review protocol, see <a href="#niceng130er.appa">Appendix A</a>:</p></div><div id="niceng130er.s1.3"><h3>PICO table</h3><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130ertab1"><a href="/books/NBK576848/table/niceng130er.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130ertab1" rid-ob="figobniceng130ertab1"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.tab1/?report=thumb" src-large="/books/NBK576848/table/niceng130er.tab1/?report=previmg" alt="Table 1. PICO table." /></a><div class="icnblk_cntnt"><h4 id="niceng130er.tab1"><a href="/books/NBK576848/table/niceng130er.tab1/?report=objectonly" target="object" rid-ob="figobniceng130ertab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO table. </p></div></div></div><div id="niceng130er.s1.4"><h3>Methods and process</h3><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>
|
|
<u>(2014)</u>. Methods specific to this review question are described in the review protocol in <a href="#niceng130er.appa">appendix A</a>. Declarations of interest were recorded according to <a href="https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/declaration-of-interests-policy.pdf" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s 2018 conflicts of interest policy</a>.</p><p>For full details of methods and processes, see <a href="#niceng130er.appb">Appendix B</a>.</p><div id="niceng130er.s1.4.1"><h4>Stratification of studies by extent of disease</h4><p>Evidence was stratified in accordance to extent of disease, as reported in the study:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Proctitis</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Proctosigmoiditis or left-sided disease</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Extensive disease</p></dd></dl></dl></p><p>Where available, evidence on subgroups of different extents of disease was taken from a study. Where a study did not include subgroups of extents of disease and included a population of participants with different extents of disease, the study was classified under the extent of disease in most (50% or more) of the population. In some studies, extent of disease was only provided in terms of distance away from the anal verge, as confirmed by sigmoidoscopy. In these cases extent of disease was defined as:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Proctitis: < 15 cm</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Proctosigmoiditis or left-sided: 15 – 50cm</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">Extensive: >50cm</p></dd></dl></dl></p></div><div id="niceng130er.s1.4.2"><h4>Stratification of drugs by dose</h4><p>Drugs were stratified into ‘high dose’ and ‘standard dose’ (also referred to as ‘low dose’ in many studies<sup><a href="#niceng130er.fn2">2</a></sup>). See <a class="figpopup" href="/books/NBK576848/table/niceng130er.tab2/?report=objectonly" target="object" rid-figpopup="figniceng130ertab2" rid-ob="figobniceng130ertab2">Table 2</a> for criteria used to define standard and high drug dose for the purpose of classifying evidence in this guideline update. The committee did not specify a standard and high-dose criteria for oral corticosteroids. However, studies reporting on corticosteroids did not exceed 9mg budesonide, 5mg beclomethasone and up to 60mg prednisolone. The committee agreed that this was in accordance with clinical practice.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130ertab2"><a href="/books/NBK576848/table/niceng130er.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130ertab2" rid-ob="figobniceng130ertab2"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.tab2/?report=thumb" src-large="/books/NBK576848/table/niceng130er.tab2/?report=previmg" alt="Table 2. Dosing criteria for the purpose of classifying evidence." /></a><div class="icnblk_cntnt"><h4 id="niceng130er.tab2"><a href="/books/NBK576848/table/niceng130er.tab2/?report=objectonly" target="object" rid-ob="figobniceng130ertab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Dosing criteria for the purpose of classifying evidence. </p></div></div></div><div id="niceng130er.s1.4.3"><h4>Protocol deviations</h4><p>The effects estimates measure for outcomes chosen in this review was odds ratios (ORs) or hazard ratios (HRs), which deviates from the protocol’s specification of risk ratios (RRs). This is because the estimates produced from the network meta-analysis required for health economic modelling were ORs. To be consistent, ORs were also produced for the pairwise meta-analysis.</p><p>The committee considered remission, complete remission and clinical remission as equivalent and direct evidence. However, it was agreed that the definition of clinical response may differ in identified evidence, and this was excluded.</p><p>The protocol specified that outcomes will be stratified by extent of disease. This was the case for clinical remission and quality of life. However, for withdrawal due to adverse events, the committee specified interest in finding which interventions had the highest overall withdrawal due to adverse events. Therefore, this outcome was not stratified by extent of disease.</p><div id="niceng130er.s1.4.3.1"><h5>Follow-up times</h5><p>Due to the availability of evidence and study reporting, clinical remission was stratified by extent of disease and the following follow-up times in the pairwise analysis:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">0 to 2 weeks,</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">3 to 4 weeks,</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">5 to 8 weeks,</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">and 9 to 12 weeks.</p></dd></dl></dl></p><p>In the network-meta-analysis, clinical remission was stratified by extent of disease and separate NMAs were conducted for each clinically important follow-up time. To avoid duplication of study samples and to maximise data available, the final follow-up times assessed were:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">0 to 2 weeks</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">0 to 4 weeks and</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">5 to 8 weeks.</p></dd></dl></dl></p></div></div></div><div id="niceng130er.s1.5"><h3>Clinical evidence</h3><div id="niceng130er.s1.5.1"><h4>Included studies</h4><p>From the 2013 guideline, 34 randomised controlled trials (RCTs) were included, . Included in these are two secondary puplications (<a class="bibr" href="#niceng130er.appe.s1.1.ref7" rid="niceng130er.appe.s1.1.ref7">Connolly 2009</a> and <a class="bibr" href="#niceng130er.appe.s1.2.ref9" rid="niceng130er.appe.s1.2.ref9">Probert 2014</a>) associated with one RCT (<a class="bibr" href="#niceng130er.appe.s1.1.ref26" rid="niceng130er.appe.s1.1.ref26">Marteau 2005</a>). In November 2017, a systematic literature search, which was combined with NICE ‘Crohn’s disease: management’ guideline update, was carried out to identify randomised controlled trials. From 9,811 articles, 50 were deemed relevant to the review protocol and retrieved in full. Of these, 15 new RCTs were included.</p><p>A top-up search in August 2018 found 20 potentially relevant articles from 1,350 articles. Of these, one RCT (<a class="bibr" href="#niceng130er.appe.s1.3.ref1" rid="niceng130er.appe.s1.3.ref1">Ogata 2018</a>) was included.</p><p>In total, 50 RCTs, reported in 52 publications, were included.</p><p>See <a href="#niceng130er.appc">Appendix C</a> for the search strategies and <a href="#niceng130er.appd">Appendix D</a> for a PRISMA diagram summarising the process of study identification. See <a href="#niceng130er.appe">Appendix E</a>: for a full list of references for the studies included in this review.</p></div><div id="niceng130er.s1.5.2"><h4>Excluded studies</h4><p>From the 2013 guideline, there were 93 RCTs included. Of these, 34 RCTs were included in this guideline update and 59 were excluded. In this guideline update, from the 50 relevant articles identified, 35 articles were excluded. Additionally, 19 articles were excluded from the top-up search conducted in August 2018. For the excluded studies list with reasons for exclusion, please see <a href="#niceng130er.appm">Appendix M</a>:. For references of excluded studies, please see <a href="#niceng130er.appe">Appendix E</a>:</p></div><div id="niceng130er.s1.5.3"><h4>Summary of clinical studies included in the evidence review</h4><p>Fifty RCTs, reported in 52 publications, were included.</p><ul><li class="half_rhythm"><div>Seven RCTs compared standard-dose oral aminosalicylate with placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref9" rid="niceng130er.appe.s1.1.ref9">Dick 1964</a>, Feurle 2013, <a class="bibr" href="#niceng130er.appe.s1.1.ref15" rid="niceng130er.appe.s1.1.ref15">Hanauer 1998</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref17" rid="niceng130er.appe.s1.1.ref17">Hetzel 1986</a>, <a class="bibr" href="#niceng130er.appe.s1.1.ref19" rid="niceng130er.appe.s1.1.ref19">Ito 2010</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref8" rid="niceng130er.appe.s1.2.ref8">Pontes 2014</a> and <a class="bibr" href="#niceng130er.appe.s1.1.ref33" rid="niceng130er.appe.s1.1.ref33">Sninsky 1991</a>.</div></li></ul></div></li><li class="half_rhythm"><div>Three RCTs compared high-dose oral aminosalicylate with placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.2.ref3" rid="niceng130er.appe.s1.2.ref3">Feagan 2013</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref32" rid="niceng130er.appe.s1.1.ref32">Scherl 2009</a> and <a class="bibr" href="#niceng130er.appe.s4.1.ref50" rid="niceng130er.appe.s4.1.ref50">Schroeder 1987</a>.</div></li></ul></div></li><li class="half_rhythm"><div>Three RCTs compared both standard-dose and high-dose oral aminosalicylate with placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer 1993</a>, <a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm 2007</a> and <a class="bibr" href="#niceng130er.appe.s1.1.ref25" rid="niceng130er.appe.s1.1.ref25">Lichtenstein 2007</a>.</div></li></ul></div></li><li class="half_rhythm"><div>Eleven RCTs compared standard-dose aminosalicylates with high-dose aminosalicylates, according to the criteria outlined in <a class="figpopup" href="/books/NBK576848/table/niceng130er.tab2/?report=objectonly" target="object" rid-figpopup="figniceng130ertab2" rid-ob="figobniceng130ertab2">Table 2</a>.
|
|
<ul class="simple-list"><li class="half_rhythm"><div>Dhaens 2006; <a class="bibr" href="#niceng130er.appe.s1.1.ref16" rid="niceng130er.appe.s1.1.ref16">Hanauer 2005</a>, Hanauer 2007; <a class="bibr" href="#niceng130er.appe.s1.1.ref18" rid="niceng130er.appe.s1.1.ref18">Irvine 2008</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref21" rid="niceng130er.appe.s1.1.ref21">Kruis 2003</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref24" rid="niceng130er.appe.s1.1.ref24">Levine 2002</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref7" rid="niceng130er.appe.s1.2.ref7">Ogata 2017</a>; <a class="bibr" href="#niceng130er.appe.s1.3.ref1" rid="niceng130er.appe.s1.3.ref1">Ogata 2018</a>; Pruit 2002; <a class="bibr" href="#niceng130er.appe.s1.1.ref30" rid="niceng130er.appe.s1.1.ref30">Sandborn 2009</a> and <a class="bibr" href="#niceng130er.appe.s1.2.ref12" rid="niceng130er.appe.s1.2.ref12">Suzuki 2016</a></div></li></ul></div></li><li class="half_rhythm"><div>One RCT compared oral aminosalicylates with topical aminosalicylates:
|
|
<ul class="simple-list"><li class="half_rhythm"><div>Gionchetti 1988</div></li></ul></div></li><li class="half_rhythm"><div>Two RCTs compared oral corticosteroids with placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.2.ref10" rid="niceng130er.appe.s1.2.ref10">Rubin 2017</a> and <a class="bibr" href="#niceng130er.appe.s1.2.ref1" rid="niceng130er.appe.s1.2.ref1">Travis 2013</a>.</div></li></ul></div></li><li class="half_rhythm"><div>One RCT compared oral aminosalicylate, oral corticosteroid and placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref31" rid="niceng130er.appe.s1.1.ref31">Sandborn 2012</a>.</div></li></ul></div></li><li class="half_rhythm"><div>Three RCTs compared oral aminosalicylates with oral corticosteroids:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref6" rid="niceng130er.appe.s1.1.ref6">Campieri 2003</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref13" rid="niceng130er.appe.s1.1.ref13">Gross 2011</a>; and LennardJones 1960.</div></li></ul></div></li><li class="half_rhythm"><div>Five RCT compared topical aminosalicylates with placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref3" rid="niceng130er.appe.s1.1.ref3">Campieri 1990</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref4" rid="niceng130er.appe.s1.1.ref4">Campieri 1990a</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref5" rid="niceng130er.appe.s1.1.ref5">Campieri 1991</a>; Poktrotnieks 2000 and Wantabe 2013.</div></li></ul></div></li><li class="half_rhythm"><div>One RCTs compared topical aminosalicylates with topical corticosteroids:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref22" rid="niceng130er.appe.s1.1.ref22">Lauritsen 1986</a>.</div></li></ul></div></li><li class="half_rhythm"><div>Four RCTs compared topical corticosteroids and placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref2" rid="niceng130er.appe.s1.1.ref2">Binder 1987</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref5" rid="niceng130er.appe.s1.2.ref5">Naganuma 2016</a>, <a class="bibr" href="#niceng130er.appe.s1.2.ref6" rid="niceng130er.appe.s1.2.ref6">Naganuma 2017</a> and <a class="bibr" href="#niceng130er.appe.s1.2.ref11" rid="niceng130er.appe.s1.2.ref11">Sandborn 2015</a>.</div></li></ul></div></li><li class="half_rhythm"><div>Two RCTs compared different preparations of topical corticosteroids:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref1" rid="niceng130er.appe.s1.1.ref1">BarMier 2003</a> and <a class="bibr" href="#niceng130er.appe.s1.1.ref12" rid="niceng130er.appe.s1.1.ref12">Gross 2006</a>.</div></li></ul></div></li><li class="half_rhythm"><div>One RCT compared a combination of aminosalicylate and corticosteroid with placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref29" rid="niceng130er.appe.s1.1.ref29">Rizzello 2002</a>.</div></li></ul></div></li><li class="half_rhythm"><div>Two RCTs compared oral aminosalicylates with oral and topical aminosalicylates:
|
|
<ul class="simple-list"><li class="half_rhythm"><div><a class="bibr" href="#niceng130er.appe.s1.1.ref26" rid="niceng130er.appe.s1.1.ref26">Marteau 2005</a> (this study had 2 secondary publications: <a class="bibr" href="#niceng130er.appe.s1.1.ref7" rid="niceng130er.appe.s1.1.ref7">Connolly 2009</a> and <a class="bibr" href="#niceng130er.appe.s1.2.ref9" rid="niceng130er.appe.s1.2.ref9">Probert 2014</a>) and <a class="bibr" href="#niceng130er.appe.s1.1.ref34" rid="niceng130er.appe.s1.1.ref34">Vecchi 2001</a>.</div></li></ul></div></li><li class="half_rhythm"><div>Two RCTs included a paediatric population:
|
|
<ul class="simple-list"><li class="half_rhythm"><div>Romano 2010 (high-dose aminosalicylate compared with beclomethasone) and <a class="bibr" href="#niceng130er.appe.s1.2.ref15" rid="niceng130er.appe.s1.2.ref15">Winter 2014</a> (compared high with standard dose high-dose aminosalicylate compared with standard-dose aminosalicylate).</div></li></ul></div></li><li class="half_rhythm"><div>One RCT compared intravenous and subcutaneous methotrexate with placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div class="half_rhythm"><a class="bibr" href="#niceng130er.appe.s1.2.ref2" rid="niceng130er.appe.s1.2.ref2">Carbonnel 2016</a></div><div class="half_rhythm">This RCT reported a minimum follow-up period of 24 weeks, and additional 12 week data was obtained from the authors via email.</div></li></ul></div></li><li class="half_rhythm"><div>One RCT compared topical (ointment) tacrolimus and placebo:
|
|
<ul class="simple-list"><li class="half_rhythm"><div class="half_rhythm"><a class="bibr" href="#niceng130er.appe.s1.2.ref4" rid="niceng130er.appe.s1.2.ref4">Lawrance 2017</a></div><div class="half_rhythm">This RCT included an ointment preparation of tacrolimus and the committee noted that suppository tacrolimus is mostly used in the UK.</div></li></ul></div></li></ul><p>All RCTs including corticosteroids were deemed as standard dose. All topical preparations of aminosalicylates and corticosteroids were classed as standard dose.</p><p>No RCTs were included that reported on oral immunomodulators. Potentially relevant RCTs were identified from the 2012 iteration of this guideline, but were excluded as more than 10% of the population included in these studies had severe ulcerative colitis.</p><p>See <a href="#niceng130er.appf">Appendix F</a> for full evidence tables.</p></div><div id="niceng130er.s1.5.4"><h4>Quality assessment of clinical studies included in the evidence review</h4><p>See the evidence tables in <a href="#niceng130er.appf">appendix F</a> for quality assessment of individual studies and <a href="#niceng130er.apph">appendix H</a> for full GRADE tables.</p></div></div><div id="niceng130er.s1.6"><h3>Economic evidence</h3><div id="niceng130er.s1.6.1"><h4>Included studies</h4><p>A literature search was conducted to identify published economic evaluations of relevance to the review question with a date limit of the previous 2013 guideline (<a href="#niceng130er.appc">Appendix C</a>). The search returned 995 records, to which 4 studies identified in the previous guideline were added. Of the total 999 studies, 993 were excluded on the basis of title and abstract. The remaining studies were screened by reviewing the full text and 4 published studies were included in the review (<a href="#niceng130er.appj">Appendix J</a>). The de novo economic model conducted in the 2013 guideline was reviewed in addition to the studies identified through the search of the published literature.</p><p>A top-up search in August 2018 identified 181 additional articles of which 180 were excluded on the basis of title and abstract. The remaining 1 study was excluded after reviewing the full text.</p></div><div id="niceng130er.s1.6.2"><h4>Excluded studies</h4><p>Details of excluded studies are provided in <a href="#niceng130er.appm">Appendix M</a>. For full referenes, see <a href="#niceng130er.appe">Appendix E</a>:</p></div><div id="niceng130er.s1.6.3"><h4>Summary of studies included in the economic evidence review</h4><p>The 4 published economic evaluations included in the review were limited to comparisons of different doses, formulations or combinations of mesalazine and are summarised in <a class="figpopup" href="/books/NBK576848/table/niceng130er.tab3/?report=objectonly" target="object" rid-figpopup="figniceng130ertab3" rid-ob="figobniceng130ertab3">Table 3</a> with further details in <a href="#niceng130er.appk">Appendix K</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130ertab3"><a href="/books/NBK576848/table/niceng130er.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130ertab3" rid-ob="figobniceng130ertab3"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.tab3/?report=thumb" src-large="/books/NBK576848/table/niceng130er.tab3/?report=previmg" alt="Table 3. Summary of economic evaluations included in the review." /></a><div class="icnblk_cntnt"><h4 id="niceng130er.tab3"><a href="/books/NBK576848/table/niceng130er.tab3/?report=objectonly" target="object" rid-ob="figobniceng130ertab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Summary of economic evaluations included in the review. </p></div></div><div id="niceng130er.s1.6.3.1"><h5>Buckland 2008</h5><p><a class="bibr" href="#niceng130er.appe.s2.1.ref2" rid="niceng130er.appe.s2.1.ref2">Buckland 2008</a> conducted a cost-utility analysis to compare 2.4g/day and 4.8g/day oral mesalazine for the induction of remission in patients with moderately active ulcerative colitis from a UK NHS perspective. The model was constructed as a decision tree with a 12-week time horizon. If remission was not achieved with mesalazine, patients were assumed to switch to oral steroids, followed by intravenous steroids, intravenous ciclosporin and then surgery. The probability of achieving remission on mesalazine was informed by a pooled analysis of 2 trials (ASCEND I/II) and assumed a treatment duration of 6 weeks regardless of the outcome. Health-state utility values were obtained from a multicentre study conducted in Spain (Casellas 2005), which reported significant correlation between EQ-5D scores and ulcerative colitis disease severity. Patients entering the model were assigned a utility of 0.50 to reflect moderate-severe disease and patients in remission were assigned a utility of 0.80. In addition to drug costs, the model captured hospital admission costs associated with intravenous adminsatration of steroids and ciclosporin. Disease-related outpatient costs and costs associated with surgery were obtained from a published single centre retrospective study of the cost of illness of inflammatory bowel disease in the UK (<a class="bibr" href="#niceng130er.appe.s3.ref1" rid="niceng130er.appe.s3.ref1">Bassi 2004</a>).</p><p>In the base case deteriministic analysis, the 4.8g/day dose of mesalazine was found to be both more effective and less costly (dominant). Probabilistic sensitivity analysis indicated that the higher dose was cost effective in 72% of iterations at a threshold of £30,000/QALY. This study was deemed partially applicable as it only compared 2 different doses of oral mesalazine and did not include any other comparators of interest to the review question or model different sequences of treatments. The study was found to have potentially serious limitations in addressing the review question because the estimates of treatment effects for mesalazine were taken from a pooled analysis of only 2 studies, the downstream sequence of treatments for patients whose disease did not enter remission with mesalazine does not reflect current practice (no biologics were considered) and the source of funding for the study indicated a potential conflict of interest.</p></div><div id="niceng130er.s1.6.3.2"><h5>Connolly 2009</h5><p><a class="bibr" href="#niceng130er.appe.s1.1.ref7" rid="niceng130er.appe.s1.1.ref7">Connolly 2009</a> conducted a cost-utility analysis to compare 4g oral mesalazine in combination with 1g/100mL topical mesalazine enema with 4g oral mesalazine in combination with placebo enema taken daily for 8 weeks from a UK NHS perspective. The analysis was constructed as a Markov model with a time horizon of 32 weeks and consisted of 5 health states: active ulcerative colitis, mesalazine-refractory active ulcerative colitis, steroid-refractory active ulcerative colitis, infliximab-responsive active ulcerative colitis and remission. The probabilities of achieving remission with mesalazine were derived from a single RCT (<a class="bibr" href="#niceng130er.appe.s1.1.ref26" rid="niceng130er.appe.s1.1.ref26">Marteau 2005</a>). Health-state utility values were obtained from a study by Poole 2008, which reported a value of 0.81 for active ulcerative colitis and 0.94 for remission measured using the EQ-5D. In addition to the cost of drugs, the model captured the costs of gastroenterologist and GP consultations and diagnostic examinations (blood tests, stool samples, sigmoidoscopy).</p><p>In the base case deterministic analysis, the combination treatment of oral and topical mesalazine was found to dominate. Probabilistic sensitivity analysis indicated that the combination treatment had the highest probability of being optimal over a range of threshold values from £0/QALY to £20,000/QALY. A scenario analysis was run restricting the time horizon to 16 weeks and excluding infliximab treatment; the combination of oral and topical mesalazine remained the dominant strategy. This study was deemed partially applicable as it only compared 2 different mesalazine treatment strategies and did not include any other comparators of interest to the review question or model different sequences of treatments. The study was found to have potentially serious limitations in addressing the review question because the estimates of treatment effects for mesalazine were taken from a single RCT and the source of funding for the study indicated a potential conflict of interest.</p></div><div id="niceng130er.s1.6.3.3"><h5>Brereton 2010</h5><p><a class="bibr" href="#niceng130er.appe.s2.1.ref1" rid="niceng130er.appe.s2.1.ref1">Brereton 2010</a> conducted a cost-utlity analysis to compare 2.4g/day oral mesalazine with 2.4g/day oral multimatrix (MMX) mesalazine from a UK NHS perspective. The analysis was constructed as a Markov model with a time horizon of 5 years and consisted of 8 health states: active disease with first-line mesalazine treatment, active disease with increased mesalazine dose (4.8g), active disease with second-line treatment (addition of oral corticosteroid), hospitalisation to receive immunosuppressant and/or intravenous steroids, surgery, post-surgery, remission and death. The probabilities of achieving remission with 2.4g/day mesalazine or MMX mesalazine were derived from a single RCT (<a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm 2007</a>). Patients whose disease did not achieve remission at a dose of 2.4g/day were assumed to receive an increased dose of 4.8g/day mesalazine or MMX mesalazine. The model additionally assumed that patients whose disease was in remission would continue on mesalazine maintenance therapy. In scenario analyses, the model explored different assumptions about adherence to maintenance therapy and the impact of a lifetime time horizon taking the risk of developing colorectal cancer into account. Health-state utility values were obtained from a pooled analysis of 2 unpublished studies of 151 patients estimated using the EQ-5D and ranged from 0.317 for severe active disease to 0.845 for remission. In addition to the cost of drugs, the model captured the costs assocated with inpatient services, surgery and outpatient visits.</p><p>In the base case deterministic analysis, the incremental cost-effectivess ratio (ICER) for MMX mesalazine versus mesalazine was £749/QALY. Probabilistic sensitivity analysis indicated that MMX mesalazine had the highest probability of being optimal over threshold values from £0/QALY to £50,000/QALY. This study was deemed partially applicable as it only compared 2 mesalazine formulations and did not include any other comparators of interest to the review question or model different sequences of treatments. The study was found to have very serious limitations in addressing the review question because the estimates of treatment effects for mesalazine were taken from a single RCT, the downstream sequence of treatments for patients whose disease did not enter remission with mesalazine does not reflect current practice (no biologics were considered), additional uncertainty was introduced in the extrapolation of assumptions about maintenance treatment and the source of funding for the study indicated a potential conflict of interest.</p></div><div id="niceng130er.s1.6.3.4"><h5>Connolly 2014</h5><p><a class="bibr" href="#niceng130er.appe.s2.1.ref4" rid="niceng130er.appe.s2.1.ref4">Connolly 2014</a> conducted a cost-utility analysis to compare 2g oral mesalazine twice daily with 4g oral msealazine once daily. The analysis was constructed as a Markov model and consisted of 5 health states: active ulcerative colitis, mesalazine-refractory active ulcerative colitis, steroid-refractory active ulcerative colitis, infliximab-responsive active ulcerative colitis and remission. The model took the perspective of the Dutch healthcare system with a time horizon of 32 weeks. The probabilities of achieving remission with mesalazine were derived from a single RCT (Flourié 2013). Health-state utility values were obtained from a study by <a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole 2010</a>, which reported a value of 0.78 for active ulcerative colitis and 0.84 for remission measured using the EQ-5D. In addition to the cost of drugs, the model captured the costs of gastroenterologist, GP and IBD nurse consultations and diagnostic examinations (laboratory tests, endoscopy, X-ray).</p><p>The authors concluded that 4g once daily mesalazine was more effective and less costly than 2g twice daily mesalazine. Only mean results of probabilistic sensitivity analysis were reported. This study was deemed partially applicable as it only compared 2 dosing schedules of oral mesalazine and did not include any other comparators of interest to the review question or model different sequences of treatments. The study was found to have potentially serious limitations in addressing the review question because the estimates of treatment effects for mesalazine were taken from a single RCT, results of probabilistic sensitivity analysis were not reported in full and the source of funding for the study indicated a potential conflict of interest.</p></div><div id="niceng130er.s1.6.3.5"><h5>2013 NICE guideline</h5><p>The economic evaluations identified in the published literature were limited to comparisons of different doses, formulations or combinations of mesalazine and did not compare the full range of treatments or explore sequences of treatments of relevance to the review question. An original economic analysis was undertaken in the 2013 NICE guideline to evaluate the cost effectiveness of sequences of pharmacological treatments for the induction of remission of mild-to-moderate ulcerative colitis. The analysis was constructed as a decision tree with a time horizon of 28 weeks. The population entering the model was adults with mild-to-moderate left-sided or extensive ulcerative colitis defined as inflammation greater than 30-40cm. Other extents of disease were not modelled. The committee considered factors such as clinical practice, the suitability of drugs in patients with left-sided or extensive disease and the availability of RCT evidence to define 10 treatment sequences of interest for the cost-effectiveness model (<a class="figpopup" href="/books/NBK576848/table/niceng130er.tab3/?report=objectonly" target="object" rid-figpopup="figniceng130ertab3" rid-ob="figobniceng130ertab3">Table 3</a>). Up to 4 lines of treatment were modelled, followed by an assumption that patients whose disease did not respond to oral prednisolone would be hospitalised to receive intravenous steroids, intravenous ciclosporin or surgery.</p><p>A systematic review was conducted to identify RCTs that reported withdrawal due to adverse events and remission. Relative treatment effects for remission conditional on non-withdrawal were estimated in a network-meta-analysis. The baseline rates of withdrawal and remission were pooled from the placebo arms of the RCTs included in the systematic review. Health-state utility estimates were obtained from <a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole 2010</a>. In addition to the cost of drugs, the model captured costs assocated with inpatient treatment (intravenous therapy and surgery), blood tests, gastroenterologist, GP, specialist registrar and IBD nurse specialist consultations.</p><p>In the base-case analysis, treatment strategy #8 (high-dose oral aminosalicylate in combination with beclometasone in first line followed by oral prednisolone in seond line) was found to generate the most QALYs while treatment strategy #10 (high-dose oral aminosalicylate alone in first line followed by the addition of beclometasone in second line and then oral prednisolone in third line) was found to generate the lowest costs. The ICER for treatment strategy #8 versus #10 was £42,622/QALY. All other treatment strategies were dominated.</p><p>Since the 2013 guideline, a number of new comparators have entered the decision space and therefore the 2013 analysis was deemed only partially applicable to current practice. In addition, the analysis was categorised as having minor limitations because downstream clinical practice with respect the use of biologics in patients with moderately to severely active ulcerative colitis has evolved over time with the availability of NICE technology appraisal guidance on the use of Infliximab for acute exacerbations of ulcerative colitis guidance (TA163), Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329) and Vedolizumab for treating moderately to severely active ulcerative colitis (TA342).</p></div></div></div><div id="niceng130er.s1.7"><h3>Economic model</h3><div id="niceng130er.s1.7.1"><h4>Introduction</h4><p>An economic analysis was undertaken in the 2013 guideline to evaluate the cost effectiveness of sequences of pharmacological treatments for the induction of remission of mild-to-moderate left-sided or extensive ulcerative colitis in adults. Since then, new RCTs were identified that would allow for additional drugs to be modelled as part of treatment sequences. In addition to the availability of new evidence, the committee wished to compare treatment sequences in all extents of disease and to update some of the assumptions underpinning the previous model to reflect current practice. Therefore, a decision was made to undertake a new cost-effectiveness analysis to compare sequences of pharmacological treatments for the induction of remission of mild-to-moderate ulcerative colitis drawing on the data from studies identified in the clinical evidence review. A summary of the methods and key findings of the economic model is provided below. A more detailed summary can be found in <a href="#niceng130er.appl">Appendix L</a>.</p></div><div id="niceng130er.s1.7.2"><h4>Methods</h4><p>The cost-effectiveness model was constructed as a decision tree and adopted a UK NHS/personal social services perspective with costs reported in GBP (£) and health outcomes reported as quality-adjusted life years (QALYs). The model only considered adults with mild-to-moderate ulcerative colitis because there was insufficient clinical evidence in young people and children to model sequences of treatments. The same model structure was used to run three separate analyses by extent of disease (proctitis, proctosigmoiditis and left-sided disease, extensive disease).</p><p>Clinically plausible treatment sequences were generated with input from the committee and after assessing the number of treatments and studies that were available to inform network meta-analyses at each time point and in each extent of disease. Although placebo was a common comparator in RCTs, the committee did not feel that ‘no treatment’ would be a clinically relevant comparator in the economic model. The analysis does not distinguish between people who are presenting with ulcerative colitis for the first time and those who are experiencing an inflammatory exacerbation. Some people may be receiving maintenance treatment such as an oral aminosalicylate prior to experiencing an inflammatory exacerbation and the committee advised that in clinical practice, people would likely continue this as the backbone of long-term treatment.</p><p>Treatment sequences contained up to 4 lines of treatment in proctitis and up to 3 lines of treatment in other extents of disease. In the model, if a person’s disease had not entered remission after 3 (or 4) lines of treatment, it was assumed that their disease had progressed to severe ulcerative colitis and they would receive rescue therapy in line with other NICE guidance. This included IV hydrocortisone as a first step, followed by IV ciclosporin, biological therapy or surgery. Surgery was assumed to be 100% effective in inducing remission so that by the end of the 30-week time horizon of the model, all patients’ disease would be in remission. Given the short time horizon, no discounting was applied to either costs or health outcomes.</p><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.tab4/?report=objectonly" target="object" rid-figpopup="figniceng130ertab4" rid-ob="figobniceng130ertab4">Table 4</a> provides a description of the general treatment strategies (at the class level) by extent of disease. For each treatment strategy, multiple sequences were specified at the drug level for topical and oral corticosteroids, leading to a total of 32 treatment sequences in the cost-effectiveness anlaysis for proctitis, 75 in proctosigmoiditis and left-sided disease and 6 in extensive disease.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130ertab4"><a href="/books/NBK576848/table/niceng130er.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130ertab4" rid-ob="figobniceng130ertab4"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.tab4/?report=thumb" src-large="/books/NBK576848/table/niceng130er.tab4/?report=previmg" alt="Table 4. Description of treatment strategies in the cost-effectiveness model by extent of disease." /></a><div class="icnblk_cntnt"><h4 id="niceng130er.tab4"><a href="/books/NBK576848/table/niceng130er.tab4/?report=objectonly" target="object" rid-ob="figobniceng130ertab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Description of treatment strategies in the cost-effectiveness model by extent of disease. </p></div></div><p>For each line of treatment, there are three possible mutually exclusive outcomes in the decision tree (<a class="figpopup" href="/books/NBK576848/figure/niceng130er.fig1/?report=objectonly" target="object" rid-figpopup="figniceng130erfig1" rid-ob="figobniceng130erfig1">Figure 1</a>):
|
|
<ul><li class="half_rhythm"><div>Withdrawal from treatment due to adverse events; switch to next line of treatment</div></li><li class="half_rhythm"><div>Non-remission; switch to next line of treatment</div></li><li class="half_rhythm"><div>Remission.</div></li></ul></p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figniceng130erfig1" co-legend-rid="figlgndniceng130erfig1"><a href="/books/NBK576848/figure/niceng130er.fig1/?report=objectonly" target="object" title="Figure 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erfig1" rid-ob="figobniceng130erfig1"><img class="small-thumb" src="/books/NBK576848/bin/niceng130erf1.gif" src-large="/books/NBK576848/bin/niceng130erf1.jpg" alt="Figure 1. Structure of the decision tree for a single sequence of treatments." /></a><div class="icnblk_cntnt" id="figlgndniceng130erfig1"><h4 id="niceng130er.fig1"><a href="/books/NBK576848/figure/niceng130er.fig1/?report=objectonly" target="object" rid-ob="figobniceng130erfig1">Figure 1</a></h4><p class="float-caption no_bottom_margin">Structure of the decision tree for a single sequence of treatments. </p></div></div><p>In discussing duration of treatment, the committee noted that, for all drugs, response to treatment would generally be assessed earlier than the follow-up durations reported across RCTs so that, in the event of non-response, a decision could be made whether to switch to another drug. In order to reflect clinical practice, the model assumed that response to treatment is assessed halfway through a full course of treatment for the induction of remission, at which point people whose disease is not responding to treatment would move to the next line of treatment in the sequence. Therefore, for any given line of treatment, it was assumed that the duration of treatment for people in the non-remission branch of the decision tree was half that of people in the remission branch. The impact of this structural assumption on model results was explored in a scenario analysis in which no early switching of treatments was modelled; in other words all people except those withdrawing due to adverse events are assumed to complete a full course of treatment irrespective of whether the outcome was remission or non-remission. The base-case approach to the model structure has the advantage of reflecting clinical practice but the scenario analysis more closely reflects the clinical effectiveness evidence in relation to the design of the RCTs.</p><p>Model inputs for the probability of remission and withdrawal due to adverse events were obtained from the network meta-analyses presented in <a href="#niceng130er.appi">Appendix I</a>. Drug costs were sourced from the online version of the British National Formulary (BNF). Estimates of health-state utility values for calculating QALYs and other healthcare resource use were sourced from published literature. Assumptions about treatment progression for severe ulcerative colitis in the hospital setting and on biological therapy were informed by data from the UK inflammatory bowel disease (IBD) national clinical audit of inpatient care (2014) and the UK IBD national clinical audit of biological therapies (2016).</p></div><div id="niceng130er.s1.7.3"><h4>Results</h4><div id="niceng130er.s1.7.3.1"><h5>Proctitis: base-case analysis</h5><p>Treatment sequences that begin with a topical aminosalicylate result in the highest proportion of people entering remission in first line (90.5%) and the lowest proportion of people requiring rescue therapy (0.1% - 3.0%). <a class="figpopup" href="/books/NBK576848/table/niceng130er.tab5/?report=objectonly" target="object" rid-figpopup="figniceng130ertab5" rid-ob="figobniceng130ertab5">Table 5</a> shows the incremental cost-effectiveness results for the base-case analysis. The strategy PRC01 is associated with the highest probability of being cost effective and is both more effective and less costly than all other strategies except PRC17. The results also suggest that the use of topical tacrolimus as a fourth line treatment is cost effective but the absolute impact on total QALYs and total costs is small because the proportion of people requiring fourth-line treatment is very low.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130ertab5"><a href="/books/NBK576848/table/niceng130er.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130ertab5" rid-ob="figobniceng130ertab5"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.tab5/?report=thumb" src-large="/books/NBK576848/table/niceng130er.tab5/?report=previmg" alt="Table 5. Base-case mean probabilistic cost-effectiveness results in proctitis." /></a><div class="icnblk_cntnt"><h4 id="niceng130er.tab5"><a href="/books/NBK576848/table/niceng130er.tab5/?report=objectonly" target="object" rid-ob="figobniceng130ertab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Base-case mean probabilistic cost-effectiveness results in proctitis. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figniceng130erfig2" co-legend-rid="figlgndniceng130erfig2"><a href="/books/NBK576848/figure/niceng130er.fig2/?report=objectonly" target="object" title="Figure 2" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erfig2" rid-ob="figobniceng130erfig2"><img class="small-thumb" src="/books/NBK576848/bin/niceng130erf2.gif" src-large="/books/NBK576848/bin/niceng130erf2.jpg" alt="Figure 2. Cost-effectiveness acceptability curve for proctitis base-case analysis." /></a><div class="icnblk_cntnt" id="figlgndniceng130erfig2"><h4 id="niceng130er.fig2"><a href="/books/NBK576848/figure/niceng130er.fig2/?report=objectonly" target="object" rid-ob="figobniceng130erfig2">Figure 2</a></h4><p class="float-caption no_bottom_margin">Cost-effectiveness acceptability curve for proctitis base-case analysis. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figniceng130erfig3" co-legend-rid="figlgndniceng130erfig3"><a href="/books/NBK576848/figure/niceng130er.fig3/?report=objectonly" target="object" title="Figure 3" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erfig3" rid-ob="figobniceng130erfig3"><img class="small-thumb" src="/books/NBK576848/bin/niceng130erf3.gif" src-large="/books/NBK576848/bin/niceng130erf3.jpg" alt="Figure 3. Cost-effectiveness acceptability frontier for proctitis base-case analysis." /></a><div class="icnblk_cntnt" id="figlgndniceng130erfig3"><h4 id="niceng130er.fig3"><a href="/books/NBK576848/figure/niceng130er.fig3/?report=objectonly" target="object" rid-ob="figobniceng130erfig3">Figure 3</a></h4><p class="float-caption no_bottom_margin">Cost-effectiveness acceptability frontier for proctitis base-case analysis. </p></div></div></div><div id="niceng130er.s1.7.3.2"><h5>Proctitis: scenario analysis with no early switching of treatments in the event of non-remission</h5><p>A scenario analysis was conducted in which the model did not allow for early assessment of response to treatment. All people, except those withdrawing due to adverse events, are assumed to complete a full course treatment irrespective of whether the outcome is remission or non-remission. This scenario resulted in an increase in costs for all sequences but incremental cost-effectiveness results were consistent with the base-case analysis and PRC01 retained the highest probability of being cost effective over the range of threshold values from £0/QALY to £50,000/QALY. Full results for this scenario are presented in <a href="#niceng130er.appl">Appendix L</a>.</p></div><div id="niceng130er.s1.7.3.3"><h5>Proctosigmoiditis and left-sided disease: base-case analysis</h5><p>In proctosigmoiditis and left-sided disease, treatment sequences that begin with a topical aminosalicylate result in the highest proportion of people entering remission in first line (80.3%) and the lowest proportion of people requiring rescue therapy (3.1% - 7.6%). The incremental cost-effectiveness results are summarised in <a class="figpopup" href="/books/NBK576848/table/niceng130er.tab6/?report=objectonly" target="object" rid-figpopup="figniceng130ertab6" rid-ob="figobniceng130ertab6">Table 6</a> along with expected net monetary benefit and the probability of each strategy being cost effective at a value of £20,000/QALY. At this threshold value, the strategy with the highest probability of being cost effective (PLS34) is not the the strategy with the highest expected net benefit (PLS31). This finding is further illustrated over a range of threshold values in the cost-effectiveness acceptability frontier (CEAF) in <a class="figpopup" href="/books/NBK576848/figure/niceng130er.fig5/?report=objectonly" target="object" rid-figpopup="figniceng130erfig5" rid-ob="figobniceng130erfig5">Figure 5</a>, which plots the probability that the optimal option (as defined by expected net benefit) is cost effective. This result arises from asymmetry in the distributions of expected value (<a class="bibr" href="#niceng130er.appe.s3.ref6" rid="niceng130er.appe.s3.ref6">Fenwick 2001</a>). Although there were more model iterations in which PLS34 generated a higher net benefit, in the iterations where PLS31 was superior, it was superior by a greater degree. The only difference between the sequences PLS31 and PLS34 is the mode of administration of the corticosteroid in the third line (oral prednisolone and topical prednisolone respectively).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130ertab6"><a href="/books/NBK576848/table/niceng130er.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130ertab6" rid-ob="figobniceng130ertab6"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.tab6/?report=thumb" src-large="/books/NBK576848/table/niceng130er.tab6/?report=previmg" alt="Table 6. Base-case mean probabilistic cost-effectiveness results in proctosigmoiditis and left-sided disease." /></a><div class="icnblk_cntnt"><h4 id="niceng130er.tab6"><a href="/books/NBK576848/table/niceng130er.tab6/?report=objectonly" target="object" rid-ob="figobniceng130ertab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Base-case mean probabilistic cost-effectiveness results in proctosigmoiditis and left-sided disease. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figniceng130erfig5" co-legend-rid="figlgndniceng130erfig5"><a href="/books/NBK576848/figure/niceng130er.fig5/?report=objectonly" target="object" title="Figure 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erfig5" rid-ob="figobniceng130erfig5"><img class="small-thumb" src="/books/NBK576848/bin/niceng130erf5.gif" src-large="/books/NBK576848/bin/niceng130erf5.jpg" alt="Figure 5. Cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease base-case analysis." /></a><div class="icnblk_cntnt" id="figlgndniceng130erfig5"><h4 id="niceng130er.fig5"><a href="/books/NBK576848/figure/niceng130er.fig5/?report=objectonly" target="object" rid-ob="figobniceng130erfig5">Figure 5</a></h4><p class="float-caption no_bottom_margin">Cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease base-case analysis. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figniceng130erfig4" co-legend-rid="figlgndniceng130erfig4"><a href="/books/NBK576848/figure/niceng130er.fig4/?report=objectonly" target="object" title="Figure 4" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erfig4" rid-ob="figobniceng130erfig4"><img class="small-thumb" src="/books/NBK576848/bin/niceng130erf4.gif" src-large="/books/NBK576848/bin/niceng130erf4.jpg" alt="Figure 4. Cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease base-case analysis." /></a><div class="icnblk_cntnt" id="figlgndniceng130erfig4"><h4 id="niceng130er.fig4"><a href="/books/NBK576848/figure/niceng130er.fig4/?report=objectonly" target="object" rid-ob="figobniceng130erfig4">Figure 4</a></h4><p class="float-caption no_bottom_margin">Cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease base-case analysis. </p></div></div></div><div id="niceng130er.s1.7.3.4"><h5>Proctosigmoiditis and left-sided disease: scenario analysis with no early switching of treatments in the event of non-remission</h5><p>This scenario analysis assumes there is no early assessment of response to treatment. All people, except those withdrawing due to adverse events, are assumed to complete a full course treatment irrespective of whether the outcome is remission or non-remission. Compared to the base case, there is an increase in costs for all sequences in this scenario and the ICER for PLS34 versus PLS31 has fallen to £17,694/ QALY. Full results for this scenario are presented in <a href="#niceng130er.appl">Appendix L</a>.</p></div><div id="niceng130er.s1.7.3.5"><h5>Extensive disease: base-case analysis</h5><p>In extensive disease, treatment sequences beginning with the combination of a high-dose oral aminosalicylate and a topical aminosalicylate result in a higher proportion of people entering remission in first line (68.3%) but also a higher proportion of people requiring rescue therapy (9.7% - 23.0%). This is beause it was only possible model up to two lines of treatment in the sequences that begin with the combination of a high-dose oral aminosalicylate and topical aminosalicylate. Although other potential treatment options may exist, no RCTs were identified for inclusion in the evidence network and so it was not possible to model a third line treatment in these sequences. This contributed to the high proportion of people progressing to rescue therapy in the economic analysis.</p><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.tab7/?report=objectonly" target="object" rid-figpopup="figniceng130ertab7" rid-ob="figobniceng130ertab7">Table 7</a> summarises the base-case cost-effectiveness results in extensive disease. The sequence EXT05 (combination of high-dose oral aminosalicylate and a topical aminosalicylate in first line) results in an ICER of £34,460/QALY in comparison to EXT02 (high-dose oral aminosalicylate alone in first line followed by the addition of a topical aminosalicylate in second line if remission is not achieved).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130ertab7"><a href="/books/NBK576848/table/niceng130er.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130ertab7" rid-ob="figobniceng130ertab7"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.tab7/?report=thumb" src-large="/books/NBK576848/table/niceng130er.tab7/?report=previmg" alt="Table 7. Base-case mean probabilistc cost-effectiveness results in extensive disease." /></a><div class="icnblk_cntnt"><h4 id="niceng130er.tab7"><a href="/books/NBK576848/table/niceng130er.tab7/?report=objectonly" target="object" rid-ob="figobniceng130ertab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Base-case mean probabilistc cost-effectiveness results in extensive disease. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figniceng130erfig6" co-legend-rid="figlgndniceng130erfig6"><a href="/books/NBK576848/figure/niceng130er.fig6/?report=objectonly" target="object" title="Figure 6" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erfig6" rid-ob="figobniceng130erfig6"><img class="small-thumb" src="/books/NBK576848/bin/niceng130erf6.gif" src-large="/books/NBK576848/bin/niceng130erf6.jpg" alt="Figure 6. Cost-effectiveness acceptability curve for extensive disease base-case analysis." /></a><div class="icnblk_cntnt" id="figlgndniceng130erfig6"><h4 id="niceng130er.fig6"><a href="/books/NBK576848/figure/niceng130er.fig6/?report=objectonly" target="object" rid-ob="figobniceng130erfig6">Figure 6</a></h4><p class="float-caption no_bottom_margin">Cost-effectiveness acceptability curve for extensive disease base-case analysis. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figniceng130erfig7" co-legend-rid="figlgndniceng130erfig7"><a href="/books/NBK576848/figure/niceng130er.fig7/?report=objectonly" target="object" title="Figure 7" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erfig7" rid-ob="figobniceng130erfig7"><img class="small-thumb" src="/books/NBK576848/bin/niceng130erf7.gif" src-large="/books/NBK576848/bin/niceng130erf7.jpg" alt="Figure 7. Cost-effectiveness acceptability frontier for extensive disease base-case analysis." /></a><div class="icnblk_cntnt" id="figlgndniceng130erfig7"><h4 id="niceng130er.fig7"><a href="/books/NBK576848/figure/niceng130er.fig7/?report=objectonly" target="object" rid-ob="figobniceng130erfig7">Figure 7</a></h4><p class="float-caption no_bottom_margin">Cost-effectiveness acceptability frontier for extensive disease base-case analysis. </p></div></div></div><div id="niceng130er.s1.7.3.6"><h5>Extensive disease: scenario analysis scenario analysis with no early switching of treatments in the event of non-remission</h5><p>A scenario analysis was run in which all people, except those withdrawing due to adverse events, are assumed to complete a full course treatment irrespective of whether the outcome was remission or non-remission. This resulted in a reduction in the ICER for EXT05 versus EXT02 to £17,087/QALY.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130ertab8"><a href="/books/NBK576848/table/niceng130er.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130ertab8" rid-ob="figobniceng130ertab8"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.tab8/?report=thumb" src-large="/books/NBK576848/table/niceng130er.tab8/?report=previmg" alt="Table 8. Mean probabilistic cost-effectiveness results for extensive disease with no early switching of treatments in the event of non-remission." /></a><div class="icnblk_cntnt"><h4 id="niceng130er.tab8"><a href="/books/NBK576848/table/niceng130er.tab8/?report=objectonly" target="object" rid-ob="figobniceng130ertab8">Table 8</a></h4><p class="float-caption no_bottom_margin">Mean probabilistic cost-effectiveness results for extensive disease with no early switching of treatments in the event of non-remission. </p></div></div></div></div></div><div id="niceng130er.s1.8"><h3>Evidence statements</h3><div id="niceng130er.s1.8.1"><h4>Clinical evidence statements</h4><p>Clinical evidence statements were based on results from network-meta-analyses, and where it was not possible to conduct a network-meta-analysis, the pairwise analyses was used. For full results of the pairwise analysis, see <a href="#niceng130er.appg">Appendix G</a>: for forest plots and <a href="#niceng130er.apph">Appendix H</a>: for GRADE tables.</p><div id="niceng130er.s1.8.1.1"><h5>Proctitis</h5><div id="niceng130er.s1.8.1.1.1"><h5>Clinical remission in adults</h5><div id="niceng130er.s1.8.1.1.1.1"><h5>0 to 2 weeks follow-up</h5><p>Moderate quality evidence from 1 network-meta-analysis with 3 RCTs containing 214 participants found that topical aminosalicylates are associated with higher clinical remission than standard-dose oral aminosalicylates or placebo at 2 weeks follow-up. The evidence could not differentiate clinical remission between placebo and standard-dose oral aminosalicylates.</p></div><div id="niceng130er.s1.8.1.1.1.2"><h5>0 to 4 weeks follow-up</h5><p>Moderate quality evidence from 1 network-meta-analysis with 4 RCTs containing 343 participants found that topical aminosalicylates are associated with higher clinical remission than placebo or standard-dose oral aminosalicylate at 3 to 4 weeks follow-up. The evidence could not differentiate clinical remission between placebo and standard-dose oral aminosalicylates.</p></div><div id="niceng130er.s1.8.1.1.1.3"><h5>5 to 8 weeks follow-up</h5><p>Low quality evidence from 1 network-meta-analysis with 3 RCTs containing 279 participants found higher clinical remission in topical immunomodulators and standard-dose oral aminosalicylates than placebo at 5 to 8 weeks follow-up. The evidence could not differentiate clinical remission between topical aminosalicylates and:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose oral aminosalicylates</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">topical immunomodulators</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">placebo</p></dd></dl></dl></p><p>The evidence could not differentiate clinical remission between topical immunomodulators and standard-dose oral aminosalicylates.</p></div></div></div><div id="niceng130er.s1.8.1.2"><h5>Proctosigmoiditis and left-sided</h5><div id="niceng130er.s1.8.1.2.1"><h5>Clinical remission in adults</h5><div id="niceng130er.s1.8.1.2.1.1"><h5>0 to 2 weeks follow-up</h5><p>Moderate quality evidence from 1 network-meta-analysis with 2 RCTs with 201 participants found that topical prednisolone or topical aminosalicylates are associated with higher clinical remission than placebo at 2 weeks follow-up. Topical aminosalicylates are associated with higher clinical remission than topical prednisolone, but 95% confidence intervals could not demonstrate a meaningful difference.</p></div><div id="niceng130er.s1.8.1.2.1.2"><h5>0 to 4 weeks follow-up</h5><p>High quality evidence from 1 network-meta-analysis with 8 RCTs with 1,356 participants found that the following are associated with higher clinical remission at 0 to 4 weeks follow-up:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">topical corticosteroid (prednisolone) compared to placebo.</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">topical aminosalicylates compared to placebo.</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose oral aminosalicylates combined with oral corticosteroid (beclomethasone) compared to oral corticosteroid (beclomethasone);</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose oral aminosalicylates combined with standard-dose oral corticosteroids (beclomethasone) compared to standard-dose oral aminosalicylates;</p></dd></dl></dl></p><p>The following are associated with higher clinical remission, but 95% confidence intervals could not demonstrate a meaningful difference:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">topical aminosalicylates compared to oral corticosteroid (beclomethasone);</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">high dose oral aminosalicylates compared to standard-dose oral aminosalicylates The evidence could not differentiate clinical remission in the remaining interventions against each other or placebo.</p></dd></dl></dl></p></div><div id="niceng130er.s1.8.1.2.1.3"><h5>5 to 8 weeks follow-up</h5><p>Low quality evidence from 1 network-meta-analysis with 26 studies containing 6352 participants found that the following are associated with higher clinical remission compared to placebo at 5 to 8 weeks follow-up:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">topical aminosalicylates;</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose oral aminosalicylates;</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">topical budesonide;</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">topical hydrocortisone and</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">high-dose oral aminosalicylates.</p></dd></dl></dl></p><p>The following are associated with higher clinical remission at 5 to 8 weeks follow-up:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">oral budesonide compared to topical aminosalicylates</p></dd></dl></dl></p><p>The following are associated with higher clinical remission, but 95% confidence intervals could not demonstrate a meaningful difference:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">oral budesonide compared to placebo;</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose oral aminosalicylates combined with topical aminosalicylates compared to placebo;</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">oral budesonide compared to topical budesonide;</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">oral budesonide compared to high-dose oral aminosalicylates;</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose oral aminosalicylates compared to topical aminosalicylates;</p></dd></dl></dl></p><p>The evidence could not differentiate clinical remission in the remaining interventions against each other or placebo.</p></div></div><div id="niceng130er.s1.8.1.2.2"><h5>Quality of life</h5><p>Moderate quality evidence from 1 meta-analysis with 1 RCT containing 458 participants could not differentiate change in quality of life (IBD-QOL) between standard-dose oral corticosteroid and placebo from baseline to 8 weeks follow-up.</p></div></div><div id="niceng130er.s1.8.1.3"><h5>Extensive</h5><div id="niceng130er.s1.8.1.3.1"><h5>Clinical remission in children</h5><p>Very low quality evidence from 1 RCT containing 81 participants could not differentiate clinical remission in standard-dose oral aminosalicylates and high-dose oral aminosalicylates (dose adjusted by body weight) at 6 weeks follow-up.</p></div><div id="niceng130er.s1.8.1.3.2"><h5>Clinical remission in adults</h5><div id="niceng130er.s1.8.1.3.2.1"><h5>3 to 4 weeks follow-up</h5><p>Low quality evidence from 1 network-meta-analysis with 3 studies containing 188 participants found higher clinical remission in high-dose oral aminosalicylates than l-standard-dose oral aminosalicylates at 3 to 4 weeks follow-up, but 95% confidence intervals could not demonstrate a meaningful difference.</p><p>The evidence could not differentiate clinical remission in the remaining interventions against each other or placebo.</p></div><div id="niceng130er.s1.8.1.3.2.2"><h5>5 to 8 weeks follow-up</h5><p>Moderate quality evidence from 1 network-meta-analysis with 4 studies containing 331 participants found that the following are associated with higher clinical remission compared to placebo at 5 to 8 weeks follow-up:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">high-dose oral aminosalicylates and</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">high-dose oral aminosalicylates combined with topical aminosalicylates.</p></dd></dl></dl></p><p>The following are associated with higher clinical remission at 5 to 8 weeks follow-up:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">high-dose oral aminosalicylates combined with topical aminosalicylates compared to oral budesonide.</p></dd></dl></dl></p><p>The following are associated with higher clinical remission, but 95% confidence intervals could not demonstrate a meaningful difference:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">high-dose oral aminosalicylates combined with topical aminosalicylates compared to high-dose oral aminosalicylates.</p></dd></dl></dl></p><p>The evidence could not differentiate clinical remission between high-dose oral aminosalicylates and standard-dose oral corticosteroids.</p></div><div id="niceng130er.s1.8.1.3.2.3"><h5>12 weeks follow-up</h5><p>Very low quality evidence from 1 RCT containing 111 participants found that methotrexate is associated with higher clinical remission at 12 weeks follow-up, but 95% confidence intervals could not demonstrate a meaningful difference.</p></div></div><div id="niceng130er.s1.8.1.3.3"><h5>Quality of life</h5><p>Moderate quality evidence 1 meta-analysis with 1 RCT containing 127 participants could not differentiate change in quality of life (EQ-5D) between high-dose oral aminosalicylates and high-dose oral aminosalicylates combined with topical aminosalicylates from baseline to 8 weeks follow-up.</p></div></div><div id="niceng130er.s1.8.1.4"><h5>All extents of disease</h5><div id="niceng130er.s1.8.1.4.1"><h5>Withdrawal due to adverse events</h5><p>Very low quality evidence from 1 network-meta-analysis with 28 studies containing 6,594 participants found higher withdrawal due to adverse events rates in high-dose oral aminosalicylates compared to the following:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose oral corticosteroid</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">topical corticosteroid</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">placebo.</p></dd></dl></dl></p><p>Higher withdrawal due to adverse events rates were found in standard-dose topical corticosteroid than standard-dose oral aminosalicylates.</p><p>The following are associated with higher clinical remission, but 95% confidence intervals could not demonstrate a meaningful difference:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose oral aminosalicylates compared to high-dose oral aminosalicylates</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">standard-dose topical corticosteroid compared to placebo</p></dd></dl></dl></p><p>The evidence could not differentiate withdrawal due to adverse events the remaining interventions against each other or placebo.</p></div></div><div id="niceng130er.s1.8.1.5"><h5>Extent of disease not reported</h5><div id="niceng130er.s1.8.1.5.1"><h5>Quality of life</h5><p>High quality evidence 1 meta-analysis with 2 RCTs containing 687 participants (extent of disease not reported in RCTs) could not differentiate change in quality of life (IBDQ) between high-dose oral aminosalicylates and standard-dose oral aminosalicylates from baseline to 6 weeks follow-up.</p></div></div></div><div id="niceng130er.s1.8.2"><h4>Economic evidence statements</h4><p>One partially applicable study with potentially serious limitations (<a class="bibr" href="#niceng130er.appe.s2.1.ref2" rid="niceng130er.appe.s2.1.ref2">Buckland 2008</a>) compared 2.4g oral mesalazine with 4.8g oral mesalazine and taken daily for 8 weeks and found the higher dose was both more effective and less costly.</p><p>One partially applicable study with potentially serious limitations (<a class="bibr" href="#niceng130er.appe.s1.1.ref7" rid="niceng130er.appe.s1.1.ref7">Connolly 2009</a>) compared 4g oral mesalazine in combination with 1g/100mL topical mesalazine enema with 4g oral mesalazine in combination with placebo enema taken daily for 8 weeks and found 4g oral mesalazine in combination with 1g/100mL topical mesalazine enema was both more effective and less costly.</p><p>One partially applicable study with very serious limitations (<a class="bibr" href="#niceng130er.appe.s2.1.ref1" rid="niceng130er.appe.s2.1.ref1">Brereton 2010</a>) compared 2.4g oral mesalazine with 2.4g multimatrix oral mesalazine taken daily for 8 weeks. The study concluded that multimatrix mesalazine was cost effective with an ICER of £749/QALY compared to mesalazine.</p><p>One partially applicable study with potentially serious limitations (<a class="bibr" href="#niceng130er.appe.s2.1.ref4" rid="niceng130er.appe.s2.1.ref4">Connolly 2014</a>) compared 2g oral mesalazine twice daily with 4g oral mesalazine once daily for 8 weeks and found that the once daily regimen was both more effective and less costly.</p><p>One partially applicable economic model with minor limitations from the 2013 guideline compared 10 sequences of treatments for the induction of remission of mild-to-moderate left-sided and extensive ulcerative colitis and concluded that the strategy of high-dose oral aminosalicylate in first line followed by the addition of beclomestaone in second line and oral prednisolone in third line was cost effective.</p><p>An original economic model was developed to compare 32 treatment sequences in proctitis, 75 treatment sequences in proctosigmoiditis and left-sided disease and 6 treatment sequences in extensive disease. In proctitis, proctosigmoiditis and left-sided disease, treatment sequences that start with a topical aminosalicylate, followed by the addition of an oral aminosalicylate and then either a topical or oral corticosteroid were found to be cost effective as they were more effective and less costly than other strategies. In extensive disease, there was more uncertainty with respect to the optimal treatment sequence but results suggest that using a high-dose oral aminosalicylate in combination with a topical aminosalicylate in first line followed by an oral corticosteroid (in combination with an oral aminosalicylate) as second-line treatment is likely to be cost effective.</p></div></div><div id="niceng130er.s1.9"><h3>The committee’s discussion of the evidence</h3><div id="niceng130er.s1.9.1"><h4>Interpreting the evidence</h4><div id="niceng130er.s1.9.1.1"><h5>The outcomes that matter most</h5><p>The committee agreed that the critical outcomes for decision making were clinical remission, withdrawal due to adverse events and quality of life. No other outcomes were included in the evidence review. The committee agreed that it was sensible to stratify the evidence and recommendations based on extent of disease: proctitis; proctosigmoiditis and left-sided; extensive ulcerative colitis. It also agreed specific follow-up times that are clinically important, including 2 weeks, 3 to 4 weeks, 5 to 8 weeks and 9 to 12 weeks. These follow up times were suggested because they represented points by which the committee agreed some clinical change would be expected.</p><p>Evidence for clinical remission and withdrawal due to adverse events in different extents of disease at the specified follow-up times were analysed in network meta-analyses. There was limited evidence for quality of life, all of which used different questionnaires including IBDQ, IBD-QOL and EQ-5D. Due to the limited evidence and the use of different questionnaires, evidence for quality of life could not be analysed in a network meta-analysis, but was presented to the committee in pairwise analyses (<a href="#niceng130er.appg">appendix G</a> and <a href="#niceng130er.apph">appendix H</a>).</p></div><div id="niceng130er.s1.9.1.2"><h5>The quality of the evidence</h5><p>The majority of the evidence in the RCTs included a population with mild-to-moderate ulcerative colitis but there was insufficient evidence to stratify results by mild and moderate ulcerative colitis separately. The dates of the studies included ranged from 1960 to 2017 and the committee noted that older studies may be less applicable to current practice. This is because drug licensing, clinical knowledge on the effectiveness of different drugs and clinical practice has evolved in the last few decades. In spite of this, the committee agreed that the evidence provided by the older studies remained useful and therefore it was included in the analysis.</p><p>The committee noted that clinical remission was reported differently between RCTs. While some report ‘clinical remission’, some use the terms ‘remission’ or ‘symptomatic remission’. The committee agreed that it was safe to assume that these outcomes are the same as clinical remission and therefore the studies were not downgraded for indirectness. The committee noted that some RCTs report ‘clinical response’ and/or ‘clinical improvement’ and that these outcomes were different from clinical remission. Therefore, these outcomes were not included in this guideline update.</p><p>The committee noted that the evidence from one RCT (<a class="bibr" href="#niceng130er.appe.s1.2.ref4" rid="niceng130er.appe.s1.2.ref4">Lawrance 2017</a>) of 20 participants which compared tacrolimus and placebo in people with procitis was of low quality and may not be directly appropriate to a UK population. This is because the tacrolimus preparation used in the RCT was an ointment applied internally, while the committee agreed that in clinical practice, the most common form of tacrolimus applied topically would be suppositories. The RCT specified that the population included contained moderate to severe ulcerative colitis, but as the mean severity score was moderate, the committee agreed that the population is applicable to the evidence review. The RCT provided evidence for clinical remission at 5 to 8 weeks follow-up, but due to the low sample size and no clinical remission in the placebo arm, the RCT contributed to heterogeneous results in the network-meta-analysis. A sensitivity analysis analysis of clinical remission at 5 to 8 weeks remission which excluded this RCT was carried out. The results of this analysis showed that standard-dose oral aminosalicylates have the highest probability of being the best treatment option, while topical aminosalicylates and placebo are second and third best treatment options. The committee agreed not to recommend topical tacrolimus or other topical immunomodulators without better evidence and wrote a research recommendation to examine the effectiveness of topical immunomodulators in achieving clinical remission in first presentation or inflammatory exacerbation of proctitis that is resistant to standard treatment. Additionally, the committee noted that it is unclear which formulation of topical immunomodulator (suppository or ointment) is more clinically effective in practice and this was included in the research recommendation.</p></div><div id="niceng130er.s1.9.1.3"><h5>Benefits and harms</h5><p>The committee noted the importance of stratifying evidence for standard and high-dose oral aminosalicylates, as doses prescribed for induction of remission in mild-to-moderate ulcerative colitis vary in clinical practice. The committee noted that there was evidence for oral corticosteroids which were above the doses specified for induction of remission in the British National Formulary (BNF). The committee agreed that in their experience, doses of oral prednisolone above 40mg per day would not be given in clinical practice due to possible adverse events. Additionally, one RCT (Rizzello 2001) included 10mg oral beclomethasone. The committee agreed that in their experience, doses above 5mg per day of oral beclomethasone would not be given in clinical practice. Therefore, these doses were not included in the final network-meta-analysis and all oral doses of steroids were considered as standard dose.</p><p>The committee noted that all RCTs including topical preparations of aminosalicylates or corticosteroids included doses within the range specified in the BNF for induction of remission, apart from one RCT (<a class="bibr" href="#niceng130er.appe.s1.2.ref5" rid="niceng130er.appe.s1.2.ref5">Naganuma 2016</a>) which included budesonide 2mg foam given twice a day. The committee agreed it was suitable to treat this as standard dose, as the committee believed there is no dose effect with increased doses of topical preparations.</p><p>The committee noted that oral corticosteroids should be recommended as a time-limited course and have included this where recommended. The committee noted that courses of corticosteroids range between 4 to 8 weeks depending on the corticosteroid. However, the committee noted that there is varying practice with regards to prescribing oral prednisolone, as a course shorter than 4 weeks or longer than 8 weeks can be prescribed. The committee feel that including ‘a time-limiting course’ and defining this as normally 4 to 8 weeks will reduce the varying prescribing practice across the UK.</p></div></div><div id="niceng130er.s1.9.2"><h4>Proctitis</h4><p>The committee reviewed the results from the network-meta-analysis for clinical remission at 2, 3 to 4 and 5 to 8 weeks follow-up. The committee noted that at both 2 weeks and 3 to 4 weeks follow-up, topical aminosalicylates (either suppository or enema) have the highest probability of being the best treatment to achieve clinical remission. The committee also noted that the network meta-analysis for withdrawal due to adverse events in proctitis showed that topical aminosalicylates have lower withdrawal rates than standard-dose oral aminosalicylates and oral corticosteroids alone, which could be because oral treatments alone are not as effective as topical treatment, and this can lead to worsening of symptoms. The committee agreed that the evidence was reflective of clinical practice, as topical aminosalicylates would be considered as first-line treatment and formulated an ‘offer’ recommendation to reflect this. The committee did not specify which preparation of topical aminosalicylate, for example, suppository or enema, as the evidence found no difference in clinical remission according to different preparations and the committee agreed either can be used in accordance with the person’s preference.</p><p>Evidence was not available in proctitis for combined treatment of topical and oral aminosalicylates. However, the committee reviewed the health economic model, which used evidence of combined treatment from proctosigmoiditis and left-sided ulcerative colitis, and noted that it would be of clinical benefit to add oral aminosalicylates as a second-line therapy if remission is not achieved within 4 weeks. Due to lack of clinical evidence for this, the committee formulated a ‘consider’ recommendation.</p><p>The committee discussed treatment options for people whose disease had not entered remission after combination treatment with both a topical and oral aminosalicylate. The evidence showed similar effectiveness and costs to support the use of either a topical or oral corticosteroid with an oral aminosalicylate as a next step in the treatment sequence. In the cost-effectiveness model, upon the advice of the committee, it was assumed that the corticosteroid would be given in addition to continuing treatment with an oral aminosalicylate. The committee also discussed that in clinical practice, a topical or oral corticosteroid may be given in addition to continuing treatment with both a topical and oral aminosalicylate. In other words, the committee felt that some people requiring third-line treatment for proctitis could benefit from receiving a triple combination of a topical corticosteroid plus topical aminosalicylate plus oral aminsalicylate or of an oral corticosteroid plus topical aminosalicylate plus oral aminosalicylate. No RCTs were identified that provided evidence of either the effectiveness or frequency of withdrawals for these triple combinations nor were they explicitly modelled in the cost-effectiveness analysis. Therefore, the committee made a consensus-based recommendation to allow all three treatments to be considered for use in combination in third-line treatment for proctitis. The committee noted that some people decline topical aminsalcylates. The committee noted that proctitis is not common in the paediatric population and there may be a preference of oral aminosalicylates over topical aminosalicylates. In situations where topical treatment is declined, the committee recommended that oral aminosalicylates can be considered as first-line treatment. However, the clinical evidence and the committee’s experience show that oral aminosalicylates are not as effective for inducing remission as topical aminosaicylates alone. The committee highlighted in the recommendation that this difference in effectiveness in oral aminosalicylates alone should be explained to the person declining topical treatment. The committee recommended to consider adding a topical or oral corticosteroid if remission is not achieved within 4 weeks in these people. As there was no direct evidence for people who decline topical aminosalicylates and recommendations were derived from the health economic model and the committee’s experience; ‘consider’ recommendations were made for these people.</p><p>The committee noted that there are people who do not tolerate aminosalicylates. The committee recommended to consider a topical or oral corticosteroid to these people.</p></div><div id="niceng130er.s1.9.3"><h4>Proctosigmoiditis and left-sided</h4><p>The committee noted that evidence from the network-meta-analyses of clinical remission at 2 weeks, 3 to 4 weeks and 5 to 8 weeks follow-up showed that both topical aminosalicylates and topical corticosteroids are effective in inducing clinical remission. Additionally, the evidence does not make a clear distinction between topical aminosalicylates and topical corticosteroids. The committee noted that, in its experience, topical aminosalicylates may work faster and more effectively than topical corticosteroids and recommended offering topical aminosalicylates as a first-line treatment for mild-to-moderate proctosigmoiditis or left-sided ulcerative colitis. In addition to evidence of clinical effectiveness of topical corticosteroids, the committee noted that evidence from the network-meta-analysis at 3 to 4 weeks and 5 to 8 weeks follow-up showed that high-dose oral aminosalicylates are effective in inducing remission and reducing withdrawal due to adverse events and showed some benefit over standard-dose oral aminosalicylates. The committee noted that despite lack of direct evidence of high-dose oral aminosalicylates in combination with topical aminosalicylates or topical corticosteroids, it is possible to infer that as topical treatments are effective and high-dose oral aminosalicylates are more effective than standard-dose, then combination treatment of high-dose oral aminosalicylates with topical aminosalicylates or topical corticosteroids would be more effective than standard-dose oral aminosalicylates alone. The committee recommended considering adding high-dose oral aminosalicylates to the topical aminosalicylate or switching to high-dose oral aminosalicylates and topical corticosteroids if remission is not achieved within 4 weeks.</p><p>The committee noted that there was limited evidence of oral corticosteroids available in proctosigmoiditis and left-sided disease. There was evidence from the network-meta-analysis at 5 to 8 weeks follow-up to suggest that oral corticosteroids are associated with higher clinical remission than placebo. However, the committee noted that this evidence is from one RCT which included budesonide. At 3 to 4 weeks, the network-meta-analysis could not differentiate clinical remission between oral corticosteroids and placebo, and this evidence was from one RCT which included beclomethasone. The committee discussed this and noted that in clinical practice, oral prednisolone would be the preferred choice of oral corticosteroids due to its established use in clinical care and lower acquisition cost. Despite the limited evidence, the committee recognised that there may be a benefit to offer an oral corticosteroid with an oral aminosalicylate if further treatment is needed.</p><p>The committee recommended that in situations where a person declines topical treatment a high-dose oral aminosalicylates alone could be considered, but that it is important to to explain to the person that this treatment is not as effective as a topical aminosalicylate. For these people, if remission is not achieved, the committee recommended that they be offered an oral corticosteroid in addition to the high-dose aminosalicylate.</p><p>The committee noted that there are people who do not tolerate topical aminosalicylates. The committee recommended to consider a topical or oral corticosteroid to these people.</p></div><div id="niceng130er.s1.9.4"><h4>Extensive disease</h4><p>No evidence was found that reported clinical remission at 2 weeks follow-up in extensive disease. The committee noted that this may be consistent with clinical practice as extensive ulcerative colitis may require a longer duration of treatment compared with proctitis, proctosigmoiditis and left-sided disease. To allow the network to become connected, the option of using the relative effectiveness of clinical remission in high-dose compared to standard-dose oral aminosalicylates in proctosigmoiditis and left-sided disease was discussed with the committee. The committee agreed that it would be suitable to assume that the relative effectiveness of this comparison in proctosigmoiditis and left-sided extent of disease would be comparable in extensive disease. Additionally, this was the only circumstance where evidence from two different corticosteroids (beclomethasone or prednisolone) were available. The committee agreed that as the clinical use, availability and cost of these different corticosteroids differs, it would be useful to stratify the corticosteroid drugs rather than combine into a class. The results of this network-meta-analysis found that either oral beclomethasone or prednisolone and high-dose oral aminosalicylate in combination with a topical aminosalicylate are the best treatment options in achieving clinical remission. Evidence of clinical remission at 5 to 8 weeks follow-up was analysed in a network-meta-analysis and found that high-dose oral aminosalicylate in combination with a topical aminosalicylate has the highest probability of being the best treatment option in achieving clinical remission. The second and third best treatment options were high-dose oral aminosalicylate and oral budesonide respectively.</p><p>The committee discussed oral beclometasone and agreed that it is not widely used in clinical practice and from their experience, the preference among people with extensive ulcerative colitis was to use other oral corticosteroids. The committee noted that oral prednisolone is most widely used, but evidence of oral prednisolone in the analysis was from one dated RCT (<a class="bibr" href="#niceng130er.appe.s1.1.ref23" rid="niceng130er.appe.s1.1.ref23">Lennard Jones 1960</a>) with a small sample size (20 participants). Due to this evidence from a low-quality RCT, the committee agreed that there is still uncertainty about the effectiveness of oral prednisolone and oral corticosteroids as first line treatment in extensive disease. The committee felt that due to this uncertainty, it would not be suitable to recommended oral corticosteroids as first-line treatment for extensive disease, but recommended offering a combination of oral high-dose aminosalicylates with a topical aminosalicylate as first-line treatment. The committee recommended to offer this for 4 weeks, as from their experience, this treatment combination is the most effective treatment within this timeframe. However, the committee recommended that if first-line treatment does not achieve clinical remission, an oral corticosteroid with a high-dose oral aminosalicylate can be offered. The committee noted that there are people who do not tolerate topical aminosalicylates. The committee recommended to consider oral corticosteroid to these people.</p><p>The committee noted that for all extents of disease, it would be reasonable to assume that the evidence found for the adult population would be comparable to paediatric population, as the same treatment options would be considered in clinical practice. The committee decided to generalise the recommendations made to include children, young people and adults, but to include a footnote to clarify that oral prednisolone, budesonide and beclomethasone are not licensed for use in children with ulcerative colitis if these are considered as second-line treatment options.</p><p>The committee reviewed evidence for clinical remission and withdrawal due to adverse events at 12 weeks follow-up received from the authors of one RCT (<a class="bibr" href="#niceng130er.appe.s1.2.ref2" rid="niceng130er.appe.s1.2.ref2">Carbonnel 2016</a>) which compared methotrexate and placebo. This was the only evidence included for extensive ulcerative colitis which for a follow-up of greater than 8 weeks and was analysed in a pairwise meta-analysis. This evidence did not show a meaningful difference of a benefit of methotrexate at the 95% confidence interval. The committee believe that evidence on the effectiveness of methotrexate is lacking and evidence on this would benefit future guidance for the induction of remission. The committee formulated a research recommendation to examine the effectiveness of systemic methotrexate (and also oral tacrolimus) in the induction of remission in mild-to-moderate ulcerative colitis.</p><div id="niceng130er.s1.9.4.1"><h5>Cost effectiveness and resource use</h5><p>A review of the published literature identified 4 cost-effectiveness analyses that compared different doses or formulations of mesalazine for the induction of remission in mild-to-moderate ulcerative colitis. None of these studies provided information on the comparative cost effectiveness of different sequences of treatments. In order to address this gap in the evidence, a cost-effectiveness model was developed as part of the 2013 guideline. It compared 10 sequences of treatments for the induction of remission of mild-to-moderate left-sided or extensive ulcerative colitis in adults. Since then, new RCTs have been published that provide data to compare additional treatment sequences. The committee also wished to explore the cost effectiveness of treatment sequences in different extents of disease and to update some of the assumptions underpinning the 2013 guideline model to reflect current practice. Therefore, a new economic model was developed to take these considerations into account.</p><p>The results of the model showed that in proctitis as well as in proctosigmoiditis and left-sided disease, treatment sequences that begin with a topical aminosalicylate, followed by the addition of a standard-dose oral aminosalicylate and then a topical or oral corticosteroid resulted in the highest proportion of people achieving remission in first line and the lowest proportion of people requiring rescue therapy. These sequences also generated the highest total QALYs and the lowest total costs. The differences in total QALYs between sequences that started with a topical aminosalicylate were very small and the committee felt there was not a strong basis for differentiating between treatment strategies in terms of the choice of corticosteroid in third line. The committee acknowledged the limited evidence base for corticosteroids in proctitis and proctosigmoiditis and left-sided disease. For example, there were no studies that compared oral prednisolone in either extent of disease. In addition, given the available evidence, it was not possible to directly establish whether a class-level effect could also be applied to corticosteroids, because for both oral corticosteroids and topical corticosteroids, the individual drugs within the class were not all connected in a common network. The committee noted that although there were differences in the weekly cost of varous topical and oral corticosteroid preparations, the sequencing model was somewhat insensitive to these differences because of the diminishing proportion of people who required subsequent lines of treatment and the relatively low cost of corticosteroids in comparison to the costs associated with rescue therapy.</p><p>In proctitis, treatment sequences were modelled both with and without topical tacrolimus as a fourth-line treatment option. The committee noted that the clinical evidence to inform the remission rate for topical tacrolimus was based on 1 RCT of 20 participants (<a class="bibr" href="#niceng130er.appe.s1.2.ref4" rid="niceng130er.appe.s1.2.ref4">Lawrance 2017</a>) and that the preparation used in the trial did not reflect UK clinical practice. Given this uncertainty and the pharmacy costs associated with compounding tacrolimus suppositories on a case by case basis, the committee decided not to recommend topical tacrolimus as part of the treatment sequence in proctitis and agreed instead to make a research recommendation.</p><p>In proctosigmoiditis and left-sided disese, the committee discussed whether the dose of the oral aminosalicylate in second line should be standard or high. Based on the available RCT evidence in proctosigmoiditis and left-sided disease, it was only possible to model standard-dose oral aminosalicylates in combination with a topical aminosalicylate as part of treatment sequences in the economic model. However, the committee noted the superior efficacy of high-dose oral aminosalicylates in comparison to standard-dose oral aminosalicylates when used alone and inferred that the superior efficacy of high-dose oral aminosalicylates was likely to hold when used in combination with a topical aminosalicylate. The committee also noted that in clinical practice, a high-dose oral aminosalicylate is more likely to be used in people who have not responded to a topical aminosalicylate alone.</p><p>In extensive disease, treatment sequences that begin with a combination of a high-dose oral aminosalicylate and a topical aminosalicylate resulted in a higher proportion of people achieving remission in first line compared to a high-dose oral aminosalicylate alone but also resulted in a higher proportion of people requiring rescue therapy. In the base-case analysis, the ICER for EXT05 (high-dose oral aminosalicylate in combination with a topical aminosalicylate in first line followed by oral beclometasone in second line) versus EXT02 (high-dose oral aminosalicylate in first line followed by the addition of a topical aminosalicylate in second line and then oral beclometasone in third line) was £34,460/QALY; this fell to £17,087/QALY in a scenario analysis in which all people, except those withdrawing due to adverse events, were assumed to complete a full course treatment irrespective of whether the outcome was remission or non-remission. It was noted that in treatment sequences that begin with a high-dose oral aminosalicylate in combination with a topical aminosalicylate, it was only possible to model two lines of treatment as no RCT evidence was identified to model a third line treatment in extensive disease. In practice, the availability of other treatment options in third line would likely further reduce the proportion of people requiring rescue therapy, leading to lower costs and reducing the ICER.</p><p>Overall, the committee felt that the recommendations would not have a significant resource impact because they are generally in line with clinical practice for all extents of disease.</p></div><div id="niceng130er.s1.9.4.2"><h5>Other factors the committee took into account</h5><p>The committee noted that topical tacrolimus, mainly suppositories, are occasionally used in clinical practice for people with proctitis. However, evidence on topical tacrolimus in people with proctitis is limited. The committee formulated a research recommendation to examine the clinical and cost-effectiveness of topical tacrolimus compared with topical aminosalicylates in the induction of remission.</p><p>The committee recognised the limited evidence base for oral corticosteroids and the uncertainty over which oral corticosteroid is most clinically and cost effective in all extents of disease, but in particular for proctosigmoiditis, left-sided and extensive disease. The committee formulated a research recommendation to examine the clinical and cost effectiveness of prednisolone, budesonide and beclomethasone in addition to aminosalicylates compared with each other for the induction of remission in people with mild-to-moderate ulcerative colitis.</p></div></div></div></div><div id="niceng130er.appa"><h2 id="_niceng130er_appa_">Appendix A. Review protocol for induction of remission in mild-to-moderate ulcerative colitis</h2><div id="niceng130er.appa.s1"><h3>Review protocol for induction of remission in mild-to-moderate ulcerative colitis</h3><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappatab1"><a href="/books/NBK576848/table/niceng130er.appa.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappatab1" rid-ob="figobniceng130erappatab1"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appa.tab1/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appa.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appa.tab1"><a href="/books/NBK576848/table/niceng130er.appa.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erappatab1">Table</a></h4><p class="float-caption no_bottom_margin">Included: Children young people and adults (18 years and older), with a diagnosis of mild-to-moderate (author defined) ulcerative colitis. Excluded: Mixed IBD populations where the results are not displayed separately for ulcerative colitis. People with <a href="/books/NBK576848/table/niceng130er.appa.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erappatab1">(more...)</a></p></div></div></div></div><div id="niceng130er.appb"><h2 id="_niceng130er_appb_">Appendix B. Methods and process</h2><div id="niceng130er.appb.s1"><h3>Evidence synthesis and meta-analysis</h3><p>Where possible, meta-analyses were conducted to combine the results of studies for each outcome. For continuous outcomes, where change from baseline data were reported in the trials and were accompanied by a measure of spread (for example standard deviation), these were extracted and used in the meta-analysis.</p></div><div id="niceng130er.appb.s2"><h3>Evidence of effectiveness of interventions</h3><div id="niceng130er.appb.s2.1"><h4>Quality assessment</h4><p>GRADE was used to assess the quality of evidence for the selected outcomes as specified in ‘Developing NICE guidelines’ (2014). Randomised controlled trials (RCTs) are initially rated as high quality and the quality of the evidence for each outcome was downgraded or not from this initial point. The risk of bias of included RCTs was assessed using the Cochrane risk of bias tool (Higgins et al 2011). This tool assesses 6 domains: selection bias; performance bias; detection bias; attrition bias; reporting bias and any other bias. If more than 2 of: selection bias, performance bias, detection bias or attrition bias in a study were classed as unclear, the study was classed as having moderate risk of bias. Studies with no blinding (i.e. open-label trials) were considered at high risk of bias for subjective outcomes (quality of life and clinical remission). For the objective outcome, withdrawal due to adverse events, these studies were considered at moderate risk of bias, as the committee believed that assessing reasons for withdrawal may be subjected to less risk of bias. Studies which were single-blinded were considered at moderate risk of bias, as these may be subjected to less risk than open-labell trials.</p><p>No indirect study populations were included. Indirectness in terms of study treatment, if a study drug uses a formulation or route of administration which was not included in the protocol, was described in the evidence tables and in GRADE.</p></div><div id="niceng130er.appb.s2.2"><h4>Methods for combining intervention evidence – pairwise meta-analysis</h4><p>Meta-analysis of interventional data was conducted with reference to the Cochrane Handbook for Systematic Reviews of Interventions (Higgins et al. 2011).</p><p>Dichotomous outcomes were pooled on the odds ratio scale (using the Mantel–Haenszel method), which was a requirement for health economic modeling. Hazard ratios were also generated from the network meta-analysis of one outcome, withdrawal due to adverse events.</p><p>Fixed- and random-effects models (der Simonian and Laird) were fitted for all syntheses, with the presented analysis dependent on the degree of heterogeneity in the assembled evidence, once pre-specified subgroup analyses had been undertaken to explore heterogeneity. Fixed-effects models were the preferred choice to report, but in situations where the assumption of a shared mean for fixed-effects model were clearly not met, even after appropriate pre-specified subgroup analyses were conducted, random-effects results are presented. Fixed-effects models were deemed to be inappropriate if one or both of the following conditions was met:
|
|
<ul><li class="half_rhythm"><div>Significant between study heterogeneity in methodology, population, intervention or comparator was identified by the reviewer in advance of data analysis. This decision was made and recorded before any data analysis was undertaken.</div></li><li class="half_rhythm"><div>The presence of significant statistical heterogeneity in the meta-analysis, defined as I<sup>2</sup>≥50%, as defined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins et al. 2011).</div></li></ul></p><p>As specified in the protocol, outcomes were stratified by mode of delivery and dose. Where it was possible to ascertain extent of disease in the study population, the outcomes were grouped by extent of disease. This was of particular interest for clinical remission, where data was further stratified by the following clinically important follow-up times:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">0 to 2 weeks</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">3 to 4 weeks</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">5 to 8 weeks</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">and 9 to 12 weeks.</p></dd></dl></dl></p><p>The committee specified interest in finding which interventions had the highest overall withdrawal due to adverse events. Therefore, this outcome was not stratified by extent of disease. Paediatric studies were assessed separately. The majority of studies included reported severity as mild-to-moderate and there was limited evidence to allow stratification of data by severity.</p><p>Meta-analyses were performed in Cochrane Review Manager v5.3.</p></div><div id="niceng130er.appb.s2.3"><h4>Minimal clinically important differences (MIDs)</h4><p>For odds ratios and hazard ratios where no other MID was available, the MID interval for dichotomous outcomes of 0.8 to 1.25 was used. For continuous outcomes, a MID interval of 0.5 and −0.5 × standard deviation of the control arm was used.</p></div><div id="niceng130er.appb.s2.4"><h4>GRADE for pairwise meta-analyses of interventional evidence</h4><p>Grading of Recommendations Assessment Development and Evaluation (GRADE) was used to assess the quality of evidence for the selected outcomes as specified in ‘Developing NICE guidelines: the manual (2014)’. Data from all study designs was initially rated as high quality and the quality of the evidence for each outcome was downgraded or not from this initial point, based on the criteria given in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appb.tab1/?report=objectonly" target="object" rid-figpopup="figniceng130erappbtab1" rid-ob="figobniceng130erappbtab1">Table 9</a>.</p><p id="niceng130er.appb.tab1"><a href="/books/NBK576848/table/niceng130er.appb.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erappbtab1" class="figpopup">Table 9. Rationale for downgrading quality of evidence for intervention studies</a></p></div></div><div id="niceng130er.appb.s3"><h3>Methods for combining direct and indirect evidence (network meta-analysis) for interventions</h3><p>In situations where there are more than two interventions, pairwise meta-analysis of the direct evidence alone is of limited use. This is because multiple pairwise comparisons need to be performed to analyse each pair of interventions in the evidence, and these results can be difficult to interpret. Furthermore, direct evidence about interventions of interest may not be available. For example studies may compare A vs B and B vs C, but there may be no direct evidence comparing A vs C. Network meta-analysis overcomes these problems by combining all evidence into a single, internally consistent model, synthesising data from direct and indirect comparisons, and providing estimates of relative effectiveness for all comparators and the ranking of different interventions. Network meta-analyses were undertaken in all situations where the following two criteria were met:
|
|
<ul><li class="half_rhythm"><div>At least three treatment alternatives.</div></li><li class="half_rhythm"><div>A connected network to enable valid estimates to be made.</div></li></ul></p><p>The outcome, clinical remission, was stratified by extent of disease. Separate NMAs were conducted for each important follow-up time. To avoid duplication of study samples and to maximise data available, the final follow-up times assessed were:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">0 to 2 weeks,</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">0 to 4 weeks and</p></dd></dl><dl class="bkr_refwrap"><dt>-</dt><dd><p class="no_top_margin">5 to 8 weeks.</p></dd></dl></dl></p><div id="niceng130er.appb.s3.1"><h4>Assessing inconsistency of network</h4><p>Inconsistency (heterogeneity) concerns the differences in treatment effects between trials within each treatment contrast (<a class="bibr" href="#niceng130er.appe.s3.ref4" rid="niceng130er.appe.s3.ref4">Dias 2011b</a> & <a class="bibr" href="#niceng130er.appe.s3.ref5" rid="niceng130er.appe.s3.ref5">2013</a>).</p><p>Inconsistency was assessed by comparing the chosen model (fixed or random effects) to an “inconsistency”, or unrelated mean effects, model (<a class="bibr" href="#niceng130er.appe.s3.ref4" rid="niceng130er.appe.s3.ref4">Dias 2011b</a> & <a class="bibr" href="#niceng130er.appe.s3.ref5" rid="niceng130er.appe.s3.ref5">2013</a>). The latter is equivalent to having separate, unrelated, meta-analyses for every pairwise contrast, with a common variance parameter assumed in the case of random effects models. Note that inconsistency can only be assessed when there are closed loops of direct evidence on 3 treatments that are informed by at least 3 distinct trials (van Valkenhoef 2016).</p></div><div id="niceng130er.appb.s3.2"><h4>Modified GRADE for network meta-analyses</h4><p>A modified version of the standard GRADE approach for pairwise interventions was used to assess the quality of evidence across the network meta-analyses undertaken. While most criteria for pairwise meta-analyses still apply, it is important to adapt some of the criteria to take into consideration additional factors, such as how each ‘link’ or pairwise comparison within the network applies to the others. As a result, the following was used when modifying the GRADE framework to a network meta-analysis. It is designed to provide a single overall quality rating for an NMA, which can then be combined with pairwise quality ratings for individual comparisons (if appropriate), to judge the overall strength of evidence for each comparison.</p><p id="niceng130er.appb.tab2"><a href="/books/NBK576848/table/niceng130er.appb.tab2/?report=objectonly" target="object" rid-ob="figobniceng130erappbtab2" class="figpopup">Table 10. Rationale for downgrading quality of evidence for intervention studies</a></p></div></div></div><div id="niceng130er.appc"><h2 id="_niceng130er_appc_">Appendix C. Literature search strategies</h2><div id="niceng130er.appc.s1"><h3>C.1. Search history</h3><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab1"><a href="/books/NBK576848/table/niceng130er.appc.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab1" rid-ob="figobniceng130erappctab1"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab1/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab1"><a href="/books/NBK576848/table/niceng130er.appc.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erappctab1">Table</a></h4></div></div><p>In addition, additional search was undertaken on 05/12/2017 with the following lines:</p><p>Mycophenolic Acid/ (MeSH) mycophenolic acid/ (Emtree)</p><p>(Mycophen* or mofetil* or myfortic* or “rs 61443” or rs-61443 or rs61443 or “erl 080*” or erl080* or melbex* or “nsc 129185” or nsc129185).tw</p><p>Numbers for targeted Mycophenolate search:</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab2"><a href="/books/NBK576848/table/niceng130er.appc.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab2" rid-ob="figobniceng130erappctab2"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab2/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab2"><a href="/books/NBK576848/table/niceng130er.appc.tab2/?report=objectonly" target="object" rid-ob="figobniceng130erappctab2">Table</a></h4><p class="float-caption no_bottom_margin">1946 to Present with Daily Update</p></div></div><p>A top-up search was undertaken on 06/08/2018:</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab3"><a href="/books/NBK576848/table/niceng130er.appc.tab3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab3" rid-ob="figobniceng130erappctab3"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab3/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab3/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab3"><a href="/books/NBK576848/table/niceng130er.appc.tab3/?report=objectonly" target="object" rid-ob="figobniceng130erappctab3">Table</a></h4></div></div></div><div id="niceng130er.appc.s2"><h3>C.2. Search strategy: medline</h3><p>Combined search strategy for ulcerative colitis and Crohn’s guideline updates:</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab4"><a href="/books/NBK576848/table/niceng130er.appc.tab4/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab4" rid-ob="figobniceng130erappctab4"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab4/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab4/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab4"><a href="/books/NBK576848/table/niceng130er.appc.tab4/?report=objectonly" target="object" rid-ob="figobniceng130erappctab4">Table</a></h4></div></div></div><div id="niceng130er.appc.s3"><h3>C.3. Health economics search strategy</h3><div id="niceng130er.appc.s3.1"><h4>C.3.1. Overview</h4><p>Sources searched:
|
|
<ul><li class="half_rhythm"><div>MEDLINE (Ovid)</div></li><li class="half_rhythm"><div>MEDLINE In-Process (Ovid)</div></li><li class="half_rhythm"><div>Embase (Ovid)</div></li><li class="half_rhythm"><div>EconLit (Ovid)</div></li><li class="half_rhythm"><div>NHS Economic Evaluation Database – NHS EED (Wiley) (legacy database)</div></li><li class="half_rhythm"><div>Health Technology Assessment (HTA Database)</div></li></ul></p><p>Searches were carried out in November 2017 with a date limit of the previous guideline from March 2012 onwards. A top-up search was carried out in August 2018.</p></div><div id="niceng130er.appc.s3.2"><h4>C.3.2. Search stratregy Ovid MEDLINE(R)</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab5"><a href="/books/NBK576848/table/niceng130er.appc.tab5/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab5" rid-ob="figobniceng130erappctab5"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab5/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab5/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab5"><a href="/books/NBK576848/table/niceng130er.appc.tab5/?report=objectonly" target="object" rid-ob="figobniceng130erappctab5">Table</a></h4></div></div></div><div id="niceng130er.appc.s3.3"><h4>C.3.3. Search strategy Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab6"><a href="/books/NBK576848/table/niceng130er.appc.tab6/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab6" rid-ob="figobniceng130erappctab6"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab6/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab6/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab6"><a href="/books/NBK576848/table/niceng130er.appc.tab6/?report=objectonly" target="object" rid-ob="figobniceng130erappctab6">Table</a></h4></div></div></div><div id="niceng130er.appc.s3.4"><h4>C.3.4. Search strategy Embase</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab7"><a href="/books/NBK576848/table/niceng130er.appc.tab7/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab7" rid-ob="figobniceng130erappctab7"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab7/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab7/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab7"><a href="/books/NBK576848/table/niceng130er.appc.tab7/?report=objectonly" target="object" rid-ob="figobniceng130erappctab7">Table</a></h4></div></div></div><div id="niceng130er.appc.s3.5"><h4>C.3.5. Search strategy EconLit</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab8"><a href="/books/NBK576848/table/niceng130er.appc.tab8/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab8" rid-ob="figobniceng130erappctab8"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab8/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab8/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab8"><a href="/books/NBK576848/table/niceng130er.appc.tab8/?report=objectonly" target="object" rid-ob="figobniceng130erappctab8">Table</a></h4></div></div></div><div id="niceng130er.appc.s3.6"><h4>C.3.6. Search strategy NHS EED and HTA</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappctab9"><a href="/books/NBK576848/table/niceng130er.appc.tab9/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappctab9" rid-ob="figobniceng130erappctab9"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appc.tab9/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appc.tab9/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appc.tab9"><a href="/books/NBK576848/table/niceng130er.appc.tab9/?report=objectonly" target="object" rid-ob="figobniceng130erappctab9">Table</a></h4></div></div></div></div></div><div id="niceng130er.appd"><h2 id="_niceng130er_appd_">Appendix D. Clinical evidence study selection</h2><div id="niceng130er.appd.fig1" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappdf1&p=BOOKS&id=576848_niceng130erappdf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappdf1.jpg" alt="Image niceng130erappdf1" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appe"><h2 id="_niceng130er_appe_">Appendix E. References</h2><div id="niceng130er.appe.s1"><h3>E.1. Included clinical studies</h3><div id="niceng130er.appe.s1.1"><h4>E.1.1. Included studies from 2013 guideline</h4><ol><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref1">Bar-Meir
|
|
S, Fidder
|
|
H H, Faszczyk
|
|
M, et al. (2003) Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Diseases of the Colon and Rectum
|
|
46(7), 929–936 [<a href="https://pubmed.ncbi.nlm.nih.gov/12847368" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12847368</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref2">Binder
|
|
V, Bondesen
|
|
S, and Bonnevie
|
|
O (1987) Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Digestive Diseases and Sciences
|
|
32(6), 598–602 [<a href="https://pubmed.ncbi.nlm.nih.gov/2882966" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2882966</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref3">Campieri
|
|
M, Defranchis
|
|
R, Porro
|
|
G B, et al. (1990) Mesalazine (5-Aminosalicyclic Acid) Suppositories in the Treatment of Ulcerative Proctitis Or Distal Proctosigmoiditis - A Randomized Controlled Trial. Scandinavian Journal of Gastroenterology
|
|
25(7), 663–668 [<a href="https://pubmed.ncbi.nlm.nih.gov/2204103" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2204103</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref4">Campieri
|
|
M, Gionchetti
|
|
P, Belluzzi
|
|
A, et al. (1990) Topical Treatment with 5-Aminosalicylic in Distal Ulcerative-Colitis by Using A New Suppository Preparation - A Double-Blind Placebo Controlled Trial. International Journal of Colorectal Disease
|
|
5(2), 79–81 [<a href="https://pubmed.ncbi.nlm.nih.gov/2193075" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2193075</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref5">Campieri
|
|
M, Gionchetti
|
|
P, Belluzzi
|
|
A, et al. (1991) Optimum Dosage of 5-Aminosalicylic Acid As Rectal Enemas in Patients with Active Ulcerative-Colitis. Gut
|
|
32(8), 929–931 [<a href="/pmc/articles/PMC1378964/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1378964</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1885075" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1885075</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref6">Campieri
|
|
M, Adamo
|
|
S, Valpiani
|
|
D, et al. (2003) Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Alimentary Pharmacology & Therapeutics
|
|
17(12), 1471–1480 [<a href="https://pubmed.ncbi.nlm.nih.gov/12823149" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12823149</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref7">Connolly
|
|
M P, Poole
|
|
C D, Currie
|
|
C J, et al. (2009) Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion
|
|
80(4), 241–246 [<a href="https://pubmed.ncbi.nlm.nih.gov/19828955" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19828955</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref8">D’haens
|
|
G, Hommes
|
|
D, Engels
|
|
L, et al. (2006) Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Alimentary pharmacology & therapeutics
|
|
24(7), 1087–1097 [<a href="https://pubmed.ncbi.nlm.nih.gov/16984503" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16984503</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref9">Dick
|
|
A P, Grayson
|
|
M J, Carpenter
|
|
R G, et al. (1964) Controlled Trial of Sulphasalazine In The Treatment Of Ulcerative Colitis. Gut
|
|
5, 437–442 [<a href="/pmc/articles/PMC1552152/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1552152</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14218553" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14218553</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref10">Feurle
|
|
G E, Theuer
|
|
D, Velasco
|
|
S, et al. (1989) Olsalazine Versus Placebo in the Treatment of Mild to Moderate Ulcerative-Colitis - A Randomized Double-Blind Trial. Gut
|
|
30(10), 1354–1361 [<a href="/pmc/articles/PMC1434384/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1434384</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2684804" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2684804</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref11">Gionchetti
|
|
P, Rizzello
|
|
F, Venturi
|
|
A, et al. (1998) Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Diseases of the Colon & Rectum
|
|
41(1), 93–97 [<a href="https://pubmed.ncbi.nlm.nih.gov/9510317" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9510317</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref12">Gross
|
|
V, Bar-Meir
|
|
S, Lavy
|
|
A, et al. (2006) Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Alimentary Pharmacology and Therapeutics
|
|
23(2), 303–312 [<a href="https://pubmed.ncbi.nlm.nih.gov/16393311" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16393311</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref13">Gross
|
|
V, Bunganic
|
|
I, Belousova
|
|
E A, et al. (2011) 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. Journal of Crohn’s and colitis
|
|
5(2), 129–138 [<a href="https://pubmed.ncbi.nlm.nih.gov/21453882" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21453882</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref14">Hanauer
|
|
S, Schwartz
|
|
J, Robinson
|
|
M, et al. (1993) Mesalamine Capsules for Treatment of Active Ulcerative-Colitis - Results of A Controlled Trial. American Journal of Gastroenterology
|
|
88(8), 1188–1197 [<a href="https://pubmed.ncbi.nlm.nih.gov/8338086" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8338086</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref15">Hanauer
|
|
S B (1998) Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentered placebo-controlled trial. Inflammatory Bowel Diseases
|
|
4(2), 79–83 [<a href="https://pubmed.ncbi.nlm.nih.gov/9589293" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9589293</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref16">Hanauer
|
|
S B, Sandborn
|
|
W J, Kornbluth
|
|
A, et al. (2005) Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. American Journal of Gastroenterology
|
|
100(11), 2478–2485 [<a href="https://pubmed.ncbi.nlm.nih.gov/16279903" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16279903</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref17">Hetzel
|
|
D J, Shearman
|
|
D J.C, Bochner
|
|
F, et al. (1986) Azodisalicylate (Olsalazine) in the Treatment of Active Ulcerative-Colitis - A Placebo Controlled Clinical-Trial and Assessment of Drug Disposition. Journal of Gastroenterology and Hepatology
|
|
1(3), 257–266 [<a href="https://pubmed.ncbi.nlm.nih.gov/3067339" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3067339</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref18">Irvine
|
|
E J, Yeh
|
|
C H, Ramsey
|
|
D, et al. (2008) The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics
|
|
28(11–12), 1278–1286 [<a href="https://pubmed.ncbi.nlm.nih.gov/18808446" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18808446</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref19">Ito
|
|
H, Iida
|
|
M, Matsumoto
|
|
T, et al. (2010) Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflammatory Bowel Diseases
|
|
16(9), 1567–1574 [<a href="/pmc/articles/PMC2972638/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2972638</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20049950" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20049950</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref20">Kamm
|
|
M A, Sandborn
|
|
W J, Gassull
|
|
M, et al. (2007) Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology
|
|
132(1), 66–75 [<a href="https://pubmed.ncbi.nlm.nih.gov/17241860" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17241860</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref21">Kruis
|
|
W, Bar-Meir
|
|
S, Feher
|
|
J, et al. (2003) The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology
|
|
1(1), 36–43 [<a href="https://pubmed.ncbi.nlm.nih.gov/15017515" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15017515</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref22">Lauritsen
|
|
K, Laursen
|
|
L S, Bukhave
|
|
K, et al. (1986) Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology
|
|
91(4), 837–844 [<a href="https://pubmed.ncbi.nlm.nih.gov/3017804" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3017804</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref23">Lennard Jones
|
|
J.E, Longmore
|
|
A J, Newell
|
|
A C, et al. F A (1960) An Assessment of Prednisone, Salazopyrin, and Topical Hydrocortisone Hemisuccinate Used As Out-Patient Treatment for Ulcerative Colitis. Gut
|
|
1(3), 217–222 [<a href="/pmc/articles/PMC1413184/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1413184</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/13760840" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13760840</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref24">Levine
|
|
D S, Riff
|
|
D S, Pruitt
|
|
R, et al. (2002) A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. American Journal of Gastroenterology
|
|
97(6), 1398–1407 [<a href="https://pubmed.ncbi.nlm.nih.gov/12094857" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12094857</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref25">Lichtenstein
|
|
G R, Kamm
|
|
M A, Boddu
|
|
P, et al. (2007) Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology
|
|
5(1), 95–102 [<a href="https://pubmed.ncbi.nlm.nih.gov/17234558" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17234558</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref26">Marteau
|
|
P, Probert
|
|
C S, Lindgren
|
|
S, et al. (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut
|
|
54(7), 960–965 [<a href="/pmc/articles/PMC1774619/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1774619</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15951542" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15951542</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref27">Pokrotnieks
|
|
J, Marlicz
|
|
K, Paradowski
|
|
L, et al. (2000) Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: A double-blind, randomized, placebo-controlled study. Alimentary Pharmacology & Therapeutics
|
|
14(9), 1191–1198 [<a href="https://pubmed.ncbi.nlm.nih.gov/10971236" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10971236</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref28">Pruitt
|
|
R, Hanson
|
|
J, Safdi
|
|
M, et al. (2002) Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. American Journal of Gastroenterology
|
|
97(12), 3078–3086 [<a href="https://pubmed.ncbi.nlm.nih.gov/12492193" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12492193</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref29">Rizzello
|
|
F, Gionchetti
|
|
P, D’Arienzo
|
|
A, et al. (2002) Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Alimentary Pharmacology and Therapeutics
|
|
16(6), 1109–1116 [<a href="https://pubmed.ncbi.nlm.nih.gov/12030952" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12030952</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref30">Sandborn
|
|
W J, Regula
|
|
J, Feagan
|
|
B G, et al. (2009) Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology
|
|
137(6), 1934–1943 [<a href="https://pubmed.ncbi.nlm.nih.gov/19766640" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19766640</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref31">Sandborn
|
|
WJ, Travis
|
|
S, Moro
|
|
L, et al. (2012) Once-Daily Budesonide MMX [REGISTERED] Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study.. Gastroenterology
|
|
143(5), 1218 [<a href="https://pubmed.ncbi.nlm.nih.gov/22892337" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22892337</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref32">Scherl
|
|
E J, Pruitt
|
|
R, Gordon
|
|
G L, et al. (2009) Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. American Journal of Gastroenterology
|
|
104(6), 1452–1459 [<a href="https://pubmed.ncbi.nlm.nih.gov/19491859" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19491859</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref33">Sninsky
|
|
C A, Cort
|
|
D H, Shanahan
|
|
F, et al. (1991) Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative-Colitis - A Multicenter Study. Annals of Internal Medicine
|
|
115(5), 350–355 [<a href="https://pubmed.ncbi.nlm.nih.gov/1863024" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1863024</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.1.ref34">Vecchi
|
|
M, Meucci
|
|
G, Gionchetti
|
|
P, et al. (2001) Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Alimentary Pharmacology and Therapeutics
|
|
15(2), 251–256 [<a href="https://pubmed.ncbi.nlm.nih.gov/11148445" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11148445</span></a>]</div></li></ol></div><div id="niceng130er.appe.s1.2"><h4>E.1.2. Included studies from 2019 guideline update</h4><ol><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref1">Travis
|
|
S P, Danese
|
|
S, Kupcinskas
|
|
L, et al. (2013) Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: Results from the randomised CORE II study. Inflammatory Bowel Disease Monitor
|
|
13(4), 161–162 [<a href="/pmc/articles/PMC3933176/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3933176</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23436336" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23436336</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref2">Carbonnel
|
|
F, Colombel
|
|
J F, Filippi
|
|
J, et al. (2016) Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Gastroenterology
|
|
150(2), 380–8.e4 [<a href="https://pubmed.ncbi.nlm.nih.gov/26632520" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26632520</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref3">Feagan
|
|
Bg, Sandborn
|
|
Wj, D’Haens
|
|
G, et al. (2013) The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology
|
|
145(1), 149–157 [<a href="https://pubmed.ncbi.nlm.nih.gov/23528626" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23528626</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref4">Lawrance
|
|
Ic, Baird
|
|
A, Lightower
|
|
D, et al. (2017) Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clinical gastroenterology and hepatology
|
|
15(8), 1248–1255 [<a href="https://pubmed.ncbi.nlm.nih.gov/28286194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28286194</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref5">Naganuma
|
|
M, Aoyama
|
|
N, Suzuki
|
|
Y, et al. (2016) Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. Journal of Crohn’s & colitis
|
|
10(7), 828–36 [<a href="/pmc/articles/PMC4955911/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4955911</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26577683" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26577683</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref6">Naganuma
|
|
M, Aoyama
|
|
N, Tada
|
|
T, et al. (2017) Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. Journal of Gastroenterology, 1–13 [<a href="/pmc/articles/PMC5866841/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5866841</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28779419" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28779419</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref7">Ogata
|
|
H, Aoyama
|
|
N, Mizushima
|
|
S, et al. (2017) Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. Intestinal Research
|
|
15(3), 368–379 [<a href="/pmc/articles/PMC5478762/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5478762</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28670234" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28670234</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref8">Pontes
|
|
C, Vives
|
|
R, Torres
|
|
F, et al. (2014) Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflammatory Bowel Diseases
|
|
20(11), 2004–12 [<a href="https://pubmed.ncbi.nlm.nih.gov/25192498" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25192498</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref9">Probert
|
|
Cs, Dignass
|
|
Au, Lindgren
|
|
S, et al. P (2014) Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. Journal of crohn’s & colitis
|
|
8(3), 200–207 [<a href="https://pubmed.ncbi.nlm.nih.gov/24012063" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24012063</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref10">Rubin
|
|
D, Cohen
|
|
R, Sandborn
|
|
W, et al. (2017) Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. Journal of Crohn’s & colitis
|
|
11(7), 785–791 [<a href="/pmc/articles/PMC5881669/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5881669</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28333362" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28333362</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref11">Sandborn
|
|
Wj, Bosworth
|
|
B, Zakko
|
|
S, et al. (2015) Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology
|
|
148(4), 740–750.e2 [<a href="https://pubmed.ncbi.nlm.nih.gov/25644096" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25644096</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref12">Suzuki
|
|
Y, Iida
|
|
M, Ito
|
|
H, et al. (2016) Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study. Intestinal Research
|
|
14(1), 50–9 [<a href="/pmc/articles/PMC4754523/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4754523</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26884735" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26884735</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref13">Travis
|
|
Sp, Danese
|
|
S, Kupcinskas
|
|
L, et al. (2014) Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut
|
|
63(3), 433–441 [<a href="/pmc/articles/PMC3933176/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3933176</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23436336" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23436336</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref14">Watanabe
|
|
M, Nishino
|
|
H, Sameshima
|
|
Y, et al. (2013) Randomised clinical trial: Evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - A placebo-controlled study. Alimentary Pharmacology and Therapeutics
|
|
38(3), 264–273 [<a href="https://pubmed.ncbi.nlm.nih.gov/23734840" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23734840</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s1.2.ref15">Winter
|
|
H, Krzeski
|
|
P, Heyman
|
|
M, et al. (2014) High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. Journal of pediatric gastroenterology and nutrition
|
|
59(6), 767–772 [<a href="/pmc/articles/PMC4255757/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4255757</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25419597" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25419597</span></a>]</div></li></ol></div><div id="niceng130er.appe.s1.3"><h4>E.1.3. Included studies from top-up search</h4><ol><li><div class="bk_ref" id="niceng130er.appe.s1.3.ref1">Ogata
|
|
H, Yokoyama
|
|
T, Mizushima
|
|
S, et al. (2018) Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. Intestinal Research
|
|
16(2), 255–266 [<a href="/pmc/articles/PMC5934598/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5934598</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29743838" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29743838</span></a>]</div></li></ol></div></div><div id="niceng130er.appe.s2"><h3>E.2. Included economic studies</h3><div id="niceng130er.appe.s2.1"><h4>E.2.1. Included studies from 2013 guideline</h4><ol><li><div class="bk_ref" id="niceng130er.appe.s2.1.ref1">Brereton
|
|
N, Bodger
|
|
K, Kamm
|
|
MA, Hodgkins
|
|
P, Yan
|
|
S, Akehurst
|
|
R. (2010). A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. Journal of Medical Economics, 13(1), 148–161 [<a href="https://pubmed.ncbi.nlm.nih.gov/20141380" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20141380</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s2.1.ref2">Buckland
|
|
A, Bodger
|
|
K. (2008). The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Alimentary Pharmacology & Therapeutics, 28(11), 1287–1296 [<a href="https://pubmed.ncbi.nlm.nih.gov/18808444" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18808444</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s2.1.ref3">Connolly
|
|
MP, Nielsen
|
|
SK, Currie
|
|
CJ, Marteau
|
|
P, Probert
|
|
CS, Travis
|
|
SP. (2009). An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. Journal of Crohn’s and Colitis, 3(3).168–174 [<a href="https://pubmed.ncbi.nlm.nih.gov/21172266" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21172266</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s2.1.ref4">Connolly
|
|
MP, Kuyvenhoven
|
|
JP, Postma
|
|
MJ, Nielsen
|
|
SK. (2014). Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing. Journal of Crohn’s and Colitis, 8(5), 357–362 [<a href="https://pubmed.ncbi.nlm.nih.gov/24094599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24094599</span></a>]</div></li></ol></div></div><div id="niceng130er.appe.s3"><h3>E.3. Additional references</h3><ol><li><div class="bk_ref" id="niceng130er.appe.s3.ref1">Bassi
|
|
A, Dodd
|
|
S, Williamson
|
|
P, Bodger
|
|
K. (2004). Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut, 53(10), 1471–1478 [<a href="/pmc/articles/PMC1774248/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1774248</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15361497" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15361497</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref2">Dias, S, Welton, et al. NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making. 2011; last updated April
|
|
2012; available from <a href="http://www.nicedsu.org.uk" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nicedsu.org.uk</a></div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref3">Dias, S, Welton, et al. NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011; last updated September
|
|
2016; available from <a href="http://www.nicedsu.org.uk" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nicedsu.org.uk</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/27466657" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27466657</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref4">Dias, S, Welton, NJ, et al. NICE DSU Technical Support Document 5: Evidence synthesis in the baseline natural history model. 2011; last updated April
|
|
2012; available from <a href="http://www.nicedsu.org.uk" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nicedsu.org.uk</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/27466660" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27466660</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref5">Dias
|
|
S, Welton
|
|
NJ, et al. (2013). Evidence Synthesis for Decision Making 4: Inconsistency in Networks of Evidence Based on Randomized Controlled Trials. <em>Medical Decision Making</em>. 33(5):641–656. [<a href="/pmc/articles/PMC3704208/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3704208</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23804508" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23804508</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref6">Fenwick
|
|
E, Claxton
|
|
K, Sculpher
|
|
M (2001). Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics. 10(8), 779–87 [<a href="https://pubmed.ncbi.nlm.nih.gov/11747057" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11747057</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref7">Kaltenthaler, E., Tappenden, P., Paisley, S., Squires, H. (2011). NICE DSU Technical Support Document 13: Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models. Available from <a href="http://www.nicedsu.org.uk" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nicedsu.org.uk</a> [<a href="https://pubmed.ncbi.nlm.nih.gov/28481494" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28481494</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref8">Modi
|
|
A, Sen
|
|
S, Adachi
|
|
JD, et al. (2017). Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS). Osteoporosis International, 28(10), 2867–2876 [<a href="/pmc/articles/PMC5624972/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5624972</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28643048" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28643048</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref9">Poole
|
|
CD, Connolly
|
|
MP, Nielsen
|
|
SK, Currie
|
|
CJ, Marteau
|
|
P. (2010). A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. Journal of Crohn’s and Colitis, 4(3), 275–282 [<a href="https://pubmed.ncbi.nlm.nih.gov/21122516" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21122516</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref10">Royal College of Physicians. National clinical audit report of inpatient care for people with ulcerative colitis: adult national report. (2014). UK IBD audit. London: Royal College of Physicians.</div></li><li><div class="bk_ref" id="niceng130er.appe.s3.ref11">Royal College of Physicians. National clinical audit of biological therapies: annual report. (2016). UK inflammatory bowel disease (IBD) audit. London: Royal College of Physicians.</div></li></ol></div><div id="niceng130er.appe.s4"><h3>E.4. Excluded clinical studies</h3><div id="niceng130er.appe.s4.1"><h4>E.4.1. Excluded studies which were included in 2013 guideline</h4><ol><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref1">Andus
|
|
T, Kocjan
|
|
A, Muser
|
|
M, et al. (2008) A novel high-dose 1g mesalamine suppository (Salofalk) is as efficacious as a 500-mg TID suppositories in mild to moderate active ulcerative proctitis: A multicenter, randomized trial. Gastroenterology
|
|
134(4 Suppl 1), T1137</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref2">Andus
|
|
T, Kocjan
|
|
A, Muser
|
|
M, et al. (2010) Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflammatory Bowel Diseases
|
|
16(11), 1947–1956 [<a href="https://pubmed.ncbi.nlm.nih.gov/20310020" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20310020</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref3">Ardizzone
|
|
S, Doldo
|
|
P, Ranzi
|
|
T, et al. (1999) Mesalazine foam (Salofalk (R) foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk (R) enema. Italian Journal of Gastroenterology and Hepatology
|
|
31(8), 677–684 [<a href="https://pubmed.ncbi.nlm.nih.gov/10730559" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10730559</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref4">Baron
|
|
J H, Connell
|
|
A M, Kanaghinis
|
|
T G, et al. (1962) Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. British Medical Journal
|
|
2(5302), 441–443 [<a href="/pmc/articles/PMC1925835/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1925835</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/13865152" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13865152</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref5">Baumgart
|
|
D C, MacDonald
|
|
J K, and Feagan
|
|
B (2008) Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database of Systematic Reviews (3), [<a href="https://pubmed.ncbi.nlm.nih.gov/18646177" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18646177</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref6">Biancone
|
|
L, Gionchetti
|
|
P, Blanco
|
|
G D.V, et al. (2007) Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. Digestive and Liver Disease
|
|
39(4), 329–337 [<a href="https://pubmed.ncbi.nlm.nih.gov/17347061" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17347061</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref7">Cai
|
|
J T, Wu
|
|
L F, Du
|
|
Q, et al. (2001) Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: Randomized controlled Clinical trial. Chinese Journal of Digestion
|
|
21(10), 593–595</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref8">Campieri
|
|
M, Gionchetti
|
|
P, Belluzzi
|
|
A, et al. (1988) 5-Aminosalicylic Acid As Enemas Or Suppositories in Distal Ulcerative-Colitis. Journal of Clinical Gastroenterology
|
|
10(4), 406–409 [<a href="https://pubmed.ncbi.nlm.nih.gov/3418088" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3418088</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref9">Campieri
|
|
M, Gionchetti
|
|
P, Belluzzi
|
|
A, et al. (1991) Sucralfate, 5-Aminosalicylic Acid and Placebo Enemas in the Treatment of Distal Ulcerative-Colitis. European Journal of Gastroenterology & Hepatology
|
|
3(1), 41–44</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref10">Campieri
|
|
M, Paoluzi
|
|
P, Dalbasio
|
|
G, et al. (1993) Better Quality of Therapy with 5-Asa Colonic Foam in Active Ulcerative-Colitis - A Multicenter Comparative Trial with 5-Asa Enema. Digestive Diseases and Sciences
|
|
38(10), 1843–1850 [<a href="https://pubmed.ncbi.nlm.nih.gov/8404405" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8404405</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref11">Cortot
|
|
A, Maetz
|
|
D, Degoutte
|
|
E, Delette
|
|
O, et al. (2008) Mesalamine Foam Enema Versus Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis. American Journal of Gastroenterology
|
|
103(12), 3106–3114 [<a href="https://pubmed.ncbi.nlm.nih.gov/19086960" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19086960</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref12">Danielsson
|
|
A, Hellers
|
|
G, Lyrenas
|
|
E, et al. (1987) A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scandinavian Journal of Gastroenterology
|
|
22(8), 987–992 [<a href="https://pubmed.ncbi.nlm.nih.gov/3317784" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3317784</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref13">Farup
|
|
P G, Hovde
|
|
O, Halvorsen
|
|
F A, et al. (1995) Mesalazine Suppositories Versus Hydrocortisone Foam in Patients with Distal Ulcerative-Colitis - A Comparison of the Efficacy and Practicality of 2 Topical Treatment Regimens. Scandinavian Journal of Gastroenterology
|
|
30(2), 164–170 [<a href="https://pubmed.ncbi.nlm.nih.gov/7732340" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7732340</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref14">Farup
|
|
P G, Hinterleitner
|
|
T A, Lukas
|
|
M, et al. (2001) Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflammatory Bowel Diseases
|
|
7(3), 237–242 [<a href="https://pubmed.ncbi.nlm.nih.gov/11515850" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11515850</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref15">Ferry
|
|
G D, Kirschner
|
|
B S, Grand
|
|
R J, et al. (1993) Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. Journal of Pediatric Gastroenterology and Nutrition
|
|
17(1), 32–38 [<a href="https://pubmed.ncbi.nlm.nih.gov/8102399" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8102399</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref16">Forbes
|
|
A, Al-Damluji
|
|
A, Ashworth
|
|
S, et al. (2005) Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics
|
|
21(9), 1099–1104 [<a href="https://pubmed.ncbi.nlm.nih.gov/15854171" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15854171</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref17">Friedman
|
|
L S, Richter
|
|
J M, Kirkham
|
|
S E, et al. (1986) 5-Aminosalicylic Acid Enemas in Refractory Distal Ulcerative-Colitis - A Randomized, Controlled Trial. American Journal of Gastroenterology
|
|
81(6), 412–418 [<a href="https://pubmed.ncbi.nlm.nih.gov/3518408" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3518408</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref18">Gibson
|
|
P R, Fixa
|
|
B, Pekarkova
|
|
B, et al. (2006) Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Alimentary Pharmacology and Therapeutics
|
|
23(7), 1017–1026 [<a href="https://pubmed.ncbi.nlm.nih.gov/16573804" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16573804</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref19">Green
|
|
J R.B, Lobo
|
|
A J, Holdsworth
|
|
C D, et al. (1998) Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology
|
|
114(1), 15–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/9428213" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9428213</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref20">Hanauer
|
|
S B, Barish
|
|
C, Pambianco
|
|
D, et al. (1996) A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis. Gastroenterology
|
|
110, A921</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref21">Hanauer
|
|
S B, Robinson
|
|
M, Pruitt
|
|
R, et al. (1998) Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study. Gastroenterology
|
|
115(3), 525–532 [<a href="https://pubmed.ncbi.nlm.nih.gov/9721148" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9721148</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref22">Hanauer
|
|
S B, Sandborn
|
|
W J, Dallaire
|
|
C, et al. (2007) Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Canadian Journal of Gastroenterology
|
|
21(12), 827–834 [<a href="/pmc/articles/PMC2658575/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2658575</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18080055" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18080055</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref23">Hartmann
|
|
F, Stein
|
|
J, and BudMesa-Study Group (2010) Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Alimentary Pharmacology and Therapeutics
|
|
32(3), 368–376 [<a href="https://pubmed.ncbi.nlm.nih.gov/20491741" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20491741</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref24">Hiwatashi
|
|
N, Suzuki
|
|
Y, Mitsuyama
|
|
K, et al. (2011) Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology
|
|
46(1), 46–56 [<a href="https://pubmed.ncbi.nlm.nih.gov/20878425" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20878425</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref25">Jewell
|
|
D P, and Truelove
|
|
S C (1974) Azathioprine in Ulcerative-Colitis - Final Report on Controlled Therapeutic Trial. British Medical Journal
|
|
4(5945), 627–630 [<a href="/pmc/articles/PMC1612983/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1612983</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/4441827" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4441827</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref26">Jiang
|
|
X L, and Cui
|
|
H F (2004) Different therapy for different types of ulcerative colitis in China. World Journal of Gastroenterology
|
|
10(10), 1513–1520 [<a href="/pmc/articles/PMC4656295/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4656295</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15133864" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15133864</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref27">Kruis
|
|
W, Kiudelis
|
|
G, Racz
|
|
I, et al. (2009) Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut
|
|
58(2), 233–240 [<a href="/pmc/articles/PMC3269751/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3269751</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18832520" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18832520</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref28">Lamet
|
|
M, Ptak
|
|
T, Dallaire
|
|
C, et al. (2005) Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflammatory Bowel Diseases
|
|
11(7), 625–630 [<a href="https://pubmed.ncbi.nlm.nih.gov/15973115" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15973115</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref29">Lamet
|
|
M (2011) A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. Digestive Diseases and Sciences
|
|
56(2), 513–522 [<a href="/pmc/articles/PMC3029674/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3029674</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20676771" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20676771</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref30">Lee
|
|
F I, Jewell
|
|
D P, Mani
|
|
V, et al. (1996) A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut
|
|
38(2), 229–233 [<a href="/pmc/articles/PMC1383028/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1383028</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8801202" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8801202</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref31">Lemann
|
|
M, Galian
|
|
A, Rutgeerts
|
|
P, et al. (1995) Comparison of Budesonide and 5-Aminosalicylic Acid Enemas in Active Distal Ulcerative-Colitis. Alimentary Pharmacology & Therapeutics
|
|
9(5), 557–562 [<a href="https://pubmed.ncbi.nlm.nih.gov/8580278" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8580278</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref32">Lindgren
|
|
S, Lofberg
|
|
R, Bergholm
|
|
L, et al. (2002) Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scandinavian Journal of Gastroenterology
|
|
37(6), 705–710 [<a href="https://pubmed.ncbi.nlm.nih.gov/12126250" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12126250</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref33">Lofberg
|
|
R, Ostergaard Thomsen
|
|
O, et al. (1994) Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.[Erratum appears in Aliment Pharmacol Ther 1995 Apr;9(2):213]. Alimentary Pharmacology and Therapeutics
|
|
8(6), 623–629 [<a href="https://pubmed.ncbi.nlm.nih.gov/7696452" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7696452</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref34">Marakhouski
|
|
Y, Fixa
|
|
B, Holoman
|
|
J, et al. (2005) A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.[Erratum appears in Aliment Pharmacol Ther. 2005 Mar 15;21(6):793]. Alimentary Pharmacology and Therapeutics
|
|
21(2), 133–140 [<a href="https://pubmed.ncbi.nlm.nih.gov/15679762" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15679762</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref35">Meyers
|
|
S, Sachar
|
|
D B, Present
|
|
D H, et al. (1987) Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology
|
|
93(6), 1255–1262 [<a href="https://pubmed.ncbi.nlm.nih.gov/2890550" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2890550</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref36">Miglioli
|
|
M, Brunetti
|
|
G, Sturniolo
|
|
G C, et al. (1989) Oral 5-ASA (Asacol) in mild ulcerative colitis. A randomized double blind dose ranging trial. Italian Journal of Gastroenterology
|
|
21(1 SUPPL.), 7–8</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref37">Mulder
|
|
C J, Tytgat
|
|
G N, Weterman
|
|
I T, et al. (1988) Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology
|
|
95(6), 1449–1453 [<a href="https://pubmed.ncbi.nlm.nih.gov/2903110" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2903110</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref38">Ogata
|
|
H, Matsui
|
|
T, Nakamura
|
|
M, et al. (2006) A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.[Erratum appears in Gut. 2006 Nov;55(11):1684 Note: Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text]. Gut
|
|
55(9), 1255–1262 [<a href="/pmc/articles/PMC1860021/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1860021</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16484504" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16484504</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref39">Ogata
|
|
H, Kato
|
|
J, Hirai
|
|
F, et al. (2012) Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroidrefractory ulcerative colitis.. Inflammatory Bowel Diseases. 18(5), 803–808 [<a href="https://pubmed.ncbi.nlm.nih.gov/21887732" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21887732</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref40">Oren
|
|
R, Arber
|
|
N, Odes
|
|
S, et al. (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology
|
|
110(5), 1416–1421 [<a href="https://pubmed.ncbi.nlm.nih.gov/8613046" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8613046</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref41">Porro
|
|
G B, Prantera
|
|
C, Campieri
|
|
M, et al. (1994) Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. European Journal of Gastroenterology and Hepatology
|
|
6(2), 125–130</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref42">Powell-Tuck
|
|
J, Bown
|
|
R L, and Lennard-Jones
|
|
J E (1978) A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scandinavian Journal of Gastroenterology
|
|
13(7), 833–837 [<a href="https://pubmed.ncbi.nlm.nih.gov/364626" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 364626</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref43">Powell-Tuck
|
|
J, Macrae
|
|
K D, Healy
|
|
M J.R, et al. (1986) A Defense of the Small Clinical-Trial - Evaluation of 3 Gastroenterological Studies. British Medical Journal
|
|
292(6520), 599–602 [<a href="/pmc/articles/PMC1339576/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1339576</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3081188" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3081188</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref44">Prantera
|
|
C, Viscido
|
|
A, Biancone
|
|
L, et al. (2005) A new oral delivery system for 5-ASA: Preliminary clinical findings for MMx. Inflammatory Bowel Diseases
|
|
11(5), 421–427 [<a href="https://pubmed.ncbi.nlm.nih.gov/15867580" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15867580</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref45">Raedler
|
|
A, Behrens
|
|
C, and Bias
|
|
P (2004) Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. . Alimentary pharmacology & therapeutics
|
|
20(11-12), 1353–1363 [<a href="https://pubmed.ncbi.nlm.nih.gov/15606398" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15606398</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref46">Rijk
|
|
M C.M, and Tongerson
|
|
J H.M (1991) The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis. Gastroenterology
|
|
100, A243</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref47">Rizzello
|
|
F, Gionchetti
|
|
P, Galeazzi
|
|
R, et al. (2001) Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Advances in Therapy
|
|
18(6), 261–271 [<a href="https://pubmed.ncbi.nlm.nih.gov/11841196" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11841196</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref48">Robinson
|
|
M, Gitnick
|
|
G, Balart
|
|
L, et al. (1988) Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology
|
|
84, A381</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref49">Romano
|
|
C, Famiani
|
|
A, Comito
|
|
D, et al. (2010) Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. Journal of Pediatric Gastroenterology and Nutrition
|
|
50(4), 385–389 [<a href="https://pubmed.ncbi.nlm.nih.gov/20179636" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20179636</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref50">Schroeder
|
|
K W, Tremaine
|
|
W J, and Ilstrup
|
|
D M (1987) Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative-Colitis - A Randomized Study. New England Journal of Medicine
|
|
317(26), 1625–1629 [<a href="https://pubmed.ncbi.nlm.nih.gov/3317057" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3317057</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref51">Selby
|
|
W S, Barr
|
|
G D, and Ireland
|
|
A (1985) Olsalazine in active ulcerative colitis. British Medical Journal
|
|
291(6506), 1373–1375 [<a href="/pmc/articles/PMC1418984/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1418984</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3933675" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3933675</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref52">Shivananda
|
|
S, Lennard-Jones
|
|
J, Logan
|
|
R, et al. (1996) Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). . Gut
|
|
39(5), 690–697 [<a href="/pmc/articles/PMC1383393/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1383393</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9014768" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9014768</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref53">Sood
|
|
A, Midha
|
|
V, Sood
|
|
N, et al. (2002) Methylprednisolone acetate versus oral prednisolone in moderately active ulcerative colitis. Indian Journal of Gastroenterology
|
|
21(1), 11–13 [<a href="https://pubmed.ncbi.nlm.nih.gov/11871829" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11871829</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref54">Sood
|
|
A, Kaushal
|
|
V, Midha
|
|
V, et al. (2002) The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. Journal of Gastroenterology
|
|
37(4), 270–274 [<a href="https://pubmed.ncbi.nlm.nih.gov/11993510" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11993510</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref55">Tarpila
|
|
S, Turunen
|
|
U, Seppala
|
|
K, et al. (1994) Budesonide enema in active haemorrhagic proctitis-a controlled trial against hydrocortisone foam enema. Alimentary Pharmacology and Therapeutics
|
|
8(6), 591–595 [<a href="https://pubmed.ncbi.nlm.nih.gov/7696447" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7696447</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref56">van Bodegraven
|
|
A A, Boer
|
|
R O, Lourens
|
|
J, et al. W (1996) Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Alimentary Pharmacology and Therapeutics
|
|
10(3), 327–332 [<a href="https://pubmed.ncbi.nlm.nih.gov/8791959" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8791959</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref57">Williams
|
|
C N, Haber
|
|
G, and Aquino
|
|
J A (1987) Double-Blind, Placebo-Controlled Evaluation of 5-Asa Suppositories in Active Distal Proctitis and Measurement of Extent of Spread Using Tc-99M-Labeled 5-Asa Suppositories. Digestive Diseases and Sciences
|
|
32(12), S71–S75 [<a href="https://pubmed.ncbi.nlm.nih.gov/3319461" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3319461</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref58">Willoughby
|
|
C P, Campieri
|
|
M, and Lanfranchi
|
|
G (1986) 5-Aminosalicylic acid (Pentasa) in enema form for the treatment of active ulcerative colitis. Italian Journal of Gastroenterology
|
|
18(1), 15–17</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.1.ref59">Zinberg
|
|
J, Molinas
|
|
S, and Das
|
|
K M (1990) Double-Blind Placebo-Controlled Study of Olsalazine in the Treatment of Ulcerative-Colitis. American Journal of Gastroenterology
|
|
85(5), 562–566 [<a href="https://pubmed.ncbi.nlm.nih.gov/2337059" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2337059</span></a>]</div></li></ol></div><div id="niceng130er.appe.s4.2"><h4>E.4.2. Excluded studies from 2019 guideline update</h4><ol><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref1">Akobeng
|
|
A K, Zhang
|
|
D, Gordon
|
|
M, et al. (2016) Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database of Systematic Reviews
|
|
2016(9), CD003715 [<a href="/pmc/articles/PMC6457838/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6457838</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27681657" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27681657</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref2">Assche
|
|
G, Manguso
|
|
F, Zibellini
|
|
M, et al. (2015) Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. American journal of gastroenterology
|
|
110(5), 708–715 [<a href="https://pubmed.ncbi.nlm.nih.gov/25869389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25869389</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref3">Assche
|
|
G, Manguso
|
|
F, Zibellini
|
|
M, et al. (2015) Erratum: oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study (American Journal of Gastroenterology (2015) 110 (708-715) DOI: 10.1038/ajg.2015.114). American journal of gastroenterology
|
|
110(6), 943 [<a href="https://pubmed.ncbi.nlm.nih.gov/25869389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25869389</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref4">Balzola
|
|
F, Cullen
|
|
G, Hoentjen
|
|
F, et al. (2013) Randomised clinical trial: Once- Vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Inflammatory Bowel Disease Monitor
|
|
13(4), 160–161</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref5">Chande
|
|
N, Wang
|
|
Y, MacDonald
|
|
J K, et al. (2014) Methotrexate for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews (8), CD006618 [<a href="/pmc/articles/PMC6486224/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6486224</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25162749" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25162749</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref6">Chen
|
|
M (2015) Pentasa enema may be superior to salofalk or glucocorticoid in patients with left-sided active ulcerative colitis. Journal of digestive diseases. 16, 96</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref7">Crispino
|
|
P, Cassieri
|
|
C, Zippi
|
|
M, et al. (2015) Efficacy of mesalazine or beclomethasone dipropionate enema or their combination in patients with distal active ulcerative colitis. Italian journal of medicine. 9, 28 [<a href="https://pubmed.ncbi.nlm.nih.gov/26241537" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26241537</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref8">Cuffari
|
|
C, Pierce
|
|
D, Korczowski
|
|
B, et al. (2016) Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis. Drug design, and development and therapy
|
|
10, 593–607 [<a href="/pmc/articles/PMC4745832/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4745832</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26893546" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26893546</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref9">D’Haens
|
|
Gr, Sandborn
|
|
Wj, Zou
|
|
G, et al. (2017) Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary pharmacology & therapeutics
|
|
46(3), 292–302 [<a href="https://pubmed.ncbi.nlm.nih.gov/28568974" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28568974</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref10">Dhaka
|
|
N, Sharma
|
|
A, Samanta
|
|
J, et al. (2016) Randomized controlled trial comparing the efficacy of measalamine and oral steroids in patients with moderately active ulcerative colitis. Journal of gastroenterology and hepatology (australia). Conference: asia pacific digestive week, and APDW 2016. Japan. Conference start: 20161102. Conference end: 20161105 31, 165</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref11">Flourié
|
|
B, Hagège
|
|
H, Tucat
|
|
G, et al. (2013) Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Alimentary pharmacology & therapeutics
|
|
37(8), 767–775 [<a href="https://pubmed.ncbi.nlm.nih.gov/23451806" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23451806</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref12">Ford
|
|
A, Khan
|
|
K, Achkar
|
|
J, et al. (2012) Efficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis (Structured abstract). American Journal of Gastroenterology
|
|
107(2), 167–176 [<a href="https://pubmed.ncbi.nlm.nih.gov/22108446" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22108446</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref13">Hindryckx
|
|
P, Zou
|
|
G, Feagan
|
|
B, et al. (2017) Biologic drugs for induction and maintenance of remission in Crohn’s disease: a network meta-analysis. Cochrane Database of Systematic Reviews (8),</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref14">Kawakami
|
|
K, Inoue
|
|
T, Murano
|
|
M, et al. (2015) Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World Journal of Gastroenterology
|
|
21(6), 1880–1886 [<a href="/pmc/articles/PMC4323466/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4323466</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25684955" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25684955</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref15">Komaki
|
|
Y, Komaki
|
|
F, Ido
|
|
A, et al. (2016) Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. Journal of Crohn’s & colitis
|
|
10(4), 484–94 [<a href="/pmc/articles/PMC4946757/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4946757</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26645641" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26645641</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref16">Kruis
|
|
W, Brandes
|
|
J W, Schreiber
|
|
S, et al. (1998) Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Alimentary Pharmacology and Therapeutics
|
|
12(8), 707–715 [<a href="https://pubmed.ncbi.nlm.nih.gov/9726382" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9726382</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref17">Lasa
|
|
J, and Olivera
|
|
P (2017) Efficacy of Tacrolimus for Induction of Remission in Patients with Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis. Arquivos de Gastroenterologia
|
|
54(2), 167–172 [<a href="https://pubmed.ncbi.nlm.nih.gov/28327826" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28327826</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref18">Lie
|
|
M R, Kanis
|
|
S L, Hansen
|
|
B E, et al. (2014) Drug therapies for ulcerative proctitis: systematic review and meta-analysis. Inflammatory Bowel Diseases
|
|
20(11), 2157–78 [<a href="https://pubmed.ncbi.nlm.nih.gov/25072502" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25072502</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref19">Manguso
|
|
F, Bennato
|
|
R, Lombardi
|
|
G, et al. (2016) Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS ONE [Electronic Resource]
|
|
11(11), e0166455 [<a href="/pmc/articles/PMC5113024/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5113024</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27846307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27846307</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref20">Mate-Jimenez
|
|
J, Hermida
|
|
C, Cantero-Perona
|
|
J, and Moreno-Otero
|
|
R (2000) 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. European Journal of Gastroenterology and Hepatology
|
|
12(11), 1227–1233 [<a href="https://pubmed.ncbi.nlm.nih.gov/11111780" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11111780</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref21">Nguyen
|
|
G C, Gulamhusein
|
|
A, and Bernstein
|
|
C N (2013) Erratum: 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: A meta-analysis of non-referral populations (American Journal of Gastroenterology (2012) 107 (1298-1304) DOI:10.1038/ajg.2012.198). American Journal of Gastroenterology
|
|
108(2), 292 [<a href="https://pubmed.ncbi.nlm.nih.gov/22751467" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22751467</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref22">Pica
|
|
R, Unim
|
|
H, Cassieri
|
|
C, et al. (2013) Oral beclomethasone dipropionate vs 5-ASA enema in active UC: lower efficacy but better compliance. Journal of gastroenterology and hepatology. 28, 577</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref23">Pica
|
|
R, Cassieri
|
|
C, Cocco
|
|
A, et al. (2015) A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. Digestive & Liver Disease
|
|
47(11), 933–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/26391602" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26391602</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref24">Raskin
|
|
J, Kamm
|
|
M, Jamal
|
|
M, et al. (2014) Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology
|
|
147(4), 793–802 [<a href="https://pubmed.ncbi.nlm.nih.gov/25038431" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25038431</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref25">Rubin
|
|
D T, Bradette
|
|
M, Gabalec
|
|
L, et al. (2016) Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. Journal of Crohn’s & colitis
|
|
10(8), 925–933 [<a href="/pmc/articles/PMC4962361/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4962361</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26908939" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26908939</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref26">Sun
|
|
J, and Yuan
|
|
Y (2016) Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study. Advances in Therapy
|
|
33(3), 410–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/26905266" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26905266</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref27">Turner
|
|
D, Yerushalmi
|
|
B, Kori
|
|
M, et al. (2016) Once versus twice daily mesalazine to induce remission in pediatric ulcerative colitis: an investigator-initiated randomized controlled trial. Journal of pediatric gastroenterology and nutrition. 62, 86–87</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref28">Turner
|
|
D, Yerushalmi
|
|
B, Kori
|
|
M, et al. (2017) Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. Journal of Crohn’s & colitis
|
|
11(5), 527–533 [<a href="https://pubmed.ncbi.nlm.nih.gov/28453754" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28453754</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref29">Van Assche, Gert , Manguso
|
|
Francesco, Zibellini
|
|
Marco, et al. (2015) Corrigendum: Oral Prolonged Release Beclomethasone Dipropionate and Prednisone in the Treatment of Active Ulcerative Colitis: Results From a Double-Blind, Randomized, Parallel Group Study.[Erratum for Am J Gastroenterol. 2015 May;110(5):708-15; PMID: 25869389]. American Journal of Gastroenterology
|
|
110(6), 943 [<a href="https://pubmed.ncbi.nlm.nih.gov/25869389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25869389</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref30">Wang
|
|
J, Shi
|
|
Y, and Liu
|
|
Z (2016) Efficacy of single vs multiple doses of 5-aminosalicylic acid (5-ASA) in the treatment of mild-moderate ulcerative colitis: An open randomized clinical trial. International Journal of Clinical and Experimental Medicine
|
|
9(11), 21654–21662</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref31">Wang
|
|
Y, Parker
|
|
C E, Bhanji
|
|
T, et al. (2016) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews
|
|
4, CD000543 [<a href="/pmc/articles/PMC7045743/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7045743</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27101467" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27101467</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref32">Zeng
|
|
J, Lv
|
|
L, and Mei
|
|
Z C (2017) Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis. Journal of Gastroenterology & Hepatology
|
|
32(3), 558–566 [<a href="https://pubmed.ncbi.nlm.nih.gov/27699863" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27699863</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref33">Zhao
|
|
X, Li
|
|
N, Ren
|
|
Y, et al. (2016) Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS ONE [Electronic Resource]
|
|
11(8), e0160500 [<a href="/pmc/articles/PMC4976912/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4976912</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27501314" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27501314</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref34">Zhao
|
|
Xiaojing, Zhou
|
|
Changcheng, Ma
|
|
Jingjing, et al. (2017) Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. Scientific Reports
|
|
7, 46693 [<a href="/pmc/articles/PMC5404224/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5404224</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28440311" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28440311</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.2.ref35">Zhu
|
|
Y, Tang
|
|
R K, Zhao
|
|
P, et al. (2012) Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. European Journal of Gastroenterology & Hepatology
|
|
24(5), 487–94 [<a href="https://pubmed.ncbi.nlm.nih.gov/22465970" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22465970</span></a>]</div></li></ol></div><div id="niceng130er.appe.s4.3"><h4>E.4.3. Excluded studies from top-up search</h4><ol><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref1">Chande
|
|
N, Wang
|
|
Y, Macdonald
|
|
J K, and McDonald
|
|
J W. D (2014) Methotrexate for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews
|
|
2017(12), CD006618 [<a href="/pmc/articles/PMC6486224/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6486224</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25162749" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25162749</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref2">D’Haens
|
|
G R, Sandborn
|
|
W J, Zou
|
|
G, Stitt
|
|
L W, Rutgeerts
|
|
P J, Gilgen
|
|
D, Jairath
|
|
V, Hindryckx
|
|
P, Shackelton
|
|
L M, Vandervoort
|
|
M K, Parker
|
|
C E, Muller
|
|
C, Pai
|
|
R K, Levchenko
|
|
O, Marakhouski
|
|
Y, Horynski
|
|
M, Mikhailova
|
|
E, Kharchenko
|
|
N, Pimanov
|
|
S, and Feagan
|
|
B G (2017) Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Alimentary Pharmacology & Therapeutics
|
|
46(3), 292–302 [<a href="https://pubmed.ncbi.nlm.nih.gov/28568974" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28568974</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref3">Dignass
|
|
Axel, Schnabel
|
|
Robert, Romatowski
|
|
Jacek, Pavlenko
|
|
Vladimir, Dorofeyev
|
|
Andrey, Derova
|
|
Jelena, Jonaitis
|
|
Laimas, Dilger
|
|
Karin, Nacak
|
|
Tanju, Greinwald
|
|
Roland, and International S A. T. Study Group (2018) Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterology Journal
|
|
6(1), 138–147 [<a href="/pmc/articles/PMC5802664/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5802664</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29435324" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29435324</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref4">Kato
|
|
S, Kani
|
|
K, Kurihara
|
|
H, Ohmori
|
|
T, and Yakabi
|
|
K (2018) Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: a prospective randomised clinical trial (CORRECT study). Journal of crohn’s and colitis. Conference: 13th congress of European crohn’s and colitis organisation, and ECCO 2018. Austria 12(Supplement 1), S434</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref5">Kokkinidis
|
|
D G, Bosdelekidou
|
|
E E, Iliopoulou
|
|
S M, Tassos
|
|
A G, Texakalidis
|
|
P T, Economopoulos
|
|
K P, and Kousoulis
|
|
A A (2017) Emerging treatments for ulcerative colitis: a systematic review. Scandinavian Journal of Gastroenterology
|
|
52(9), 923–931 [<a href="https://pubmed.ncbi.nlm.nih.gov/28503977" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28503977</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref6">Komaki
|
|
Y, Komaki
|
|
F, Micic
|
|
D, Yamada
|
|
A, Suzuki
|
|
Y, and Sakuraba
|
|
A (2017) Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. Journal of Gastroenterology & Hepatology
|
|
32(6), 1143–1151 [<a href="https://pubmed.ncbi.nlm.nih.gov/27957761" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27957761</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref7">Kreijne
|
|
Je, Lie
|
|
Mr, Dijkstra
|
|
G, Lowenberg
|
|
M, Assche
|
|
G, West
|
|
Rl, Noord
|
|
D, Meulen-De Jong
|
|
Aa, Hansen
|
|
Be, Vries
|
|
Ac, and Woude
|
|
Cj (2018) Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trial. Journal of crohn’s and colitis. Conference: 13th congress of european crohn’s and colitis organisation, and ECCO 2018. Austria 12(Supplement 1), S45</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref8">Lasa
|
|
J, Rausch
|
|
A, and Zubiaurre
|
|
I (2018) Efficacy and safety of anti-integrin antibodies in inflammatory bowel disease: Systematic review and meta-analysis. Acta Gastroenterologica Latinoamericana
|
|
48(2), 106–116</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref9">Lawrance
|
|
I C, Baird
|
|
A, Lightower
|
|
D, Radford-Smith
|
|
G, Andrews
|
|
J M, and Connor
|
|
S (2017) Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clinical Gastroenterology & Hepatology
|
|
15(8), 1248–1255 [<a href="https://pubmed.ncbi.nlm.nih.gov/28286194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28286194</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref10">Loftus
|
|
Ev, Sands
|
|
Be, Colombel
|
|
J-F, Dotan
|
|
I, Khalid
|
|
Jm, Tudor
|
|
D, and Geransar
|
|
P (2018) Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: a post hoc analysis of GEMINI 1. Journal of crohn’s and colitis. Conference: 13th congress of european crohn’s and colitis organisation, and ECCO 2018. Austria 12(Supplement 1), S317–s318</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref11">Fang
|
|
WB, and Cai1
|
|
QF (2018) Mesalazine combined with golden bifid for treatment of patients with ulcerative colitis: effect on inflammatory response and anorectal motility. World chinese journal of digestology
|
|
26(10), 594–600</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref12">Perez-Calle
|
|
J L, and Lopez-Serrano
|
|
P (2016) Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulce-rative colitis. Enfermedad Inflamatoria Intestinal al Dia
|
|
15(2), 76–78 [<a href="https://pubmed.ncbi.nlm.nih.gov/26632520" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26632520</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref13">Roblin
|
|
X, Paul
|
|
S, Boschetti
|
|
G, Phelip
|
|
Jm, Tedesco
|
|
E, Berger
|
|
A, Nancey
|
|
S, Williet
|
|
N, and Flourie
|
|
B (2018) Interest in the addition of azathioprine (AZA) to the switch of anti-TNF in IBD patients in loss of response with undetectable anti-TNF trough levels and anti-drug antibodies: a prospective randomised trial. Journal of crohn’s and colitis. Conference: 13th congress of european crohn’s and colitis organisation, and ECCO 2018. Austria 12(Supplement 1), S414–s415</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref14">Rubin
|
|
D T, Cohen
|
|
R D, Sandborn
|
|
W J, Lichtenstein
|
|
G R, Axler
|
|
J, Riddell
|
|
R H, Zhu
|
|
C, Barrett
|
|
A C, Bortey
|
|
E, and Forbes
|
|
W P (2017) Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. Journal of Crohn’s & colitis
|
|
11(7), 785–791 [<a href="/pmc/articles/PMC5881669/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5881669</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28333362" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28333362</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref15">Sherlock
|
|
M E, Macdonald
|
|
J K, Griffiths
|
|
A M, Steinhart
|
|
A H, and Seow
|
|
C H (2015) Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews
|
|
2015(10), CD007698 [<a href="/pmc/articles/PMC9239584/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9239584</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26497719" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26497719</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref16">Simadibrata
|
|
Marcellus, Halimkesuma
|
|
Christopher Christian, and Suwita
|
|
Benedicta Mutiara (2017) Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: an Evidence-based Clinical Review. Acta Medica Indonesiana
|
|
49(4), 363–368 [<a href="https://pubmed.ncbi.nlm.nih.gov/29348389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29348389</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref17">Turner
|
|
Dan, Yerushalmi
|
|
Baruch, Kori
|
|
Michal, Broide
|
|
Efrat, Mozer-Glassberg
|
|
Yael, Shaoul
|
|
Ron, Kolho
|
|
Kaija-Leena, Shteyer
|
|
Eyal, Shamaly
|
|
Hussein, Ledder
|
|
Oren, Cohen
|
|
Shlomi, Peleg
|
|
Sarit, On
|
|
Avi, and Levine
|
|
Arie (2016) Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. Journal of Crohn’s & colitis
|
|
03, 03 [<a href="https://pubmed.ncbi.nlm.nih.gov/28453754" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28453754</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref18">Turner
|
|
D, Yerushalmi
|
|
B, Kori
|
|
M, Broide
|
|
E, Mozer-Glassberg
|
|
Y, Shaoul
|
|
R, Kolho
|
|
K L, Shteyer
|
|
E, Shamaly
|
|
H, Ledder
|
|
O, Cohen
|
|
S, Peleg
|
|
S, On
|
|
A, and Levine
|
|
A (2017) Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. Journal of Crohn’s & colitis
|
|
11(5), 527–533 [<a href="https://pubmed.ncbi.nlm.nih.gov/28453754" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28453754</span></a>]</div></li><li><div class="bk_ref" id="niceng130er.appe.s4.3.ref19">van Gennep , Sara , de Boer , Nanne K, D’Haens
|
|
Geert R, and Lowenberg
|
|
Mark (2017) Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. Inflammatory Bowel Diseases
|
|
24(1), 67–77 [<a href="https://pubmed.ncbi.nlm.nih.gov/29272488" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29272488</span></a>]</div></li></ol></div></div></div><div id="niceng130er.appf"><h2 id="_niceng130er_appf_">Appendix F. Clinical evidence tables</h2><p id="niceng130er.appf.et1"><a href="/books/NBK576848/bin/niceng130er-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (925K)</span></p></div><div id="niceng130er.appg"><h2 id="_niceng130er_appg_">Appendix G. Forest plots - pairwise meta-analysis</h2><div id="niceng130er.appg.s1"><h3>G.1. Clinical remission</h3><div id="niceng130er.appg.s1.1"><h4>G.1.1. Proctitis</h4><div id="niceng130er.appg.s1.1.1"><h5>2 weeks follow-up</h5><div id="niceng130er.appg.s1.1.1.1"><h5>Low-dose oral ASA v topical ASA</h5><div id="niceng130er.appg.fig1" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf1&p=BOOKS&id=576848_niceng130erappgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf1.jpg" alt="Image niceng130erappgf1" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s1.1.1.2"><h5>Topical ASA v placebo</h5><div id="niceng130er.appg.fig2" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf2&p=BOOKS&id=576848_niceng130erappgf2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf2.jpg" alt="Image niceng130erappgf2" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div><div id="niceng130er.appg.s1.1.2"><h5>3 to 4 weeks follow-up</h5><div id="niceng130er.appg.s1.1.2.1"><h5>Low-dose oral ASA v topical ASA</h5><div id="niceng130er.appg.fig3" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf3&p=BOOKS&id=576848_niceng130erappgf3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf3.jpg" alt="Image niceng130erappgf3" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s1.1.2.2"><h5>ASA v placebo</h5><div id="niceng130er.appg.fig4" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf4&p=BOOKS&id=576848_niceng130erappgf4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf4.jpg" alt="Image niceng130erappgf4" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div><div id="niceng130er.appg.s1.1.3"><h5>5 to 8 weeks follow-up</h5><div id="niceng130er.appg.s1.1.3.1"><h5>Low-dose oral ASA v placebo</h5><div id="niceng130er.appg.fig5" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf5&p=BOOKS&id=576848_niceng130erappgf5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf5.jpg" alt="Image niceng130erappgf5" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s1.1.3.2"><h5>Topical ASA v placebo</h5><div id="niceng130er.appg.fig6" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf6&p=BOOKS&id=576848_niceng130erappgf6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf6.jpg" alt="Image niceng130erappgf6" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s1.1.3.3"><h5>Topical immunomodulator (tacrolimus) v placebo</h5><div id="niceng130er.appg.fig7" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf7&p=BOOKS&id=576848_niceng130erappgf7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf7.jpg" alt="Image niceng130erappgf7" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div></div></div><div id="niceng130er.appg.s2"><h3>G.2. Proctosigmoiditis and left-sided</h3><div id="niceng130er.appg.s2.1"><h4>2 weeks follow-up</h4><div id="niceng130er.appg.s2.1.1"><h5>Topical corticosteroid (prednisolone) v placebo</h5><div id="niceng130er.appg.fig8" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf8&p=BOOKS&id=576848_niceng130erappgf8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf8.jpg" alt="Image niceng130erappgf8" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.1.2"><h5>ASA v placebo</h5><div id="niceng130er.appg.fig9" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf9&p=BOOKS&id=576848_niceng130erappgf9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf9.jpg" alt="Image niceng130erappgf9" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div><div id="niceng130er.appg.s2.2"><h4>3 to 4 weeks follow-up</h4><div id="niceng130er.appg.s2.2.1"><h5>Topical ASA v placebo</h5><div id="niceng130er.appg.fig10" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf10&p=BOOKS&id=576848_niceng130erappgf10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf10.jpg" alt="Image niceng130erappgf10" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.2.2"><h5>Topical ASA v topical corticosteroid (prednisolone)</h5><div id="niceng130er.appg.fig11" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf11&p=BOOKS&id=576848_niceng130erappgf11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf11.jpg" alt="Image niceng130erappgf11" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.2.3"><h5>Topical corticosteroid v topical corticosteroid</h5><div id="niceng130er.appg.fig12" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf12&p=BOOKS&id=576848_niceng130erappgf12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf12.jpg" alt="Image niceng130erappgf12" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.2.4"><h5>Low-dose oral ASA v high-dose oral ASA</h5><div id="niceng130er.appg.fig13" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf13&p=BOOKS&id=576848_niceng130erappgf13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf13.jpg" alt="Image niceng130erappgf13" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.2.5"><h5>Low-dose oral ASA v low-dose oral ASA and oral corticosteroid</h5><div id="niceng130er.appg.fig14" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf14&p=BOOKS&id=576848_niceng130erappgf14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf14.jpg" alt="Image niceng130erappgf14" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.2.6"><h5>Low-dose oral ASA v oral corticosteroid (beclomethasone)</h5><div id="niceng130er.appg.fig15" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf15&p=BOOKS&id=576848_niceng130erappgf15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf15.jpg" alt="Image niceng130erappgf15" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.2.7"><h5>Low-dose oral ASA v placebo</h5><div id="niceng130er.appg.fig16" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf16&p=BOOKS&id=576848_niceng130erappgf16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf16.jpg" alt="Image niceng130erappgf16" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div><div id="niceng130er.appg.s2.3"><h4>5 to 8 weeks follow-up</h4><div id="niceng130er.appg.s2.3.1"><h5>Low-dose oral ASA v placebo</h5><div id="niceng130er.appg.fig17" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf17&p=BOOKS&id=576848_niceng130erappgf17.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf17.jpg" alt="Image niceng130erappgf17" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.3.2"><h5>High-dose oral ASA v placebo</h5><div id="niceng130er.appg.fig18" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf18&p=BOOKS&id=576848_niceng130erappgf18.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf18.jpg" alt="Image niceng130erappgf18" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.3.3"><h5>Oral corticosteroid (budesonide) v placebo</h5><div id="niceng130er.appg.fig19" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf19&p=BOOKS&id=576848_niceng130erappgf19.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf19.jpg" alt="Image niceng130erappgf19" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.3.4"><h5>Topical corticosteroid (budesonide) v placebo</h5><div id="niceng130er.appg.fig20" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf20&p=BOOKS&id=576848_niceng130erappgf20.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf20.jpg" alt="Image niceng130erappgf20" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.3.5"><h5>Topical ASA v placebo</h5><div id="niceng130er.appg.fig21" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf21&p=BOOKS&id=576848_niceng130erappgf21.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf21.jpg" alt="Image niceng130erappgf21" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.3.6"><h5>Topical corticosteroid v topical corticosteroid</h5><div id="niceng130er.appg.fig22" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf22&p=BOOKS&id=576848_niceng130erappgf22.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf22.jpg" alt="Image niceng130erappgf22" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.3.7"><h5>Low-dose oral ASA v high-dose oral ASA</h5><div id="niceng130er.appg.fig23" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf23&p=BOOKS&id=576848_niceng130erappgf23.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf23.jpg" alt="Image niceng130erappgf23" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.3.8"><h5>Low-dose oral ASA v low-dose oral ASA and topical ASA</h5><div id="niceng130er.appg.fig24" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf24&p=BOOKS&id=576848_niceng130erappgf24.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf24.jpg" alt="Image niceng130erappgf24" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s2.3.9"><h5>High-dose oral ASA v oral corticosteroid (budesonide)</h5><div id="niceng130er.appg.fig25" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf25&p=BOOKS&id=576848_niceng130erappgf25.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf25.jpg" alt="Image niceng130erappgf25" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div></div><div id="niceng130er.appg.s3"><h3>G.3. Extensive - children</h3><div id="niceng130er.appg.s3.1"><h4>6 weeks follow-up</h4><div id="niceng130er.appg.s3.1.1"><h5>Low-dose oral ASA v high-dose oral ASA</h5><div id="niceng130er.appg.fig26" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf26&p=BOOKS&id=576848_niceng130erappgf26.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf26.jpg" alt="Image niceng130erappgf26" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div></div><div id="niceng130er.appg.s4"><h3>G.4. Extensive – adults</h3><div id="niceng130er.appg.s4.1"><h4>3 to 4 weeks follow-up</h4><div id="niceng130er.appg.s4.1.1"><h5>High-dose oral ASA vs high dose oral ASA + topical ASA</h5><div id="niceng130er.appg.fig27" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf27&p=BOOKS&id=576848_niceng130erappgf27.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf27.jpg" alt="Image niceng130erappgf27" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s4.1.2"><h5>Low-dose oral ASA vs oral corticosteroid</h5><div id="niceng130er.appg.fig28" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf28&p=BOOKS&id=576848_niceng130erappgf28.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf28.jpg" alt="Image niceng130erappgf28" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div><div id="niceng130er.appg.s4.2"><h4>5 to 8 weeks</h4><div id="niceng130er.appg.s4.2.1"><h5>Corticosteroid (budesonide) v placebo</h5><div id="niceng130er.appg.fig29" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf29&p=BOOKS&id=576848_niceng130erappgf29.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf29.jpg" alt="Image niceng130erappgf29" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s4.2.2"><h5>High-dose oral ASA v oral corticosteroid</h5><div id="niceng130er.appg.fig30" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf30&p=BOOKS&id=576848_niceng130erappgf30.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf30.jpg" alt="Image niceng130erappgf30" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s4.2.3"><h5>High-dose oral ASA vs high dose oral ASA + topical ASA</h5><div id="niceng130er.appg.fig31" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf31&p=BOOKS&id=576848_niceng130erappgf31.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf31.jpg" alt="Image niceng130erappgf31" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div><div id="niceng130er.appg.s4.3"><h4>12 weeks follow-up</h4><div id="niceng130er.appg.s4.3.1"><h5>Methotrexate v placebo</h5><div id="niceng130er.appg.fig32" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf32&p=BOOKS&id=576848_niceng130erappgf32.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf32.jpg" alt="Image niceng130erappgf32" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div></div><div id="niceng130er.appg.s5"><h3>G.5. Withdrawal due to adverse events – children</h3><div id="niceng130er.appg.s5.1"><h4>Low-dose oral ASA v high-dose oral ASA</h4><div id="niceng130er.appg.fig33" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf33&p=BOOKS&id=576848_niceng130erappgf33.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf33.jpg" alt="Image niceng130erappgf33" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div><div id="niceng130er.appg.s6"><h3>G.6. Withdrawal due to adverse events – adults</h3><div id="niceng130er.appg.s6.1"><h4>Low-dose ASA v beclomethasone</h4><div id="niceng130er.appg.fig34" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf34&p=BOOKS&id=576848_niceng130erappgf34.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf34.jpg" alt="Image niceng130erappgf34" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s6.2"><h4>Low-dose oral ASA v Placebo</h4><div id="niceng130er.appg.fig35" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf35&p=BOOKS&id=576848_niceng130erappgf35.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf35.jpg" alt="Image niceng130erappgf35" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s6.3"><h4>High-dose oral ASA v Placebo</h4><div id="niceng130er.appg.fig36" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf36&p=BOOKS&id=576848_niceng130erappgf36.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf36.jpg" alt="Image niceng130erappgf36" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s6.4"><h4>Low-dose oral ASA v low-dose oral ASA + oral beclomethasone</h4><div id="niceng130er.appg.fig37" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf37&p=BOOKS&id=576848_niceng130erappgf37.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf37.jpg" alt="Image niceng130erappgf37" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s6.5"><h4>Low-dose oral ASA v high-dose oral ASA</h4><div id="niceng130er.appg.fig38" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf38&p=BOOKS&id=576848_niceng130erappgf38.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf38.jpg" alt="Image niceng130erappgf38" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s6.6"><h4>Oralcorticosteroid (budesonide) v Placebo</h4><div id="niceng130er.appg.fig39" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf39&p=BOOKS&id=576848_niceng130erappgf39.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf39.jpg" alt="Image niceng130erappgf39" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s6.7"><h4>Methotrexate (subcutaneous/IV) versus placebo</h4><div id="niceng130er.appg.fig40" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf40&p=BOOKS&id=576848_niceng130erappgf40.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf40.jpg" alt="Image niceng130erappgf40" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s6.8"><h4>Topical corticosteroid v Placebo</h4><div id="niceng130er.appg.fig41" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf41&p=BOOKS&id=576848_niceng130erappgf41.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf41.jpg" alt="Image niceng130erappgf41" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div><div id="niceng130er.appg.s7"><h3>G.7. Quality of life – adults</h3><div id="niceng130er.appg.s7.1"><h4>Oral corticosteroid (Budesonide) - Placebo (IBD-QOL)</h4><div id="niceng130er.appg.fig42" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf42&p=BOOKS&id=576848_niceng130erappgf42.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf42.jpg" alt="Image niceng130erappgf42" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s7.2"><h4>Low-dose ASA v High-dose ASA (IBDQ)</h4><div id="niceng130er.appg.fig43" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf43&p=BOOKS&id=576848_niceng130erappgf43.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf43.jpg" alt="Image niceng130erappgf43" class="tileshop" title="Click on image to zoom" /></a></div></div></div><div id="niceng130er.appg.s7.3"><h4>High-dose ASA v high-dose oral ASA + topical ASA (EQ5D)</h4><div id="niceng130er.appg.fig44" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf44&p=BOOKS&id=576848_niceng130erappgf44.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappgf44.jpg" alt="Image niceng130erappgf44" class="tileshop" title="Click on image to zoom" /></a></div></div></div></div></div><div id="niceng130er.apph"><h2 id="_niceng130er_apph_">Appendix H. GRADE tables</h2><div id="niceng130er.apph.s1"><h3>H.1. GRADE tables for pairwise evidence</h3><div id="niceng130er.apph.s1.1"><h4>H.1.1. Topical aminosalicylates</h4><div id="niceng130er.apph.s1.1.1"><h5>Topical aminosalicylates versus placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab1"><a href="/books/NBK576848/table/niceng130er.apph.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab1" rid-ob="figobniceng130erapphtab1"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab1/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab1"><a href="/books/NBK576848/table/niceng130er.apph.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab1">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.1.2"><h5>Topical aminosalicylates versus topical corticosteroid</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab2"><a href="/books/NBK576848/table/niceng130er.apph.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab2" rid-ob="figobniceng130erapphtab2"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab2/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab2"><a href="/books/NBK576848/table/niceng130er.apph.tab2/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab2">Table</a></h4></div></div></div></div><div id="niceng130er.apph.s1.2"><h4>H.1.2. Topical immunomodulator</h4><div id="niceng130er.apph.s1.2.1"><h5>Topical immunomodulator (ointment) versus placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab3"><a href="/books/NBK576848/table/niceng130er.apph.tab3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab3" rid-ob="figobniceng130erapphtab3"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab3/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab3/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab3"><a href="/books/NBK576848/table/niceng130er.apph.tab3/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab3">Table</a></h4></div></div></div></div><div id="niceng130er.apph.s1.3"><h4>H.1.3. Topical corticosteroids</h4><div id="niceng130er.apph.s1.3.1"><h5>Topical corticosteroid v placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab4"><a href="/books/NBK576848/table/niceng130er.apph.tab4/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab4" rid-ob="figobniceng130erapphtab4"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab4/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab4/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab4"><a href="/books/NBK576848/table/niceng130er.apph.tab4/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab4">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.3.2"><h5>Topical budesonide (foam) v topical budesonide (enema)</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab5"><a href="/books/NBK576848/table/niceng130er.apph.tab5/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab5" rid-ob="figobniceng130erapphtab5"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab5/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab5/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab5"><a href="/books/NBK576848/table/niceng130er.apph.tab5/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab5">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.3.3"><h5>Topical budesonide (foam) v topical hydrocortisone (foam)</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab6"><a href="/books/NBK576848/table/niceng130er.apph.tab6/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab6" rid-ob="figobniceng130erapphtab6"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab6/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab6/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab6"><a href="/books/NBK576848/table/niceng130er.apph.tab6/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab6">Table</a></h4></div></div></div></div><div id="niceng130er.apph.s1.3.4"><h4>H.1.4. Standard-dose oral aminosalicylates</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab7"><a href="/books/NBK576848/table/niceng130er.apph.tab7/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab7" rid-ob="figobniceng130erapphtab7"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab7/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab7/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab7"><a href="/books/NBK576848/table/niceng130er.apph.tab7/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab7">Table</a></h4></div></div><div id="niceng130er.apph.s1.3.5"><h5>Standard-dose oral aminosalicylates versus topical aminosalicylates</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab8"><a href="/books/NBK576848/table/niceng130er.apph.tab8/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab8" rid-ob="figobniceng130erapphtab8"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab8/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab8/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab8"><a href="/books/NBK576848/table/niceng130er.apph.tab8/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab8">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.3.6"><h5>Standard-dose oral aminosalicylates versus combined standard-dose oral aminosalicylates and topical aminosalicylates</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab9"><a href="/books/NBK576848/table/niceng130er.apph.tab9/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab9" rid-ob="figobniceng130erapphtab9"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab9/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab9/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab9"><a href="/books/NBK576848/table/niceng130er.apph.tab9/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab9">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.3.7"><h5>Standard-dose oral aminosalicylates versus high-dose oral aminosalicylates</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab10"><a href="/books/NBK576848/table/niceng130er.apph.tab10/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab10" rid-ob="figobniceng130erapphtab10"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab10/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab10/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab10"><a href="/books/NBK576848/table/niceng130er.apph.tab10/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab10">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.3.8"><h5>Standard- dose oral aminosalicylates versus oral corticosteroid</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab11"><a href="/books/NBK576848/table/niceng130er.apph.tab11/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab11" rid-ob="figobniceng130erapphtab11"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab11/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab11/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab11"><a href="/books/NBK576848/table/niceng130er.apph.tab11/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab11">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.3.9"><h5>Standard-dose oral aminosalicylates versus combined standard-dose oral aminosalicylates and oral corticosteroid</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab12"><a href="/books/NBK576848/table/niceng130er.apph.tab12/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab12" rid-ob="figobniceng130erapphtab12"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab12/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab12/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab12"><a href="/books/NBK576848/table/niceng130er.apph.tab12/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab12">Table</a></h4></div></div></div></div><div id="niceng130er.apph.s1.4"><h4>H.1.5. High-dose oral aminosalicylates</h4><div id="niceng130er.apph.s1.4.1"><h5>High-dose oral aminosalicylates versus placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab13"><a href="/books/NBK576848/table/niceng130er.apph.tab13/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab13" rid-ob="figobniceng130erapphtab13"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab13/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab13/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab13"><a href="/books/NBK576848/table/niceng130er.apph.tab13/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab13">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.4.2"><h5>High-dose oral aminosalicylates versus oral corticosteroid (budesonide)</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab14"><a href="/books/NBK576848/table/niceng130er.apph.tab14/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab14" rid-ob="figobniceng130erapphtab14"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab14/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab14/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab14"><a href="/books/NBK576848/table/niceng130er.apph.tab14/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab14">Table</a></h4></div></div></div><div id="niceng130er.apph.s1.4.3"><h5>High-dose oral aminosalicylates versus combined high-dose oral aminosalicylates and topical aminosalicylates</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab15"><a href="/books/NBK576848/table/niceng130er.apph.tab15/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab15" rid-ob="figobniceng130erapphtab15"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab15/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab15/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab15"><a href="/books/NBK576848/table/niceng130er.apph.tab15/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab15">Table</a></h4></div></div></div></div><div id="niceng130er.apph.s1.5"><h4>H.1.6. Oral corticosteroids</h4><div id="niceng130er.apph.s1.5.1"><h5>Oral corticosteroids versus placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab16"><a href="/books/NBK576848/table/niceng130er.apph.tab16/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab16" rid-ob="figobniceng130erapphtab16"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab16/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab16/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab16"><a href="/books/NBK576848/table/niceng130er.apph.tab16/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab16">Table</a></h4></div></div></div></div><div id="niceng130er.apph.s1.6"><h4>H.1.7. Methotrexate versus placebo</h4><div id="niceng130er.apph.s1.6.1"><h5>Methotrexate versus placebo</h5><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab17"><a href="/books/NBK576848/table/niceng130er.apph.tab17/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab17" rid-ob="figobniceng130erapphtab17"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab17/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab17/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab17"><a href="/books/NBK576848/table/niceng130er.apph.tab17/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab17">Table</a></h4></div></div></div></div></div><div id="niceng130er.apph.s2"><h3>H.2. GRADE tables for indirect evidence from network meta-analysis</h3><div id="niceng130er.apph.s2.1"><h4>Proctitis</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab18"><a href="/books/NBK576848/table/niceng130er.apph.tab18/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab18" rid-ob="figobniceng130erapphtab18"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab18/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab18/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab18"><a href="/books/NBK576848/table/niceng130er.apph.tab18/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab18">Table</a></h4></div></div></div><div id="niceng130er.apph.s2.2"><h4>Proctosigmoiditis and left-sided</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab19"><a href="/books/NBK576848/table/niceng130er.apph.tab19/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab19" rid-ob="figobniceng130erapphtab19"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab19/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab19/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab19"><a href="/books/NBK576848/table/niceng130er.apph.tab19/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab19">Table</a></h4></div></div></div><div id="niceng130er.apph.s2.3"><h4>Extensive</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab20"><a href="/books/NBK576848/table/niceng130er.apph.tab20/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab20" rid-ob="figobniceng130erapphtab20"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab20/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab20/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab20"><a href="/books/NBK576848/table/niceng130er.apph.tab20/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab20">Table</a></h4></div></div></div><div id="niceng130er.apph.s2.4"><h4>All extents of disease</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erapphtab21"><a href="/books/NBK576848/table/niceng130er.apph.tab21/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erapphtab21" rid-ob="figobniceng130erapphtab21"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.apph.tab21/?report=thumb" src-large="/books/NBK576848/table/niceng130er.apph.tab21/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.apph.tab21"><a href="/books/NBK576848/table/niceng130er.apph.tab21/?report=objectonly" target="object" rid-ob="figobniceng130erapphtab21">Table</a></h4></div></div></div></div></div><div id="niceng130er.appi"><h2 id="_niceng130er_appi_">Appendix I. Network meta-analysis</h2><div id="niceng130er.appi.s1"><h3>I.1. General methods</h3><p>For details of the generic methods adopted for these analyses, please see <a href="#niceng130er.appb">Appendix B</a>:</p><div id="niceng130er.appi.s1.1"><h4>I.1.1. Analyses undertaken</h4><p>For the critical effectiveness outcome of clinical remission, the models were fitted for 3 different extents of disease:
|
|
<ul><li class="half_rhythm"><div>Proctitis</div></li><li class="half_rhythm"><div>Proctosigmoiditis and left-sided</div></li><li class="half_rhythm"><div>Extensive</div></li></ul></p><p>at up to 3 different timepoints (depending on availability of data):
|
|
<ul><li class="half_rhythm"><div>2 weeks</div></li><li class="half_rhythm"><div>0–4 weeks</div></li><li class="half_rhythm"><div>5–8 weeks</div></li></ul></p></div><div id="niceng130er.appi.s1.2"><h4>I.1.2. Synthesis</h4><p>Hierarchical Bayesian Network Meta-Analysis (NMA) was performed using WinBUGS version 1.4.3. The models used reflected the recommendations of the NICE Decision Support Unit’s Technical Support Documents (TSDs) on evidence synthesis, particularly TSD 2 (<a href="http://nicedsu.org.uk/technical-support-documents/technical-support-documents/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">‘A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials’</a>). The WinBUGS code provided in the appendices of TSD 2 was used without substantive alteration to specify synthesis models.</p><p>Results were reported summarising 10,000 samples from the posterior distribution of each model, thinned from 100,000 iterations, having first run and discarded 10,000 ‘burn-in’ iterations (convergence was then checked by visual inspection of trace and BGR plots). Three separate chains with different initial values were used.</p><p>Non-informative prior distributions were used in all models. Unless otherwise specified, trial-specific baselines and treatment effects were assigned Normal (0,10000) priors, and the between-trial standard deviations used in random-effects models were given Uniform(0,5) priors. These are consistent with the recommendations in TSD 2 for dichotomous outcomes. Fixed- and random-effects models were explored for each outcome, with the final choice of model based on deviance information criterion (DIC): if DIC was at least 3 points lower for the random-effects model, it was preferred; otherwise, the fixed-effect model was considered to provide an equivalent fit to the data in a more parsimonious analysis, and was preferred. The goodness-of-fit of each model was assessed using the total residual deviance. This value was compared tothe total number of data points to check if the model fit can be improved. A value closer to the number of data points was preferred.</p><p>Model selection was based on the most evidence available at a time point of analysis and this was undertaken in proctosigmoiditis and left-sided at 5 to 8 weeks.</p><p>For clinical remission, a binomial likelihood and logit link model was fitted for different extents of disease at different clinically important follow-up time points. Using a logit model implies one of the following assumptions: that all people with ulcerative colitis who reach the end-point do so by some specific follow-up time, and further follow-up would make no difference; or that the proportional odds assumption holds. In one network, clinical remission in extensive disease at up to 4 weeks follow-up, the network could not be connected with the evidence available. However, options to connect the network to provide the committee with results were examined. No data was available from extensive disease at a different time-point. The network could be connected by using the relative effectiveness of standard-dose oral aminosalicylate compared to high-dose oral aminosalicylate from proctosigmoiditis and left-sided extent of disease. The committee agreed that this was a reasonable solution as at at the level of relative effects, they believed a similar difference could be expected between low- and high-dose oral aminosalicylates. Further details can be found in <a href="#niceng130er.appi.s3.1.7">I.3.1.7</a>.</p><p>For withdrawal due to adverse events, there was limited evidence available at each clinically important follow-up time, as the majority of studies reported withdrawals at final follow-up. To incorporate all available evidence and comparisons, a binomial likelihood and cloglog link model was fitted for all extents of disease. To account for the different length of follow-up in each trial (data from up to 10 weeks was available), an underlying Poisson process for each trial arm is assumed, with a constant event rate. The assumptions made in this model are, namely, that the hazards are constant over the entire duration of follow-up. This implies homogeneity of the hazard across people with ulcerative colitis in each trial.</p></div></div><div id="niceng130er.appi.s2"><h3>I.2. Model selection</h3><div id="niceng130er.appi.s2.1"><h4>I.2.1. Potential models</h4><p>The main challenge presented by the dataset of included evidence was to identify the most appropriate way of defining the interventions. The data could be subdivided in a variety of different ways to form more or less granular networks of comparisons – i.e. interventions could be ‘lumped’ or ‘split’, according to multiple characteristics. The critical factors were dose, mode of administration, preparation, agent and class – e.g. a 500 mg suppository of Asacol, which is a preparation of mesalazine, which is an aminosalicylate. The committee advised that all these factors could potentially have an influence on probability of remission. However, in order to construct a tractable decision problem, it was agreed that dose could be dichotomised into ‘low’ and ‘high’ categories and that, once this had been done, there was little reason to distinguish between different preparations of the same agent (while, for example, different preparations of mesalazine are known to have different potency, there is broad agreement as to equivalent dosages, so that a ‘low’ or ‘high’ dose of each agent would be expected to have similar effects).</p><p>The remaining characteristics were combined to define 8 models that – provided appropriate data were available – could reasonably be fitted:
|
|
<ul><li class="half_rhythm"><div>01. class level
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. aminosalicylates versus corticosteroids versus placebo</div></li><li class="half_rhythm"><div>all agents, doses and modes of delivery combined</div></li></ul></div></li><li class="half_rhythm"><div>02. drug level
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. mesalazine versus balsalazide versus budesonide</div></li><li class="half_rhythm"><div>all doses and modes of delivery combined</div></li></ul></div></li><li class="half_rhythm"><div>03. dose and class
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. low-dose aminosalicylates versus high-dose aminosalicylates versus corticosteroids</div></li><li class="half_rhythm"><div>all agents and modes of delivery combined</div></li></ul></div></li><li class="half_rhythm"><div>04. dose and drug
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. low-dose mesalazine versus high-dose mesalazine versus high-dose balsalazide versus low-dose budesonide</div></li><li class="half_rhythm"><div>all modes of delivery combined</div></li></ul></div></li><li class="half_rhythm"><div>05. mode of delivery and class
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. oral aminosalicylates versus topical aminosalicylates versus oral corticosteroids versus topical corticosteroids</div></li><li class="half_rhythm"><div>all doses and agents combined</div></li></ul></div></li><li class="half_rhythm"><div>06. mode of delivery and drug
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. oral mesalazine versus topical mesalazine versus oral balsalazide versus oral budesonide versus topical budesonide</div></li><li class="half_rhythm"><div>all doses combined</div></li></ul></div></li><li class="half_rhythm"><div>07. mode of delivery and dose and class
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. low-dose oral aminosalicylates versus high-dose oral aminosalicylates versus low-dose topical aminosalicylates versus low-dose oral corticosteroids versus high-dose topical corticosteroids</div></li><li class="half_rhythm"><div>all agents combined</div></li></ul></div></li><li class="half_rhythm"><div>08. mode of delivery and dose and drug
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. low-dose oral mesalazine versus high-dose oral mesalazine versus low-dose topical mesalazine versus low-dose oral balsalazide versus low-dose oral budesonide versus low-dose topical budesonide</div></li></ul></div></li></ul></p><p>In addition, an expanded mode of delivery model was tested, which expands topical treatments to different topical preparations, including: liquid enema, foam, suppository or ointment. The expanded mode was named mode2 and the following were tested:
|
|
<ul><li class="half_rhythm"><div>09. mode2 and class
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. oral aminosalicylates versus topical (enema) aminosalicylates versus topical (foam) aminosalicylates versus oral corticosteroids versus topical (enema) corticosteroids versus topical (foam) corticosteroids</div></li><li class="half_rhythm"><div>all doses and agents combined</div></li></ul></div></li><li class="half_rhythm"><div>10. mode2 and drug
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. oral mesalazine versus oral balsalazide versus topical (enema) mesalazine versus topical (foam) mesalazine versus oral budesonide versus topical (enema) budesonide versus topical (foam) budesonide</div></li><li class="half_rhythm"><div>all doses combined</div></li></ul></div></li><li class="half_rhythm"><div>11. mode2 and dose and class
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. low-dose oral aminosalicylates versus high-dose oral aminosalicylates versus low-dose topical (enema) aminosalicylates versus low-dose topical (foam) aminosalicylates versus low-dose oral corticosteroids versus high-dose oral corticosteroids versus low-dose topical (enema) corticosteroids versus low-dose topical (foam) corticosteroids</div></li><li class="half_rhythm"><div>all agents combined</div></li></ul></div></li><li class="half_rhythm"><div>12. mode2 and dose and drug
|
|
<ul class="circle"><li class="half_rhythm"><div>e.g. low-dose oral mesalazine versus high-dose oral mesalazine versus low-dose oral balsalazide versus low-dose topical (enema) mesalazine versus low-dose topical (foam) mesalazine versus low-dose oral budesonide versus high-dose oral budesonide versus low-dose topical (enema) budesonide versus low-dose topical (foam) budesonide</div></li></ul></div></li></ul></p><p>In practice, it was not possible to make all these distinctions in all cases. For all classes of treatment other than oral aminosalicylates, there was no meaningful heterogeneity in dosage – that is, all studied drugs could be considered ‘low dose’ (also referred to as ‘standard dose’) – so the distinction was only applied to oral aminosalicylates (at class and drug level). Data constraints meant it was also not possible to explore the appropriateness of analysing oral corticosteroids as a class or at agent level as, while multiple different agents appear at least once in the overall evidence base, individual networks only contained a single option within the class. Therefore, oral corticosteroids were analysed at drug level in all models as were topical corticosteroids for consistency.</p><p>Consideration was given to whether more parsimonious models could be constructed using a meta-regression approach to quantify the shared effect of characteristics across different drugs – e.g. a shared covariate for topical administration that could apply equally to different agents and classes, or a shared effect of dosage that could be assumed to apply across the dataset. However, the committee advised that it would be hard to support such assumptions as, at least at the class level, different mechanisms of action would be expected to interact differently with these overarching factors.</p><p>Consideration was also given to the use of class-level models that allowed an exchangeable effect of agents-within-class. While, in theory, this would have been an attractive approach, in practice, data were much too sparse to be able to identify a class-level heterogeneity parameter, and constraining this parameter with a strongly informative prior was considered no more helpful than testing models assuming independent and identical effects.</p></div><div id="niceng130er.appi.s2.2"><h4>I.2.2. Choosing the best model</h4><p>If plentiful data had been available for each extent of disease and timepoint, it would theoretically have been possible to assess goodness of fit for the different models in every case. In practice, paucity of data made such an approach impossible. Moreover, it would not have been desirable to present different models for different datasets, as it would be difficult to derive coherent recommendations and especially challenging to configure the health economic model to vary its unit of analysis between different extents and/or timepoints. It would also have demanded that up over 200 models would have to be fitted, which was considered impractical.</p><p>Therefore, thorough model selection was undertaken on the largest dataset available (proctosigmoiditis and left-sided disease at 5–8 weeks), and the model identified as optimal was used in all other datasets (although fixed- or random-effects models were fitted and the better choice selected for each network – see <a href="#niceng130er.appb">Appendix B</a>: for general principles for preferring fixed- or random-effects approaches).</p><p>Goodness-of-fit measures for the candidate models are presented in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab1/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab1" rid-ob="figobniceng130erappitab1">Table 11</a>. The following observations can be made:
|
|
<ul><li class="half_rhythm"><div>In simpler models that do not account for mode of delivery and/or dose (01–06, 09–10), the total residual deviance of fixed-effect models is always conspicuously higher than the number of datapoints in the model. Introducing a random-effects term to these models produces results in lower deviance, and the Deviance Information Crierion (DIC) is always superior compared with the analogous fixed-effect model. Once mode of delivery and dose are accounted for (models 07–08, 11–12), fixed-effect models provide a much more acceptable fit to the data, and it is noticeable that the random-effects distribution required to account for any residual heterogeneity becomes much narrower. Therefore, we should only consider models that make these distinctions.</div></li><li class="half_rhythm"><div>There is no evidence that distinguishing between aminosalicylates is desirable. Comparing the random-effects terms for pairs of models (e.g. 05 -v- 06 & 07 -v- 08) shows that no additional heterogeneity is explained in the drug-level analysis. The DIC is somewhat higher for the models that distinguish between drugs, suggesting that the inclusion of this additional information provides no benefit – indeed, it may introduce the risk of overfitting. We also note that, in the most granular analysis available (model 12), there is no evidence of different effect between the 2 aminosalicylates for which evidence is available (mesalazine and balsalazide); indeed, at low dose, the NMA estimates an odds ratio of 1.01 (0.33, 2.75) between the 2 (see cells highlighted in yellow in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab2/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab2" rid-ob="figobniceng130erappitab2">Table 12</a>). For all these reasons, we concluded that it would not be helpful to distinguish between aminosalicylates at the level of individual agents.</div></li><li class="half_rhythm"><div>It is more difficult to discern whether the introduction of an expanded classification of mode of administration (i.e. ‘mode2’ as opposed to ‘mode’) results in a better model. Goodness of fit is very similar between models 07 and 11 (which are the 2 remaining models we would be interested in, given the decisions outlined above). The estimated odds ratio for enema -v- foam in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab2/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab2" rid-ob="figobniceng130erappitab2">Table 12</a> is 2.27 (0.69, 7.61), and we found similar uncertainty in exploratory analyses in other extents of disease – e.g. for proctitis (where topical treatments are more universally used) at 3–4 weeks, aminosalicylate suppositories were associated with an odds ratio of 0.93 (0.19, 4.86) compared with liquid enemas. Given the substantial uncertainty around this point, we concluded that we should not attempt to distinguish between different modes of topical administration, as it was clear that no useful results would be possible.</div></li></ul></p><p>Taking all the above into account, we determined that the optimal model was 07 – that is, treating aminosalicylates as a class (but distinguishing between low- and high-dose oral regimens), and making a distinction between oral and topical modes of administration (but not different types of topical preparation). Having adopted this model, it was clear that the fixed-effect analysis provided a good fit to the data, so there was no need to introduce the additional random-effects term. However, as noted above, this decision was repeated for each analysis in turn when the model was fitted. In practice, fixed-effect models were preferred in every case, either because they demonstrably provided no worse fit to the data than the analogous random-effects analysis or because there were insufficient data to estimate a heterogeneity parameter. The comparison of fixed-effect and random-effect analysis is presented in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab3/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab3" rid-ob="figobniceng130erappitab3">Table 13</a>.</p><p>A similar approach was used for selecting the most appropriate model for withdrawal due to adverse events. No differences were found in topical foam or topical liquid aminosalicylates or drugs. Therefore, a model incorporating mode, dose and class model was fitted. The WinBUGS code used in the model selection process for estimating relative treatment effects is provided below in <a href="#niceng130er.appi.s4">section I.4</a>. Baseline synthesis models to inform the cost-effectiveness analysis are discussed in <a href="#niceng130er.appm">Appendix M</a>.</p><p id="niceng130er.appi.tab1"><a href="/books/NBK576848/table/niceng130er.appi.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erappitab1" class="figpopup">Table 11. Model selection for network meta-analysis</a></p><p id="niceng130er.appi.tab2"><a href="/books/NBK576848/table/niceng130er.appi.tab2/?report=objectonly" target="object" rid-ob="figobniceng130erappitab2" class="figpopup">Table 12. Clinical remission for proctosigmoiditis and left-sided at 5–8 weeks’ follow-up: expanded mode, dose and drug model (FE)</a></p><p id="niceng130er.appi.tab3"><a href="/books/NBK576848/table/niceng130er.appi.tab3/?report=objectonly" target="object" rid-ob="figobniceng130erappitab3" class="figpopup">Table 13. Model selection based on fixed- and random-effects for each model</a></p></div></div><div id="niceng130er.appi.s3"><h3>I.3. Results</h3><div id="niceng130er.appi.s3.1"><h4>I.3.1. Clinical remission</h4><div id="niceng130er.appi.s3.1.1"><h5>I.3.1.1. Proctitis: 2 weeks’ follow-up</h5><p id="niceng130er.appi.fig1"><a href="/books/NBK576848/figure/niceng130er.appi.fig1/?report=objectonly" target="object" rid-ob="figobniceng130erappifig1" class="figpopup">Figure 8. Proctitis; clinical remission at 2 weeks; mode, dose and class – evidence network</a></p><p id="niceng130er.appi.tab4"><a href="/books/NBK576848/table/niceng130er.appi.tab4/?report=objectonly" target="object" rid-ob="figobniceng130erappitab4" class="figpopup">Table 14. Proctitis; clinical remission at 2 weeks; mode, dose and class – input data</a></p><p id="niceng130er.appi.tab5"><a href="/books/NBK576848/table/niceng130er.appi.tab5/?report=objectonly" target="object" rid-ob="figobniceng130erappitab5" class="figpopup">Table 15. Proctitis; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig2"><a href="/books/NBK576848/figure/niceng130er.appi.fig2/?report=objectonly" target="object" rid-ob="figobniceng130erappifig2" class="figpopup">Figure 9. Proctitis; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.tab6"><a href="/books/NBK576848/table/niceng130er.appi.tab6/?report=objectonly" target="object" rid-ob="figobniceng130erappitab6" class="figpopup">Table 16. Proctitis mode, dose and class fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig3"><a href="/books/NBK576848/figure/niceng130er.appi.fig3/?report=objectonly" target="object" rid-ob="figobniceng130erappifig3" class="figpopup">Figure 10. Proctitis; clinical remission at 2 weeks; mode, dose and drug/class; fixed-effect – rank probability histograms </a></p><p id="niceng130er.appi.tab7"><a href="/books/NBK576848/table/niceng130er.appi.tab7/?report=objectonly" target="object" rid-ob="figobniceng130erappitab7" class="figpopup">Table 17. Proctitis mode, dose and class fixed-effect – model fit statistics</a></p></div><div id="niceng130er.appi.s3.1.2"><h5>I.3.1.2. Proctitis: 0 to 4 weeks’ follow-up</h5><p id="niceng130er.appi.fig4"><a href="/books/NBK576848/figure/niceng130er.appi.fig4/?report=objectonly" target="object" rid-ob="figobniceng130erappifig4" class="figpopup">Figure 11. Proctitis; clinical remission at 0–4 weeks; mode, dose and class – evidence network </a></p><p id="niceng130er.appi.tab8"><a href="/books/NBK576848/table/niceng130er.appi.tab8/?report=objectonly" target="object" rid-ob="figobniceng130erappitab8" class="figpopup">Table 18. Proctitis; clinical remission at 0–4 weeks; mode, dose and class – input data</a></p><p id="niceng130er.appi.tab9"><a href="/books/NBK576848/table/niceng130er.appi.tab9/?report=objectonly" target="object" rid-ob="figobniceng130erappitab9" class="figpopup">Table 19. Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig5"><a href="/books/NBK576848/figure/niceng130er.appi.fig5/?report=objectonly" target="object" rid-ob="figobniceng130erappifig5" class="figpopup">Figure 12. Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option </a></p><p id="niceng130er.appi.tab10"><a href="/books/NBK576848/table/niceng130er.appi.tab10/?report=objectonly" target="object" rid-ob="figobniceng130erappitab10" class="figpopup">Table 20. Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig6"><a href="/books/NBK576848/figure/niceng130er.appi.fig6/?report=objectonly" target="object" rid-ob="figobniceng130erappifig6" class="figpopup">Figure 13. Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms</a></p><p id="niceng130er.appi.tab11"><a href="/books/NBK576848/table/niceng130er.appi.tab11/?report=objectonly" target="object" rid-ob="figobniceng130erappitab11" class="figpopup">Table 21. Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – model fit statistics</a></p></div><div id="niceng130er.appi.s3.1.3"><h5>I.3.1.3. Proctitis: 5 to 8 weeks’ follow-up</h5><p id="niceng130er.appi.fig7"><a href="/books/NBK576848/figure/niceng130er.appi.fig7/?report=objectonly" target="object" rid-ob="figobniceng130erappifig7" class="figpopup">Figure 14. Proctitis; clinical remission at 5–8 weeks; mode, dose and class – evidence network</a></p><p id="niceng130er.appi.tab12"><a href="/books/NBK576848/table/niceng130er.appi.tab12/?report=objectonly" target="object" rid-ob="figobniceng130erappitab12" class="figpopup">Table 22. Proctitis; clinical remission at 5–8 weeks; mode, dose and class – input data</a></p><p id="niceng130er.appi.tab13"><a href="/books/NBK576848/table/niceng130er.appi.tab13/?report=objectonly" target="object" rid-ob="figobniceng130erappitab13" class="figpopup">Table 23. Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig8"><a href="/books/NBK576848/figure/niceng130er.appi.fig8/?report=objectonly" target="object" rid-ob="figobniceng130erappifig8" class="figpopup">Figure 15. Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.tab14"><a href="/books/NBK576848/table/niceng130er.appi.tab14/?report=objectonly" target="object" rid-ob="figobniceng130erappitab14" class="figpopup">Table 24. Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig9"><a href="/books/NBK576848/figure/niceng130er.appi.fig9/?report=objectonly" target="object" rid-ob="figobniceng130erappifig9" class="figpopup">Figure 16. Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms</a></p><p id="niceng130er.appi.tab15"><a href="/books/NBK576848/table/niceng130er.appi.tab15/?report=objectonly" target="object" rid-ob="figobniceng130erappitab15" class="figpopup">Table 25. Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – model fit statistics</a></p></div><div id="niceng130er.appi.s3.1.4"><h5>I.3.1.4. Proctosigmoiditis and left-sided: 2 weeks’ follow-up</h5><p id="niceng130er.appi.fig10"><a href="/books/NBK576848/figure/niceng130er.appi.fig10/?report=objectonly" target="object" rid-ob="figobniceng130erappifig10" class="figpopup">Figure 17. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class – evidence network</a></p><p id="niceng130er.appi.tab16"><a href="/books/NBK576848/table/niceng130er.appi.tab16/?report=objectonly" target="object" rid-ob="figobniceng130erappitab16" class="figpopup">Table 26. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class – input data</a></p><p id="niceng130er.appi.tab17"><a href="/books/NBK576848/table/niceng130er.appi.tab17/?report=objectonly" target="object" rid-ob="figobniceng130erappitab17" class="figpopup">Table 27. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig11"><a href="/books/NBK576848/figure/niceng130er.appi.fig11/?report=objectonly" target="object" rid-ob="figobniceng130erappifig11" class="figpopup">Figure 18. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.tab18"><a href="/books/NBK576848/table/niceng130er.appi.tab18/?report=objectonly" target="object" rid-ob="figobniceng130erappitab18" class="figpopup">Table 28. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig12"><a href="/books/NBK576848/figure/niceng130er.appi.fig12/?report=objectonly" target="object" rid-ob="figobniceng130erappifig12" class="figpopup">Figure 19. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – rank probability histograms</a></p><p id="niceng130er.appi.tab19"><a href="/books/NBK576848/table/niceng130er.appi.tab19/?report=objectonly" target="object" rid-ob="figobniceng130erappitab19" class="figpopup">Table 29. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – model fit statistics</a></p></div><div id="niceng130er.appi.s3.1.5"><h5>I.3.1.5. Proctosigmoiditis and left-sided: 0 to 4 weeks’ follow-up</h5><p id="niceng130er.appi.fig13"><a href="/books/NBK576848/figure/niceng130er.appi.fig13/?report=objectonly" target="object" rid-ob="figobniceng130erappifig13" class="figpopup">Figure 20. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class – evidence network</a></p><p id="niceng130er.appi.tab20"><a href="/books/NBK576848/table/niceng130er.appi.tab20/?report=objectonly" target="object" rid-ob="figobniceng130erappitab20" class="figpopup">Table 30. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class - input data</a></p><p id="niceng130er.appi.tab21"><a href="/books/NBK576848/table/niceng130er.appi.tab21/?report=objectonly" target="object" rid-ob="figobniceng130erappitab21" class="figpopup">Table 31. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig14"><a href="/books/NBK576848/figure/niceng130er.appi.fig14/?report=objectonly" target="object" rid-ob="figobniceng130erappifig14" class="figpopup">Figure 21. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.tab22"><a href="/books/NBK576848/table/niceng130er.appi.tab22/?report=objectonly" target="object" rid-ob="figobniceng130erappitab22" class="figpopup">Table 32. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig15"><a href="/books/NBK576848/figure/niceng130er.appi.fig15/?report=objectonly" target="object" rid-ob="figobniceng130erappifig15" class="figpopup">Figure 22. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms</a></p><p id="niceng130er.appi.tab23"><a href="/books/NBK576848/table/niceng130er.appi.tab23/?report=objectonly" target="object" rid-ob="figobniceng130erappitab23" class="figpopup">Table 33. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – model fit statistics</a></p></div><div id="niceng130er.appi.s3.1.6"><h5>I.3.1.6. Proctosigmoiditis and left-sided: 5 to 8 weeks’ follow-up</h5><p id="niceng130er.appi.fig16"><a href="/books/NBK576848/figure/niceng130er.appi.fig16/?report=objectonly" target="object" rid-ob="figobniceng130erappifig16" class="figpopup">Figure 23. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class – evidence network</a></p><p id="niceng130er.appi.tab24"><a href="/books/NBK576848/table/niceng130er.appi.tab24/?report=objectonly" target="object" rid-ob="figobniceng130erappitab24" class="figpopup">Table 34. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class – input data</a></p><p id="niceng130er.appi.tab25"><a href="/books/NBK576848/table/niceng130er.appi.tab25/?report=objectonly" target="object" rid-ob="figobniceng130erappitab25" class="figpopup">Table 35. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig17"><a href="/books/NBK576848/figure/niceng130er.appi.fig17/?report=objectonly" target="object" rid-ob="figobniceng130erappifig17" class="figpopup">Figure 24. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.fig18"><a href="/books/NBK576848/figure/niceng130er.appi.fig18/?report=objectonly" target="object" rid-ob="figobniceng130erappifig18" class="figpopup">Figure 25. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.tab26"><a href="/books/NBK576848/table/niceng130er.appi.tab26/?report=objectonly" target="object" rid-ob="figobniceng130erappitab26" class="figpopup">Table 36. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig19"><a href="/books/NBK576848/figure/niceng130er.appi.fig19/?report=objectonly" target="object" rid-ob="figobniceng130erappifig19" class="figpopup">Figure 26. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms</a></p><p id="niceng130er.appi.tab27"><a href="/books/NBK576848/table/niceng130er.appi.tab27/?report=objectonly" target="object" rid-ob="figobniceng130erappitab27" class="figpopup">Table 37. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – model fit statistics</a></p></div><div id="niceng130er.appi.s3.1.7"><h5>I.3.1.7. Extensive disease in adults: 0 to 4 weeks’ follow-up</h5><p>Examination of available data for extensive disease in adults at 0–4 weeks’ follow-up showed that it was not possible to form a single, connected network of evidence. Two disconnected networks were present: 1 comparing high-dose oral aminosalicylate monotherapy with combined high-dose oral aminosalicylate and topical aminosalicylate, and 1 comparing low-dose oral aminosalicylates with oral prednisolone and oral beclometasone. In order to connect these 2 networks, it was necessary to make an assumption about the relationship between them (see NICE DSU TSD1). The committee advised that, although absolute probabilities of remission are expected to be different between extensive disease and proctosigmoiditis/left-sided disease, at the level of relative effects a similar difference could be expected between low- and high-dose oral aminosalicylates. Therefore, the posterior mean and variance of this contrast from the proctosigmoiditis/left-sided disease NMA (that is, the log-odds ratio of remission with high-dose aminosalicylates, compared with low-dose aminosalicylates) was entered into the network as data (assuming normality on a log-odds scale), enabling the estimation of all other relevant contrasts.</p><p id="niceng130er.appi.fig20"><a href="/books/NBK576848/figure/niceng130er.appi.fig20/?report=objectonly" target="object" rid-ob="figobniceng130erappifig20" class="figpopup">Figure 27. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class – evidence network</a></p><p id="niceng130er.appi.tab28"><a href="/books/NBK576848/table/niceng130er.appi.tab28/?report=objectonly" target="object" rid-ob="figobniceng130erappitab28" class="figpopup">Table 38. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class – input data</a></p><p id="niceng130er.appi.tab29"><a href="/books/NBK576848/table/niceng130er.appi.tab29/?report=objectonly" target="object" rid-ob="figobniceng130erappitab29" class="figpopup">Table 39. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig21"><a href="/books/NBK576848/figure/niceng130er.appi.fig21/?report=objectonly" target="object" rid-ob="figobniceng130erappifig21" class="figpopup">Figure 28. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.tab30"><a href="/books/NBK576848/table/niceng130er.appi.tab30/?report=objectonly" target="object" rid-ob="figobniceng130erappitab30" class="figpopup">Table 40. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig22"><a href="/books/NBK576848/figure/niceng130er.appi.fig22/?report=objectonly" target="object" rid-ob="figobniceng130erappifig22" class="figpopup">Figure 29. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms</a></p><p id="niceng130er.appi.tab31"><a href="/books/NBK576848/table/niceng130er.appi.tab31/?report=objectonly" target="object" rid-ob="figobniceng130erappitab31" class="figpopup">Table 41. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – model fit statistics</a></p></div><div id="niceng130er.appi.s3.1.8"><h5>I.3.1.8. Extensive disease in adults: 5 to 8 weeks’ follow-up</h5><p id="niceng130er.appi.fig23"><a href="/books/NBK576848/figure/niceng130er.appi.fig23/?report=objectonly" target="object" rid-ob="figobniceng130erappifig23" class="figpopup">Figure 30. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class – evidence network</a></p><p id="niceng130er.appi.tab32"><a href="/books/NBK576848/table/niceng130er.appi.tab32/?report=objectonly" target="object" rid-ob="figobniceng130erappitab32" class="figpopup">Table 42. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class – input data</a></p><p id="niceng130er.appi.tab33"><a href="/books/NBK576848/table/niceng130er.appi.tab33/?report=objectonly" target="object" rid-ob="figobniceng130erappitab33" class="figpopup">Table 43. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig24"><a href="/books/NBK576848/figure/niceng130er.appi.fig24/?report=objectonly" target="object" rid-ob="figobniceng130erappifig24" class="figpopup">Figure 31. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.tab34"><a href="/books/NBK576848/table/niceng130er.appi.tab34/?report=objectonly" target="object" rid-ob="figobniceng130erappitab34" class="figpopup">Table 44. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig25"><a href="/books/NBK576848/figure/niceng130er.appi.fig25/?report=objectonly" target="object" rid-ob="figobniceng130erappifig25" class="figpopup">Figure 32. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms</a></p><p id="niceng130er.appi.tab35"><a href="/books/NBK576848/table/niceng130er.appi.tab35/?report=objectonly" target="object" rid-ob="figobniceng130erappitab35" class="figpopup">Table 45. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – model fit statistics</a></p></div></div><div id="niceng130er.appi.s3.2"><h4>I.3.2. Withdrawal due to adverse events</h4><div id="niceng130er.appi.s3.2.1"><h5>I.3.2.1. All extents of disease</h5><p id="niceng130er.appi.fig26"><a href="/books/NBK576848/figure/niceng130er.appi.fig26/?report=objectonly" target="object" rid-ob="figobniceng130erappifig26" class="figpopup">Figure 33. All extents: rate of withdrawal due to adverse events; mode, dose and class – evidence network</a></p><p id="niceng130er.appi.tab36"><a href="/books/NBK576848/table/niceng130er.appi.tab36/?report=objectonly" target="object" rid-ob="figobniceng130erappitab36" class="figpopup">Table 46. All extents: rate of withdrawal due to adverse events; mode, dose and class – input data</a></p><p id="niceng130er.appi.tab37"><a href="/books/NBK576848/table/niceng130er.appi.tab37/?report=objectonly" target="object" rid-ob="figobniceng130erappitab37" class="figpopup">Table 47. All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</a></p><p id="niceng130er.appi.fig27"><a href="/books/NBK576848/figure/niceng130er.appi.fig27/?report=objectonly" target="object" rid-ob="figobniceng130erappifig27" class="figpopup">Figure 34. All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – relative effect of all options versus reference option</a></p><p id="niceng130er.appi.tab38"><a href="/books/NBK576848/table/niceng130er.appi.tab38/?report=objectonly" target="object" rid-ob="figobniceng130erappitab38" class="figpopup">Table 48. All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – rankings for each comparator</a></p><p id="niceng130er.appi.fig28"><a href="/books/NBK576848/figure/niceng130er.appi.fig28/?report=objectonly" target="object" rid-ob="figobniceng130erappifig28" class="figpopup">Figure 35. All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effectfixed-effect – rank probability histograms</a></p><p id="niceng130er.appi.tab39"><a href="/books/NBK576848/table/niceng130er.appi.tab39/?report=objectonly" target="object" rid-ob="figobniceng130erappitab39" class="figpopup">Table 49. All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – model fit statistics</a></p></div></div></div><div id="niceng130er.appi.s4"><h3>I.4. Inconsistency checking</h3><p>Inconsistency, were possible due to the presence of closed loops of direct evidence, was checked by comparing the chosen consistency model to an inconsistency model. No inconsistency was found in any of the models were inconsistency checking was possible.</p></div><div id="niceng130er.appi.s5"><h3>I.5. WinBUGS code</h3><div id="niceng130er.appi.s5.1"><h4>Relative effects clinical remission (fixed-effect)</h4><pre>
|
|
# Binomial likelihood, logit link
|
|
# Fixed-effect model for multi-arm trials
|
|
# based on
|
|
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
|
|
# NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
|
|
# for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011.
|
|
# <a href="http://www.nicedsu.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.nicedsu.org.uk</a>
|
|
|
|
model {
|
|
for(i in 1:NumStudies) { # indexes studies
|
|
mu[i] ~ dnorm(0, .0001) # vague priors for all trial baselines
|
|
for (j in 1:NumArms[i]) { # indexes arms
|
|
k[i,j] ~ dbin(p[i,j],N[i,j]) # binomial likelihood
|
|
logit(p[i,j]) <- mu[i] + d[Rx[i,j]] - d[Rx[i,1]] # model for linear predictor
|
|
rhat[i,j] <- p[i,j] * N[i,j] # expected value of the numerators
|
|
dev[i,j] <- 2 * (k[i,j] * (log(k[i,j])-log(rhat[i,j]))
|
|
+ (N[i,j]-k[i,j]) * (log(N[i,j]-k[i,j]) - log(N[i,j]-rhat[i,j])))
|
|
# deviance contribution
|
|
dummy[i,j] <- ArmNo[i,j] # data not used in this model
|
|
} # close arm loop
|
|
resdev[i] <- sum(dev[i,1:NumArms[i]]) # summed deviance contribution
|
|
dummy2[i] <- Yrs[i] * RefID[i] # data not used in this model
|
|
} # close study loop
|
|
totresdev <- sum(resdev[]) # total residual deviance
|
|
|
|
d[1]<-0 # effect is 0 for reference treatment
|
|
for (j in 2:NumRx) { # indexes treatments
|
|
d[j] ~ dnorm(0, .0001) # vague priors for treatment effects
|
|
} # close treatment loop
|
|
|
|
# Provide estimates of treatment effects T[j] on the natural (probability) scale
|
|
# Given a Mean Effect, meanA, for ‘standard’ treatment A,
|
|
# with precision (1/variance) precA
|
|
|
|
AMean ~ dnorm(meanA, precA)
|
|
APred ~ dnorm(predA, predPrecA)
|
|
for (j in 1:NumRx) {
|
|
logit(Tmean[j]) <- AMean + d[j]
|
|
logit(Tpred[j]) <- APred + d[j]
|
|
}
|
|
|
|
# pairwise ORs and LORs for all possible pair-wise comparisons
|
|
for (c in 1:(NumRx-1)) {
|
|
for (j in (c+1):NumRx) {
|
|
lOR[c,j] <- (d[j]-d[c])
|
|
OR[c,j] <- exp(lOR[c,j])
|
|
}
|
|
}
|
|
|
|
# ranking on relative scale
|
|
for (j in 1:NumRx) {
|
|
rk[j] <- blnHiGood*(NumRx+1-rank(d[],j)) + (1-blnHiGood)*rank(d[],j)
|
|
best[j] <- equals(rk[j],1) # probability that treat j is best
|
|
for (h in 1:NumRx) {
|
|
pRk[h,j] <- equals(rk[j],h) # probability that treat j is hth best
|
|
}
|
|
}
|
|
dummy3 <- YrsA # data not used in this model
|
|
}
|
|
</pre></div><div id="niceng130er.appi.s5.2"><h4>Relative effects clinical remission (random effects)</h4><pre>
|
|
# Binomial likelihood, logit link
|
|
# Random effects model for multi-arm trials
|
|
# based on
|
|
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
|
|
# NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
|
|
# for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011.
|
|
# <a href="http://www.nicedsu.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.nicedsu.org.uk</a>
|
|
|
|
model {
|
|
for(i in 1:NumStudies) { # indexes studies
|
|
mu[i] ~ dnorm(0, .0001) # vague priors for all trial baselines
|
|
delta[i,1] <- 0 # effect is zero for control arm
|
|
w[i,1] <- 0 # multi-arm adjustment = zero for ctrl
|
|
for (j in 1:NumArms[i]) { # indexes arms
|
|
k[i,j] ~ dbin(p[i,j],N[i,j]) # binomial likelihood
|
|
logit(p[i,j]) <- mu[i] + delta[i,j] # model for linear predictor
|
|
rhat[i,j] <- p[i,j] * N[i,j] # expected value of the numerators
|
|
dev[i,j] <- 2 * (k[i,j] * (log(k[i,j])-log(rhat[i,j]))
|
|
+ (N[i,j]-k[i,j]) * (log(N[i,j]-k[i,j]) - log(N[i,j]-rhat[i,j])))
|
|
# deviance contribution
|
|
dummy[i,j] <- ArmNo[i,j] # data not used in this model
|
|
} # close arm loop
|
|
for (j in 2:NumArms[i]) { # indexes arms
|
|
delta[i,j] ~ dnorm(md[i,j],taud[i,j]) # trial-specific LOR distributions
|
|
md[i,j] <- d[Rx[i,j]] - d[Rx[i,1]] + sw[i,j] # mean of LOR distributions (with multi-arm trial correction)
|
|
taud[i,j] <- tau *2*(j-1)/j # precision of LOR distributions (with multi-arm trial correction)
|
|
w[i,j] <- (delta[i,j] - d[Rx[i,j]] + d[Rx[i,1]])
|
|
# adjustment for multi-arm RCTs
|
|
sw[i,j] <- sum(w[i,1:j-1])/(j-1) # cumulative adjustment for multi-arm trials
|
|
}
|
|
resdev[i] <- sum(dev[i,1:NumArms[i]]) # summed deviance contribution
|
|
dummy2[i] <- Yrs[i] * RefID[i] # data not used in this model
|
|
} # close study loop
|
|
totresdev <- sum(resdev[]) # total residual deviance
|
|
|
|
d[1]<-0 # effect is 0 for reference treatment
|
|
for (j in 2:NumRx) { # indexes treatments
|
|
d[j] ~ dnorm(0, .0001) # vague priors for treatment effects
|
|
} # close treatment loop
|
|
sd ~ dunif(RFXpriorParam1, RFXpriorParam2) # uniform between-trial prior
|
|
tau <- pow(sd,-2) # between-trial precision
|
|
|
|
|
|
|
|
# Provide estimates of treatment effects T[k] on the natural (probability) scale
|
|
AMean ~ dnorm(meanA, precA)
|
|
APred ~ dnorm(predA, predPrecA)
|
|
for (j in 1:NumRx) {
|
|
logit(Tmean[j]) <- AMean + d[j]
|
|
logit(Tpred[j]) <- APred + d[j]
|
|
}
|
|
|
|
# pairwise ORs and LORs for all possible pair-wise comparisons
|
|
for (c in 1:(NumRx-1)) {
|
|
for (j in (c+1):NumRx) {
|
|
lOR[c,j] <- (d[j]-d[c])
|
|
OR[c,j] <- exp(d[j]-d[c])
|
|
}
|
|
}
|
|
|
|
# ranking on relative scale
|
|
for (j in 1:NumRx) {
|
|
rk[j] <- blnHiGood*(NumRx+1-rank(d[],j)) + (1-blnHiGood)*rank(d[],j)
|
|
best[j] <- equals(rk[j],1) # probability that treat j is best
|
|
for (h in 1:NumRx) {
|
|
pRk[h,j] <- equals(rk[j],h) # probability that treat j is hth best
|
|
}
|
|
}
|
|
dummy3 <- YrsA # not used in this model
|
|
}
|
|
</pre></div><div id="niceng130er.appi.s5.3"><h4>Relative effects withdrawal due to adverse events (fixed-effect)</h4><pre>
|
|
# Binomial likelihood, cloglog link
|
|
# Random effects model for multi-arm trials
|
|
# based on
|
|
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
|
|
# NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
|
|
# for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011.
|
|
# <a href="http://www.nicedsu.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.nicedsu.org.uk</a>
|
|
|
|
model {
|
|
for(i in 1:NumStudies) { # indexes studies
|
|
mu[i] ~ dnorm(0, .0001) # vague priors for all trial baselines
|
|
for (j in 1:NumArms[i]) { # indexes arms
|
|
k[i,j] ~ dbin(p[i,j],N[i,j]) # binomial likelihood
|
|
cloglog(p[i,j]) <- log(Yrs[i]/1) + mu[i] + d[Rx[i,j]] - d[Rx[i,1]]
|
|
# model for linear predictor
|
|
rhat[i,j] <- p[i,j] * N[i,j] # expected value of the numerators
|
|
dev[i,j] <- 2 * (k[i,j] * (log(k[i,j])-log(rhat[i,j]))
|
|
+ (N[i,j]-k[i,j]) * (log(N[i,j]-k[i,j]) - log(N[i,j]-rhat[i,j])))
|
|
# deviance contribution
|
|
dummy[i,j] <- ArmNo[i,j] # data not used in this model
|
|
} # close arm loop
|
|
resdev[i] <- sum(dev[i,1:NumArms[i]]) # summed deviance contribution
|
|
dummy2[i] <- RefID[i] # data not used in this model
|
|
} # close study loop
|
|
totresdev <- sum(resdev[]) # total residual deviance
|
|
|
|
d[1]<-0 # effect is 0 for reference treatment
|
|
for (j in 2:NumRx) { # indexes treatments
|
|
d[j] ~ dnorm(0, .0001) # vague priors for treatment effects
|
|
} # close treatment loop
|
|
|
|
# Provide estimates of treatment effects T[j] on the natural (probability) scale
|
|
# Given a Mean Effect, meanA, for ‘standard’ treatment A,
|
|
# with precision (1/variance) precA, over a time period timeA
|
|
|
|
AMean ~ dnorm(meanA, precA)
|
|
APred ~ dnorm(predA, predPrecA)
|
|
for (j in 1:NumRx) {
|
|
cloglog(Tmean[j]) <- log(YrsA) + AMean + d[j]
|
|
cloglog(Tpred[j]) <- log(YrsA) + APred + d[j]
|
|
}
|
|
|
|
# pairwise HRs and LHRs for all possible pair-wise comparisons
|
|
for (c in 1:(NumRx-1)) {
|
|
for (j in (c+1):NumRx) {
|
|
lHR[c,j] <- d[j] - d[c]
|
|
log(HR[c,j]) <- lHR[c,j]
|
|
}
|
|
}
|
|
|
|
# ranking on relative scale
|
|
for (j in 1:NumRx) {
|
|
rk[j] <- blnHiGood*(NumRx+1-rank(d[],j)) + (1-blnHiGood)*rank(d[],j)
|
|
best[j] <- equals(rk[j],1) # probability that treat j is best
|
|
for (h in 1:NumRx) {
|
|
pRk[h,j] <- equals(rk[j],h) # probability that treat j is hth best
|
|
}
|
|
}
|
|
}
|
|
</pre></div><div id="niceng130er.appi.s5.4"><h4>Relative effects withdrawal due to adverse events (random effects)</h4><pre>
|
|
# Binomial likelihood, cloglog link
|
|
# Random effects model for multi-arm trials
|
|
# based on
|
|
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
|
|
# NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework
|
|
# for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011.
|
|
# <a href="http://www.nicedsu.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.nicedsu.org.uk</a>
|
|
|
|
model {
|
|
for(i in 1:NumStudies) { # indexes studies
|
|
mu[i] ~ dnorm(0, .0001) # vague priors for all trial baselines
|
|
delta[i,1] <- 0 # effect is zero for control arm
|
|
w[i,1] <- 0 # multi-arm adjustment = zero for ctrl
|
|
for (j in 1:NumArms[i]) { # indexes arms
|
|
k[i,j] ~ dbin(p[i,j],N[i,j]) # binomial likelihood
|
|
cloglog(p[i,j]) <- log(Yrs[i] / 1) + mu[i] + delta[i,j] # model for linear predictor
|
|
rhat[i,j] <- p[i,j] * N[i,j] # expected value of the numerators
|
|
dev[i,j] <- 2 * (k[i,j] * (log(k[i,j])-log(rhat[i,j]))
|
|
+ (N[i,j]-k[i,j]) * (log(N[i,j]-k[i,j]) - log(N[i,j]-rhat[i,j])))
|
|
# deviance contribution
|
|
dummy[i,j] <- ArmNo[i,j] # data not used in this model
|
|
} # close arm loop
|
|
for (j in 2:NumArms[i]) { # indexes arms
|
|
delta[i,j] ~ dnorm(md[i,j],taud[i,j]) # trial-specific LOR distributions
|
|
md[i,j] <- d[Rx[i,j]] - d[Rx[i,1]] + sw[i,j] # mean of LOR distributions (with
|
|
# multi-arm trial correction)
|
|
taud[i,j] <- tau *2*(j-1)/j # precision of LOR distributions (with
|
|
# multi-arm trial correction)
|
|
w[i,j] <- (delta[i,j] - d[Rx[i,j]] + d[Rx[i,1]]) # adjustment for multi-arm RCTs
|
|
sw[i,j] <- sum(w[i,1:j-1])/(j-1) # cumulative adjustment for multi-arm
|
|
# trials
|
|
}
|
|
resdev[i] <- sum(dev[i,1:NumArms[i]]) # summed deviance contribution
|
|
dummy2[i] <- RefID[i] # data not used in this model
|
|
} # close study loop
|
|
totresdev <- sum(resdev[]) # total residual deviance
|
|
|
|
d[1]<-0 # effect is 0 for reference treatment
|
|
for (j in 2:NumRx) { # indexes treatments
|
|
d[j] ~ dnorm(0, .0001) # vague priors for treatment effects
|
|
} # close treatment loop
|
|
sd ~ dunif(RFXpriorParam1, RFXpriorParam2) # uniform between-trial prior
|
|
tau <- pow(sd,-2) # between-trial precision
|
|
|
|
# Provide estimates of treatment effects T[j] on the natural (probability) scale
|
|
# Given a Mean Effect, meanA, for ‘standard’ treatment A,
|
|
# with precision (1/variance) precA, over a time period timeA
|
|
|
|
AMean ~ dnorm(meanA, precA)
|
|
APred ~ dnorm(predA, predPrecA)
|
|
for (j in 1:NumRx) {
|
|
cloglog(Tmean[j]) <- log(YrsA) + AMean + d[j]
|
|
cloglog(Tpred[j]) <- log(YrsA) + APred + d[j]
|
|
}
|
|
|
|
# pairwise HRs and LHRs for all possible pair-wise comparisons
|
|
for (c in 1:(NumRx-1)) {
|
|
for (j in (c+1):NumRx) {
|
|
lHR[c,j] <- d[j] - d[c]
|
|
log(HR[c,j]) <- lHR[c,j]
|
|
}
|
|
}
|
|
|
|
# ranking on relative scale
|
|
for (j in 1:NumRx) {
|
|
rk[j] <- blnHiGood*(NumRx+1-rank(d[],j)) + (1-blnHiGood)*rank(d[],j)
|
|
best[j] <- equals(rk[j],1) # probability that treat j is best
|
|
for (h in 1:NumRx) {
|
|
pRk[h,j] <- equals(rk[j],h) # probability that treat j is hth best
|
|
}
|
|
}
|
|
}
|
|
</pre></div></div></div><div id="niceng130er.appj"><h2 id="_niceng130er_appj_">Appendix J. Economic evidence study selection</h2><div id="niceng130er.appj.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=*The%20de%20novo%20economic%20model%20conducted%20in%20the%202013%20guideline%20was%20reviewed%20in%20addition%20to%20the%20studies%20identified%20through%20the%20search%20of%20the%20published%20literature&p=BOOKS&id=576848_niceng130erappjf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK576848/bin/niceng130erappjf1.jpg" alt="*The de novo economic model conducted in the 2013 guideline was reviewed in addition to the studies identified through the search of the published literature" class="tileshop" title="Click on image to zoom" /></a></div><div class="caption"><p>*The de novo economic model conducted in the 2013 guideline was reviewed in addition to the studies identified through the search of the published literature.</p></div></div></div><div id="niceng130er.appk"><h2 id="_niceng130er_appk_">Appendix K. Economic evidence tables</h2><p id="niceng130er.appk.et1"><a href="/books/NBK576848/bin/niceng130er-appk-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (253K)</span></p></div><div id="niceng130er.appl"><h2 id="_niceng130er_appl_">Appendix L. Health economic analysis</h2><div id="niceng130er.appl.s1"><h3>L.1. Introduction</h3><p>An economic analysis was undertaken in the 2013 Ulcerative colitis guideline to evaluate the cost effectiveness of sequences of pharmacological treatments for the induction of remission of mild-to-moderate left-sided or extensive ulcerative colitis in adults. Since then, new evidence was identified that could affect the 2013 guideline recommendations. This included new randomised controlled trials (RCTs) of treatments that were previously compared in the 2013 cost-effectiveness analysis as well as new RCTs of treatments that were not previously considered.</p><p>In addition to the availability of new evidence, the committee wished to revise the approach to the classification of extent of disease and to update some of the assumptions underpinning the cost-effectiveness model in the 2013 guideline to reflect current practice. Therefore, a decision was made to undertake a new cost-effectiveness analysis to compare sequences of pharmacological treatments for the induction of remission of mild-to-moderate ulcerative colitis drawing on the data from RCTs identified in the clinical evidence review and synthesised using network meta-analysis as described in <a href="#niceng130er.appi">Appendix I</a>.</p></div><div id="niceng130er.appl.s2"><h3>L.2. Methods</h3><div id="niceng130er.appl.s2.1"><h4>L.2.1. Overview</h4><p>A cost–utility analysis was constructed from a UK NHS/personal social services perspective with costs reported in GBP (£) and health outcomes reported as quality-adjusted life years (QALYs).</p></div><div id="niceng130er.appl.s2.2"><h4>L.2.2. Population</h4><p>The cost-effectiveness model in the 2013 guideline considered adults with mild-to-moderate left-sided or extensive ulcerative colitis, defined as greater than 30–40cm from the anal verge. The committee agreed that a revised approach to classification of extent of disease should be adopted based on the following definitions:
|
|
<ul><li class="half_rhythm"><div>proctitis: <15cm</div></li><li class="half_rhythm"><div>proctosigmoiditis and left-sided: 15–50cm</div></li><li class="half_rhythm"><div>extensive: >50cm.</div></li></ul></p><p>The new cost-effectiveness model compares different treatment sequences in adults (18 years and older) for each of the 3 sub-populations listed above. There was insufficient evidence to inform a comparative cost-effectiveness analysis of treatment sequences for any extent of disease in young people and children. Dosing for some of the drugs of interest to the anlaysis differs between adults and children and therefore it was not considered appropriate to do a combined cost-effectiveness analysis.</p></div><div id="niceng130er.appl.s2.3"><h4>L.2.3. Comparators</h4><p>Treatment sequences for the cost-effectiveness model were defined by taking into consideration:
|
|
<ul><li class="half_rhythm"><div>the approach to the economic analysis described in the 2013 guideline</div></li><li class="half_rhythm"><div>the available clinical evidence for different treatments in each extent of disease</div></li><li class="half_rhythm"><div>the committee’s experience of current clinical practice and areas of uncertainty where modelling specific treatment sequences could help inform clinical practice.</div></li></ul></p><p>An initial list of clinically plausible treatment sequences was generated based on the following guidance from the committee:
|
|
<ul><li class="half_rhythm"><div>Aminosalicylates are generally used as first-line treatment in all extents of disease and can be given as oral preparations, topical preparations or a combination of both. The use of oral corticosteroids is generally reserved for later lines of treatment because of cocnerns about side effects. Topical corticosteroids are less commonly used than topical aminosalicylates; however, the committee was unaware of an evidence base for this practice, and agreed that there are circumstances under which it could be reasonable to treat a new episode of active disease with first-line topical corticosteroids (for example, if a person has a history of response to or preference for topical corticosteroids). Therefore, the committee agreed it would be useful to simulate sequences starting with topical corticosteroids in the model for proctosigmoiditis and left-sided disease.</div></li><li class="half_rhythm"><div>For people whose disease does not respond to initial treatment with a topical aminosalicylate, it is common to add an oral aminosalicylate.</div></li><li class="half_rhythm"><div>For people whose disease does not respond to initial treatment with an oral aminosalicylate, options include: 1) increasing the dose (if not already on high dose) 2) adding a topical aminosalicylate preparation 3) adding a corticosteroid.</div></li><li class="half_rhythm"><div>If a person withdraws from treatment with an oral aminosalicylate due to side effects, options include: 1) lowering the dose (if not already on low dose) 2) trying a different aminosalicylate.</div></li><li class="half_rhythm"><div>Sequences should not include more than 1 line of oral corticosteroid treatment before considering rescue therapy.</div></li><li class="half_rhythm"><div>Although placebo was a common comparator in RCTs, the committee did not feel that ‘no treatment’ would be a clinically relevant comparator in the economic model. The analysis does not distinguish between people who are presenting with ulcerative colitis for the first time and those who are experiencing an inflammatory exacerbation. Some people may be receiving maintenance treatment such as an oral aminosalicylate prior to experiencing an inflammatory exacerbation and the committee advised that in clinical practice, people would likely continue this as the backbone of long-term treatment. In addition, the objective of this analysis was to compare different sequences of treatments to induce remission. The analysis did not consider different strategies with respect to the optimal timing of initiating treatment, for example no treatment initially followed by treatment at a later point in time or initial treatment followed by no treatment in people whose disease was still active.</div></li></ul></p><p>The majority (>80%) of RCTs of oral aminosalicylates that were included in the clinical evidence review were of mesalazine preparations. The committee agreed that mesalazine should be the preferred or default aminosalicylate in the cost-effectiveness model but that olsalazine or balsalzide could be considered if a person withdraws from mesalazine treatment due to side effects. In adults, sulfasalazine would generally not be used unless the person also had inflammatory joint disease.</p><p>The committee noted that, in current clinical practice, when oral and topical corticosteroids are used for induction of remission of mild-to-moderate ulcerative colitis, they are generally added to oral aminosalicylate treatment. However, in many RCTs, concomitant treatments were not consistently reported. In the cost-effectiveness model, it was assumed that:
|
|
<ul><li class="half_rhythm"><div>In line with its licensed indication, oral beclometasone would only be used as adjunct treatment to aminosalicylates</div></li><li class="half_rhythm"><div>Other oral corticosteroids (budesonide, prednisolone) and topical corticosteroids (budesonide, prednisolone and hydrocortisone) would also be used in addition to a low-dose oral aminosalicylate unless a person had withdrawn from oral aminosalicylate treatment earlier in the sequence, in which case these drugs would be used alone.</div></li></ul></p><p>These principles only applied in calculating the costs of treatment; it was assumed that the effect of concomitant aminosalicylate therapy would be captured in the RCT evidence.</p><p>Treatment sequences contained up to 4 lines of treatment in proctitis and up to 3 lines of treatment in other extents of disease. In the model, if a person’s disease had not entered remission after 3 or 4 lines of treatment, it was assumed that their disease had progressed to severe ulcerative colitis and that they would receive further treatment as described in the 2013 guideline and NICE technologicy appraisals Infliximab for acute exacerbations of ulcerative colitis (TA163), Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329) and Vedolizumab for treating moderately to severely active ulcerative colitis (TA342). This included IV hydrocortisone as a first step, followed by IV ciclosporin, biological therapy or surgery.</p></div><div id="niceng130er.appl.s2.4"><h4>L.2.4. Structure</h4><p>None of the RCTs included in the evidence review compared sequences of treatments or more than 1 line of treatment for the induction of remission of mild-to-moderate ulcerative colitis. In order to model the cost effectiveness of different treatment sequences, the committee discussed and agreed it was necessary to make a number of key assumptions about the model structure, including:
|
|
<ul><li class="half_rhythm"><div>The probability of a person’s disease entering remission is independent of the line of treatment in which a drug is used.</div></li><li class="half_rhythm"><div>Once a person’s disease enters remission, it is assumed to remain in remission for the duration of the model.</div></li></ul></p><p>The cost-effectiveness model was constructed as a decision tree. For each line of treatment, there are three possible mutually exclusive outcomes:
|
|
<ul><li class="half_rhythm"><div>Withdrawal from treatment due to adverse events; switch to next line of treatment</div></li><li class="half_rhythm"><div>Non-remission; switch to next line of treatment</div></li><li class="half_rhythm"><div>Remission.</div></li></ul></p><p id="niceng130er.appl.fig1"><a href="/books/NBK576848/figure/niceng130er.appl.fig1/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig1" class="figpopup">Figure 36. Structure of the decision tree for a single sequence of treatments</a></p><p>The time-point at which clinical remission was reported varied across the RCTs that were included in the clinical review. To inform assumptions about treatment duration in the cost-effectiveness model, the length of follow-up across RCTs was summarised for each drug and presented to the committee to discuss their relevance to current UK clinical practice. In most cases, the most frequently reported time point for remission that was reported in RCTs was aligned with the duration of treatment in clinical practice except for the following:
|
|
<ul><li class="half_rhythm"><div>Only 1 study (<a class="bibr" href="#niceng130er.appe.s1.1.ref23" rid="niceng130er.appe.s1.1.ref23">Lennard Jones 1960</a>) provided information on remission rates for oral prednisolone in extensive disease; in this study, clinical remission was reported at 4 weeks but the committee agreed this did not reflect current practice and that an 8-week tapering course should be assumed in the model</div></li><li class="half_rhythm"><div>Studies of topical budesonide and topical hydrocortisone ranged from 5 to 8 weeks with the most frequently reported timepoint at 6 weeks, but the committee agreed that the model should assume a 4-week duration for all topical corticosteroids.</div></li><li class="half_rhythm"><div>Only 1 study (<a class="bibr" href="#niceng130er.appe.s1.1.ref34" rid="niceng130er.appe.s1.1.ref34">Vecchi 2001</a>) reported remission rates for low-dose oral mesalazine in combination with topical mesalazine at 6 weeks in people with proctosigmoiditis and left-sided disease; the committee agreed that, in clinical practice, the combination was likely to be given for 8 weeks, which was in line with the duration of treatment for high-dose oral mesalazine in combination with topical mesalazine in extensive disease.</div></li></ul></p><p>In discussing duration of treatment, the committee noted that, for all drugs, response to treatment would generally be assessed earlier than the follow-up durations reported across RCTs so that, in the event of non-response, a decision could be made whether to switch to another drug. It was therefore necessary to make the following additional assumptions:
|
|
<ul><li class="half_rhythm"><div>According to the committee, response to treatment would generally be assessed halfway through a full course of treatment for the induction of remission, at which point people whose disease is not responding to treatment would move to the next line of treatment in the sequence. In the model, for any given line of treatment, it was assumed that the duration of treatment for people in the non-remission branch of the decision tree was half that of people in the remission branch. This assumption is a departure from the approach adopted in the 2013 model, in which people who did not withdraw owing to adverse events were all assumed to undergo treatment of the same duration, regardless of response. The assumption we have adopted for this update has the advantage of reflecting real-world practice, in which people whose disease shows no response to treatment would be very unlikely to complete a full course of equal duration to people whose condition is improving. It has the disadvantage that we are effectively assuming that remission status can be accurately known partway through a full course of treatment. A superior approach would be to model final clinical remission conditional on initial response as a separate outcome; however, while some RCTs report ‘clinical response’ (or a similar outcome that might be usable for this purpose), there were insufficient data reported across the range of treatments and extents of disease needed to make this approach feasible. Similarly, very few RCTs reported remission at multiple timepoints. Given the potential importance of these assumptions, we configured the model to be able to adopt the assumption of equal duration of treatment for remission and non-remission – as per the 2013 model – and tested the impact in sensitivity analysis for all extents of disease.</div></li><li class="half_rhythm"><div>In common with the 2013 model, the new analysis also assumes that people in the remission branch would begin to experience improvements in health status associated with their disease entering remission halfway through a full course of treatment.</div></li><li class="half_rhythm"><div>As adverse events are, on average, likely to emerge relatively early in treatment, the duration of treatment for people in the withdrawal branch of the decision tree was assumed to be half of that of people in the non-remission branch.</div></li><li class="half_rhythm"><div>The model allows for the next line of treatment in a sequence to differ following withdrawal versus non-remission. This flexibility, which represents a departure from the 2013 modelling, is critical to prevent illogical sequences. For example, people discontinuing a low-dose aminosalicylate owing to toxicity would not move to a high dose of the same agent, whereas this is an entirely rational strategy if the switch is made because the person’s disease has not responded to low-dose therapy.</div></li></ul></p><p id="niceng130er.appl.tab1"><a href="/books/NBK576848/table/niceng130er.appl.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erappltab1" class="figpopup">Table 50. Treatment sequences for proctitis</a></p><p id="niceng130er.appl.tab2"><a href="/books/NBK576848/table/niceng130er.appl.tab2/?report=objectonly" target="object" rid-ob="figobniceng130erappltab2" class="figpopup">Table 51. Treatment sequences for proctosigmoiditis and left-sided disease</a></p><p id="niceng130er.appl.tab3"><a href="/books/NBK576848/table/niceng130er.appl.tab3/?report=objectonly" target="object" rid-ob="figobniceng130erappltab3" class="figpopup">Table 52. Treatment sequences for extensive disease</a></p><p>The base-case assumptions about the duration of treatment for each drug in the event of remission, non-remission and withdrawal are summarised in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab4/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab4" rid-ob="figobniceng130erappltab4">Table 53</a> and were applied in all extents of disease. Given these assumptions, the length of the longest treatment sequence (including rescue therapy) was 30 weeks and this was adopted as the time horizon for the cost-effectiveness model. No discounting was applied to either costs or health outcomes as the time horizon was less than 1 year.</p><p id="niceng130er.appl.tab4"><a href="/books/NBK576848/table/niceng130er.appl.tab4/?report=objectonly" target="object" rid-ob="figobniceng130erappltab4" class="figpopup">Table 53. Treatment duration assumptions in the base-case cost-effectiveness analyses</a></p><p>For some drugs, there was a discrepancy between the duration of follow-up reported in RCTs and the assumption about duration of treatment for achieving remission in clinical practice. In the base-case cost-effectiveness analyses, a conservative approach was adopted and drugs were only included if the RCT evidence reported remission at a timepoint that was equal to or less than the assumption about the duration of treatment in clinical practice. For example, the duration of treatment for oral prednisolone was assumed to be 8 weeks while RCT evidence reported remission at 4 weeks and therefore sequences containing oral prednisolone were permitted. However, for topical budesonide and topical hydrocortisone, treatment duration was assumed to be 4 weeks in clinical practice while RCT evidence of remission was only available at 5-8 weeks and therefore sequences containing these drugs were not modelled in the base case. A sensitivity analysis was run in which the duration of treatment was set to the maximum follow-up reported for each drug across all RCTs, allowing for additional sequences with topical budesonide and topical hydrocortisone to be modelled in proctosigmoiditis and left-sided disease.</p></div><div id="niceng130er.appl.s2.5"><h4>L.2.5. Model parameters</h4><div id="niceng130er.appl.s2.5.1"><h5>L.2.5.1. General approach</h5><p>With the exception of remission and withdrawal rates, which were based on the systematic review and network meta-analyses reported in <a href="#niceng130er.appi">Appendix I</a>, parameter inputs were identified by reviewing the economic model in the 2013 guideline and by undertaking informal searches to identify additional sources of information that may have been published since then. The aim of the informal searches was to satisfy the principle of saturation (<a class="bibr" href="#niceng130er.appe.s3.ref7" rid="niceng130er.appe.s3.ref7">Kaltenthaler 2011</a>). Searches were conducted in a variety of general databases, including Medline (via PubMed), Google Scholar and the CEA (Cost-Effectiveness Analysis) Registry. As part of the systematic review of published cost-effectiveness evaluations, articles that did not meet formal inclusion criteria but appeared to be relevant to the decision problem were retrieved and the reference lists of these articles were scanned to identify further sources of inputs for the model.</p></div><div id="niceng130er.appl.s2.5.2"><h5>L.2.5.2. Clinical outcomes</h5><div id="niceng130er.appl.s2.5.2.1"><h5>Baseline estimates for remission and withdrawals due to adverse events</h5><p>The baseline estimates of remission and withdrawals due to adverse events were informed by the reference treatment arms of RCTs in each of the evidence networks described in <a href="#niceng130er.appi">Appendix I</a>. Alternative sources for estimating baseline events were considered, as recommended in NICE DSU TSD5. However, while the epidemiological literature provides some insight into the clinical course of ulcerative colitis with respect to duration of remission and risk of relapse over time, the outcomes of interest to the cost-effectiveness analysis (induction of remission and withdrawal due to adverse events) are more readily characterised within the context of RCTs.</p><p>Low-dose oral aminosalicylate was chosen as the reference treatment because it was the only active treatment that was present in all networks across all time points and extents of disease, with the exception of extensive disease at 5-8 weeks where it was necessary to use high-dose oral aminosalicylate as the reference treatment. Only 1 arm was available to inform the baseline probability of remission in proctitis at 0-4 weeks (<a class="bibr" href="#niceng130er.appe.s1.1.ref11" rid="niceng130er.appe.s1.1.ref11">Gionchetti 1998</a>) and at 5-8 weeks (<a class="bibr" href="#niceng130er.appe.s1.1.ref19" rid="niceng130er.appe.s1.1.ref19">Ito 2010</a>). In all other cases, all available reference treatment arms were included in the pooled estimates presented in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab5/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab5" rid-ob="figobniceng130erappltab5">Table 54</a> (see <a href="#niceng130er.appl.s5">L.5</a> for WinBUGS code used for synthesis).</p><p id="niceng130er.appl.tab5"><a href="/books/NBK576848/table/niceng130er.appl.tab5/?report=objectonly" target="object" rid-ob="figobniceng130erappltab5" class="figpopup">Table 54. Baseline log-rate for withdrawal and log-odds of remission</a></p><p>Due to the sparseness of the evidence networks in proctitis, the baseline odds of remission for low-dose oral aminosalicylates at both 0–4 weeks and 5–8 weeks were estimated on the basis of only one study each. This produced a higher point estimate for the probability of remission at 0–4 weeks (0.414, 95% CI 0.244 to 0.594) than at 5–8 weeks (0.346, 95% CI 0.283 to 0.416). This finding appears at odds with our assumption (and the committee’s expectation) that more people achieve remission as time goes on; however, the substantially overlapping confidence intervals suggest that the result may be explained by simple sampling error. Nevertheless, although the cost-effectiveness model does not rely on direct comparisons of baseline events between timepoints, in order to improve coherence of model inputs, an additional constraint was applied in probabilistic sensitivity analysis that required the baseline probability of remission at 5–8 weeks to be equal to or greater than the baseline probability of remission at 0–4 weeks.</p></div><div id="niceng130er.appl.s2.5.2.2"><h5>Relative treatment effects for remission</h5><p>Where there was information on remission rates for more than 1 drug of the same class at the same timepoint in the same extent of disease, different models were tested to determine if there was any statistical benefit to accounting for heterogeneity at the individual drug level, by mode of administration and by dose (<a href="#niceng130er.appb">Appendix B</a> and <a href="#niceng130er.appi">I</a>). In proctosigmoiditis and left-sided disease, where the largest number of studies was identified, no statistical differences between topical aminosalicylate preparations were found and therefore remission rates were modelled at the class level. Oral aminosalicylates were divided into low-dose and high-dose regimens (used alone or in combination) and analysed at the class level. These class-level effects for aminosalicylates were assumed to also apply to other timepoints and other extents of disease.</p><p>To maximise the amount of data informing the economic model, estimates of relative effects were based on the results of the relevant network meta-analyses for 0-4 weeks and 5-8 weeks in each extent of disease. Given the available evidence, it was not possible to directly establish whether a class-level effect could also be applied to corticosteroids, because the individual drugs within the class were not all connected in a common network. For topical corticosteroids, information on remission rates was available for prednisolone at 0–4 weeks and for budesonide and hydrocortisone at 5–8 weeks in proctosigmoiditis and left-sided disease. For oral corticosteroids, information on remission rates was available for beclomestasone at 0–4 weeks and budesonide at 5–8 weeks in proctosigmoiditis and left-sided disease and for prednisolone at 0–4 weeks in extensive disease. Therefore, in the cost-effectiveness analyses it was necessary to model remission rates for topical and oral corticosteroids at the level of the individual drugs.</p><p>In several cases, there was no information available from RCTs to estimate remission rates for a given drug in a specific extent of disease at a specific time point where the committee was interested in including that drug as part of a treatment sequence. This was particularly relevant in the following cases:
|
|
<ul><li class="half_rhythm"><div>There was only 1 study (<a class="bibr" href="#niceng130er.appe.s1.1.ref23" rid="niceng130er.appe.s1.1.ref23">Lennard Jones 1960</a>) in the evidence review that provided data on remission rates for oral prednisolone. This study was a comparison of oral prednisolone and low-dose sulfasalazine in extensive disease and reported remission rates at 4 weeks. Given the role of oral prednisolone in clinical practice, the committee felt it was important to model sequences containing predinsolone in all extents of disease.</div></li><li class="half_rhythm"><div>In proctitis, the evidence review did not identify any studies of topical corticosteroids, oral corticosteroids or combination treatment with an oral and topical aminosalicylate, but the committee felt all of these would be relevant options.</div></li></ul></p><p>To address these gaps, we configured the cost-effectiveness model to be able to borrow information on relative effectiveness from elsewhere in the evidence base according to the following hierarchy:
|
|
<ul><li class="half_rhythm"><div>from an earlier timepoint in the same extent of disease or, failing that,</div></li><li class="half_rhythm"><div>from the same timepoint in a greater extent of disease or, failing that,</div></li><li class="half_rhythm"><div>from an earlier timepoint in a greater extent of disease.</div></li></ul></p><p>This was considered to be a conservative approach because it was assumed that, all other things equal, the relative effectiveness of a drug could be expected to be the same or lower at an earlier timepoint in a greater extent of disease.</p></div><div id="niceng130er.appl.s2.5.2.3"><h5>Relative treatment effects for withdrawal</h5><p>Not all RCTs identified in the evidence review reported withdrawal rates due to adverse events. There were insufficient data to inform withdrawal rates by extent of disease for all drugs. Therefore, it was necessary to combine withdrawal data from all studies into a single network that was used to inform the cost-effectiveness analyses for all extents of disease. The committee agreed that this was a reasonable approach, based on their experience that extent of disease has much less influence on tolerability than on effectiveness.</p><p>No studies reported information on withdrawal due to adverse events for oral prednisolone, topical prednisolone, topical hydrocortisone or topical tacrolimus. Where possible, assumptions about withdrawal due to adverse events were borrowed from another drug of the same class and mode of administration. For example, an assumption was made that oral prednisolone would have the same rate of withdrawal as oral budesonide, which reported the highest point-estimate for withdrawal out of the oral corticosteroids in the network meta-analysis (<a href="#niceng130er.appi">Appendix I</a>). Topical prednisolone and topical hydrocortisone were assigned the same withdrawal rate as topical budesonide. However, as topical tacrolimus was the only immunomodulator in the analysis, it was assumed to have the same withdrawal rate as topical aminosalicylates. Uncertainty surrounding estimates of withdrawal rates was explored in probabilistic sensitivity analysis.</p></div><div id="niceng130er.appl.s2.5.2.4"><h5>Calculating probability of remission conditional on non-withdrawal</h5><p>The results of the network meta-analyses are summarised in <a href="#niceng130er.appi">Appendix I</a> with remission rates presented as odds ratios and withdrawal rates as hazard ratios. As withdrawal, remission and non-remission are treated as mutually exclusive events, the following approach was used to calculate the probability of remission and non-remission conditional on non-withdrawal from treatment in the cost-effectiveness model:</p><div id="niceng130er.appl.s2.5.2.4.1"><h5>Probability of withdrawal</h5><p><i>BH</i> and <i>HR</i> are the baseline hazard and treatment-specific hazard ratio for withdrawal due to adverse events; let θ<sub><i>w</i></sub> denote the treatment-specific instantaneous rate of withdrawal on a log scale and <i>P</i><sub><i>w</i></sub> the probability of withdrawal (assuming a constant rate) over time period <i>t</i>. Then:
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="niceng130er.appl.deq1"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="niceng130er.appl.eq1" display="block"><mtable><mtr><mtd><msub><mi>θ</mi><mi>w</mi></msub><mo>=</mo><mtext mathvariant="italic">ln</mtext><mrow><mo>[</mo><mrow><mtext mathvariant="italic">BH</mtext></mrow><mo>]</mo></mrow><mo>+</mo><mtext mathvariant="italic">ln</mtext><mrow><mo>[</mo><mrow><mtext mathvariant="italic">HR</mtext></mrow><mo>]</mo></mrow></mtd></mtr><mtr><mtd><msub><mi>P</mi><mi>w</mi></msub><mo>=</mo><mn>1</mn><mo>−</mo><mtext mathvariant="italic">exp</mtext><mrow><mo>[</mo><mrow><mo>−</mo><mtext mathvariant="italic">exp</mtext><mrow><mo>(</mo><mrow><msub><mi>θ</mi><mi>w</mi></msub></mrow><mo>)</mo></mrow><mo>*</mo><mi>t</mi></mrow><mo>]</mo></mrow></mtd></mtr></mtable></math>
|
|
</div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div></p></div><div id="niceng130er.appl.s2.5.2.4.2"><h5>Probability of remission</h5><p><i>BO</i> and <i>OR</i> are the baseline odds of remission and the treatment-specific odds of remission; let θ<sub><i>r</i></sub> denote the treatment-specific log odds for remission and <i>P</i><sub><i>r</i></sub> the probability of remission. Then:
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="niceng130er.appl.deq2"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="niceng130er.appl.eq2" display="block"><mtable><mtr><mtd><msub><mi>θ</mi><mi>r</mi></msub><mo>=</mo><mtext mathvariant="italic">ln</mtext><mrow><mo>[</mo><mrow><mtext mathvariant="italic">BO</mtext></mrow><mo>]</mo></mrow><mo>+</mo><mtext mathvariant="italic">ln</mtext><mrow><mo>[</mo><mrow><mtext mathvariant="italic">OR</mtext></mrow><mo>]</mo></mrow></mtd></mtr><mtr><mtd><msub><mi>P</mi><mi>r</mi></msub><mo>=</mo><mfrac><mrow><mtext mathvariant="italic">exp</mtext><mrow><mo>[</mo><mrow><msub><mi>θ</mi><mi>r</mi></msub></mrow><mo>]</mo></mrow></mrow><mrow><mn>1</mn><mo>+</mo><mtext mathvariant="italic">exp</mtext><mrow><mo>[</mo><mrow><msub><mi>θ</mi><mi>r</mi></msub></mrow><mo>]</mo></mrow></mrow></mfrac></mtd></mtr></mtable></math>
|
|
</div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div></p><p>Let <i>P</i><sub><i>r|w</i><sup><i>c</i></sup></sub> denote the probability of remission conditional on non-withdrawal. Then:
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="niceng130er.appl.deq3"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="niceng130er.appl.eq3" display="block"><mrow><msub><mi>P</mi><mrow><mi>r</mi><mo>|</mo><msup><mi>w</mi><mi>c</mi></msup></mrow></msub><mo>=</mo><msub><mi>P</mi><mi>r</mi></msub><mo>*</mo><mrow><mo>[</mo><mrow><mn>1</mn><mo>−</mo><msub><mi>P</mi><mi>W</mi></msub></mrow><mo>]</mo></mrow></mrow></math>
|
|
</div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div>
|
|
</p><p>Let <i>P</i><sub><i>nr|w</i><sup><i>c</i></sup></sub> denote the probability of non-remission conditional on non-withdrawal. Then:
|
|
<div class="pmc_disp_formula whole_rhythm clearfix" id="niceng130er.appl.deq4"><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow twelve_col"><math id="niceng130er.appl.eq4" display="block"><mrow><msub><mi>P</mi><mrow><mtext mathvariant="italic">nr</mtext><mo>|</mo><msup><mi>w</mi><mi>c</mi></msup></mrow></msub><mo>=</mo><mn>1</mn><mo>−</mo><mrow><mo>(</mo><mrow><msub><mi>P</mi><mi>W</mi></msub><mo>+</mo><msub><mi>P</mi><mrow><mi>r</mi><mo>|</mo><msup><mi>w</mi><mi>c</mi></msup></mrow></msub></mrow><mo>)</mo></mrow></mrow></math>
|
|
</div><div class="inline_block pmc_inline_block pmc_va_middle pmc_hide_overflow last bk_equ_label "><div><span class="nowrap"></span></div></div></div>
|
|
</p><p>An alternate approach to estimating the probability of remission conditional on nonwithdrawal would have been to fit a conditional logistic regression model in the network meta-analysis using RCTs that reported both outcomes. However, as such studies formed a minority of the available RCTs, it would be unduly wasteful to discard all the other evidence. We recognise that the approach described above biases the remission probabilities downward by a small amount; however, because withdrawal rates are generally low for all treatments, we concluded that the bias that would be introduced to the analysis by treating the probabilities as sequential and conditional would be relatively minor and would be by nature conservative. An additional alternative would have been to treat the probabilities as independent; this would have had the advantage of not biasing the point-estimate for remission downwards; however, it would have been necessary to introduce an artificial constraint to prevent probabilities summing to >1 in probabilistic sampling, which would bias results in a much more unpredictable way.</p><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab6/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab6" rid-ob="figobniceng130erappltab6">Table 55</a> summarises the absolute probabilities of withdrawal and of remission and non-remission conditional on non-withdrawal used in the base case cost-effectiveness analyses.</p><p id="niceng130er.appl.tab6"><a href="/books/NBK576848/table/niceng130er.appl.tab6/?report=objectonly" target="object" rid-ob="figobniceng130erappltab6" class="figpopup">Table 55. Absolute probabilities of withdrawal due to adverse events and remission and non-remission conditional on non-withdrawal</a></p></div></div></div><div id="niceng130er.appl.s2.5.3"><h5>L.2.5.3. Health-state utilities</h5><p>Health-state utility values were sourced from published literature in order to estimate QALYs in the cost-effectiveness model. Utility values reflecting active mild-to-moderate disease, remission and severe relapse were taken from <a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole (2010)</a>, which mapped disease severity measured in 2 RCTs using the Ulcerative Colitis Disease Activity Index (UCDAI) to the EQ-5D.</p><p>In the cost-effectiveness model, a proportion of patients were assumed to withdraw from treatment due to adverse events. A search of the published literature did not identify any utility values that quantified the impact of treatment-specific adverse events on quality of life in ulcerative colitis patients. Instead, an estimate of the disutility associated with the use of systemic corticosteroids across a variety of medical conditions was obtained from Sullivan (2016). According to the Summary Product of Characteristics for oral mesalazine, the most common side effects reported are gastrointestinal, including nausea, diarrhoea and abdominal pain. Therefore, an estimate of the disutility associated with gastrointestinal side effects of treatments for osteoporosis served as a proxy for the disutility associated with withdrawal from oral aminosalicylates (<a class="bibr" href="#niceng130er.appe.s3.ref8" rid="niceng130er.appe.s3.ref8">Modi 2017</a>).</p><p id="niceng130er.appl.tab7"><a href="/books/NBK576848/table/niceng130er.appl.tab7/?report=objectonly" target="object" rid-ob="figobniceng130erappltab7" class="figpopup">Table 56. Health state utility values used in the cost-effectiveness model</a></p></div><div id="niceng130er.appl.s2.5.4"><h5>L.2.5.4. Costs</h5><p>The model captures 3 main categories of costs:
|
|
<ul><li class="half_rhythm"><div>Drug costs for induction of remission</div></li><li class="half_rhythm"><div>Drug costs for maintenance treatment following remission</div></li><li class="half_rhythm"><div>Other healthcare resource use</div></li></ul></p><p>A description of the assumptions about costs and remission rates associated with rescue therapy are summarised separately below.</p><div id="niceng130er.appl.s2.5.4.1"><h5>Drug costs for induction of remission</h5><p>Drug costs were obtained from the online version of the British National Formulary (BNF) in November 2017. For mesalazine, multiple oral preparations and multiple topical preparations are available. Estimates of the probability of withdrawal and remission for oral and topical aminosalicylates were modelled at the class level so, to keep the total number of treatment sequences in the model to a reasonable level, a practical decision was made not to define separate sequences for each of the different mesalazine preparations. Instead, the volume of prescriptions across different mesalazine preparations was obtained from NHS Prescription Cost Analysis data (November 2017) and used to estimate a weighted average cost per week. For oral mesalazine, separate weekly weighted average costs were estimated for low-dose and high-dose regimens. For the purpose of calculating weekly cost drug costs, the assumptions about dose were based on the most common dose used in the clinical trials included in the evidence review (categorised according to <a class="figpopup" href="/books/NBK576848/table/niceng130er.tab2/?report=objectonly" target="object" rid-figpopup="figniceng130ertab2" rid-ob="figobniceng130ertab2">Table 2</a>). In the event of any discrepancies between trials, the lower limit (for low dose) and upper limit (for high dose) of the treatment dose ranges specified for each preparation in the BNF was assumed. For topical mesalazine, weighted average costs in proctosigmoiditis, left-sided and extensive disease excluded suppositories as these preparations are only used in proctitis.</p><p id="niceng130er.appl.tab8"><a href="/books/NBK576848/table/niceng130er.appl.tab8/?report=objectonly" target="object" rid-ob="figobniceng130erappltab8" class="figpopup">Table 57. Weighted average cost per week for low-dose oral mesalazine</a></p><p id="niceng130er.appl.tab9"><a href="/books/NBK576848/table/niceng130er.appl.tab9/?report=objectonly" target="object" rid-ob="figobniceng130erappltab9" class="figpopup">Table 58. Weighted average cost per week for high-dose oral mesalazine</a></p><p id="niceng130er.appl.tab10"><a href="/books/NBK576848/table/niceng130er.appl.tab10/?report=objectonly" target="object" rid-ob="figobniceng130erappltab10" class="figpopup">Table 59. Weighted average cost per week for topical mesalazine (proctitis)</a></p><p id="niceng130er.appl.tab11"><a href="/books/NBK576848/table/niceng130er.appl.tab11/?report=objectonly" target="object" rid-ob="figobniceng130erappltab11" class="figpopup">Table 60. Weighted average cost per week for topical mesalazine (proctosigmoiditis, left-sided and extensive disease)</a></p><p>The costs of all other drugs for the induction of remission are summarised in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab12/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab12" rid-ob="figobniceng130erappltab12">Table 61</a>. For topical prednisolone, 3 different preparations were available. The lowest cost formulation (prednisolone liquid enema) was used in the base case but sensitivity analyses were run varying the cost to £77.06 per week to reflect the cost of prednisolone suppositories in proctitis and to £93.50 per week to reflect the cost of prednisolone foam enemas in proctosigmoiditis and left-sided disease.</p><p>The cost per week for topical tacrolimus was based on the description of the dose and formulation of the drug administered as an ointment in the trial by <a class="bibr" href="#niceng130er.appe.s1.2.ref4" rid="niceng130er.appe.s1.2.ref4">Lawrance 2017</a>. The committee commented that this does not reflect current practice in the UK and that topical tacrolimus is more likely to be prepared in suppository form as a special on a case by case basis. The cost of compounding this formulation was considered in a sensitivity anlaysis.</p><p id="niceng130er.appl.tab12"><a href="/books/NBK576848/table/niceng130er.appl.tab12/?report=objectonly" target="object" rid-ob="figobniceng130erappltab12" class="figpopup">Table 61. Cost per week for other drugs for the induction of remission</a></p></div><div id="niceng130er.appl.s2.5.4.2"><h5>Drugs costs for maintenance treatment following remission</h5><p>In the cost-effectiveness model, once remission is achieved, an assumption was made that, in order to maintain remission for the duration of the analysis, a proportion of people would receive maintenance treatment. An assumption about the proportion of people receiving either low-dose oral aminosalicylates or azathioprine as maintenance treatment was based on the findings of a small audit of 4 practices in South West London (Alexakis 2016) and validated with the committee. It was assumed that maintenance treatment contributed to the costs in people whose disease had entered remission but did not have any additional effect on health outcomes. Disease relapse was not modelled due to the short time horizon for the analysis.</p><p id="niceng130er.appl.tab13"><a href="/books/NBK576848/table/niceng130er.appl.tab13/?report=objectonly" target="object" rid-ob="figobniceng130erappltab13" class="figpopup">Table 62. Assumptions about the proportion of people receiving maintenance treatment and the weekly cost</a></p></div><div id="niceng130er.appl.s2.5.4.3"><h5>Healthcare resource use</h5><p>Estimates of ulcerative colitis-related healthcare resource use for people with active disease and disease in remission were obtained from a published retrospective chart review that recruited patients from 33 general practitioner and 34 gastroenterologist sites in the UK (Bodger 2014). The study included patients who had been diagnosed with mild-to-moderate ulcerative colitis at least 1 year prior to the inception date. Resource use estimates were combined with relevant unit costs sourced from the PSSRU and NHS Reference Costs.</p><p id="niceng130er.appl.tab14"><a href="/books/NBK576848/table/niceng130er.appl.tab14/?report=objectonly" target="object" rid-ob="figobniceng130erappltab14" class="figpopup">Table 63. Other healthcare resource use assumptions</a></p></div></div><div id="niceng130er.appl.s2.5.5"><h5>L.2.5.5. Rescue therapy</h5><p>In the cost-effectiveness model, if remission had not been induced after 3 lines of treatment (up to 4 lines in proctitis), it was assumed the person would require hospitalisation and receive rescue therapy to treat severe ulcerative colitis. The scope of this review question and cost-effectiveness analysis is restricted to the induction of remission for mild-to-moderate ulcerative colitis; therefore, no systematic reviews of the literature were undertaken to evaluate the comparative effectiveness of individual treatments that were included as part of rescue therapy. Instead, assumptions about response to rescue therapy are based on the 2014 IBD national clinical audit of inpatient care and the 2016 IBD national clinical audit of biological therapies. The assumptions about rescue therapy were the same across all arms in the cost-effectiveness model.</p><p id="niceng130er.appl.fig2"><a href="/books/NBK576848/figure/niceng130er.appl.fig2/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig2" class="figpopup">Figure 37. Structure of rescue therapy assumptions in the cost-effectiveness model</a></p><p id="niceng130er.appl.tab15"><a href="/books/NBK576848/table/niceng130er.appl.tab15/?report=objectonly" target="object" rid-ob="figobniceng130erappltab15" class="figpopup">Table 64. Assumptions for response to rescue therapy</a></p><p id="niceng130er.appl.tab16"><a href="/books/NBK576848/table/niceng130er.appl.tab16/?report=objectonly" target="object" rid-ob="figobniceng130erappltab16" class="figpopup">Table 65. Dose and cost of biological therapies</a></p><p id="niceng130er.appl.tab17"><a href="/books/NBK576848/table/niceng130er.appl.tab17/?report=objectonly" target="object" rid-ob="figobniceng130erappltab17" class="figpopup">Table 66. Combined cost and durations for each branch of rescue therapy</a></p><p>In the base case, it was assumed that response to treatment for people receiving biological therapies is assessed at 6 weeks. In people whose disease is responding, maintenance treatment would continue for an additional 8 weeks. However, the committee indicated that in clinical practice, treatment would likely continue beyond 14 weeks and therefore a sensitivity analysis was run in which people whose disease had entered remission continued to receive biological therapy for the remaining time horizon of the model.</p></div><div id="niceng130er.appl.s2.5.6"><h5>L.2.5.6. Sensitivity analysis</h5><div id="niceng130er.appl.s2.5.6.1"><h5>Probabilistic sensitivity analyses</h5><p>To take parameter uncertainty into account, probability distributions were estimated for all input variables with the exception of:
|
|
<ul><li class="half_rhythm"><div>Duration of treatment for induction of remission – these were assumed to be fixed in the model but different assumptions are explored in structural sensitivity analyses described below</div></li><li class="half_rhythm"><div>Duration of treatment for rescue therapies</div></li><li class="half_rhythm"><div>Cost of biological therapies</div></li></ul></p><p>Distribution parameters were sourced from the study in which the value was obtained, where possible, or were estimated based on the properties of the specific type of data. Beta distributions are used for variables denoting a probability, as bounded between 0 and 1 where data are reported to estimate the standard error, otherwise a triangular distribution is estimated. A beta distribution is also estimated for utility values, which are also traditionally confined to values between 0 and 1. Gamma distributions are used to represent uncertainty in cost parameters, which are non-negative and often highly skewed. A summary of all parameters and the distributions assumed in probabilistic analysis is provided in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab18/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab18" rid-ob="figobniceng130erappltab18">Table 67</a>. Drug costs for the induction of remission were entered in the model as weekly costs. A decision was made to introduce uncertainty into the estimates of weekly drug costs by estimating standard errors equal to 0.20 of the mean and fitting gamma distributions. This was done for two reasons:
|
|
<ul><li class="half_rhythm"><div>For several drugs, a number of different preparations are available and the prescription volumes used to estimate weighted average costs are subject to uncertainty. Allowing for uncertainty in weekly drug costs can serve as a simple proxy for variation in prescribing patterns and adherence.</div></li><li class="half_rhythm"><div>Durations of treatment in the model are assumed to be fixed and class-level effects were assumed for aminosalicylates. If costs were not subject to uncertainty, within-class ranking of treatments would be preserved 100% of the time, leading to an artificially high level of certainty in results.</div></li></ul></p><p>Monte Carlo simulation was used to randomly sample 1,000 times from all available distributions. Results are presented using cost-effectiveness acceptability curves (CEACs), which show the probability that a given sequence is more cost effective than the alternative sequences over a range of threshold values.</p><p id="niceng130er.appl.tab18"><a href="/books/NBK576848/table/niceng130er.appl.tab18/?report=objectonly" target="object" rid-ob="figobniceng130erappltab18" class="figpopup">Table 67. Summary of assumptions for parameter uncertainty used in probabilistic sensitivity analyses</a></p></div><div id="niceng130er.appl.s2.5.6.2"><h5>Scenario analyses</h5><p>A number of scenario analyses were conducted in order to explore the impact of several assumptions on model results:
|
|
<ul><li class="half_rhythm"><div class="half_rhythm">SA1: Duration of treatment set to maximum of all RCTs for each drug</div><div class="half_rhythm">For certain drugs, the committee specified that the duration of treatment in clinical practice would be shorter than the most frequently reported duration of follow-up in RCTs. This meant that, in the base case, sequences containing topical hydrocortisone or topical budesonide could not be modelled in proctosigmoiditis and left-sided disease. In this sensitivity analysis, the duration for each treatment is set to the maximum duration of follow-up reported in RCTs for each drug and allows all 75 sequences listed in <a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab2/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab2" rid-ob="figobniceng130erappltab2">Table 51</a></div></li><li class="half_rhythm"><div class="half_rhythm">SA2: No early switching of treatments in the event of non-remission</div><div class="half_rhythm">This scenario analysis (which reverts the analysis to the approach used the 2013 guideline model) was run for each extent of disease and assumed there is no early assessment of response to treatment. All people, except those withdrawing due to adverse events, are assumed to complete a full course treatment irrespective of whether the outcome is remission or non-remission.</div></li><li class="half_rhythm"><div class="half_rhythm">SA3: Duration of maintenance on biological therapies</div><div class="half_rhythm">In this scenario analysis, people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model. This scenario anlaysis was run for all extents of disease.</div></li><li class="half_rhythm"><div class="half_rhythm">SA4: Vary drug prices for topical prednisolone and topical tacrolimus</div><div class="half_rhythm">This scenario analysis was run in proctitis varying the price of topical prednisolone from £7.50 (liquid enema) to £77.06 (suppository) and the price of topical tacrolimus from £16.55 (ointment) to £47.56 (suppository). A scenario analysis was also run in proctosigmoiditis and left-sided disease varying the price of topical prednisolone from £7.50 (liquid enema) to £93.50 (foam enema).</div></li></ul></p></div></div></div></div><div id="niceng130er.appl.s3"><h3>L.3. Results</h3><p>Results for proctosigmoiditis and left-sided disease are presented first because this is the extent of disease with the largest number of treatment sequences and the most RCT evidence available to estimate relative treatment effects. This is followed by results in proctitis; due to the limited number of RCTs that were conducted specifically in people with proctitis, it was necessary to borrow information on the relative effectiveness of a number of treatments from other extents of disease. Results in extensive disease are presented last.</p><div id="niceng130er.appl.s3.1"><h4>L.3.1. Proctosigmoiditis and left-sided disease</h4><div id="niceng130er.appl.s3.1.1"><h5>L.3.1.1. Remission by line of treatment</h5><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab19/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab19" rid-ob="figobniceng130erappltab19">Table 68</a> shows the proportion of people whose disease is predicted to enter clinical remission in each line of treatment for each sequence in the base-case analysis for proctosigmoiditis and left-sided disease. Sequences containing topical hydrocortisone or topical budesonide were omitted from the base-case analysis (see <a href="#niceng130er.appl.s2.4">L.2.4</a>). Sequences that begin with topical aminosalicylate (PLS31–PLS34) have the highest proportion of people entering remission in first line (80.3%) and the lowest proportion of people requiring rescue therapy (3.1–7.6%) with on average 3.0–3.3 weeks out of a total time horizon of 30 weeks spent in an active disease state.</p><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab19/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab19" rid-ob="figobniceng130erappltab19">Table 68</a> also shows the costs of each treatment sequence broken down into the following categories: cost of drugs for induction of remission, cost of rescue therapy, cost of other healthcare resource use (consultant, nurse, GP, outpatient appointments, A&E attendances and blood tests) and cost of maintenance treatment. The widest variation in absolute costs is seen with rescue therapy (range £99 – £1,204). In other words, the proportion of patients requiring rescue therapy accounts for the biggest differences in costs when comparing treatment sequences.</p><p id="niceng130er.appl.tab19"><a href="/books/NBK576848/table/niceng130er.appl.tab19/?report=objectonly" target="object" rid-ob="figobniceng130erappltab19" class="figpopup">Table 68. Proportion of people whose disease enters remission by line of treatment, average time spent in active disease vs. remission and breakdown of costs for each treatment sequence in the base-case analysis for proctosigmoiditis and left-sided disease (excludes sequences with topical budesonide and topical hydrocortisone)</a></p></div><div id="niceng130er.appl.s3.1.2"><h5>L.3.1.2. Cost-effectiveness results</h5><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab20/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab20" rid-ob="figobniceng130erappltab20">Table 69</a> summarises the base-case cost-effectiveness results in proctosigmoiditis and left-sided disease with sequences ordered from least costly to most costly. Treatment sequence PLS31, which begins with a topical aminosalicylate, followed by the addition of an oral aminosalicylate and then oral prednisolone in combination with an oral aminoalicylate is expected to generate more QALYs and incur lower costs than all other treatment sequences except PLS34. However, the difference in QALYs between strategies is very small.</p><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab20/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab20" rid-ob="figobniceng130erappltab20">Table 69</a> also presents the probability that each strategy is cost effective and expected net monetary benefit at a threshold value of £20,000/QALY. Note that at this threshold value, the strategy with the highest probability of being cost effective (PLS34) is not the the strategy with the highest expected net benefit (PLS31). This finding is further illustrated in <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig3/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig3" rid-ob="figobniceng130erapplfig3">Figure 38</a> and <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig4/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig4" rid-ob="figobniceng130erapplfig4">Figure 39</a>. <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig3/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig3" rid-ob="figobniceng130erapplfig3">Figure 38</a> presents the cost-effectiveness acceptability curve (CEAC), which shows all treatment strategies with a >3% probability of being cost effective. <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig4/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig4" rid-ob="figobniceng130erapplfig4">Figure 39</a> presents the cost-effectiveness acceptability frontier (CEAF), which plots the probability that the optimal option (as defined by expected net benefit) is cost effective. The switch point in the CEAF where the optimal strategy changes from PLS31 to PLS34 occurs at the ICER between the two options (approximately £25,000/QALY). The results seen here arise from asymmetry in the distributions of expected value (<a class="bibr" href="#niceng130er.appe.s3.ref6" rid="niceng130er.appe.s3.ref6">Fenwick 2001</a>). Although there were more model iterations in which PLS34 generated a higher net benefit, in the iterations where PLS31 was superior, it was superior by a greater degree. The only difference between the sequences PLS31 and PLS34 is the mode of administration of the corticosteroid in the third line (oral prednisolone and topical prednisolone respectively). The results of the network meta-analysis showed there was considerable uncertainty in the estimate of the relative effectiveness of topical prednisolone as there was only one small study directly comparing this option to topical aminosaliycylates.</p><p id="niceng130er.appl.tab20"><a href="/books/NBK576848/table/niceng130er.appl.tab20/?report=objectonly" target="object" rid-ob="figobniceng130erappltab20" class="figpopup">Table 69. Base-case mean probabilistic cost-effectiveness results for proctosigmoiditis and left-sided disease</a></p><p id="niceng130er.appl.fig3"><a href="/books/NBK576848/figure/niceng130er.appl.fig3/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig3" class="figpopup">Figure 38. Cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease base-case analysis</a></p><p id="niceng130er.appl.fig4"><a href="/books/NBK576848/figure/niceng130er.appl.fig4/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig4" class="figpopup">Figure 39. Cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease base-case analysis</a></p></div><div id="niceng130er.appl.s3.1.3"><h5>L.3.1.3. Scenario analyses</h5><p>The incremental cost-effectiveness results, CEACs and CEAFs for various scenario analyses for proctosigmoiditis and left-sided disease are presented below.</p><div id="niceng130er.appl.s3.1.3.1"><h5>SA1: Duration of treatment set to maximum of all RCTs for each drug</h5><p>In this scenario analysis, the duration for each treatment is set to the maximum duration of follow-up reported in RCTs for each drug and allows for sequences containing topical hydrocortisone or topical budesonide to be compared using data from RCTs with a follow-up duration of 8 weeks. Estimates of the relative effectiveness of topical hydrocortisone, topical budesonide and topical aminosalicylates are derived from the evidence network at 5-8 weeks whereas topical prednisolone remains informed by the evidence network at 0-4 weeks. This results in sequences beginning with topical prednisolone generating higher QALYs and lower costs.</p><p>The CEAC in <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig5/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig5" rid-ob="figobniceng130erapplfig5">Figure 40</a> shows that PLS64, which begins with topical prednisolone, followed by a high-dose oral aminosalicylate and then a low-dose oral aminosalicylate in combination with an oral corticosteroid, is the most cost-effective strategy across the full range of threshold values but this result is associated with considerable uncertainty because 3 other strategies that begin with topical prednisolone (PLS73, PLS65, PLS74) all have approximately a 20% probability of being the most cost-effective strategy.</p><p id="niceng130er.appl.tab21"><a href="/books/NBK576848/table/niceng130er.appl.tab21/?report=objectonly" target="object" rid-ob="figobniceng130erappltab21" class="figpopup">Table 70. SA1 cost-effectiveness results for proctosigmoiditis and left-sided disease with duration of treatment set to maximum of all RCTs for each drug</a></p><p id="niceng130er.appl.fig5"><a href="/books/NBK576848/figure/niceng130er.appl.fig5/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig5" class="figpopup">Figure 40. SA1 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease with duration of treatment set to maximum of all RCTs for each drug</a></p><p id="niceng130er.appl.fig6"><a href="/books/NBK576848/figure/niceng130er.appl.fig6/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig6" class="figpopup">Figure 41. SA1 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease with duration of treatment set to maximum of all RCTs for each drug</a></p></div><div id="niceng130er.appl.s3.1.3.2"><h5>SA2: No early switching of treatments in the event of non-remission</h5><p>This scenario analysis assumes there is no early assessment of response to treatment. All people, except those withdrawing due to adverse events, are assumed to complete a full course treatment irrespective of whether the outcome is remission or non-remission.</p><p>Compared to the base case, there is an increase in costs for all sequences in this scenario analysis but sequences that start with a topical aminosalicylate still dominate. <a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab22/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab22" rid-ob="figobniceng130erappltab22">Table 71</a> shows that although PLS34 is associated with a higher probability of being the most cost-effective option at a threshold value of £20,000/QALY, PLS31 and PLS34 produce almost the same expected net monetary benefit.</p><p id="niceng130er.appl.tab22"><a href="/books/NBK576848/table/niceng130er.appl.tab22/?report=objectonly" target="object" rid-ob="figobniceng130erappltab22" class="figpopup">Table 71. SA2 cost-effectiveness results for proctosigmoiditis and left-sided disease with no early switching of treatments in the event of non-remission</a></p><p id="niceng130er.appl.fig7"><a href="/books/NBK576848/figure/niceng130er.appl.fig7/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig7" class="figpopup">Figure 42. SA2 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease with no early switching of treatments in the event of non-remission</a></p><p id="niceng130er.appl.fig8"><a href="/books/NBK576848/figure/niceng130er.appl.fig8/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig8" class="figpopup">Figure 43. SA2 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease with no early switching of treatments in the event of non-remission</a></p></div><div id="niceng130er.appl.s3.1.3.3"><h5>SA3: Duration of maintenance on biological therapies</h5><p>This scenario analysis was run for each extent of disease and assumed that people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model.</p><p>There is an increase in costs for all sequences in this scenario analysis compared to the base-case analysis but sequences that start with a topical aminosalicylate still dominate. <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig9/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig9" rid-ob="figobniceng130erapplfig9">Figure 44</a> and <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig10/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig10" rid-ob="figobniceng130erapplfig10">Figure 45</a> show that at a threshold value of £20,000/QALY, PLS31 produces the highest expected net benefit even though PLS34 has a higher probability of being the most cost-effective option. Once again, this is due to asymmetry in the distributions of expected value as previously noted in the results for the base-case analysis.</p><p id="niceng130er.appl.tab23"><a href="/books/NBK576848/table/niceng130er.appl.tab23/?report=objectonly" target="object" rid-ob="figobniceng130erappltab23" class="figpopup">Table 72. SA3 cost-effectiveness results for proctosigmoiditis and left-sided disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p><p id="niceng130er.appl.fig9"><a href="/books/NBK576848/figure/niceng130er.appl.fig9/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig9" class="figpopup">Figure 44. SA3 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p><p id="niceng130er.appl.fig10"><a href="/books/NBK576848/figure/niceng130er.appl.fig10/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig10" class="figpopup">Figure 45. SA3 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p></div><div id="niceng130er.appl.s3.1.3.4"><h5>SA4: Vary drug price for topical prednisolone</h5><p>Two different preparations of topical prednisolone are available and costs vary considerably. A scenario analysis was run in proctosigmoiditis and left-sided disease varying the price of topical prednisolone from £7.50 (liquid enema) to £93.50 (foam enema).</p><p>The cost of sequences containing topical prednisolone increase but sequences that start with a topical aminosalicylate still dominate. With the increase in cost of topical prednisolone as third-line treatment in PLS34, PLS31 now produces the highest expected net benefit over the range of threshold values from £0/QALY to £50,000/QALY as shown in <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig12/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig12" rid-ob="figobniceng130erapplfig12">Figure 47</a>.</p><p id="niceng130er.appl.tab24"><a href="/books/NBK576848/table/niceng130er.appl.tab24/?report=objectonly" target="object" rid-ob="figobniceng130erappltab24" class="figpopup">Table 73. SA4 cost-effectiveness results for proctosigmoiditis and left-sided disease varying the cost of topical prednisolone</a></p><p id="niceng130er.appl.fig11"><a href="/books/NBK576848/figure/niceng130er.appl.fig11/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig11" class="figpopup">Figure 46. SA4 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease varying the cost of topical prednisolone</a></p><p id="niceng130er.appl.fig12"><a href="/books/NBK576848/figure/niceng130er.appl.fig12/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig12" class="figpopup">Figure 47. SA4 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease varying the cost of topical prednisolone</a></p></div></div></div><div id="niceng130er.appl.s3.2"><h4>L.3.2. Proctitis</h4><p>In proctitis, RCT evidence was only available to estimate relative effectiveness of 3 active treatments: low-dose oral aminosalicylates, topical aminosalicylates and topical tacrolimus. In order to conduct a cost-effectiveness analysis of sequences of treatments of interest to the committee, it was necessary to assume that the estimates of relative effectiveness that were reported for other treatments in other extents of disease would also be applicable to proctitis.</p><div id="niceng130er.appl.s3.2.1"><h5>L.3.2.1. Remission by line of treatment</h5><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab25/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab25" rid-ob="figobniceng130erappltab25">Table 74</a> shows the proportion of people whose disease entered clinical remission in each line of treatment for each sequence in the base case analysis for proctitis. Sequences PRC17 – PRC32 are the same as sequences PRC01 – PRC16 but without topical tacrolimus as a fourth line treatment option. PRC09 – PRC12 and PRC13 – PRC16 appear identical in terms of the sequence of treatments if remission is not achieved but differ in terms of the treatment assumption in the event of withdrawal (see <a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab1/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab1" rid-ob="figobniceng130erappltab1">Table 50</a>). The same explanation applies to PRC25 – PRC28 and PRC29 – PRC32.</p><p>Sequences that begin with topical aminosalicylate (PRC01 – PRC04), have the highest proportion of people entering remission in first line (90.5%) and the lowest proportion of people requiring rescue therapy (0.1% - 0.4%). For these sequences, people spend on average 2.5 – 2.7 weeks out of 30 weeks with active disease. In constrast, sequences that begin with low-dose oral aminosalicylate (PRC06 – PRC08), followed by escalation to high-dose oral aminosalicylate and then the addition of an oral corticosteroid, result in people spending on average more than twice the amount of time (7.9 – 8.1 weeks) with active disease.</p><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab25/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab25" rid-ob="figobniceng130erappltab25">Table 74</a> also shows the costs of each treatment sequence broken down into the following categories: cost of drugs for induction of remission, cost of rescue therapy, cost of other healthcare resource use (consultant, nurse, GP, outpatient appointments, A&E attendances and blood tests) and cost of maintenance treatment. As with the results for proctosigmoiditis and left-sided disease, the proportion of patients requiring rescue therapy accounts for the biggest differences in costs when comparing treatment sequences. Where fewer lines of treatment have been modelled, the proportion of people requiring rescue therapy is higher; giving more lines treatment to induce remission even in a small proportion of people with active disease can offset the much higher costs of rescue therapy.</p><p id="niceng130er.appl.tab25"><a href="/books/NBK576848/table/niceng130er.appl.tab25/?report=objectonly" target="object" rid-ob="figobniceng130erappltab25" class="figpopup">Table 74. Proportion of people whose disease enters remission by line of treatment, average time spent in active disease vs. remission and breakdown of costs for each treatment sequence in base case analysis for proctitis</a></p></div><div id="niceng130er.appl.s3.2.2"><h5>L.3.2.2. Cost-effectiveness results</h5><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab26/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab26" rid-ob="figobniceng130erappltab26">Table 75</a> summarises the base-case cost-effectiveness results in proctitis with sequences ordered from least costly to most costly. Treatment sequences beginning with a topical aminosalicylate, followed by the addition of an oral aminosalicylate, then a topical or oral corticosteroid and then topical tacrolimus are expected to generate more QALYs and incur lower costs than all other treatment sequences.</p><p>The CEAC in <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig13/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig13" rid-ob="figobniceng130erapplfig13">Figure 48</a> shows all treatment sequences that have a >3% probability of being cost effective. <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig14/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig14" rid-ob="figobniceng130erapplfig14">Figure 49</a> confirms that PRC01 has the highest expected net benefit over the range of threshold values from £0/QALY to £50,000/QALY.</p><p id="niceng130er.appl.tab26"><a href="/books/NBK576848/table/niceng130er.appl.tab26/?report=objectonly" target="object" rid-ob="figobniceng130erappltab26" class="figpopup">Table 75. Base-case cost-effectiveness results for proctitis</a></p><p id="niceng130er.appl.fig13"><a href="/books/NBK576848/figure/niceng130er.appl.fig13/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig13" class="figpopup">Figure 48. Cost-effectiveness acceptability curve for proctitis base-case analysis</a></p><p id="niceng130er.appl.fig14"><a href="/books/NBK576848/figure/niceng130er.appl.fig14/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig14" class="figpopup">Figure 49. Cost-effectiveness acceptability frontier for proctitis base-case analysis</a></p></div><div id="niceng130er.appl.s3.2.3"><h5>L.3.2.3. Scenario analyses</h5><p>The incremental cost-effectiveness results, CEACs and CEAFs for various scenario analyses for proctitis are presented below.</p><div id="niceng130er.appl.s3.2.3.1"><h5>SA2: No early switching of treatments in the event of non-remission</h5><p>This scenario analysis assumes there is no early assessment of response to treatment. All people, except those withdrawing due to adverse events, are assumed to complete a full course treatment irrespective of whether the outcome is remission or non-remission.</p><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab27/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab27" rid-ob="figobniceng130erappltab27">Table 76</a> shows an increase in costs for all sequences in this scenario analysis but sequences that start with topical aminosalicylate still dominate. As <a class="figpopup" href="/books/NBK576848/figure/niceng130er.appl.fig16/?report=objectonly" target="object" rid-figpopup="figniceng130erapplfig16" rid-ob="figobniceng130erapplfig16">Figure 51</a> shows, PRC01 retains the highest probability of being cost effective and the highest expected net benefit over the range of threshold values from £0/QALY to £50,000/QALY.</p><p id="niceng130er.appl.tab27"><a href="/books/NBK576848/table/niceng130er.appl.tab27/?report=objectonly" target="object" rid-ob="figobniceng130erappltab27" class="figpopup">Table 76. SA2 cost-effectiveness results for proctitis with no early switching of treatments in the event of non-remission</a></p><p id="niceng130er.appl.fig15"><a href="/books/NBK576848/figure/niceng130er.appl.fig15/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig15" class="figpopup">Figure 50. SA2 cost-effectveness acceptability curve for proctitis with no early switching of treatments in the event of non-remission</a></p><p id="niceng130er.appl.fig16"><a href="/books/NBK576848/figure/niceng130er.appl.fig16/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig16" class="figpopup">Figure 51. SA2 cost-effectveness acceptability frontier for proctitis with no early switching of treatments in the event of non-remission</a></p></div><div id="niceng130er.appl.s3.2.3.2"><h5>SA3: Duration of maintenance on biological therapies</h5><p>This scenario analysis assumes that people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model.</p><p>There is an increase in costs for all sequwences but sequences that start with a topical aminosalicylate still dominate and PRC01 retains the highest expected net benefit over the range of threshold values from £0/QALY to £50,000/QALY.</p><p id="niceng130er.appl.tab28"><a href="/books/NBK576848/table/niceng130er.appl.tab28/?report=objectonly" target="object" rid-ob="figobniceng130erappltab28" class="figpopup">Table 77. SA3 cost-effectiveness results for proctitis assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p><p id="niceng130er.appl.fig17"><a href="/books/NBK576848/figure/niceng130er.appl.fig17/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig17" class="figpopup">Figure 52. SA3 cost-effectiveness acceptability curve for proctitis assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p><p id="niceng130er.appl.fig18"><a href="/books/NBK576848/figure/niceng130er.appl.fig18/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig18" class="figpopup">Figure 53. SA3 cost-effectiveness acceptability frontier for proctitis assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p></div><div id="niceng130er.appl.s3.2.3.3"><h5>SA4: Vary drug price for topical prednisolone and topical tacrolimus</h5><p>This scenario analysis varied the price of topical prednisolone from £7.50 to £77.06 to reflect the price of the suppository formulation instead of the liquid enema and also varied the price of topical tacrolimus from £16.55 to £47.56 to reflect the estimated cost of preparing a suppository on a case by case basis instead of using the ointment preparation. In this scenario, PRC01 has the highest expected net benefit above a threshold value of approximately £3,800/QALY.</p><p id="niceng130er.appl.tab29"><a href="/books/NBK576848/table/niceng130er.appl.tab29/?report=objectonly" target="object" rid-ob="figobniceng130erappltab29" class="figpopup">Table 78. SA4 cost-effectiveness results for proctitis varying the cost of topical prednisolone and topical tacrolimus</a></p><p id="niceng130er.appl.fig19"><a href="/books/NBK576848/figure/niceng130er.appl.fig19/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig19" class="figpopup">Figure 54. SA4 cost-effectiveness acceptability curve for proctitis varying the cost of topical prednisolone and topical tacrolimus</a></p><p id="niceng130er.appl.fig20"><a href="/books/NBK576848/figure/niceng130er.appl.fig20/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig20" class="figpopup">Figure 55. SA4 cost-effectiveness acceptability frontier for proctitis varying the cost of topical prednisolone and topical tacrolimus</a></p></div></div></div><div id="niceng130er.appl.s3.3"><h4>L.3.3. Extensive disease</h4><div id="niceng130er.appl.s3.3.1"><h5>L.3.3.1. Remission by line of treatment</h5><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab30/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab30" rid-ob="figobniceng130erappltab30">Table 79</a> shows the proportion of people whose disease entered clinical remission in each line of treatment for each sequence in the base-case analysis for extensive disease. Sequences that begin with the combination of a high-dose oral aminosalicylate and topical aminosalicylate (EXT04 – EXT06) have a higher proportion of people entering remission in first line (68.3%) but also a higher proportion of people requiring rescue therapy (9.7% - 23.0%). This is beause it was only possible model up to two lines of treatment in the sequences that begin with the combination of a high-dose oral aminosalicylate and topical aminosalicylate. The average number of weeks spent with active disease is lower for the sequences that begin with combination treatment (4.8 – 5.6 weeks).</p><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab30/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab30" rid-ob="figobniceng130erappltab30">Table 79</a> also shows the costs of each treatment sequence broken down into the following categories: cost of drugs for induction of remission, cost of rescue therapy, cost of other healthcare resource use (consultant, nurse, GP, outpatient appointments, A&E attendances and blood tests) and cost of maintenance treatment. The widest variation in absolute costs is seen with rescue therapy (range £164- £726), suggesting that the proportion of patients requiring rescue therapy accounts for the biggest differences in costs when comparing treatment sequences.</p><p id="niceng130er.appl.tab30"><a href="/books/NBK576848/table/niceng130er.appl.tab30/?report=objectonly" target="object" rid-ob="figobniceng130erappltab30" class="figpopup">Table 79. Proportion of people whose disease enters remission by line of treatment, average time spent in active disease vs. remission and breakdown of costs for each treatment sequence in base-case analysis for extensive disease</a></p></div><div id="niceng130er.appl.s3.3.2"><h5>L.3.3.2. Cost-effectiveness results</h5><p><a class="figpopup" href="/books/NBK576848/table/niceng130er.appl.tab31/?report=objectonly" target="object" rid-figpopup="figniceng130erappltab31" rid-ob="figobniceng130erappltab31">Table 80</a> summarises the base case cost-effectiveness results in extensive disease with sequences ordered from least costly to most costly. Treatment sequences EXT02 and EXT03, which begin with a high-dose oral aminosalicylate given alone and differ only in terms of the oral corticosteroid assumed in third line, produce similar costs and QALYs. In comparison to EXT02 the sequence EXT05, which begins with the combination of a high-dose oral aminosalicylate and topical aminosalicylate, produces an ICER of £34,460/QALY. All other treatment sequences are dominated.</p><p id="niceng130er.appl.tab31"><a href="/books/NBK576848/table/niceng130er.appl.tab31/?report=objectonly" target="object" rid-ob="figobniceng130erappltab31" class="figpopup">Table 80. Base-case cost-effectiveness results for extensive disease</a></p><p id="niceng130er.appl.fig21"><a href="/books/NBK576848/figure/niceng130er.appl.fig21/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig21" class="figpopup">Figure 56. Cost-effectiveness acceptability curve for extensive disease case-case analysis</a></p><p id="niceng130er.appl.fig22"><a href="/books/NBK576848/figure/niceng130er.appl.fig22/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig22" class="figpopup">Figure 57. Cost-effectiveness acceptability frontier for extensive disease base-case analysis</a></p></div><div id="niceng130er.appl.s3.3.3"><h5>L.3.3.3. Scenario analyses</h5><p>The incremental cost-effectiveness results, CEACs and CEAFs for various scenario analyses for extensive disease are presented below.</p><div id="niceng130er.appl.s3.3.3.1"><h5>SA2: No early switching of treatments in the event of non-remission</h5><p>This scenario analysis assumes there is no early assessment of response to treatment. All people, except those withdrawing due to adverse events, are assumed to complete a full course treatment irrespective of whether the outcome is remission or non-remission. The ICER for the comparison of EXT05 with EXT02 has fallen from a value of £34,460/QALY in the base-case analysis to £17,087/QALY.</p><p id="niceng130er.appl.tab32"><a href="/books/NBK576848/table/niceng130er.appl.tab32/?report=objectonly" target="object" rid-ob="figobniceng130erappltab32" class="figpopup">Table 81. SA2 cost-effectiveness results for extensive disease with no early switching of treatments in the event of non-remission</a></p><p id="niceng130er.appl.fig23"><a href="/books/NBK576848/figure/niceng130er.appl.fig23/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig23" class="figpopup">Figure 58. SA2 cost-effectiveness acceptability curve for extensive disease with no early switching of treatments in the event of non-remission</a></p><p id="niceng130er.appl.fig24"><a href="/books/NBK576848/figure/niceng130er.appl.fig24/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig24" class="figpopup">Figure 59. SA2 cost-effectiveness acceptability frontier for extensive disease with no early switching of treatments in the event of non-remission</a></p></div><div id="niceng130er.appl.s3.3.3.2"><h5>SA3: Duration of maintenance on biological therapies</h5><p>This scenario analysis assumes that people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model. Compared to the base case, there is a small increase in costs for all sequences in this scenario analysis and the ICER for the comparison of EXT05 with EXT02 has risen to £38,630/QALY.</p><p id="niceng130er.appl.tab33"><a href="/books/NBK576848/table/niceng130er.appl.tab33/?report=objectonly" target="object" rid-ob="figobniceng130erappltab33" class="figpopup">Table 82. SA3 deterministic cost-effectiveness results for extensive assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p><p id="niceng130er.appl.fig25"><a href="/books/NBK576848/figure/niceng130er.appl.fig25/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig25" class="figpopup">Figure 60. SA3 cost-effectiveness acceptability curve for extensive disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p><p id="niceng130er.appl.fig26"><a href="/books/NBK576848/figure/niceng130er.appl.fig26/?report=objectonly" target="object" rid-ob="figobniceng130erapplfig26" class="figpopup">Figure 61. SA3 cost-effectiveness acceptability frontier for extensive disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</a></p></div></div></div></div><div id="niceng130er.appl.s4"><h3>L.4. Discussion</h3><div id="niceng130er.appl.s4.1"><h4>L.4.1. Main findings</h4><p>This cost-effectiveness analysis was undertaken to compare sequences of treatments for the induction of remission of mild-to-moderate ulcerative colitis by extent of disease. The results suggest:
|
|
<ul><li class="half_rhythm"><div>In proctosigmoiditis and left-sided disease, treatment sequences that begin with a topical aminosalicylate in first line followed by the addition of an oral aminosalicylate in second line and then a topical or oral corticosteroid in third line result in more QALYs and lower costs and dominate all other treatment strategies. There was not a strong basis for differentiating between treatment strategies in terms of the choice of corticosteroid in third line. The committee discussed whether the dose of the oral aminosalicylate in second line should be low or high. Based on the available RCT evidence in proctosigmoiditis and left-sided disease, it was only possible to model low-dose oral aminosalicylates in combination with a topical aminosalicylate as part of treatment sequences. However, the committee noted the superior efficacy of high-dose oral aminosalicylates in comparison to low-dose oral aminosalicylates and decided to infer that this was likely to hold when used in combination with a topical aminosalicylate.</div></li><li class="half_rhythm"><div>In proctitis, treatment sequences that begin with a topical aminosalicylate in first line followed by the addition of an oral aminosalicylate in second line, a topical or oral corticosteroid in third line and topical tacrolimus in fourth line result in more QALYs and lower costs and dominate all other treatment strategies. The committee noted that the evidence to inform the remission rate for topical tacrolimus was based on 1 RCT of 20 participants and that the preparation used in the trial did not reflect UK clinical practice or costs. Given this uncertainty, all treatment sequences in proctitis were modelled both with and without topical tacrolimus as a fourth line option. When omitting topical tacrolimus, treatment sequences that begin with a topical aminosalicylate in first line followed by the addition of an oral aminosalicylate in second line and a topical or oral corticosteroid in third line remain cost effective. Again, there was not a strong basis for differentiating between treatment strategies in terms of the choice of corticosteroid (oral or topical) in third line.</div></li><li class="half_rhythm"><div>In extensive disease, treatment sequences that begin with the combination of a high-dose oral aminosalicylate and a topical aminosalicylate generate more QALYs but also higher costs than sequences that begin with a high-dose oral aminosalicylate alone. This is because, based on the limited amount of RCT evidence in extensive disease, it was not possible to specify a third-line treatment option for sequences that begin with the combination treatment, resulting in higher proportions of patients requiring rescue therapy. In the base case, the ICER for EXT05 (high-dose oral aminosalicylate + topical aminosalicylate in first line followed by oral belcometasone in second line) versus EXT02 (high-dose oral aminosalicylate in first line followed by the addition of a topical aminosalicylate in second line and then oral beclometasone in third line) was £34,460/QALY. The ICER fell to £17,087/QALY in a scenario analysis in which it was assumed there was no early switching of treatments in the event of non-response.</div></li></ul></p></div><div id="niceng130er.appl.s4.2"><h4>L.4.2. Strengths and limitations</h4><p>The committee felt that sequencing of treatments for the induction of remission of mild-to-moderate ulcerative colitis was an area of both clinical and economic uncertainty where modelling would be informative. The main strength of this analysis is that it incorporates new RCT evidence that has emerged since the 2013 guideline was produced, expands the number of treatment sequences under comparison, updates the assumptions about rescue therapy to reflect current practice and produces separate cost-effectiveness results for each extent of disease. The model makes use of all available data by drawing on evidence synthesised using network meta-analysis to estimate the relative effects of all treatments of interest in terms of both withdrawal due to adverse events and probability of achieving remission. However, there are a number of important assumptions and limitations to consider:
|
|
<ul><li class="half_rhythm"><div>RCT evidence was categorised by extent of disease and duration of follow-up, which resulted in sparse evidence networks for proctitis and extensive disease. Sparseness of data and small sample sizes resulted in high levels of uncertainty in the estimates of relative effectiveness for a number of comparisons. This uncertainty was considered in probabilistic sensitivity analyses but given the structural assumptions of the cost-effectiveness model, this had relatively little impact on the overall conclusions. Due to the limited number of RCTs conducted specifically in proctitis, it was necessary to borrow estimates of relative effectiveness for several drugs from proctosigmoiditis and left-sided disease in order to model a number of treatment sequences. The results in proctitis should be interpreted with caution.</div></li><li class="half_rhythm"><div>In early committee discussions about the structure for the cost-effectiveness model, two important discrepancies between the design of clinical trials and current clinical practice emerged. The first was that the duration of follow-up in trials for some of the drugs did not match the committee’s experience regarding duration of treatment in practice. This resulted in a mismatch between the timepoint at which remission was reported in some RCTs for some drugs and the assumption about duration (and therefore cost) of treatment in the cost-effectiveness model. Taking a conservative approach, if the trial duration was shorter than the duration of treatment in clinical practice, the model allowed for remission rates from an earlier time point to be applied at a later time point in the model but not the inverse. This meant that 2 drugs, topical hydrocortisone and topical budesonide, could not be modelled in the base case analysis but were included in sensitivity analyses for proctosigmoiditis and left-sided disease. The second discrepancy that emerged is that, in clinical practice, an assessment of response to treatment would generally take place approximately halfway through a full course of treatment so that people whose disease was not responding to treatment could be switched to another treatment. The base case analyses allowed for early treatment switching to take place but could lead to underestimation of treatment costs in relation to treatment benefits reported in RCTs. To address this issue, sensitivity analyses were run for each extent of disease in which no early treatment switching was permitted.</div></li><li class="half_rhythm"><div>In line with the clinical evidence review, induction of remission was the primary outcome of interest in the economic model. There was no evidence to suggest different treatments would have any impact on mortality rates. The choice of time horizon for the model was therefore a pragmatic balance between being long enough to reflect the time it would take to achieve remission but short enough to assume that once remission was achieved, everyone in the model would remain in remission for the duration of the analysis. Disease relapse was not modelled. The differences in QALYs between treatment sequences is therefore driven by the proportion of people and amount of time spent in remission versus active disease over the 30-week time horizon. This resulted in very small differences in QALYs across sequences.</div></li><li class="half_rhythm"><div>In the model, if induction of remission was not achieved following treatment with one of the drugs under comparison, a standard assumption about rescue therapy was applied to all arms in the decision tree. The costs associated with rescue therapy for treating severe disease are much higher than the costs associated with drugs for the induction of remission of mild-to-moderate disease. As the model results demonstrate, costs were most sensitive to the proportion of people requiring rescue therapy. To maintain structural coherence, the model did not consider potential long-term differences in QALYs and costs beyond achieving remission. For example, it did not take into account the long-term impact of surgery on health-state utilities, costs associated with post-surgical care, costs of long-term maintenance with biological therapies or costs associated with treating subsequent relapses. All of these longer-term consequences are expected to increase downstream costs and further amplify the importance of inducing remission as early as possible in the treatment sequence in order to avoid the need for rescue therapy.</div></li></ul></p></div><div id="niceng130er.appl.s4.3"><h4>L.4.3. Comparison with 2013 guideline economic model</h4><p>No RCTs were identified that directly compare sequences of treatment for the induction of remission of mild-to-moderate ulcerative colitis. In order to evaluate the cost effectiveness of treatment sequences in both the 2013 model and the current model, it was necessary to make a number of strong assumptions:
|
|
<ul><li class="half_rhythm"><div>The probability of a person’s disease entering remission is independent of the line of treatment in which a drug is used.</div></li><li class="half_rhythm"><div>Once a person’s disease enters remission, it is assumed to remain in remission for the duration of the model.</div></li></ul></p><p>Beyond these assumptions, there are a number of differences between the 2013 model and the current model that limit the comparability of results:
|
|
<ul><li class="half_rhythm"><div>The categorisation of extent of disease differs between the 2 analyses. The 2013 model considered adults with left-sided or extensive ulcerative colitis and all 10 treatment strategies began with an oral aminosalicylate either alone or in combination in first line. In the current analysis, extensive disease is considered as a separate subgroup and left-sided disease is grouped with proctosigmoiditis. In the latter subgroup, due to the location of disease distal to the splenic flexure, topical aminosalicylates are a relevant first-line treatment option. The current analysis compared 32 treatment sequences in proctitis, 75 in proctosigmoiditis and left-sided disease and 6 in extensive disease.</div></li><li class="half_rhythm"><div>The 2013 model included the following comparators: low-dose oral aminosalicylates, high-dose oral aminosalicylates, topical aminosalicylates, oral beclometasone and prednisolone. For the current analysis, the following additional treatments were considered: oral budesonide, topical budesonide, topical hydrocortisone, topical prednisolone and topical tacrolimus.</div></li><li class="half_rhythm"><div>In the 2013 model, it was assumed that people who withdrew from treatment and people who did not respond to a given treatment went on to receive the same treatment in the following line of each sequence. The current model allowed for the next treatment in the sequence to differ following withdrawal due to adverse events and non-response to treatment.</div></li><li class="half_rhythm"><div>In both the 2013 model and the current model, there was insufficient data in RCTs to model remission conditional on response to treatment. In the 2013 model, it was assumed people would remain on treatment for the full duration regardless of whether the outcome was remission or non-remission. The current model permitted early switching to the next line of treatment for people whose disease did not enter remission but a sensitivity analysis was conducted adopting the approach taken in the 2013 model.</div></li><li class="half_rhythm"><div>In the 2013 model, the probability of remission conditional on non-withdrawal was estimated in the network meta-analysis by removing the number of withdrawals from the denominator when entering remission data. This approach was not adopted in the current model as a minority of studies reported both outcomes.</div></li><li class="half_rhythm"><div>In the 2013 model, rescue therapy comprised inpatient treatment with intravenous drugs or surgery. In the current model, the use of biological therapies to induce remission were modelled as part of rescue therapy, informed by national audit data.</div></li></ul></p></div><div id="niceng130er.appl.s4.4"><h4>L.4.4. Conclusions</h4><p>Overall, the analyses demonstrate that in proctitis, proctosigmoiditis and left-sided disease, treatment sequences that start with a topical aminosalicylate, followed by the addition of an oral aminosalicylate and then either a topical or oral corticosteroid are cost effective because they result in the highest proportion of people whose disease enters remission as early as possible and the lowest proportion of people requiring hospitalisation and rescue therapy. In extensive disease, there was more uncertainty with respect to the optimal treatment sequence but a scenario analysis in which all people, other than those withdrawing due to adverse events, were assumed to receive a full course of treatment suggests that using a high-dose oral aminosalicylate in combination with a topical aminosalicylate in first line followed by an oral corticosteroid (in combination with an oral aminosalicylate) as second-line treatment is likely to be cost effective.</p></div></div><div id="niceng130er.appl.s5"><h3>L.5. WinBUGS code for baseline synthesis</h3><div id="niceng130er.appl.s5.1"><h4>Baseline model clinical remission (fixed-effect)</h4><pre>
|
|
# Binomial likelihood, logit link
|
|
# Fixed-effect model
|
|
# based on
|
|
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
|
|
# NICE DSU Technical Support Document 5: Evidence synthesis in the baseline
|
|
# natural history model. 2011.
|
|
# <a href="http://www.nicedsu.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.nicedsu.org.uk</a>
|
|
|
|
model {
|
|
for(i in 1:NumStudies) { # indexes studies
|
|
k[i] ~ dbin(p[i], N[i]) # binomial likelihood
|
|
logit(p[i]) <- m # model for linear predictor
|
|
dummy[i] <- Yrs[i] # not used in this model
|
|
} # close study loop
|
|
m ~ dnorm(0, 0.0001) # vague prior for baseline
|
|
logit(prob) <- m # posterior probability of response
|
|
</pre></div><div id="niceng130er.appl.s5.2"><h4>Baseline model clinical remission (random effects)</h4><pre>
|
|
# Binomial likelihood, logit link
|
|
# Random effect model
|
|
# based on
|
|
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
|
|
# NICE DSU Technical Support Document 5: Evidemce synthesis in the baseline
|
|
# natural history model. 2011.
|
|
# <a href="http://www.nicedsu.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.nicedsu.org.uk</a>
|
|
|
|
model {
|
|
for(i in 1:NumStudies) { # indexes studies
|
|
k[i] ~ dbin(p[i], N[i]) # binomial likelihood
|
|
logit(p[i]) <- mu[i] # model for linear predictor
|
|
mu[i] ~ dnorm(m, tau.m) # trial-specific baseline with random effects
|
|
dummy[i] <- Yrs[i] # not used in this model
|
|
} # close study loop
|
|
sd.m ~ dunif(0, 5) # vague prior for SD (baseline)
|
|
tau.m <- pow(sd.m, -2) # between-trial precision (baseline)
|
|
m ~ dnorm(0, .0001) # vague prior for mean (baseline)
|
|
logit(prob) <- m # posterior probability of response
|
|
mu.new ~ dnorm(m, tau.m) # pred. dist. for baseline (log-odds)
|
|
logit(pred) <- mu.new # predictive probability of response
|
|
}
|
|
</pre></div><div id="niceng130er.appl.s5.3"><h4>Baseline model withdrawal due to adverse events (fixed-effect)</h4><pre>
|
|
# Binomial likelihood, cloglog link
|
|
# based on
|
|
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
|
|
# NICE DSU Technical Support Document 5: Evidemce synthesis in the baseline
|
|
# natural history model. 2011.
|
|
# <a href="http://www.nicedsu.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.nicedsu.org.uk</a>
|
|
|
|
model {
|
|
for(i in 1:NumStudies) { # indexes studies
|
|
k[i] ~ dbin(p[i], N[i]) # binomial likelihood
|
|
cloglog(p[i]) <- log(Yrs[i]) + m # model for linear predictor
|
|
} # close study loop
|
|
m ~ dnorm(0, 0.0001) # vague prior for baseline
|
|
cloglog(prob) <- log(1) + m # posterior mean yearly response rate
|
|
}
|
|
</pre></div><div id="niceng130er.appl.s5.4"><h4>Baseline model withdrawal due to adverse events (random effects)</h4><pre>
|
|
# Binomial likelihood, cloglog link
|
|
# based on
|
|
# Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E.
|
|
# NICE DSU Technical Support Document 5: Evidence synthesis in the baseline
|
|
# natural history model. 2011.
|
|
# <a href="http://www.nicedsu.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www.nicedsu.org.uk</a>
|
|
|
|
model {
|
|
for(i in 1:NumStudies) { # indexes studies
|
|
k[i] ~ dbin(p[i], N[i]) # binomial likelihood
|
|
cloglog(p[i]) <- log(Yrs[i]) + mu[i] # model for linear predictor
|
|
mu[i] ~ dnorm(m, tau.m) # trial-specific baseline with random effects
|
|
} # close study loop
|
|
sd.m ~ dunif(0, 5) # vague prior for SD (baseline)
|
|
tau.m <- pow(sd.m, -2) # between-trial precision (baseline)
|
|
m ~ dnorm(0, .0001) # vague prior for mean (baseline)
|
|
cloglog(prob) <- log(1) + m # posterior mean yearly response rate
|
|
mu.new ~ dnorm(m, tau.m) # pred. dist. for baseline (log-HR)
|
|
cloglog(pred) <- log(1) + mu.new # predictive mean yearly response rate
|
|
}
|
|
</pre></div></div></div><div id="niceng130er.appm"><h2 id="_niceng130er_appm_">Appendix M. Excluded studies</h2><div id="niceng130er.appm.s1"><h3>Clinical studies</h3><div id="niceng130er.appm.s1.1"><h4>Excluded studies which were included in 2013 guideline</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappmtab1"><a href="/books/NBK576848/table/niceng130er.appm.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappmtab1" rid-ob="figobniceng130erappmtab1"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appm.tab1/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appm.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appm.tab1"><a href="/books/NBK576848/table/niceng130er.appm.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erappmtab1">Table</a></h4></div></div></div><div id="niceng130er.appm.s1.2"><h4>Excluded studies from 2019 guideline update</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappmtab2"><a href="/books/NBK576848/table/niceng130er.appm.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappmtab2" rid-ob="figobniceng130erappmtab2"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appm.tab2/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appm.tab2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appm.tab2"><a href="/books/NBK576848/table/niceng130er.appm.tab2/?report=objectonly" target="object" rid-ob="figobniceng130erappmtab2">Table</a></h4></div></div></div><div id="niceng130er.appm.s1.3"><h4>Excluded studies from 2019 guideline update top-up search</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappmtab3"><a href="/books/NBK576848/table/niceng130er.appm.tab3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappmtab3" rid-ob="figobniceng130erappmtab3"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appm.tab3/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appm.tab3/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appm.tab3"><a href="/books/NBK576848/table/niceng130er.appm.tab3/?report=objectonly" target="object" rid-ob="figobniceng130erappmtab3">Table</a></h4></div></div></div></div></div><div id="niceng130er.appn"><h2 id="_niceng130er_appn_">Appendix N. Research recommendations</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappntab1"><a href="/books/NBK576848/table/niceng130er.appn.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappntab1" rid-ob="figobniceng130erappntab1"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appn.tab1/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appn.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appn.tab1"><a href="/books/NBK576848/table/niceng130er.appn.tab1/?report=objectonly" target="object" rid-ob="figobniceng130erappntab1">Table</a></h4><p class="float-caption no_bottom_margin">Clinical remission Endoscopic remission</p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappntab2"><a href="/books/NBK576848/table/niceng130er.appn.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappntab2" rid-ob="figobniceng130erappntab2"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appn.tab2/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appn.tab2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appn.tab2"><a href="/books/NBK576848/table/niceng130er.appn.tab2/?report=objectonly" target="object" rid-ob="figobniceng130erappntab2">Table</a></h4><p class="float-caption no_bottom_margin">Clinical remission Endoscopic remission</p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng130erappntab3"><a href="/books/NBK576848/table/niceng130er.appn.tab3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng130erappntab3" rid-ob="figobniceng130erappntab3"><img class="small-thumb" src="/books/NBK576848/table/niceng130er.appn.tab3/?report=thumb" src-large="/books/NBK576848/table/niceng130er.appn.tab3/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng130er.appn.tab3"><a href="/books/NBK576848/table/niceng130er.appn.tab3/?report=objectonly" target="object" rid-ob="figobniceng130erappntab3">Table</a></h4><p class="float-caption no_bottom_margin">Clinical remission Endoscopic remission</p></div></div></div><div><h2 id="NBK576848_footnotes">Footnotes</h2><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.fn1"><p class="no_top_margin">A trial duration limit of 12 weeks was applied. It was thought that any drug taking longer than 12 weeks to have an effect would not be suitable for the induction of remission and was more likely to be maintenance of remission treatment.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.fn2"><p class="no_top_margin">The committee agreed that the doses given in studies as ‘low dose’ coincided with the standard dose given in clinical practice.</p></div></dd></dl></dl></div><div style="display:none"><div style="display:none" id="figniceng130erapplfig3"><img alt="Image niceng130erapplf3" src-large="/books/NBK576848/bin/niceng130erapplf3.jpg" /></div><div style="display:none" id="figniceng130erapplfig4"><img alt="Image niceng130erapplf4" src-large="/books/NBK576848/bin/niceng130erapplf4.jpg" /></div><div style="display:none" id="figniceng130erapplfig5"><img alt="Image niceng130erapplf5" src-large="/books/NBK576848/bin/niceng130erapplf5.jpg" /></div><div style="display:none" id="figniceng130erapplfig9"><img alt="Image niceng130erapplf9" src-large="/books/NBK576848/bin/niceng130erapplf9.jpg" /></div><div style="display:none" id="figniceng130erapplfig10"><img alt="Image niceng130erapplf10" src-large="/books/NBK576848/bin/niceng130erapplf10.jpg" /></div><div style="display:none" id="figniceng130erapplfig12"><img alt="Image niceng130erapplf12" src-large="/books/NBK576848/bin/niceng130erapplf12.jpg" /></div><div style="display:none" id="figniceng130erapplfig13"><img alt="Image niceng130erapplf13" src-large="/books/NBK576848/bin/niceng130erapplf13.jpg" /></div><div style="display:none" id="figniceng130erapplfig14"><img alt="Image niceng130erapplf14" src-large="/books/NBK576848/bin/niceng130erapplf14.jpg" /></div><div style="display:none" id="figniceng130erapplfig16"><img alt="Image niceng130erapplf16" src-large="/books/NBK576848/bin/niceng130erapplf16.jpg" /></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>This evidence review was developed by the NICE Guideline Updates Team</p></div><div><p><b>Disclaimer:</b> The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2019.</div><div class="small"><span class="label">Bookshelf ID: NBK576848</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35072992" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">35072992</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng130ertab1"><div id="niceng130er.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO table</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng130er.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng130er.tab1_1_1_1_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Included: Adults (18 years and older), young people and children with a diagnosis of mild-to-moderate (author defined) ulcerative colitis.</p>
|
|
<p>Excluded: Mixed IBD populations where the results are not displayed separately for ulcerative colitis. People with indeterminate or idiopathic colitis. Chronic active ulcerative colitis. Inflammatory bowel disease-undefined (IBD-U) and colitis. Greater than 10% of the study population has severe ulcerative colitis (author defined).</p>
|
|
</td></tr><tr><th id="hd_b_niceng130er.tab1_1_1_2_1" rowspan="13" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><th id="hd_b_niceng130er.tab1_1_1_2_2" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">Corticosteroids</th><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Prednisolone</p>
|
|
<p>(alone only when Aminosalicylates not tolerated)</p>
|
|
</td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hydrocortisone</td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Budesonide</p>
|
|
<p>(alone only when Aminosalicylates not tolerated)</p>
|
|
</td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Beclometasone</p>
|
|
<p>(alone only when Aminosalicylates not tolerated)</p>
|
|
</td></tr><tr><th id="hd_b_niceng130er.tab1_1_1_6_1" rowspan="4" colspan="1" style="text-align:left;vertical-align:top;">Aminosalicylates</th><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine</td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine</td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Balsalazide</td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sulphasalazine</td></tr><tr><th id="hd_b_niceng130er.tab1_1_1_10_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">Immunomodulators</th><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methotrexate</td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tacrolimus</td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mycophenolate</td></tr><tr><th id="hd_b_niceng130er.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Placebo</th><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_b_niceng130er.tab1_1_1_2_1 hd_b_niceng130er.tab1_1_1_13_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Excluded
|
|
<ul><li class="half_rhythm"><div>Azathioprine and Mercaptopurine – excluded as both considered to be for maintenance of remission rather than induction.</div></li><li class="half_rhythm"><div>Hydrocortisone, Beclometasone and Budesonide excluded for children but included for adults.</div></li></ul>
|
|
The doses included are those considered effective for inducing remission for an acute exacerbation of ulcerative colitis.</p>
|
|
<p>Only drug treatments and preparations available in the UK are included.</p>
|
|
</td></tr><tr><th id="hd_b_niceng130er.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</th><td headers="hd_b_niceng130er.tab1_1_1_15_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Placebo</div></li><li class="half_rhythm"><div>Interclass comparisons</div></li><li class="half_rhythm"><div>Combinations of drugs</div></li><li class="half_rhythm"><div>Dose</div></li></ul></td></tr><tr><th id="hd_b_niceng130er.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng130er.tab1_1_1_16_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">RRs will be used for outcomes
|
|
<ul><li class="half_rhythm"><div>Clinical remission (author defined) at
|
|
<ul class="circle"><li class="half_rhythm"><div>< 2weeks</div></li><li class="half_rhythm"><div>2 to < 4 weeks</div></li><li class="half_rhythm"><div>4 to < 6 weeks</div></li><li class="half_rhythm"><div>6 to < 8weeks</div></li><li class="half_rhythm"><div>>8 weeks to 12 weeks<sup><a href="#niceng130er.fn1">1</a></sup></div></li></ul></div></li><li class="half_rhythm"><div>Withdrawal due to adverse events</div></li><li class="half_rhythm"><div>Quality of life</div></li></ul></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130ertab2"><div id="niceng130er.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Dosing criteria for the purpose of classifying evidence</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard dose</th><th id="hd_h_niceng130er.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High dose</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.tab2_1_1_1_1" id="hd_b_niceng130er.tab2_1_1_1_1" rowspan="4" colspan="1" style="text-align:left;vertical-align:top;">Corticosteroids</th><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisolone (alone only when Aminosalicylates not tolerated)</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_1_1 hd_b_niceng130er.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No criteria specified.</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_1_1 hd_b_niceng130er.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No criteria specified.</td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hydrocortisone</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_1_1 hd_b_niceng130er.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No criteria specified.</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_1_1 hd_b_niceng130er.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No criteria specified.</td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Budesonide (alone only when Aminosalicylates not tolerated)</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_1_1 hd_b_niceng130er.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults: 9mg per day</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_1_1 hd_b_niceng130er.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults: over 9mg per day</td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beclometasone (alone only when Aminosalicylates not tolerated)</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_1_1 hd_b_niceng130er.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No criteria specified.</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_1_1 hd_b_niceng130er.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No criteria specified.</td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_1" id="hd_b_niceng130er.tab2_1_1_5_1" rowspan="4" colspan="1" style="text-align:left;vertical-align:top;">Aminosalicylates</th><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_5_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_5_1 hd_b_niceng130er.tab2_1_1_5_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Asacol and octasa: 2.4 – <4.8g/day</p>
|
|
<p>Pentasa: up to 2g/day</p>
|
|
<p>Salofalk granules: up to 1.5g/day</p>
|
|
</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_5_1 hd_b_niceng130er.tab2_1_1_5_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Asacol and octasa: 4.8g/day</p>
|
|
<p>Pentasa: 4g/day or over</p>
|
|
<p>Salofalk granules: 3g/day or over</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_5_1 hd_b_niceng130er.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Up to 3g/day</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_5_1 hd_b_niceng130er.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3g/day and over</td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Balsalazide</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_5_1 hd_b_niceng130er.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">< 6.75g/day</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_5_1 hd_b_niceng130er.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.75g/day and over<sup>*</sup></td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sulphasalazine</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_5_1 hd_b_niceng130er.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 to 6g/day</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_5_1 hd_b_niceng130er.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Over 6g/day</td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_1" id="hd_b_niceng130er.tab2_1_1_9_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">Immunomodulators</th><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_9_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methotrexate</th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_9_1 hd_b_niceng130er.tab2_1_1_9_2 hd_b_niceng130er.tab2_1_1_10_1 hd_b_niceng130er.tab2_1_1_11_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">No criteria specified.</td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_9_1 hd_b_niceng130er.tab2_1_1_9_2 hd_b_niceng130er.tab2_1_1_10_1 hd_b_niceng130er.tab2_1_1_11_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">No criteria specified</td></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tacrolimus</th></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mycophenolate</th></tr><tr><th headers="hd_h_niceng130er.tab2_1_1_1_1" id="hd_b_niceng130er.tab2_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Placebo</th><th headers="hd_h_niceng130er.tab2_1_1_1_2" id="hd_b_niceng130er.tab2_1_1_12_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><td headers="hd_h_niceng130er.tab2_1_1_1_3 hd_b_niceng130er.tab2_1_1_12_1 hd_b_niceng130er.tab2_1_1_12_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab2_1_1_1_4 hd_b_niceng130er.tab2_1_1_12_1 hd_b_niceng130er.tab2_1_1_12_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>*</dt><dd><div id="niceng130er.tab2_1"><p class="no_margin">Note that one study (<a class="bibr" href="#niceng130er.appe.s1.1.ref32" rid="niceng130er.appe.s1.1.ref32">Scherl 2009</a>) reported a daily dose of 6.6g/day of Balsalazide. This was considered equivalent to 6.75g and was classified as high dose.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130ertab3"><div id="niceng130er.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Summary of economic evaluations included in the review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.tab3_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab3_1_1_1_1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng130er.tab3_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab3_1_1_1_2" style="text-align:left;vertical-align:bottom;">Comparators</th><th id="hd_h_niceng130er.tab3_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.tab3_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab3_1_1_1_4" style="text-align:left;vertical-align:bottom;">Uncertainty</th><th id="hd_h_niceng130er.tab3_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab3_1_1_1_5" style="text-align:left;vertical-align:bottom;">Applicability</th><th id="hd_h_niceng130er.tab3_1_1_1_6" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab3_1_1_1_6" style="text-align:left;vertical-align:bottom;">Limitations</th></tr><tr><th headers="hd_h_niceng130er.tab3_1_1_1_3" id="hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab3_1_1_1_3" id="hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effects</th><th headers="hd_h_niceng130er.tab3_1_1_1_3" id="hd_h_niceng130er.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost effectiveness</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s2.1.ref2" rid="niceng130er.appe.s2.1.ref2">Buckland 2008</a> (CUA)</td><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 1: Oral mesalazine (2.4g/day)</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,474</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1378 QALYs</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">INT 2 dominates<sup>(a)</sup> INT 1</td><td headers="hd_h_niceng130er.tab3_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Results were sensitive to duration of mesalazine treatment; in PSA, probability that INT 2 is cost effective at a threshold of £30K/QALY is 72%</td><td headers="hd_h_niceng130er.tab3_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable</td><td headers="hd_h_niceng130er.tab3_1_1_1_6" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 2: Oral mesalazine (4.8g/day)</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,382</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1394 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref7" rid="niceng130er.appe.s1.1.ref7">Connolly 2009</a> (CUA)</td><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 1: Oral mesalazine (4g/day) + placebo enema</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,388</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.55 QALYs</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">INT 2 dominates<sup>(a)</sup> INT 1</td><td headers="hd_h_niceng130er.tab3_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">In PSA, INT 2 had a higher probability of being cost effective over threshold values from £0 - £20K/QALY</td><td headers="hd_h_niceng130er.tab3_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable</td><td headers="hd_h_niceng130er.tab3_1_1_1_6" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 2: Oral mesalazine (4g/day) + mesalazine enema (1g/100mL)</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,813</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.56 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s2.1.ref1" rid="niceng130er.appe.s2.1.ref1">Brereton 2010</a> (CUA)</td><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 1: Oral mesalazine (2.4g/day)</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5,574</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.434 QALYs</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>ICER (INT 2 vs. INT 1):</p>
|
|
<p>£749/QALY</p>
|
|
</td><td headers="hd_h_niceng130er.tab3_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">In PSA, the probability that INT 2 is cost effective at a threshold of £20K/QALY is 74%</td><td headers="hd_h_niceng130er.tab3_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable</td><td headers="hd_h_niceng130er.tab3_1_1_1_6" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Very serious limitations</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 2: Modified release multimatrix oral mesalazine (2.4g/day)</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5,582</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.445 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s2.1.ref4" rid="niceng130er.appe.s2.1.ref4">Connolly 2014</a> (CUA)</td><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 1: Oral mesalazine 2g oral twice daily</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,978</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.56 QALYs</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">INT 2 dominates<sup>(a)</sup> INT 1</td><td headers="hd_h_niceng130er.tab3_1_1_1_4" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">PSA was conducted varying remission rates only; only mean results reported</td><td headers="hd_h_niceng130er.tab3_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable</td><td headers="hd_h_niceng130er.tab3_1_1_1_6" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 2: Oral mesalazine 4g once daily</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,600</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.57 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_1" rowspan="10" colspan="1" style="text-align:left;vertical-align:top;">2013 NICE Guideline (CUA)</td><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 1: High-dose oral ASA, add topical ASA, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,316</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.468 QALYs</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>ICER (INT 8 vs. INT 10):</p>
|
|
<p>£42,622/QALY</p>
|
|
</td><td headers="hd_h_niceng130er.tab3_1_1_1_4" rowspan="10" colspan="1" style="text-align:left;vertical-align:top;">In PSA, INT 10 had the highest probability of being cost effective at a threshold of £20K/QALY (54%)</td><td headers="hd_h_niceng130er.tab3_1_1_1_5" rowspan="10" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable</td><td headers="hd_h_niceng130er.tab3_1_1_1_6" rowspan="10" colspan="1" style="text-align:left;vertical-align:top;">Minor limitations</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 2: High-dose oral ASA, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,144</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.463 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 3: Low-dose oral ASA, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,345</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.458 QALYs</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_3" rowspan="8" colspan="1" style="text-align:left;vertical-align:top;">All other strategies are dominated</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 4: Low-dose oral ASA, add topical ASA, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,386</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.465 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 5: Low-dose oral ASA, high oral ASA, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,509</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.459 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 6: Low-dose oral ASA, high oral ASA, add topical ASA, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,013</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.461 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 7: High-dose oral ASA + topical ASA, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,953</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.472 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 8: High-dose oral ASA + beclometasone, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,364</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.481 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 9: Low-dose oral ASA, high oral ASA + beclometasone, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,012</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.469 QALYs</td></tr><tr><td headers="hd_h_niceng130er.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INT 10: High-dose oral ASA, high oral ASA + beclometasone, prednisolone</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£984</td><td headers="hd_h_niceng130er.tab3_1_1_1_3 hd_h_niceng130er.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.472 QALYs</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">ASA = aminosalicylate; CUA = cost-utility analysis; QALY = quality-adjusted life year; PSA = probabilistic sensitivity analysis</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.tab3_1"><p class="no_margin">INT 2 is both more effective and less costly than INT 1</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130ertab4"><div id="niceng130er.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Description of treatment strategies in the cost-effectiveness model by extent of disease</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.tab4_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.tab4_1_1_1_1" colspan="4" rowspan="1" style="text-align:left;vertical-align:top;">Proctitis</th></tr><tr><th headers="hd_h_niceng130er.tab4_1_1_1_1" id="hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1<sup>st</sup> line</th><th headers="hd_h_niceng130er.tab4_1_1_1_1" id="hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2<sup>nd</sup> line</th><th headers="hd_h_niceng130er.tab4_1_1_1_1" id="hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3<sup>rd</sup> line</th><th headers="hd_h_niceng130er.tab4_1_1_1_1" id="hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4<sup>th</sup> line</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical tacrolimus</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical tacrolimus</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical tacrolimus</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical tacrolimus</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA + topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical tacrolimus</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA + topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical tacrolimus</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Ad topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA + topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA + topical ASA</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.tab4_1_1_1_1 hd_h_niceng130er.tab4_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr></tbody></table><table><thead><tr><th id="hd_h_niceng130er.tab4_1_2_1_1" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">Proctosigmoiditis and left-sided disease</th></tr><tr><th headers="hd_h_niceng130er.tab4_1_2_1_1" id="hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1<sup>st</sup> line</th><th headers="hd_h_niceng130er.tab4_1_2_1_1" id="hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2<sup>nd</sup> line</th><th headers="hd_h_niceng130er.tab4_1_2_1_1" id="hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3<sup>rd</sup> line</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">HD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">HD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">HD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">HD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA + topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA + topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add LD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add HD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Topical CS</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">LD oral ASA + topical ASA</td><td headers="hd_h_niceng130er.tab4_1_2_1_1 hd_h_niceng130er.tab4_1_2_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td></tr></tbody></table><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.tab4_1_3_1_1" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">Extensive disease</th></tr><tr><th headers="hd_h_niceng130er.tab4_1_3_1_1" id="hd_h_niceng130er.tab4_1_3_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1<sup>st</sup> line</th><th headers="hd_h_niceng130er.tab4_1_3_1_1" id="hd_h_niceng130er.tab4_1_3_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2<sup>nd</sup> line</th><th headers="hd_h_niceng130er.tab4_1_3_1_1" id="hd_h_niceng130er.tab4_1_3_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3<sup>rd</sup> line</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.tab4_1_3_1_1 hd_h_niceng130er.tab4_1_3_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">HD oral ASA</td><td headers="hd_h_niceng130er.tab4_1_3_1_1 hd_h_niceng130er.tab4_1_3_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Add topical ASA</td><td headers="hd_h_niceng130er.tab4_1_3_1_1 hd_h_niceng130er.tab4_1_3_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td></tr><tr><td headers="hd_h_niceng130er.tab4_1_3_1_1 hd_h_niceng130er.tab4_1_3_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">HD oral ASA + topical ASA</td><td headers="hd_h_niceng130er.tab4_1_3_1_1 hd_h_niceng130er.tab4_1_3_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Oral CS<sup>*</sup></td><td headers="hd_h_niceng130er.tab4_1_3_1_1 hd_h_niceng130er.tab4_1_3_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">ASA = aminosalicylate; CS = corticosteroid; HD = high-dose; LD = low-dose</p></div></dd></dl><dl class="bkr_refwrap"><dt>*</dt><dd><div id="niceng130er.tab4_1"><p class="no_margin">Oral CS and topical CS are assumed to be given in addition to LD oral ASA unless a person has previously withdrawn from ASA treatment due to adverse events</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erfig1"><div id="niceng130er.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Structure%20of%20the%20decision%20tree%20for%20a%20single%20sequence%20of%20treatments.&p=BOOKS&id=576848_niceng130erf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erf1.jpg" alt="Figure 1. Structure of the decision tree for a single sequence of treatments." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Structure of the decision tree for a single sequence of treatments</span></h3></div></article><article data-type="table-wrap" id="figobniceng130ertab5"><div id="niceng130er.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Base-case mean probabilistic cost-effectiveness results in proctitis</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.tab5_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.tab5_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.tab5_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Total</th><th id="hd_h_niceng130er.tab5_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">Incremental</th><th id="hd_h_niceng130er.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab5_1_1_1_4" style="text-align:left;vertical-align:top;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.tab5_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab5_1_1_1_5" style="text-align:left;vertical-align:top;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.tab5_1_1_1_2" id="hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab5_1_1_1_2" id="hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.tab5_1_1_1_3" id="hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab5_1_1_1_3" id="hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.tab5_1_1_1_3" id="hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER<sup>(a)</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC01</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£437</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5320</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.9%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,202</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC03</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£448</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5318</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.9%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,189</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC02</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£451</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5314</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£14</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0006</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.4%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,177</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC04</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£470</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5312</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£33</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0008</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,154</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC17</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£472</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5321</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£34</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0001</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£359,175</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.3%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,169</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC19</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£500</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5320</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£28</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.9%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,139</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC18</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£512</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5316</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£40</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0005</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,119</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC20</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£558</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5314</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£86</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0006</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,071</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC05</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£651</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£180</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0141</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,709</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC09</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£675</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5232</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£203</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0089</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,788</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC13</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£678</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5230</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£206</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0091</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,782</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC07</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£694</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5174</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£222</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,655</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC06</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£714</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5154</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£242</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0166</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,595</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC11</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£744</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5222</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£272</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0098</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,701</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC15</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£748</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5220</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£276</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0100</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,692</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC10</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£779</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5188</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£307</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,597</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC14</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£783</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5186</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£311</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0135</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,588</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC08</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£793</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5146</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£322</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0174</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,499</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC21</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£797</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5184</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£325</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0137</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,571</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC12</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£913</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5175</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£442</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,436</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC25</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£917</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5238</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£446</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0082</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,559</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC23</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£918</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£446</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0140</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,443</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC16</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£920</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5172</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£448</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0148</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,425</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC29</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£924</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5237</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£452</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0084</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,549</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC22</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£985</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5162</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£514</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0159</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,338</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC27</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,116</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5232</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£644</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0088</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,349</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC31</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,127</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5230</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£655</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0090</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,334</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC24</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,179</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5157</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£707</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0164</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,135</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC26</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,234</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5200</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£762</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0120</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,166</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC30</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,245</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5198</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£773</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0122</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,151</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC28</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,563</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5192</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,091</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0128</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,821</td></tr><tr><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC32</td><td headers="hd_h_niceng130er.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,579</td><td headers="hd_h_niceng130er.tab5_1_1_1_2 hd_h_niceng130er.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5190</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,107</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0131</td><td headers="hd_h_niceng130er.tab5_1_1_1_3 hd_h_niceng130er.tab5_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,801</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PRC = proctitis; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; tTAC = topical tacrolimus; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.tab5_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erfig2"><div id="niceng130er.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20Cost-effectiveness%20acceptability%20curve%20for%20proctitis%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erf2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erf2.jpg" alt="Figure 2. Cost-effectiveness acceptability curve for proctitis base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">Cost-effectiveness acceptability curve for proctitis base-case analysis</span></h3></div></article><article data-type="fig" id="figobniceng130erfig3"><div id="niceng130er.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20Cost-effectiveness%20acceptability%20frontier%20for%20proctitis%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erf3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erf3.jpg" alt="Figure 3. Cost-effectiveness acceptability frontier for proctitis base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3</span><span class="title">Cost-effectiveness acceptability frontier for proctitis base-case analysis</span></h3></div></article><article data-type="table-wrap" id="figobniceng130ertab6"><div id="niceng130er.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">Base-case mean probabilistic cost-effectiveness results in proctosigmoiditis and left-sided disease</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.tab6_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.tab6_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.tab6_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.tab6_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab6_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.tab6_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab6_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.tab6_1_1_1_2" id="hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab6_1_1_1_2" id="hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.tab6_1_1_1_3" id="hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab6_1_1_1_3" id="hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.tab6_1_1_1_3" id="hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER<sup>(a)</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS31</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, <i><b>LD oASA + oCS (pred)</b></i></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£749</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5286</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.9%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,823</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS34</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£769</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5294</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£20</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0008</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£24,396</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.5%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,819</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS64</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£775</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5266</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0028</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.6%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,757</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS73</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£779</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5269</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0025</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.6%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,759</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS32</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£788</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5293</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£19</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.6%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,799</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS55</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£789</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5263</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£20</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0031</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.9%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,737</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS74</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£830</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5279</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£61</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0015</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.5%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,727</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS65</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£830</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5277</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£61</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0017</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.8%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,723</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS56</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£850</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5274</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£81</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0020</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,699</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS33</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£874</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5283</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£104</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0011</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,692</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS75</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£942</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5265</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£173</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0029</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,588</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS66</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£953</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5262</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£184</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0032</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,570</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS57</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£987</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5258</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£218</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0036</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,529</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS10</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,034</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£265</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,287</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS07</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,048</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£279</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,273</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS28</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,055</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5174</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£285</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0120</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,294</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS22</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,055</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5164</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£285</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0130</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,273</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS25</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, <b><i>LD oASA+ oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,063</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5173</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£293</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0121</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,283</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS19</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,068</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5163</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£299</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0131</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,259</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS04</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,181</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£412</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.4%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,084</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS16</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,188</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5138</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£419</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0156</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.3%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,087</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS01</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,195</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£426</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,069</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS13</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,202</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5137</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£433</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0157</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,073</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS40</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,233</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5228</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£464</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0066</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,224</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS46</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,238</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5227</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£469</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0067</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,216</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS26</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,269</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5168</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£500</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0126</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.7%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,067</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS17</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,285</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£516</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0138</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,027</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS05</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,286</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5152</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£517</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0142</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.6%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,019</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS14</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,299</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£530</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0139</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,012</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS02</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,300</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5152</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£531</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0142</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,004</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS37</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,430</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5190</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£661</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0104</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,949</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS43</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,439</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5188</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£670</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0106</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,937</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS27</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,465</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5143</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£695</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0151</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,822</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS18</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,506</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5130</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£737</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0165</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,753</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS15</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,522</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5129</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£753</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0165</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,736</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS06</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,528</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5123</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£758</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0171</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,719</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS03</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,544</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5123</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£775</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0171</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,702</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS38</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,582</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5218</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£813</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0076</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,854</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS44</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,594</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5217</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£825</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0077</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,840</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS39</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,902</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5178</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,133</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0116</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,453</td></tr><tr><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS45</td><td headers="hd_h_niceng130er.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,916</td><td headers="hd_h_niceng130er.tab6_1_1_1_2 hd_h_niceng130er.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5176</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,147</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0118</td><td headers="hd_h_niceng130er.tab6_1_1_1_3 hd_h_niceng130er.tab6_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,435</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PLS = proctosigmoiditis and left-sided disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.tab6_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erfig4"><div id="niceng130er.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%204.%20Cost-effectiveness%20acceptability%20curve%20for%20proctosigmoiditis%20and%20left-sided%20disease%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erf4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erf4.jpg" alt="Figure 4. Cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 4</span><span class="title">Cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease base-case analysis</span></h3></div></article><article data-type="fig" id="figobniceng130erfig5"><div id="niceng130er.fig5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%205.%20Cost-effectiveness%20acceptability%20frontier%20for%20proctosigmoiditis%20and%20left-sided%20disease%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erf5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erf5.jpg" alt="Figure 5. Cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 5</span><span class="title">Cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease base-case analysis</span></h3></div></article><article data-type="table-wrap" id="figobniceng130ertab7"><div id="niceng130er.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">Base-case mean probabilistc cost-effectiveness results in extensive disease</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.tab7_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.tab7_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.tab7_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.tab7_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.tab7_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab7_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.tab7_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab7_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.tab7_1_1_1_2" id="hd_h_niceng130er.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab7_1_1_1_2" id="hd_h_niceng130er.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.tab7_1_1_1_3" id="hd_h_niceng130er.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab7_1_1_1_3" id="hd_h_niceng130er.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.tab7_1_1_1_3" id="hd_h_niceng130er.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER<sup>(a)</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT02</td><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£895</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5197</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.8%</td><td headers="hd_h_niceng130er.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,500</td></tr><tr><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT03</td><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£929</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5185</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£34</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0012</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.6%</td><td headers="hd_h_niceng130er.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,442</td></tr><tr><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT05</td><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,069</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5248</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£174</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0050</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£34,460</td><td headers="hd_h_niceng130er.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.1%</td><td headers="hd_h_niceng130er.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,427</td></tr><tr><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT06</td><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,128</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5225</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£59</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0022</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.4%</td><td headers="hd_h_niceng130er.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,323</td></tr><tr><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT01</td><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,132</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£63</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0068</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,227</td></tr><tr><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT04</td><td headers="hd_h_niceng130er.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,505</td><td headers="hd_h_niceng130er.tab7_1_1_1_2 hd_h_niceng130er.tab7_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5216</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£436</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0032</td><td headers="hd_h_niceng130er.tab7_1_1_1_3 hd_h_niceng130er.tab7_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,926</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">EXT = extensive disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.tab7_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erfig6"><div id="niceng130er.fig6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%206.%20Cost-effectiveness%20acceptability%20curve%20for%20extensive%20disease%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erf6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erf6.jpg" alt="Figure 6. Cost-effectiveness acceptability curve for extensive disease base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 6</span><span class="title">Cost-effectiveness acceptability curve for extensive disease base-case analysis</span></h3></div></article><article data-type="fig" id="figobniceng130erfig7"><div id="niceng130er.fig7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%207.%20Cost-effectiveness%20acceptability%20frontier%20for%20extensive%20disease%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erf7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erf7.jpg" alt="Figure 7. Cost-effectiveness acceptability frontier for extensive disease base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 7</span><span class="title">Cost-effectiveness acceptability frontier for extensive disease base-case analysis</span></h3></div></article><article data-type="table-wrap" id="figobniceng130ertab8"><div id="niceng130er.tab8" class="table"><h3><span class="label">Table 8</span><span class="title">Mean probabilistic cost-effectiveness results for extensive disease with no early switching of treatments in the event of non-remission</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.tab8_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.tab8_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.tab8_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.tab8_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.tab8_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab8_1_1_1_4" style="text-align:left;vertical-align:bottom;">
|
|
<p>Prob CE at £20K/ QALY</p>
|
|
</th><th id="hd_h_niceng130er.tab8_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.tab8_1_1_1_5" style="text-align:left;vertical-align:bottom;">
|
|
<p>NMB at £20K/ QALY</p>
|
|
</th></tr><tr><th headers="hd_h_niceng130er.tab8_1_1_1_2" id="hd_h_niceng130er.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab8_1_1_1_2" id="hd_h_niceng130er.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.tab8_1_1_1_3" id="hd_h_niceng130er.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.tab8_1_1_1_3" id="hd_h_niceng130er.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.tab8_1_1_1_3" id="hd_h_niceng130er.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT02</td><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£985</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5103</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.8%</td><td headers="hd_h_niceng130er.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,221</td></tr><tr><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT03</td><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,030</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5084</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£45</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0018</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.6%</td><td headers="hd_h_niceng130er.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,138</td></tr><tr><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT05</td><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,148</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5198</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£163</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0095</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£17,087</td><td headers="hd_h_niceng130er.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.9%</td><td headers="hd_h_niceng130er.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,248</td></tr><tr><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT06</td><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,225</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5166</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£77</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0032</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.7%</td><td headers="hd_h_niceng130er.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,107</td></tr><tr><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT01</td><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,246</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5071</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£98</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0127</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,897</td></tr><tr><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT04</td><td headers="hd_h_niceng130er.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,605</td><td headers="hd_h_niceng130er.tab8_1_1_1_2 hd_h_niceng130er.tab8_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.5143</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£457</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.0055</td><td headers="hd_h_niceng130er.tab8_1_1_1_3 hd_h_niceng130er.tab8_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,682</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">EXT = extensive disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.tab8_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappatab1"><div id="niceng130er.appa.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appa.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ID</th><th id="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Field (based on <a href="http://www.prisma-statement.org/Extensions/Protocols.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PRISMA-P</a>)</th><th id="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Content</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">I</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">In adults, children and young people with mild-to-moderate ulcerative colitis, what is the clinical and cost-effectiveness of corticosteroids, aminosalicylates, immunomodulators (methotrexate, mycophenolate and tacrolimus) for the induction of remission compared to themselves (different preparations and doses), each other, combinations of preparations (oral and topical) and placebo?</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">II</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Intervention</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">III</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">To update and expand the question in CG166. To assess the clinical and cost effectiveness of corticosteroids, aminosalicylates, immunomodulators and other relevant drugs vs. placebo, themselves and each other for the induction of remission in ulcerative colitis and to develop a recommended sequence strategy for drug treatment in induction of remission in ulcerative colitis.</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IV</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – population</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Included: Children young people and adults (18 years and older), with a diagnosis of mild-to-moderate (author defined) ulcerative colitis.</p>
|
|
<p>Excluded: Mixed IBD populations where the results are not displayed separately for ulcerative colitis. People with indeterminate or idiopathic colitis. Chronic active ulcerative colitis. Inflammatory bowel disease-undefined (IBD-U) and colitis. Greater than 10% of the study population has severe ulcerative colitis.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_5_1 hd_b_niceng130er.appa.tab1_1_1_9_1 hd_b_niceng130er.appa.tab1_1_1_13_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="13" colspan="1" style="text-align:center;vertical-align:top;">V</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2 hd_b_niceng130er.appa.tab1_1_1_5_1 hd_b_niceng130er.appa.tab1_1_1_9_1 hd_b_niceng130er.appa.tab1_1_1_13_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="13" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Interventions</b>
|
|
</td><th headers="hd_h_niceng130er.appa.tab1_1_1_1_3" id="hd_b_niceng130er.appa.tab1_1_1_5_1" rowspan="4" colspan="1" style="text-align:left;vertical-align:top;">Corticosteroids</th><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Prednisolone</p>
|
|
<p>(alone only when Aminosalicylates not tolerated)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hydrocortisone</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Budesonide</p>
|
|
<p>(alone only when Aminosalicylates not tolerated)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Beclometasone</p>
|
|
<p>(alone only when Aminosalicylates not tolerated)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appa.tab1_1_1_1_3" id="hd_b_niceng130er.appa.tab1_1_1_9_1" rowspan="4" colspan="1" style="text-align:left;vertical-align:top;">Aminosalicylates</th><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Balsalazide</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sulphasalazine</td></tr><tr><th headers="hd_h_niceng130er.appa.tab1_1_1_1_3" id="hd_b_niceng130er.appa.tab1_1_1_13_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">Immunomodulators</th><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methotrexate</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tacrolimus</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mycophenolate</td></tr><tr><th headers="hd_h_niceng130er.appa.tab1_1_1_1_3" id="hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Placebo</th><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Excluded
|
|
<ul><li class="half_rhythm"><div>Azathioprine and Mercaptopurine – excluded as both considered for maintenance of remission.</div></li><li class="half_rhythm"><div>Hydrocortisone, Beclometasone and Budesonide excluded for children but included for adults.</div></li></ul>
|
|
The doses included are those considered effective for inducing remission for an acute exacerbation of ulcerative colitis.</p>
|
|
<p>Only drug treatments and preparations available in the UK are included.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">VI</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Placebo</div></li><li class="half_rhythm"><div>Interclass comparisons</div></li><li class="half_rhythm"><div>Combinations of drugs</div></li><li class="half_rhythm"><div>Dose</div></li></ul></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">VII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">RRs will be used for outcomes
|
|
<ul><li class="half_rhythm"><div>Clinical remission (author defined) at
|
|
<ul class="circle"><li class="half_rhythm"><div>< 2weeks</div></li><li class="half_rhythm"><div>2 to < 4 weeks</div></li><li class="half_rhythm"><div>4 to < 6 weeks</div></li><li class="half_rhythm"><div>6 to < 8weeks</div></li><li class="half_rhythm"><div>>8 weeks to 12 weeks</div></li></ul></div></li><li class="half_rhythm"><div>Withdrawal due to adverse events</div></li></ul>
|
|
Quality of life (including short QOL questionnaire, IMPACT 3)</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">VIII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – study design</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>RCTs</div></li><li class="half_rhythm"><div>Systematic reviews of RCTs</div></li></ul></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IX</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other exclusion criteria</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div class="half_rhythm">Non English- language papers will be excluded</div></li><li class="half_rhythm"><div class="half_rhythm">A trial duration limit of 12 weeks. Any drug taking longer than 12 weeks to have an effect would not be suitable for the induction of remission and more likely to be a maintenance treatment, unless 12 week data can be disaggregated.</div><div class="half_rhythm">Protocols, abstracts, conference proceedings, theses, non-peer reviewed publications</div></li></ul></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">X</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity/sub-group analysis, or meta-regression</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Data will be stratified based on:
|
|
<ul class="circle"><li class="half_rhythm"><div>Dose – please see standard and high dose definitions in methods section.</div></li><li class="half_rhythm"><div>Mode of delivery:
|
|
<ul class="circle"><li class="half_rhythm"><div>Topical (including foam enema, liquid enema and suppository) – suitable alone for proctitis</div></li><li class="half_rhythm"><div>Oral (including: modified release granule sachet modified release tablet, gastro-resistant tablets)</div></li><li class="half_rhythm"><div>Subcutaneous – methotrexate only</div></li></ul></div></li></ul>
|
|
Subgroups:
|
|
<ul class="circle"><li class="half_rhythm"><div>Extent of disease
|
|
<ul class="circle"><li class="half_rhythm"><div>proctitis</div></li><li class="half_rhythm"><div>proctosigmoiditis</div></li><li class="half_rhythm"><div>left-sided or extensive</div></li></ul></div></li><li class="half_rhythm"><div>Mild/moderate disease</div></li><li class="half_rhythm"><div>Children, young people, adults</div></li></ul>
|
|
If there is heterogeneity the following will be analysed separately:
|
|
<ul class="circle"><li class="half_rhythm"><div>Formulation (sachet, tablets, coated and not coated)</div></li><li class="half_rhythm"><div>Regimen (for example, once versus twice a day)</div></li></ul></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XI</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process – duplicate screening/selection/analysis</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">10% of the abstracts were reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. If meaningful disagreements were found between the different reviewers, a further 10% of the abstracts were reviewed by two reviewers, with this process continued until agreement is achieved between the two reviewers. From this point, the remaining abstracts will be screened by a single reviewer</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management (software)</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appb">Appendix B</a></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XIII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources – databases and dates</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appc">appendix C</a> of the relevant chapter</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XIV</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Update of 2013 guideline</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XV</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Guideline updates team</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XVI</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to previous protocol</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">For details please see section 4.5 of <a href="https://www.nice.org.uk/article/pmg20/chapter/4-Developing-review-questions-and-planning-the-evidence-review#planning-the-evidence-review" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XVII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy – for one database</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">For details please see <a href="#niceng130er.appc">appendix C</a> of relevant chapter</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XVIII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process – forms/duplicate</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table format will be used, and published as <a href="#niceng130er.appe">appendix E</a> (clinical evidence tables) or <a href="#niceng130er.apph">H</a> (economic evidence tables). 10% of the data extraction were reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer.</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XIX</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items – define all variables to be collected</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">For details please see evidence tables in <a href="#niceng130er.appe">appendix E</a> (clinical evidence tables) or <a href="#niceng130er.apph">H</a> (economic evidence tables).</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XX</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at outcome/study level</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appb">Appendix B</a></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXI</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative synthesis (where suitable)</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appb">Appendix B</a></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for analysis – combining studies and exploring (in)consistency</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appb">Appendix B</a></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXIII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment – publication bias, selective reporting bias</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appb">Appendix B</a></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXIV</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assessment of confidence in cumulative evidence</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appb">Appendix B</a></td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXV</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale/context – Current management</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">For details please see the introduction to the evidence review in the main file.</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXVI</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of authors and guarantor</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>A multidisciplinary committee developed the evidence review. The committee was convened by the NICE Guideline Updates Team and chaired by Tessa Lewis in line with section 3 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
<p>Staff from NICE undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details please see <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXVII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding/support</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">The NICE Guideline Updates Team is an internal team within NICE.</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXVIII</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">The NICE Guideline Updates Team is an internal team within NICE.</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXIX</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">The NICE Guideline Updates Team is an internal team within NICE.</td></tr><tr><td headers="hd_h_niceng130er.appa.tab1_1_1_1_1 hd_b_niceng130er.appa.tab1_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">XXX</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration number</td><td headers="hd_h_niceng130er.appa.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">N/A</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappbtab1"><div id="niceng130er.appb.tab1" class="table"><h3><span class="label">Table 9</span><span class="title">Rationale for downgrading quality of evidence for intervention studies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GRADE criteria</th><th id="hd_h_niceng130er.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reasons for downgrading quality</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</td><td headers="hd_h_niceng130er.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Not serious: If less than 33.3% of the weight in a meta-analysis came from studies at moderate or high risk of bias, the overall outcome was not downgraded.</p>
|
|
<p>Serious: If greater than 33.3% of the weight in a meta-analysis came from studies at moderate or high risk of bias, the outcome was downgraded one level.</p>
|
|
<p>Very serious: If greater than 33.3% of the weight in a meta-analysis came from studies at high risk of bias, the outcome was downgraded two levels.</p>
|
|
<p>Outcomes meeting the criteria for downgrading above were not downgraded if there was evidence the effect size was not meaningfully different between studies at high and low risk of bias.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</td><td headers="hd_h_niceng130er.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Not serious: If less than 33.3% of the weight in a meta-analysis came from partially indirect or indirect studies, the overall outcome was not downgraded.</p>
|
|
<p>Serious: If greater than 33.3% of the weight in a meta-analysis came from partially indirect or indirect studies, the outcome was downgraded one level.</p>
|
|
<p>Very serious: If greater than 33.3% of the weight in a meta-analysis came from indirect studies, the outcome was downgraded two levels.</p>
|
|
<p>Outcomes meeting the criteria for downgrading above were not downgraded if there was evidence the effect size was not meaningfully different between direct and indirect studies.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</td><td headers="hd_h_niceng130er.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Concerns about inconsistency of effects across studies, occurring when there is unexplained variability in the treatment effect demonstrated across studies (heterogeneity), after appropriate pre-specified subgroup analyses have been conducted. This was assessed using the I<sup>2</sup> statistic.</p>
|
|
<p>N/A: Inconsistency was marked as not applicable if data on the outcome was only available from one study.</p>
|
|
<p>Not serious: If the I<sup>2</sup> was less than 33.3%, the outcome was not downgraded.</p>
|
|
<p>Serious: If the I<sup>2</sup> was between 33.3% and 66.7%, the outcome was downgraded one level.</p>
|
|
<p>Very serious: If the I<sup>2</sup> was greater than 66.7%, the outcome was downgraded two levels.</p>
|
|
<p>Outcomes meeting the criteria for downgrading above were not downgraded if there was evidence the effect size was not meaningfully different between studies with the smallest and largest effect sizes.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</td><td headers="hd_h_niceng130er.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>If an MID other than the line of no effect was defined for the outcome, the outcome was downgraded once if the 95% confidence interval for the effect size crossed one line of the MID, and twice if it crosses both lines of the MID.</p>
|
|
<p>If the line of no effect was defined as an MID for the outcome, it was downgraded once if the 95% confidence interval for the effect size crossed the line of no effect (i.e. the outcome was not statistically significant), and twice if the sample size of the study was sufficiently small that it is not plausible any realistic effect size could have been detected.</p>
|
|
<p>Outcomes meeting the criteria for downgrading above were not downgraded if the confidence interval was sufficiently narrow that the upper and lower bounds would correspond to clinically equivalent scenarios.</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappbtab2"><div id="niceng130er.appb.tab2" class="table"><h3><span class="label">Table 10</span><span class="title">Rationale for downgrading quality of evidence for intervention studies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appb.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GRADE criteria</th><th id="hd_h_niceng130er.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reasons for downgrading quality</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Risk of bias</td><td headers="hd_h_niceng130er.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Not serious: If fewer than 33.3% of the studies in the network meta-analysis were at moderate or high risk of bias, the overall network was not downgraded.</p>
|
|
<p>Serious: If greater than 33.3% of the studies in the network meta-analysis were at moderate or high risk of bias, the network was downgraded one level.</p>
|
|
<p>Very serious: If greater than 33.3% of the studies in the network meta-analysis were at high risk of bias, the network was downgraded two levels.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Indirectness</td><td headers="hd_h_niceng130er.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Not serious: If fewer than 33.3% of the studies in the network meta-analysis were partially indirect or indirect, the overall network was not downgraded.</p>
|
|
<p>Serious: If greater than 33.3% of the studies in the network meta-analysis were partially indirect or indirect, the network was downgraded one level.</p>
|
|
<p>Very serious: If greater than 33.3% of the studies in the network meta-analysis were indirect, the network was downgraded two levels.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inconsistency</td><td headers="hd_h_niceng130er.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>N/A: Inconsistency was marked as not applicable if there were no links in the network where data from multiple studies (either direct or indirect) were synthesised.</p>
|
|
<p>For network meta-analyses, the network was downgraded one level if the DIC for a random-effects model was lower than the DIC for a fixed-effect model.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Imprecision</td><td headers="hd_h_niceng130er.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The overall network was downgraded for imprecision if it was not possible to differentiate between any meaningfully distinct treatments options in the network (based on 95% confidence/credible intervals). Whether two options were meaningfully distinct was judged using the MIDs defined above for pairwise meta-analysis of the outcomes, if available; or statistical significance if MIDs were not available.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab1"><div id="niceng130er.appc.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Databases</th><th id="hd_h_niceng130er.appc.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Date searched</th><th id="hd_h_niceng130er.appc.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Version/files</th><th id="hd_h_niceng130er.appc.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. retrieved</th><th id="hd_h_niceng130er.appc.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">EndNote data (post de-dupe)</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Cochrane Central Register of Controlled Trials (CENTRAL)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">02/11/2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 10 of 12, October 2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1025</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">758</td></tr><tr><td headers="hd_h_niceng130er.appc.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Cochrane Database of Systematic Reviews (CDSR)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">02/11/2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 11 of 12, November 2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td></tr><tr><td headers="hd_h_niceng130er.appc.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Database of Abstracts of Reviews of Effect (DARE)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">02/11/2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 2 of 4, April 2015</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11</td></tr><tr><td headers="hd_h_niceng130er.appc.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Health Technology Assessment (HTA Database)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">02/11/2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 4 of 4, October 2016</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15</td></tr><tr><td headers="hd_h_niceng130er.appc.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Embase (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">02/11/2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974 to 2017 Week 44</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8906</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6032</td></tr><tr><td headers="hd_h_niceng130er.appc.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MEDLINE (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">02/11/2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1946 to October Week 4 2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3230</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2544</td></tr><tr><td headers="hd_h_niceng130er.appc.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MEDLINE In-Process (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">02/11/2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">November 01, 2017</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">303</td><td headers="hd_h_niceng130er.appc.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">269</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab2"><div id="niceng130er.appc.tab2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Databases</th><th id="hd_h_niceng130er.appc.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Date searched</th><th id="hd_h_niceng130er.appc.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Version/files</th><th id="hd_h_niceng130er.appc.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. retrieved</th><th id="hd_h_niceng130er.appc.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">EndNote data (post de-dupe)</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Cochrane Central Register of Controlled Trials (CENTRAL)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">05/12/2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 11 of 12, November 2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td></tr><tr><td headers="hd_h_niceng130er.appc.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Cochrane Database of Systematic Reviews (CDSR)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">05/12/2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 12 of 12, December 2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td></tr><tr><td headers="hd_h_niceng130er.appc.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Database of Abstracts of Reviews of Effect (DARE)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">05/12/2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 2 of 4, April 2015</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td></tr><tr><td headers="hd_h_niceng130er.appc.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Health Technology Assessment (HTA Database)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">05/12/2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 4 of 4, October 2016</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td></tr><tr><td headers="hd_h_niceng130er.appc.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Embase (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">05/12/2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974 to 2017 Week 49</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35</td></tr><tr><td headers="hd_h_niceng130er.appc.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MEDLINE (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">05/12/2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1946 to Present with</p>
|
|
<p>Daily Update</p>
|
|
</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td></tr><tr><td headers="hd_h_niceng130er.appc.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MEDLINE In-Process (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">05/12/2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">December 04, 2017</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_niceng130er.appc.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab3"><div id="niceng130er.appc.tab3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Databases</th><th id="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Date searched</th><th id="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Version/files</th><th id="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. retrieved</th><th id="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Post dedupe</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Cochrane Central Register of Controlled Trials (CENTRAL)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">06/08/2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 7 of 12, July 2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">187</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">152</td></tr><tr><td headers="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Cochrane Database of Systematic Reviews (CDSR)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">06/08/2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Issue 8 of 12, August 2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td></tr><tr><td headers="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://onlinelibrary.wiley.com/cochranelibrary/search/quick" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Database of Abstracts of Reviews of Effect (DARE)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">n/a</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LEGACY DATABASE - NO UPDATE SINCE ORIGINAL SEARCH</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td></tr><tr><td headers="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Embase (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">06/08/2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974 to 2018 August 03</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">858</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">705</td></tr><tr><td headers="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MEDLINE (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">06/08/2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1946 to August 03, 2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">352</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">348</td></tr><tr><td headers="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MEDLINE In-Process (Ovid)</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">06/08/2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">August 03, 2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84</td></tr><tr><td headers="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ovidsp.uk.ovid.com/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MEDLINE Epub Ahead of Print</a>
|
|
</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">06/08/2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">August 03, 2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68</td></tr><tr><td headers="hd_h_niceng130er.appc.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MHRA</a> – Drug Safety Alerts</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">06/08/2018</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">n/a</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_niceng130er.appc.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">n/a</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab4"><div id="niceng130er.appc.tab4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab4_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database: Medline</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 Colitis, Ulcerative/ (32987)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 exp Proctitis/ (3053)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 exp inflammatory bowel diseases/ (75028)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (inflamm* adj4 (colon* or bowel)).ti,ab. (39606)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 (ulcer* adj4 colitis).tw. (32358)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (pancolitis or rectitis or proctocolitis or procto-colitis or colorectitis or rectocolitis or recto-colitis or recto-sigmoiditis or rectosigmoiditis or procto-sigmoiditis or proctosigmoiditis or proctitis).tw. (4083)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 ((total or sub-total or subtotal or extensive or left-sided or universal) adj colitis).tw. (598)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 or/1-7 (94390)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 exp glucocorticoids/ (190101)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 prednisolone/ (32971)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 budesonide/ (4217)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 beclomethasone/ (3030)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 cortisone/ (20315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 hydrocortisone/ (71981)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 (beclomethasone or betnelan or betnesol or betamethasone or aerobec forte or aerobec or aldecin or apo-beclomethasone or ascocortonyl or asmabec clickhaler or beclamet or beclazone or beclo azu or beclo asma or beclocort or becloforte or beclomet or beclometasone or budesonide or budenofalk or clobetasol or cortisone or deflazacort or depomedrone or depo-medrone or desoximetasone or dexamethasone or diflucortolone or efcortesol or entocort or flumethasone or hydrocortisone or kenalog or medrone or melengestrol or methylprednisolone or methylprednisone or prednisolone or prednisone or solucortel or solu-cortel or solumedrone or solu-medrone or triamcinolone or beclorhinol or becloturmant or beclovent or becodisk* or beconase or becotide or bemedrex or bronchocort or ecobec or filair or junik or nasobec or prolair or propaderm or qvar or respocort or sanasthmax or sanasthmyl or vancenase or vanceril or ventolair or viarin or fluocinonide or fluocortolone or fluorometholone or fluprednisolone or flurandrenolone or paramethasone or prednisolone or prednimustine or triamcinolone or kenalog or deflazacort or calcort or fludrocortisone or MMX or cortisol or cortifair or cortril or epicortisol or adreson).tw. (195985)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 methotrexate/ (38313)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 (“4 amino 10 methylfolic acid" or “4 amino 10 methylpteroylglutamic acid” or “4 amino n10 methylpteroylglutamic acid” or methopterine or abitrexate or amethopterin* or ametopterine or antifolan or biotrexate or canceren or “cl 14377” or cl14377 or emtexate or emthexat* or emtrexate or enthexate or farmitrexat* or farmotrex or folex or ifamet or imeth or “intradose MTX” or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrex* or methylaminopterin* or meticil or metoject or metotrex* or metrex or mexate* or “mpi 5004” or mpi5004 or MTX or neotrexate or nordimet or novatrex or “nsc 740” or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or texate* or texorate or trexall or xaken or zexate).tw. (39039)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 6-mercaptopurine/ (6315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 (?mercaptopurin* or leupurin* or “puri nethol” or puri-nethol or purimethol or purinethol or “6 thiohypoxanthine” or 6-thiohypoxanthine or “6 thiopurine” or 6-thiopurine or “bw 57-323h” or “bw 57-323h” or “bw 57323h” or “1,7-dihydro-6h-purine-6-thione” or “mercapto purine” or “6 mp” or classen or empurine or ismipur or leukerin or loulla or mercaleukin or mercaptopurin* or mercapurene or mern or mycaptine or “nsc 755” or nsc755 or “puri nethol” or puri-nethol or “purine 6 thiol” or “purine thiol” or purinethiol or purinethol or purixan or thiohypoxanthine or thiopurine or xaluprine).tw. (5586)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 azathioprine/ (14798)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 (azathio* or azothiop* or immuran or Imuran* or imurel or arathiop* or aza-q or azafalk or azahexal or azamedac or azamun or azamune or azanin or azapin or azapress or azaprine or azarex or azasan or azathropsin or azatioprina or azatox or azatrilem or azopi or azoran or “bw 57 322” or bw 57-322 or “bw 57322” or bw57-322 or bw57322 or colinsan or immurel or immuthera or imunen or imuprin or imurek or imuren or “nsc 39084” or nsc39084 or thioazeprine or thioprine or transimune or zytrim).tw. (14464)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22 tacrolimus/ (15065)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 (“fk 506” or fk-506 or fk506 or “fr 900506” or fr-900506 or fr900506 or prograf* or tacrolimus or advagraf or astagraf or envarsus or fujimycin or hecoria or modigraf or “mustopic oint” or protopic or protopy or tsukubaenolide).tw. (19144)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 cyclosporine/ (29288)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25 (ciclosporin* or cyclosporin* or sandimmun* or neoral or deximune or cipol-n or implanta or imusporin).tw. (48758)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 mesalamine/ (3355)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27 sulfasalazine/ (4249)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28 (aminosalicyl* or 5-aminosalicyl* or 5-ASA or 5ASA or 5aminosalicyl* or pentasa or mesalazine or mesalamine or asacol or mezavant or ipocol or mesren or salofalk or asacolon or ascolitin or canasa or claversal or fivasa or lixacol or mesalamine or mesasal or “2 hydroxy 5 aminobenzoic acid” or “5 amino 2 hydroxybenzoic acid” or “5 aminosalicylate” or “5 aminosalicylic acid” or “5-asa 400” or apriso or asacolitin or asalex or asalit or asavixin or azalan or claversal or colitofalk or delzicol or fisalamine or fiv-asa or fivasa or kenzomyl or lialda or lixacol or mesacol or mesagran or mesalin or mesalmin or mesavance or mesavancol or mesavant or “mesren mr” or “meta aminosalicylic acid” or neoasa or norasa or pentacol or quintasa or rowasa or salisofar or salogran or sfrowasa or “spd 476” or spd476).tw. (5768)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29 (sulfasalazine* or sulphasalazine or salazopyrin* or salazosulfapyridine* or asulfidine* or “colo pleon” or colo-pleon or pleon or pyralin or azulfadine* or azulfidine* or salicylazosulfapyridine or ucine or ulcol or azopyrin* or azosulfidine or azulfid* or azulfin or benzosulfa or colopleon or disalazin or gastropyrin or “pleon ra” or “pyralin en” or rorasul or rosulfant or salazine or “salazo sulfapyridine” or salazodin or salazopirina or salazopyr* or salazopyrin* or salazosulf* or “salicyl azo sulfapyridine” or salicylazosulfapyridin* or salisulf or salopyr or saridine or “sas 500” or sulcolon or sulfasalizine or sulfosalazine or sulphosalazine or zopyrin).tw. (4733)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 (olsalazine or balsalazide or dipentum or colazide or balsalazine or Giazo or Colazal).tw. (289)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31 or/9-30 (435912)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32 8 and 31 (12442)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33 (201203* or 201204* or 201205* or 201206* or 201207* or 201208*or 201209* or 20121* or 2013* or 2014* or 2015* or 2016* or 2017*).ed. (4930039)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 32 and 33 (3059)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 exp crohn disease/ (37290)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 ((crohn or crohn’s or crohns) adj4 (disease* or colitis)).tw. (37837)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 ((ileitis or enteritis) adj4 (terminal or regional)).tw. (1587)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38 ((colitis or enteritis) adj4 granuloma*).tw. (648)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 ileocoli*.tw. (1925)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 (epithelioid adj4 granuloma*).tw. (1842)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41 exp inflammatory bowel diseases/ (75028)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42 (inflamm* adj4 bowel).tw. (35973)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43 or/35-42 (92978)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44 exp glucocorticoids/ (190101)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 dexamethasone isonicotinate/ or dexamethasone/ (51008)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46 fluprednisolone/ (281)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47 methylprednisolone hemisuccinate/ or methylprednisolone/ (19252)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48 prednisolone/ (32971)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49 prednisone/ (39961)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50 hydrocortisone/ (71981)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51 cortisone/ (20315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52 (beclomethasone or betnelan or betnesol or betamethasone or aerobec forte or aerobec or aldecin or apo-beclomethasone or ascocortonyl or asmabec clickhaler or beclamet or beclazone or beclo azu or beclo asma or beclocort or becloforte or beclomet or beclometasone or budesonide or budenofalk or clobetasol or cortisone or deflazacort or depomedrone or depo-medrone or desoximetasone or dexamethasone or diflucortolone or efcortesol or entocort or flumethasone or hydrocortisone or kenalog or medrone or melengestrol or methylprednisolone or methylprednisone or prednisolone or diadresonf or predate or predonine or prednisone or solucortel or solu-cortel or solumedrone or solu-medrone or triamcinolone or beclorhinol or becloturmant or beclovent or becodisk* or beconase or becotide or bemedrex or bronchocort or ecobec or filair or junik or nasobec or prolair or propaderm or qvar or respocort or sanasthmax or sanasthmyl or vancenase or vanceril or ventolair or viarin or fluocinonide or fluocortolone or fluorometholone or fluprednisolone or flurandrenolone or paramethasone or prednisolone or prednimustine or triamcinolone or kenalog or deflazacort or calcort or fludrocortisone or MMX or cortisol or cortifair or cortril or epicortisol or adreson).tw. (197102)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53 methotrexate/ (38313)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54 (“4 amino 10 methylfolic acid” or “4 amino 10 methylpteroylglutamic acid” or “4 amino n10 methylpteroylglutamic acid” or methopterine or abitrexate or amethopterin* or ametopterine or antifolan or biotrexate or canceren or “cl 14377” or cl14377 or emtexate or emthexat* or emtrexate or enthexate or farmitrexat* or farmotrex or folex or ifamet or imeth or “intradose MTX” or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrex* or methylaminopterin* or meticil or metoject or metotrex* or metrex or mexate* or “mpi 5004” or mpi5004 or MTX or neotrexate or nordimet or novatrex or “nsc 740” or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or texate* or texorate or trexall or xaken or zexate).tw. (39039)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55 6-mercaptopurine/ (6315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56 (?mercaptopurin* or leupurin* or “puri nethol” or puri-nethol or purimethol or purinethol or “6 thiohypoxanthine” or 6-thiohypoxanthine or “6 thiopurine” or 6-thiopurine or “bw 57 323h” or “bw 57323h” or “bw 57323h” or “1,7-dihydro-6h-purine-6-thione” or “mercapto purine” or “6 mp” or classen or empurine or ismipur or leukerin or loulla or mercaleukin or mercaptopurin or mercaptopurina or mercapurene or mern or mycaptine or “nsc 755” or nsc755 or “puri nethol” or puri-nethol or “purine 6 thiol” or “purine thiol” or purinethiol or purinethol or purixan or thiohypoxanthine or thiopurine or xaluprine).tw. (5586)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 azathioprine/ (14798)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58 (azathio* or azothiop* or immuran or Imuran* or imurel or arathiop* or aza-q or azafalk or azahexal or azamedac or azamun or azamune or azanin or azapin or azapress or azaprine or azarex or azasan or azathropsin or azatioprina or azatox or azatrilem or azopi or azoran or “bw 57 322” or bw 57-322 or “bw 57322” or bw57-322 or bw57322 or colinsan or immurel or immuthera or imunen or imuprin or imurek or imuren or “nsc 39084” or nsc39084 or thioazeprine or thioprine or transimune or zytrim).tw. (14464)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59 mesalamine/ (3355)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60 sulfasalazine/ (4249)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61 (aminosalicyl* or 5-aminosalicyl* or 5-ASA or 5ASA or 5aminosalicyl* or pentasa or mesalazine or mesalamine or asacol or mezavant or ipocol or mesren or salofalk or asacolon or ascolitin or canasa or claversal or fivasa or lixacol or mesalamine or mesasal or “2 hydroxy 5 aminobenzoic acid” or “5 amino 2 hydroxybenzoic acid” or “5 aminosalicylate” or “5 aminosalicylic acid” or “5-asa 400” or apriso or asacolitin or asalex or asalit or asavixin or azalan or claversal or colitofalk or delzicol or fisalamine or fiv-asa or fivasa or kenzomyl or lialda or lixacol or mesacol or mesagran or mesalin or mesalmin or mesavance or mesavancol or mesavant or “mesren mr” or “meta aminosalicylic acid” or neoasa or norasa or pentacol or quintasa or rowasa or salisofar or salogran or sfrowasa or “spd 476” or spd476).tw. (5768)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62 (sulfasalazine* or sulphasalazine or salazopyrin* or salazosulfapyridine* or asulfidine* or “colo pleon” or colo-pleon or pleon or pyralin or azulfadine* or azulfidine* or salicylazosulfapyridine or ucine or ulcol or azopyrin* or azosulfidine or azulfid* or azulfin or benzosulfa or colopleon or disalazin or gastropyrin or “pleon ra” or “pyralin en” or rorasul or rosulfant or salazine or “salazo sulfapyridine” or salazodin or salazopirina or salazopyr* or salazopyrin* or salazosulf* or “salicyl azo sulfapyridine” or salicylazosulfapyridin* or salisulf or salopyr or saridine or “sas 500” or sulcolon or sulfasalizine or sulfosalazine or sulphosalazine or zopyrin).tw. (4733)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63 (olsalazine or balsalazide or dipentum or colazide or balsalazine or Giazo or Colazal).tw. (289)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64 enteral nutrition/ (19487)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65 ((enteral* or force* or tube*) adj4 (nutrition* or feeding*)).tw. (18406)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66 food, formulated/ (6245)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67 exp food/ (1215042)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68 exp diet/ (258677)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69 lactose/ (11264)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70 ((polymeric or elemental or liquid or peptide or whole protein) adj (diet* or food* or formula*)).tw. (7013)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71 (formula* adj4 (diet* or food*)).tw. (5857)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72 ((diet or nutrition) adj therapy).tw. (3175)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 enteral nutrition.tw. (6821)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74 dh.fs. (48474)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75 exp anti-bacterial agents/ (677899)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76 exp nitroimidazoles/ (18134)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77 or/44-76 (2412648)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78 43 and 77 (19101)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79 (201203* or 201204* or 201205* or 201206* or 201207* or 201208*or 201209* or 20121* or 2013* or 2014* or 2015* or 2016* or 2017*).ed. (4930039)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80 78 and 79 (4984)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81 Infliximab/ (9326)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82 (infliximab or “mab ca2” or remicade or avakine or flixabi or revellex).tw. (9412)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83 Adalimumab/ (4382)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84 (Adalimumab or d2e7 or humira).tw. (4481)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85 or/81-84 (14247)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86 43 and 85 (5079)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87 34 or 80 or 86 (9567)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88 Randomized Controlled Trial.pt. (497588)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89 Controlled Clinical Trial.pt. (99265)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90 Clinical Trial.pt. (547948)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91 exp Clinical Trials as Topic/ (332607)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92 Placebos/ (36441)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93 Random Allocation/ (99781)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94 Double-Blind Method/ (157733)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95 Single-Blind Method/ (26629)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96 Cross-Over Studies/ (45112)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97 ((random$ or control$ or clinical$) adj3 (trial$ or stud$)).tw. (990056)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">98 (random$ adj3 allocat$).tw. (27830)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">99 placebo$.tw. (192664)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw. (154732)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">101 (crossover$ or (cross adj over$)).tw. (71695)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">102 or/88-101 (1755240)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">103 Meta-Analysis.pt. (92040)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">104 Network Meta-Analysis/ (226)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">105 Meta-Analysis as Topic/ (17172)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">106 Review.pt. (2334380)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">107 exp Review Literature as Topic/ (10190)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">108 (metaanaly$ or metanaly$ or (meta adj3 analy$)).tw. (107952)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">109 (review$ or overview$).ti. (364972)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110 (systematic$ adj5 (review$ or overview$)).tw. (103479)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111 ((quantitative$ or qualitative$) adj5 (review$ or overview$)).tw. (6797)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">112 ((studies or trial$) adj2 (review$ or overview$)).tw. (34673)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">113 (integrat$ adj3 (research or review$ or literature)).tw. (8116)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">114 (pool$ adj2 (analy$ or data)).tw. (22232)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">115 (handsearch$ or (hand adj3 search$)).tw. (7405)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">116 (manual$ adj3 search$).tw. (4478)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">117 or/103-116 (2543434)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">118 102 or 117 (3977465)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">119 87 and 118 (3791)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">120 animals/ not humans/ (4648315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">121 Comment/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference paper or “conference review” or letter or editorial or case report).pt. (1888307)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">122 119 not (120 or 121) (3603)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">123 limit 122 to english language (3230)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab5"><div id="niceng130er.appc.tab5" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database: Ovid MEDLINE(R)</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 Colitis, Ulcerative/ (32987)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 exp Proctitis/ (3053)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 exp inflammatory bowel diseases/ (75028)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (inflamm* adj4 (colon* or bowel)).ti,ab. (39606)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 (ulcer* adj4 colitis).tw. (32358)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (pancolitis or rectitis or proctocolitis or procto-colitis or colorectitis or rectocolitis or recto-colitis or recto-sigmoiditis or rectosigmoiditis or procto-sigmoiditis or proctosigmoiditis or proctitis).tw. (4083)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 ((total or sub-total or subtotal or extensive or left-sided or universal) adj colitis).tw. (598)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 or/1-7 (94390)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 exp glucocorticoids/ (190101)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 prednisolone/ (32971)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 budesonide/ (4217)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 beclomethasone/ (3030)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 cortisone/ (20315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 hydrocortisone/ (71981)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 (beclomethasone or betnelan or betnesol or betamethasone or aerobec forte or aerobec or aldecin or apo-beclomethasone or ascocortonyl or asmabec clickhaler or beclamet or beclazone or beclo azu or beclo asma or beclocort or becloforte or beclomet or beclometasone or budesonide or budenofalk or clobetasol or cortisone or deflazacort or depomedrone or depo-medrone or desoximetasone or dexamethasone or diflucortolone or efcortesol or entocort or flumethasone or hydrocortisone or kenalog or medrone or melengestrol or methylprednisolone or methylprednisone or prednisolone or prednisone or solucortel or solu-cortel or solumedrone or solu-medrone or triamcinolone or beclorhinol or becloturmant or beclovent or becodisk* or beconase or becotide or bemedrex or bronchocort or ecobec or filair or junik or nasobec or prolair or propaderm or qvar or respocort or sanasthmax or sanasthmyl or vancenase or vanceril or ventolair or viarin or fluocinonide or fluocortolone or fluorometholone or fluprednisolone or flurandrenolone or paramethasone or prednisolone or prednimustine or triamcinolone or kenalog or deflazacort or calcort or fludrocortisone or MMX or cortisol or cortifair or cortril or epicortisol or adreson).tw. (195985)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 methotrexate/ (38313)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 (“4 amino 10 methylfolic acid” or “4 amino 10 methylpteroylglutamic acid” or “4 amino n10 methylpteroylglutamic acid” or methopterine or abitrexate or amethopterin* or ametopterine or antifolan or biotrexate or canceren or “cl 14377” or cl14377 or emtexate or emthexat* or emtrexate or enthexate or farmitrexat* or farmotrex or folex or ifamet or imeth or “intradose MTX” or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrex* or methylaminopterin* or meticil or metoject or metotrex* or metrex or mexate* or “mpi 5004” or mpi5004 or MTX or neotrexate or nordimet or novatrex or “nsc 740” or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or texate* or texorate or trexall or xaken or zexate).tw. (39039)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 6-mercaptopurine/ (6315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 (?mercaptopurin* or leupurin* or “puri nethol” or puri-nethol or purimethol or purinethol or “6 thiohypoxanthine” or 6-thiohypoxanthine or “6 thiopurine” or 6-thiopurine or “bw 57 323h” or “bw 57-323h” or “bw 57323h” or “1,7-dihydro-6h-purine-6-thione” or “mercapto purine” or “6 mp” or classen or empurine or ismipur or leukerin or loulla or mercaleukin or mercaptopurin* or mercapurene or mern or mycaptine or “nsc 755” or nsc755 or “puri nethol” or puri-nethol or “purine 6 thiol” or “purine thiol” or purinethiol or purinethol or purixan or thiohypoxanthine or thiopurine or xaluprine).tw. (5586)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 azathioprine/ (14798)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 (azathio* or azothiop* or immuran or Imuran* or imurel or arathiop* or aza-q or azafalk or azahexal or azamedac or azamun or azamune or azanin or azapin or azapress or azaprine or azarex or azasan or azathropsin or azatioprina or azatox or azatrilem or azopi or azoran or “bw 57 322” or bw 57-322 or “bw 57322” or bw57-322 or bw57322 or colinsan or immurel or immuthera or imunen or imuprin or imurek or imuren or “nsc 39084” or nsc39084 or thioazeprine or thioprine or transimune or zytrim).tw. (14464)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22 tacrolimus/ (15065)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 (“fk 506” or fk-506 or fk506 or “fr 900506” or fr-900506 or fr900506 or prograf* or tacrolimus or advagraf or astagraf or envarsus or fujimycin or hecoria or modigraf or “mustopic oint” or protopic or protopy or tsukubaenolide).tw. (19144)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 cyclosporine/ (29288)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25 (ciclosporin* or cyclosporin* or sandimmun* or neoral or deximune or cipol-n or implanta or imusporin).tw. (48758)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 mesalamine/ (3355)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27 sulfasalazine/ (4249)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28 (aminosalicyl* or 5-aminosalicyl* or 5-ASA or 5ASA or 5aminosalicyl* or pentasa or mesalazine or mesalamine or asacol or mezavant or ipocol or mesren or salofalk or asacolon or ascolitin or canasa or claversal or fivasa or lixacol or mesalamine or mesasal or “2 hydroxy 5 aminobenzoic acid” or “5 amino 2 hydroxybenzoic acid” or “5 aminosalicylate” or “5 aminosalicylic acid” or “5-asa 400” or apriso or asacolitin or asalex or asalit or asavixin or azalan or claversal or colitofalk or delzicol or fisalamine or fiv-asa or fivasa or kenzomyl or lialda or lixacol or mesacol or mesagran or mesalin or mesalmin or mesavance or mesavancol or mesavant or “mesren mr” or “meta aminosalicylic acid” or neoasa or norasa or pentacol or quintasa or rowasa or salisofar or salogran or sfrowasa or “spd 476” or spd476).tw. (5768)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29 (sulfasalazine* or sulphasalazine or salazopyrin* or salazosulfapyridine* or asulfidine* or “colo pleon” or colo-pleon or pleon or pyralin or azulfadine* or azulfidine* or salicylazosulfapyridine or ucine or ulcol or azopyrin* or azosulfidine or azulfid* or azulfin or benzosulfa or colopleon or disalazin or gastropyrin or “pleon ra” or “pyralin en” or rorasul or rosulfant or salazine or “salazo sulfapyridine” or salazodin or salazopirina or salazopyr* or salazopyrin* or salazosulf* or “salicyl azo sulfapyridine” or salicylazosulfapyridin* or salisulf or salopyr or saridine or “sas 500” or sulcolon or sulfasalizine or sulfosalazine or sulphosalazine or zopyrin).tw. (4733)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 (olsalazine or balsalazide or dipentum or colazide or balsalazine or Giazo or Colazal).tw. (289)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31 or/9-30 (435912)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32 8 and 31 (12442)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33 (201203* or 201204* or 201205* or 201206* or 201207* or 201208*or 201209* or 20121* or 2013* or 2014* or 2015* or 2016* or 2017*).ed. (4930039)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 32 and 33 (3059)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 Economics/ (27434)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 exp “Costs and Cost Analysis”/ (222141)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 Economics, Dental/ (1902)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38 exp Economics, Hospital/ (23287)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 exp Economics, Medical/ (14356)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 Economics, Nursing/ (3992)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41 Economics, Pharmaceutical/ (2967)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42 Budgets/ (11098)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43 exp Models, Economic/ (13757)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44 Markov Chains/ (13195)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 Monte Carlo Method/ (27425)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46 Decision Trees/ (10674)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47 econom$.tw. (208611)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48 cba.tw. (9739)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49 cea.tw. (19814)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50 cua.tw. (951)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51 markov$.tw. (16071)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52 (monte adj carlo).tw. (28826)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53 (decision adj3 (tree$ or analys$)).tw. (11483)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54 (cost or costs or costing$ or costly or costed).tw. (407706)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55 (price$ or pricing$).tw. (29605)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56 budget$.tw. (21669)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 expenditure$.tw. (45011)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58 (value adj3 (money or monetary)).tw. (1803)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59 (pharmacoeconomic$ or (pharmaco adj economic$)).tw. (3472)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60 or/35-59 (837448)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61 “Quality of Life”/ (167314)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62 quality of life.tw. (197524)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63 “Value of Life”/ (5803)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64 Quality-Adjusted Life Years/ (10621)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65 quality adjusted life.tw. (9189)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66 (qaly$ or qald$ or qale$ or qtime$).tw. (7543)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67 disability adjusted life.tw. (2172)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68 daly$.tw. (2012)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69 Health Status Indicators/ (23476)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw. (20634)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw. (1237)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw. (4144)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw. (23)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw. (386)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75 (euroqol or euro qol or eq5d or eq 5d).tw. (6843)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76 (qol or hql or hqol or hrqol).tw. (36769)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77 (hye or hyes).tw. (65)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78 health$ year$ equivalent$.tw. (45)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79 utilit$.tw. (151862)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80 (hui or hui1 or hui2 or hui3).tw. (1134)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81 disutili$.tw. (331)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82 rosser.tw. (86)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83 quality of wellbeing.tw. (10)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84 quality of well-being.tw. (379)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85 qwb.tw. (198)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86 willingness to pay.tw. (3552)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87 standard gamble$.tw. (798)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88 time trade off.tw. (962)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89 time tradeoff.tw. (258)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90 tto.tw. (819)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91 or/61-90 (434819)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92 60 or 91 (1211787)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93 34 and 92 (211)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94 animals/ not humans/ (4648315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95 93 not 94 (208)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96 limit 95 to english language (191)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab6"><div id="niceng130er.appc.tab6" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab6_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 Colitis, Ulcerative/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 exp Proctitis/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 exp inflammatory bowel diseases/ (11)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (inflamm* adj4 (colon* or bowel)).ti,ab. (4975)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 (ulcer* adj4 colitis).tw. (2787)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (pancolitis or rectitis or proctocolitis or procto-colitis or colorectitis or rectocolitis or recto-colitis or recto-sigmoiditis or rectosigmoiditis or procto-sigmoiditis or proctosigmoiditis or proctitis).tw. (258)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 ((total or sub-total or subtotal or extensive or left-sided or universal) adj colitis).tw. (40)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 or/1-7 (6542)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 exp glucocorticoids/ (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 prednisolone/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 budesonide/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 beclomethasone/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 cortisone/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 hydrocortisone/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 (beclomethasone or betnelan or betnesol or betamethasone or aerobec forte or aerobec or aldecin or apo-beclomethasone or ascocortonyl or asmabec clickhaler or beclamet or beclazone or beclo azu or beclo asma or beclocort or becloforte or beclomet or beclometasone or budesonide or budenofalk or clobetasol or cortisone or deflazacort or depomedrone or depo-medrone or desoximetasone or dexamethasone or diflucortolone or efcortesol or entocort or flumethasone or hydrocortisone or kenalog or medrone or melengestrol or methylprednisolone or methylprednisone or prednisolone or prednisone or solucortel or solu-cortel or solumedrone or solu-medrone or triamcinolone or beclorhinol or becloturmant or beclovent or becodisk* or beconase or becotide or bemedrex or bronchocort or ecobec or filair or junik or nasobec or prolair or propaderm or qvar or respocort or sanasthmax or sanasthmyl or vancenase or vanceril or ventolair or viarin or fluocinonide or fluocortolone or fluorometholone or fluprednisolone or flurandrenolone or paramethasone or prednisolone or prednimustine or triamcinolone or kenalog or deflazacort or calcort or fludrocortisone or MMX or cortisol or cortifair or cortril or epicortisol or adreson).tw. (11841)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 methotrexate/ (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 (“4 amino 10 methylfolic acid” or “4 amino 10 methylpteroylglutamic acid” or “4 amino n10 methylpteroylglutamic acid” or methopterine or abitrexate or amethopterin* or ametopterine or antifolan or biotrexate or canceren or “cl 14377” or cl14377 or emtexate or emthexat* or emtrexate or enthexate or farmitrexat* or farmotrex or folex or ifamet or imeth or “intradose MTX” or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrex* or methylaminopterin* or meticil or metoject or metotrex* or metrex or mexate* or “mpi 5004” or mpi5004 or MTX or neotrexate or nordimet or novatrex or “nsc 740” or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or texate* or texorate or trexall or xaken or zexate).tw. (2627)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 6-mercaptopurine/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 (?mercaptopurin* or leupurin* or “puri nethol” or puri-nethol or purimethol or purinethol or “6 thiohypoxanthine” or 6-thiohypoxanthine or “6 thiopurine” or 6-thiopurine or “bw 57 323h” or “bw 57-323h” or “bw 57323h” or “1,7-dihydro-6h-purine-6-thione” or “mercapto purine” or “6 mp” or classen or empurine or ismipur or leukerin or loulla or mercaleukin or mercaptopurin* or mercapurene or mern or mycaptine or “nsc 755” or nsc755 or “puri nethol” or puri-nethol or “purine 6 thiol” or “purine thiol” or purinethiol or purinethol or purixan or thiohypoxanthine or thiopurine or xaluprine).tw. (318)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 azathioprine/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 (azathio* or azothiop* or immuran or Imuran* or imurel or arathiop* or aza-q or azafalk or azahexal or azamedac or azamun or azamune or azanin or azapin or azapress or azaprine or azarex or azasan or azathropsin or azatioprina or azatox or azatrilem or azopi or azoran or “bw 57 322” or bw 57-322 or “bw 57322” or bw57-322 or bw57322 or colinsan or immurel or immuthera or imunen or imuprin or imurek or imuren or “nsc 39084” or nsc39084 or thioazeprine or thioprine or transimune or zytrim).tw. (901)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22 tacrolimus/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 (“fk 506” or fk-506 or fk506 or “fr 900506” or fr-900506 or fr900506 or prograf* or tacrolimus or advagraf or astagraf or envarsus or fujimycin or hecoria or modigraf or “mustopic oint” or protopic or protopy or tsukubaenolide).tw. (1315)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 cyclosporine/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25 (ciclosporin* or cyclosporin* or sandimmun* or neoral or deximune or cipol-n or implanta or imusporin).tw. (1831)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 mesalamine/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27 sulfasalazine/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28 (aminosalicyl* or 5-aminosalicyl* or 5-ASA or 5ASA or 5aminosalicyl* or pentasa or mesalazine or mesalamine or asacol or mezavant or ipocol or mesren or salofalk or asacolon or ascolitin or canasa or claversal or fivasa or lixacol or mesalamine or mesasal or “2 hydroxy 5 aminobenzoic acid” or “5 amino 2 hydroxybenzoic acid” or “5 aminosalicylate” or “5 aminosalicylic acid” or “5-asa 400” or apriso or asacolitin or asalex or asalit or asavixin or azalan or claversal or colitofalk or delzicol or fisalamine or fiv-asa or fivasa or kenzomyl or lialda or lixacol or mesacol or mesagran or mesalin or mesalmin or mesavance or mesavancol or mesavant or “mesren mr” or “meta aminosalicylic acid” or neoasa or norasa or pentacol or quintasa or rowasa or salisofar or salogran or sfrowasa or “spd 476” or spd476).tw. (497)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29 (sulfasalazine* or sulphasalazine or salazopyrin* or salazosulfapyridine* or asulfidine* or “colo pleon” or colo-pleon or pleon or pyralin or azulfadine* or azulfidine* or salicylazosulfapyridine or ucine or ulcol or azopyrin* or azosulfidine or azulfid* or azulfin or benzosulfa or colopleon or disalazin or gastropyrin or “pleon ra” or “pyralin en” or rorasul or rosulfant or salazine or “salazo sulfapyridine” or salazodin or salazopirina or salazopyr* or salazopyrin* or salazosulf* or “salicyl azo sulfapyridine” or salicylazosulfapyridin* or salisulf or salopyr or saridine or “sas 500” or sulcolon or sulfasalizine or sulfosalazine or sulphosalazine or zopyrin).tw. (279)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 (olsalazine or balsalazide or dipentum or colazide or balsalazine or Giazo or Colazal).tw. (13)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31 or/9-30 (17564)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32 8 and 31 (695)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33 (201203* or 201204* or 201205* or 201206* or 201207* or 201208*or 201209* or 20121* or 2013* or 2014* or 2015* or 2016* or 2017*).dc. (1815973)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 32 and 33 (545)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 Economics/ (2)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 exp “Costs and Cost Analysis”/ (15)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 Economics, Dental/ (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38 exp Economics, Hospital/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 exp Economics, Medical/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 Economics, Nursing/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41 Economics, Pharmaceutical/ (6)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42 Budgets/ (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43 exp Models, Economic/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44 Markov Chains/ (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 Monte Carlo Method/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46 Decision Trees/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47 econom$.tw. (30506)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48 cba.tw. (312)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49 cea.tw. (1428)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50 cua.tw. (136)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51 markov$.tw. (3970)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52 (monte adj carlo).tw. (12728)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53 (decision adj3 (tree$ or analys$)).tw. (1403)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54 (cost or costs or costing$ or costly or costed).tw. (66586)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55 (price$ or pricing$).tw. (4210)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56 budget$.tw. (3661)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 expenditure$.tw. (4687)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58 (value adj3 (money or monetary)).tw. (265)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59 (pharmacoeconomic$ or (pharmaco adj economic$)).tw. (463)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60 or/35-59 (115867)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61 “Quality of Life”/ (11)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62 quality of life.tw. (28398)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63 “Value of Life”/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64 Quality-Adjusted Life Years/ (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65 quality adjusted life.tw. (1160)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66 (qaly$ or qald$ or qale$ or qtime$).tw. (982)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67 disability adjusted life.tw. (343)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68 daly$.tw. (308)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69 Health Status Indicators/ (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw. (2198)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw. (561)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw. (572)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw. (6)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw. (14)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75 (euroqol or euro qol or eq5d or eq 5d).tw. (1214)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76 (qol or hql or hqol or hrqol).tw. (5476)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77 (hye or hyes).tw. (5)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78 health$ year$ equivalent$.tw. (2)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79 utilit$.tw. (21827)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80 (hui or hui1 or hui2 or hui3).tw. (132)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81 disutili$.tw. (47)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82 rosser.tw. (5)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83 quality of wellbeing.tw. (3)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84 quality of well-being.tw. (22)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85 qwb.tw. (8)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86 willingness to pay.tw. (558)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87 standard gamble$.tw. (59)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88 time trade off.tw. (83)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89 time tradeoff.tw. (15)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90 tto.tw. (85)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91 or/61-90 (52080)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92 60 or 91 (161067)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93 34 and 92 (43)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94 animals/ not humans/ (225)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95 93 not 94 (43)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96 limit 95 to english language (42)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab7"><div id="niceng130er.appc.tab7" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab7_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database: Embase</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 ulcerative colitis/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 exp proctitis/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 exp inflammatory bowel disease/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (inflamm* adj4 (colon* or bowel)).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 (ulcer* adj4 colitis).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (pancolitis or rectitis or proctocolitis or procto-colitis or colorectitis or rectocolitis or recto-colitis or recto-sigmoiditis or rectosigmoiditis or procto-sigmoiditis or proctosigmoiditis or proctitis).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 ((total or sub-total or subtotal or extensive or left-sided or universal) adj colitis).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 or/1-7</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 exp glucocorticoid/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 prednisolone/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 budesonide/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 beclometasone/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 cortisone/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 hydrocortisone/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 (beclomethasone or betnelan or betnesol or betamethasone or aerobec forte or aerobec or aldecin or apo-beclomethasone or ascocortonyl or asmabec clickhaler or beclamet or beclazone or beclo azu or beclo asma or beclocort or becloforte or beclomet or beclometasone or budesonide or budenofalk or clobetasol or cortisone or deflazacort or depomedrone or depo-medrone or desoximetasone or dexamethasone or diflucortolone or efcortesol or entocort or flumethasone or hydrocortisone or kenalog or medrone or melengestrol or methylprednisolone or methylprednisone or prednisolone or prednisone or solucortel or solu-cortel or solumedrone or solu-medrone or triamcinolone or beclorhinol or becloturmant or beclovent or becodisk* or beconase or becotide or bemedrex or bronchocort or ecobec or filair or junik or nasobec or prolair or propaderm or qvar or respocort or sanasthmax or sanasthmyl or vancenase or vanceril or ventolair or viarin or fluocinonide or fluocortolone or fluorometholone or fluprednisolone or flurandrenolone or paramethasone or prednisolone or prednimustine or triamcinolone or kenalog or deflazacort or calcort or fludrocortisone or MMX or cortisol or cortifair or cortril or epicortisol or adreson).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 methotrexate/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 (“4 amino 10 methylfolic acid” or “4 amino 10 methylpteroylglutamic acid” or “4 amino n10 methylpteroylglutamic acid” or methopterine or abitrexate or amethopterin* or ametopterine or antifolan or biotrexate or canceren or “cl 14377” or cl14377 or emtexate or emthexat* or emtrexate or enthexate or farmitrexat* or farmotrex or folex or ifamet or imeth or “intradose MTX” or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrex* or methylaminopterin* or meticil or metoject or metotrex* or metrex or mexate* or “mpi 5004” or mpi5004 or MTX or neotrexate or nordimet or novatrex or “nsc 740” or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or texate* or texorate or trexall or xaken or zexate).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 mercaptopurine/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 (?mercaptopurin* or leupurin* or “puri nethol” or puri-nethol or purimethol or purinethol or “6 thiohypoxanthine” or 6-thiohypoxanthine or “6 thiopurine” or 6-thiopurine or “bw 57 323h” or “bw 57-323h” or “bw 57323h” or “1,7-dihydro-6h-purine-6-thione” or “mercapto purine” or “6 mp” or classen or empurine or ismipur or leukerin or loulla or mercaleukin or mercaptopurin* or mercapurene or mern or mycaptine or “nsc 755” or nsc755 or “puri nethol” or puri-nethol or “purine 6 thiol” or “purine thiol” or purinethiol or purinethol or purixan or thiohypoxanthine or thiopurine or xaluprine).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 azathioprine/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 (azathio* or azothiop* or immuran or Imuran* or imurel or arathiop* or aza-q or azafalk or azahexal or azamedac or azamun or azamune or azanin or azapin or azapress or azaprine or azarex or azasan or azathropsin or azatioprina or azatox or azatrilem or azopi or azoran or “bw 57 322” or bw 57-322 or “bw 57322” or bw57-322 or bw57322 or colinsan or immurel or immuthera or imunen or imuprin or imurek or imuren or “nsc 39084” or nsc39084 or thioazeprine or thioprine or transimune or zytrim).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22 tacrolimus/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 (“fk 506” or fk-506 or fk506 or “fr 900506” or fr-900506 or fr900506 or prograf* or tacrolimus or advagraf or astagraf or envarsus or fujimycin or hecoria or modigraf or “mustopic oint” or protopic or protopy or tsukubaenolide).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 cyclosporin/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25 (ciclosporin* or cyclosporin* or sandimmun* or neoral or deximune or cipol-n or implanta or imusporin).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 mesalazine/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27 salazosulfapyridine/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28 (aminosalicyl* or 5-aminosalicyl* or 5-ASA or 5ASA or 5aminosalicyl* or pentasa or mesalazine or mesalamine or asacol or mezavant or ipocol or mesren or salofalk or asacolon or ascolitin or canasa or claversal or fivasa or lixacol or mesalamine or mesasal or “2 hydroxy 5 aminobenzoic acid” or “5 amino 2 hydroxybenzoic acid” or “5 aminosalicylate” or “5 aminosalicylic acid” or “5-asa 400” or apriso or asacolitin or asalex or asalit or asavixin or azalan or claversal or colitofalk or delzicol or fisalamine or fiv-asa or fivasa or kenzomyl or lialda or lixacol or mesacol or mesagran or mesalin or mesalmin or mesavance or mesavancol or mesavant or “mesren mr” or “meta aminosalicylic acid” or neoasa or norasa or pentacol or quintasa or rowasa or salisofar or salogran or sfrowasa or “spd 476” or spd476).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29 (sulfasalazine* or sulphasalazine or salazopyrin* or salazosulfapyridine* or asulfidine* or “colo pleon” or colo-pleon or pleon or pyralin or azulfadine* or azulfidine* or salicylazosulfapyridine or ucine or ulcol or azopyrin* or azosulfidine or azulfid* or azulfin or benzosulfa or colopleon or disalazin or gastropyrin or “pleon ra” or “pyralin en” or rorasul or rosulfant or salazine or “salazo sulfapyridine” or salazodin or salazopirina or salazopyr* or salazopyrin* or salazosulf* or “salicyl azo sulfapyridine” or salicylazosulfapyridin* or salisulf or salopyr or saridine or “sas 500” or sulcolon or sulfasalizine or sulfosalazine or sulphosalazine or zopyrin).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30 (olsalazine or balsalazide or dipentum or colazide or balsalazine or Giazo or Colazal).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31 or/9-30</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32 8 and 31</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33 (201203* or 201204* or 201205* or 201206* or 201207* or 201208*or 201209* or 20121* or 2013* or 2014* or 2015* or 2016* or 2017*).dc.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 32 and 33</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 exp Health Economics/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 exp “Health Care Cost"/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 exp Pharmacoeconomics/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38 Monte Carlo Method/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 Decision Tree/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40 econom$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41 cba.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42 cea.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43 cua.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44 markov$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45 (monte adj carlo).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46 (decision adj3 (tree$ or analys$)).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47 (cost or costs or costing$ or costly or costed).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48 (price$ or pricing$).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49 budget$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50 expenditure$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51 (value adj3 (money or monetary)).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52 (pharmacoeconomic$ or (pharmaco adj economic$)).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53 or/35-52</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54 “Quality of Life"/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55 Quality Adjusted Life Year/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56 Quality of Life Index/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 Short Form 36/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58 Health Status/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59 quality of life.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60 quality adjusted life.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61 (qaly$ or qald$ or qale$ or qtime$).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62 disability adjusted life.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63 daly$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69 (euroqol or euro qol or eq5d or eq 5d).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70 (qol or hql or hqol or hrqol).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71 (hye or hyes).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72 health$ year$ equivalent$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 utilit$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74 (hui or hui1 or hui2 or hui3).tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75 disutili$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76 rosser.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77 quality of wellbeing.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78 quality of well-being.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79 qwb.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80 willingness to pay.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81 standard gamble$.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82 time trade off.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83 time tradeoff.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84 tto.tw.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85 or/54-84</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86 53 or 85</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87 34 and 86</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88 nonhuman/ not human/</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89 Abstract report/ or Conference abstract/ or Conference paper/ or Conference review/ or Letter/ or Editorial/ or Historical article/ or (conference abstract or conference paper or “conference review” or letter or editorial or case report).pt.</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90 87 not (88 or 89)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91 limit 90 to english language</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab8"><div id="niceng130er.appc.tab8" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab8_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database: EconLit</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (inflamm* adj4 (colon* or bowel)).tw. (9)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (ulcer* adj4 colitis).tw. (4)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (pancolitis or rectitis or proctocolitis or procto-colitis or colorectitis or rectocolitis or recto-colitis or recto-sigmoiditis or rectosigmoiditis or procto-sigmoiditis or proctosigmoiditis or proctitis).tw. (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 ((total or sub-total or subtotal or extensive or left-sided or universal) adj colitis).tw. (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 or/1-4 (12)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (beclomethasone or betnelan or betnesol or betamethasone or aerobec forte or aerobec or aldecin or apo-beclomethasone or ascocortonyl or asmabec clickhaler or beclamet or beclazone or beclo azu or beclo asma or beclocort or becloforte or beclomet or beclometasone or budesonide or budenofalk or clobetasol or cortisone or deflazacort or depomedrone or depo-medrone or desoximetasone or dexamethasone or diflucortolone or efcortesol or entocort or flumethasone or hydrocortisone or kenalog or medrone or melengestrol or methylprednisolone or methylprednisone or prednisolone or prednisone or solucortel or solu-cortel or solumedrone or solu-medrone or triamcinolone or beclorhinol or becloturmant or beclovent or becodisk* or beconase or becotide or bemedrex or bronchocort or ecobec or filair or junik or nasobec or prolair or propaderm or qvar or respocort or sanasthmax or sanasthmyl or vancenase or vanceril or ventolair or viarin or fluocinonide or fluocortolone or fluorometholone or fluprednisolone or flurandrenolone or paramethasone or prednisolone or prednimustine or triamcinolone or kenalog or deflazacort or calcort or fludrocortisone or MMX or cortisol or cortifair or cortril or epicortisol or adreson).tw. (30)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 (“4 amino 10 methylfolic acid” or “4 amino 10 methylpteroylglutamic acid” or “4 amino n10 methylpteroylglutamic acid” or methopterine or abitrexate or amethopterin* or ametopterine or antifolan or biotrexate or canceren or “cl 14377” or cl14377 or emtexate or emthexat* or emtrexate or enthexate or farmitrexat* or farmotrex or folex or ifamet or imeth or “intradose MTX” or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrex* or methylaminopterin* or meticil or metoject or metotrex* or metrex or mexate* or “mpi 5004” or mpi5004 or MTX or neotrexate or nordimet or novatrex or “nsc 740” or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or texate* or texorate or trexall or xaken or zexate).tw. (6)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 (?mercaptopurin* or leupurin* or “puri nethol” or puri-nethol or purimethol or purinethol or “6 thiohypoxanthine” or 6-thiohypoxanthine or “6 thiopurine” or 6-thiopurine or “bw 57 323h” or “bw 57-323h” or “bw 57323h” or “1,7-dihydro-6h-purine-6-thione” or “mercapto purine” or “6 mp” or classen or empurine or ismipur or leukerin or loulla or mercaleukin or mercaptopurin* or mercapurene or mern or mycaptine or “nsc 755” or nsc755 or “puri nethol” or puri-nethol or “purine 6 thiol” or “purine thiol” or purinethiol or purinethol or purixan or thiohypoxanthine or thiopurine or xaluprine).tw. (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 (azathio* or azothiop* or immuran or Imuran* or imurel or arathiop* or aza-q or azafalk or azahexal or azamedac or azamun or azamune or azanin or azapin or azapress or azaprine or azarex or azasan or azathropsin or azatioprina or azatox or azatrilem or azopi or azoran or “bw 57 322” or bw 57-322 or “bw 57322” or bw57-322 or bw57322 or colinsan or immurel or immuthera or imunen or imuprin or imurek or imuren or “nsc 39084” or nsc39084 or thioazeprine or thioprine or transimune or zytrim).tw. (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 (“fk 506” or fk-506 or fk506 or “fr 900506” or fr-900506 or fr900506 or prograf* or tacrolimus or advagraf or astagraf or envarsus or fujimycin or hecoria or modigraf or “mustopic oint” or protopic or protopy or tsukubaenolide).tw. (4)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 (ciclosporin* or cyclosporin* or sandimmun* or neoral or deximune or cipol-n or implanta or imusporin).tw. (9)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 (aminosalicyl* or 5-aminosalicyl* or 5-ASA or 5ASA or 5aminosalicyl* or pentasa or mesalazine or mesalamine or asacol or mezavant or ipocol or mesren or salofalk or asacolon or ascolitin or canasa or claversal or fivasa or lixacol or mesalamine or mesasal or “2 hydroxy 5 aminobenzoic acid” or “5 amino 2 hydroxybenzoic acid” or “5 aminosalicylate” or “5 aminosalicylic acid” or “5-asa 400” or apriso or asacolitin or asalex or asalit or asavixin or azalan or claversal or colitofalk or delzicol or fisalamine or fiv-asa or fivasa or kenzomyl or lialda or lixacol or mesacol or mesagran or mesalin or mesalmin or mesavance or mesavancol or mesavant or “mesren mr” or “meta aminosalicylic acid” or neoasa or norasa or pentacol or quintasa or rowasa or salisofar or salogran or sfrowasa or “spd 476” or spd476).tw. (1)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 (sulfasalazine* or sulphasalazine or salazopyrin* or salazosulfapyridine* or asulfidine* or “colo pleon” or colo-pleon or pleon or pyralin or azulfadine* or azulfidine* or salicylazosulfapyridine or ucine or ulcol or azopyrin* or azosulfidine or azulfid* or azulfin or benzosulfa or colopleon or disalazin or gastropyrin or “pleon ra” or “pyralin en” or rorasul or rosulfant or salazine or “salazo sulfapyridine” or salazodin or salazopirina or salazopyr* or salazopyrin* or salazosulf* or “salicyl azo sulfapyridine” or salicylazosulfapyridin* or salisulf or salopyr or saridine or “sas 500” or sulcolon or sulfasalizine or sulfosalazine or sulphosalazine or zopyrin).tw. (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 (olsalazine or balsalazide or dipentum or colazide or balsalazine or Giazo or Colazal).tw. (0)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 or/6-14 (49)</td></tr><tr><td headers="hd_h_niceng130er.appc.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 5 and 15 (1)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappctab9"><div id="niceng130er.appc.tab9" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appc.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appc.tab9_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database: NHS EED and HTA</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 [mh ^"Colitis, Ulcerative"]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2 [mh Proctitis]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3 [mh “inflammatory bowel diseases"]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4 inflamm* near/4 (colon* or bowel):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5 (ulcer* near/4 colitis):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6 (pancolitis or rectitis or proctocolitis or procto-colitis or colorectitis or rectocolitis or recto-colitis or recto-sigmoiditis or rectosigmoiditis or procto-sigmoiditis or proctosigmoiditis or proctitis):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7 (total or sub-total or subtotal or extensive or left-sided or universal) near/1 colitis:ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8 {or #1-#7}</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9 [mh glucocorticoids]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10 [mh ^prednisolone]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11 [mh ^budesonide]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12 [mh ^beclomethasone]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13 [mh ^cortisone]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#14 [mh ^hydrocortisone]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#15 (beclomethasone or betnelan or betnesol or betamethasone or aerobec forte or aerobec or aldecin or apo-beclomethasone or ascocortonyl or asmabec clickhaler or beclamet or beclazone or beclo azu or beclo asma or beclocort or becloforte or beclomet or beclometasone or budesonide or budenofalk or clobetasol or cortisone or deflazacort or depomedrone or depo-medrone or desoximetasone or dexamethasone or diflucortolone or efcortesol or entocort or flumethasone or hydrocortisone or kenalog or medrone or melengestrol or methylprednisolone or methylprednisone or prednisolone or prednisone or solucortel or solu-cortel or solumedrone or solu-medrone or triamcinolone or beclorhinol or becloturmant or beclovent or becodisk* or beconase or becotide or bemedrex or bronchocort or ecobec or filair or junik or nasobec or prolair or propaderm or qvar or respocort or sanasthmax or sanasthmyl or vancenase or vanceril or ventolair or viarin or fluocinonide or fluocortolone or fluorometholone or fluprednisolone or flurandrenolone or paramethasone or prednisolone or prednimustine or triamcinolone or kenalog or deflazacort or calcort or fludrocortisone or MMX or cortisol or cortifair or cortril or epicortisol or adreson):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#16 [mh ^methotrexate]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#17 (“4 amino 10 methylfolic acid” or “4 amino 10 methylpteroylglutamic acid” or “4 amino n10 methylpteroylglutamic acid” or methopterine or abitrexate or amethopterin* or ametopterine or antifolan or biotrexate or canceren or “cl 14377” or cl14377 or emtexate or emthexat* or emtrexate or enthexate or farmitrexat* or farmotrex or folex or ifamet or imeth or “intradose MTX” or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrex* or methylaminopterin* or meticil or metoject or metotrex* or metrex or mexate* or “mpi 5004” or mpi5004 or MTX or neotrexate or nordimet or novatrex or “nsc 740” or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or texate* or texorate or trexall or xaken or zexate):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#18 [mh ^6-mercaptopurine]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#19 (?mercaptopurin* or leupurin* or “puri nethol” or puri-nethol or purimethol or purinethol or “6 thiohypoxanthine” or 6-thiohypoxanthine or “6 thiopurine” or 6-thiopurine or “bw 57 323h” or “bw 57-323h” or “bw 57323h” or “1,7-dihydro-6h-purine-6-thione” or “mercapto purine” or “6 mp” or classen or empurine or ismipur or leukerin or loulla or mercaleukin or mercaptopurin* or mercapurene or mern or mycaptine or “nsc 755” or nsc755 or “puri nethol” or puri-nethol or “purine 6 thiol” or “purine thiol” or purinethiol or purinethol or purixan or thiohypoxanthine or thiopurine or xaluprine):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#20 [mh ^azathioprine]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#21 (azathio* or azothiop* or immuran or Imuran* or imurel or arathiop* or aza-q or azafalk or azahexal or azamedac or azamun or azamune or azanin or azapin or azapress or azaprine or azarex or azasan or azathropsin or azatioprina or azatox or azatrilem or azopi or azoran or “bw 57 322” or bw 57-322 or “bw 57322” or bw57-322 or bw57322 or colinsan or immurel or immuthera or imunen or imuprin or imurek or imuren or “nsc 39084” or nsc39084 or thioazeprine or thioprine or transimune or zytrim):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#22 [mh ^tacrolimus]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#23 (“fk 506” or fk-506 or fk506 or “fr 900506” or fr-900506 or fr900506 or prograf* or tacrolimus or advagraf or astagraf or envarsus or fujimycin or hecoria or modigraf or “mustopic oint” or protopic or protopy or tsukubaenolide):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#24 [mh ^cyclosporine]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#25 (ciclosporin* or cyclosporin* or sandimmun* or neoral or deximune or cipol-n or implanta or imusporin):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#26 [mh ^mesalamine]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#27 [mh ^sulfasalazine]</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#28 (aminosalicyl* or 5-aminosalicyl* or 5-ASA or 5ASA or 5aminosalicyl* or pentasa or mesalazine or mesalamine or asacol or mezavant or ipocol or mesren or salofalk or asacolon or ascolitin or canasa or claversal or fivasa or lixacol or mesalamine or mesasal or “2 hydroxy 5 aminobenzoic acid” or “5 amino 2 hydroxybenzoic acid” or “5 aminosalicylate” or “5 aminosalicylic acid” or “5-asa 400” or apriso or asacolitin or asalex or asalit or asavixin or azalan or claversal or colitofalk or delzicol or fisalamine or fiv-asa or fivasa or kenzomyl or lialda or lixacol or mesacol or mesagran or mesalin or mesalmin or mesavance or mesavancol or mesavant or “mesren mr” or “meta aminosalicylic acid” or neoasa or norasa or pentacol or quintasa or rowasa or salisofar or salogran or sfrowasa or “spd 476” or spd476):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#29 (sulfasalazine* or sulphasalazine or salazopyrin* or salazosulfapyridine* or asulfidine* or “colo pleon” or colo-pleon or pleon or pyralin or azulfadine* or azulfidine* or salicylazosulfapyridine or ucine or ulcol or azopyrin* or azosulfidine or azulfid* or azulfin or benzosulfa or colopleon or disalazin or gastropyrin or “pleon ra” or “pyralin en” or rorasul or rosulfant or salazine or “salazo sulfapyridine” or salazodin or salazopirina or salazopyr* or salazopyrin* or salazosulf* or “salicyl azo sulfapyridine” or salicylazosulfapyridin* or salisulf or salopyr or saridine or “sas 500” or sulcolon or sulfasalizine or sulfosalazine or sulphosalazine or zopyrin):ti,ab,kw</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#30 (olsalazine or balsalazide or dipentum or colazide or balsalazine or Giazo or Colazal):ti,ab,kw 128</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#31 {or #9-#30}</td></tr><tr><td headers="hd_h_niceng130er.appc.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#32 #8 and #31 Publication Year from 2012 to 2017</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappdfig1"><div id="niceng130er.appd.fig1" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappdf1&p=BOOKS&id=576848_niceng130erappdf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappdf1.jpg" alt="Image niceng130erappdf1" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig1"><div id="niceng130er.appg.fig1" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf1&p=BOOKS&id=576848_niceng130erappgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf1.jpg" alt="Image niceng130erappgf1" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig2"><div id="niceng130er.appg.fig2" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf2&p=BOOKS&id=576848_niceng130erappgf2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf2.jpg" alt="Image niceng130erappgf2" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig3"><div id="niceng130er.appg.fig3" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf3&p=BOOKS&id=576848_niceng130erappgf3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf3.jpg" alt="Image niceng130erappgf3" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig4"><div id="niceng130er.appg.fig4" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf4&p=BOOKS&id=576848_niceng130erappgf4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf4.jpg" alt="Image niceng130erappgf4" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig5"><div id="niceng130er.appg.fig5" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf5&p=BOOKS&id=576848_niceng130erappgf5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf5.jpg" alt="Image niceng130erappgf5" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig6"><div id="niceng130er.appg.fig6" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf6&p=BOOKS&id=576848_niceng130erappgf6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf6.jpg" alt="Image niceng130erappgf6" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig7"><div id="niceng130er.appg.fig7" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf7&p=BOOKS&id=576848_niceng130erappgf7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf7.jpg" alt="Image niceng130erappgf7" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig8"><div id="niceng130er.appg.fig8" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf8&p=BOOKS&id=576848_niceng130erappgf8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf8.jpg" alt="Image niceng130erappgf8" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig9"><div id="niceng130er.appg.fig9" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf9&p=BOOKS&id=576848_niceng130erappgf9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf9.jpg" alt="Image niceng130erappgf9" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig10"><div id="niceng130er.appg.fig10" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf10&p=BOOKS&id=576848_niceng130erappgf10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf10.jpg" alt="Image niceng130erappgf10" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig11"><div id="niceng130er.appg.fig11" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf11&p=BOOKS&id=576848_niceng130erappgf11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf11.jpg" alt="Image niceng130erappgf11" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig12"><div id="niceng130er.appg.fig12" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf12&p=BOOKS&id=576848_niceng130erappgf12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf12.jpg" alt="Image niceng130erappgf12" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig13"><div id="niceng130er.appg.fig13" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf13&p=BOOKS&id=576848_niceng130erappgf13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf13.jpg" alt="Image niceng130erappgf13" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig14"><div id="niceng130er.appg.fig14" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf14&p=BOOKS&id=576848_niceng130erappgf14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf14.jpg" alt="Image niceng130erappgf14" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig15"><div id="niceng130er.appg.fig15" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf15&p=BOOKS&id=576848_niceng130erappgf15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf15.jpg" alt="Image niceng130erappgf15" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig16"><div id="niceng130er.appg.fig16" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf16&p=BOOKS&id=576848_niceng130erappgf16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf16.jpg" alt="Image niceng130erappgf16" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig17"><div id="niceng130er.appg.fig17" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf17&p=BOOKS&id=576848_niceng130erappgf17.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf17.jpg" alt="Image niceng130erappgf17" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig18"><div id="niceng130er.appg.fig18" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf18&p=BOOKS&id=576848_niceng130erappgf18.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf18.jpg" alt="Image niceng130erappgf18" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig19"><div id="niceng130er.appg.fig19" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf19&p=BOOKS&id=576848_niceng130erappgf19.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf19.jpg" alt="Image niceng130erappgf19" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig20"><div id="niceng130er.appg.fig20" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf20&p=BOOKS&id=576848_niceng130erappgf20.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf20.jpg" alt="Image niceng130erappgf20" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig21"><div id="niceng130er.appg.fig21" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf21&p=BOOKS&id=576848_niceng130erappgf21.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf21.jpg" alt="Image niceng130erappgf21" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig22"><div id="niceng130er.appg.fig22" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf22&p=BOOKS&id=576848_niceng130erappgf22.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf22.jpg" alt="Image niceng130erappgf22" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig23"><div id="niceng130er.appg.fig23" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf23&p=BOOKS&id=576848_niceng130erappgf23.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf23.jpg" alt="Image niceng130erappgf23" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig24"><div id="niceng130er.appg.fig24" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf24&p=BOOKS&id=576848_niceng130erappgf24.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf24.jpg" alt="Image niceng130erappgf24" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig25"><div id="niceng130er.appg.fig25" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf25&p=BOOKS&id=576848_niceng130erappgf25.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf25.jpg" alt="Image niceng130erappgf25" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig26"><div id="niceng130er.appg.fig26" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf26&p=BOOKS&id=576848_niceng130erappgf26.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf26.jpg" alt="Image niceng130erappgf26" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig27"><div id="niceng130er.appg.fig27" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf27&p=BOOKS&id=576848_niceng130erappgf27.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf27.jpg" alt="Image niceng130erappgf27" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig28"><div id="niceng130er.appg.fig28" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf28&p=BOOKS&id=576848_niceng130erappgf28.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf28.jpg" alt="Image niceng130erappgf28" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig29"><div id="niceng130er.appg.fig29" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf29&p=BOOKS&id=576848_niceng130erappgf29.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf29.jpg" alt="Image niceng130erappgf29" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig30"><div id="niceng130er.appg.fig30" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf30&p=BOOKS&id=576848_niceng130erappgf30.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf30.jpg" alt="Image niceng130erappgf30" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig31"><div id="niceng130er.appg.fig31" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf31&p=BOOKS&id=576848_niceng130erappgf31.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf31.jpg" alt="Image niceng130erappgf31" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig32"><div id="niceng130er.appg.fig32" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf32&p=BOOKS&id=576848_niceng130erappgf32.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf32.jpg" alt="Image niceng130erappgf32" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig33"><div id="niceng130er.appg.fig33" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf33&p=BOOKS&id=576848_niceng130erappgf33.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf33.jpg" alt="Image niceng130erappgf33" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig34"><div id="niceng130er.appg.fig34" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf34&p=BOOKS&id=576848_niceng130erappgf34.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf34.jpg" alt="Image niceng130erappgf34" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig35"><div id="niceng130er.appg.fig35" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf35&p=BOOKS&id=576848_niceng130erappgf35.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf35.jpg" alt="Image niceng130erappgf35" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig36"><div id="niceng130er.appg.fig36" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf36&p=BOOKS&id=576848_niceng130erappgf36.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf36.jpg" alt="Image niceng130erappgf36" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig37"><div id="niceng130er.appg.fig37" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf37&p=BOOKS&id=576848_niceng130erappgf37.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf37.jpg" alt="Image niceng130erappgf37" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig38"><div id="niceng130er.appg.fig38" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf38&p=BOOKS&id=576848_niceng130erappgf38.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf38.jpg" alt="Image niceng130erappgf38" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig39"><div id="niceng130er.appg.fig39" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf39&p=BOOKS&id=576848_niceng130erappgf39.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf39.jpg" alt="Image niceng130erappgf39" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig40"><div id="niceng130er.appg.fig40" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf40&p=BOOKS&id=576848_niceng130erappgf40.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf40.jpg" alt="Image niceng130erappgf40" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig41"><div id="niceng130er.appg.fig41" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf41&p=BOOKS&id=576848_niceng130erappgf41.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf41.jpg" alt="Image niceng130erappgf41" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig42"><div id="niceng130er.appg.fig42" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf42&p=BOOKS&id=576848_niceng130erappgf42.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf42.jpg" alt="Image niceng130erappgf42" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig43"><div id="niceng130er.appg.fig43" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf43&p=BOOKS&id=576848_niceng130erappgf43.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf43.jpg" alt="Image niceng130erappgf43" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="fig" id="figobniceng130erappgfig44"><div id="niceng130er.appg.fig44" class="figure"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Image%20niceng130erappgf44&p=BOOKS&id=576848_niceng130erappgf44.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappgf44.jpg" alt="Image niceng130erappgf44" class="tileshop" title="Click on image to zoom" /></a></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab1"><div id="niceng130er.apph.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab1_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_h_niceng130er.apph.tab1_1_1_1_2 hd_h_niceng130er.apph.tab1_1_1_1_3 hd_h_niceng130er.apph.tab1_1_1_1_4 hd_h_niceng130er.apph.tab1_1_1_1_5 hd_h_niceng130er.apph.tab1_1_1_1_6 hd_h_niceng130er.apph.tab1_1_1_1_7 hd_h_niceng130er.apph.tab1_1_1_1_8 hd_h_niceng130er.apph.tab1_1_1_1_9" id="hd_b_niceng130er.apph.tab1_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctitis at 2 weeks follow-up – (higher values favour topical aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (<a class="bibr" href="#niceng130er.appe.s1.1.ref3" rid="niceng130er.appe.s1.1.ref3">Campieri 1990</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref4" rid="niceng130er.appe.s1.1.ref4">Campieri 1990a</a>)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_2 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_3 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">156</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_4 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 3.47 (1.45, 8.28)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_5 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_6 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_7 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_8 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_9 hd_b_niceng130er.apph.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_h_niceng130er.apph.tab1_1_1_1_2 hd_h_niceng130er.apph.tab1_1_1_1_3 hd_h_niceng130er.apph.tab1_1_1_1_4 hd_h_niceng130er.apph.tab1_1_1_1_5 hd_h_niceng130er.apph.tab1_1_1_1_6 hd_h_niceng130er.apph.tab1_1_1_1_7 hd_h_niceng130er.apph.tab1_1_1_1_8 hd_h_niceng130er.apph.tab1_1_1_1_9" id="hd_b_niceng130er.apph.tab1_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctitis at 3 to 4 weeks follow-up – (higher values favour topical aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (<a class="bibr" href="#niceng130er.appe.s1.1.ref3" rid="niceng130er.appe.s1.1.ref3">Campieri 1990</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref4" rid="niceng130er.appe.s1.1.ref4">Campieri 1990a</a>; Wantabe 2013)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_2 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_3 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">285</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_4 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 7.10 (4.07, 12.40)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_5 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_6 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_7 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_8 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_9 hd_b_niceng130er.apph.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_h_niceng130er.apph.tab1_1_1_1_2 hd_h_niceng130er.apph.tab1_1_1_1_3 hd_h_niceng130er.apph.tab1_1_1_1_4 hd_h_niceng130er.apph.tab1_1_1_1_5 hd_h_niceng130er.apph.tab1_1_1_1_6 hd_h_niceng130er.apph.tab1_1_1_1_7 hd_h_niceng130er.apph.tab1_1_1_1_8 hd_h_niceng130er.apph.tab1_1_1_1_9" id="hd_b_niceng130er.apph.tab1_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctitis at 5 to 8 weeks follow-up – (higher values favour topical aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref27" rid="niceng130er.appe.s1.1.ref27">Pokrotnieks 2000</a>)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_2 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_3 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_4 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.75 (0.43, 7.17)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_5 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_6 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_7 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_8 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_9 hd_b_niceng130er.apph.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_h_niceng130er.apph.tab1_1_1_1_2 hd_h_niceng130er.apph.tab1_1_1_1_3 hd_h_niceng130er.apph.tab1_1_1_1_4 hd_h_niceng130er.apph.tab1_1_1_1_5 hd_h_niceng130er.apph.tab1_1_1_1_6 hd_h_niceng130er.apph.tab1_1_1_1_7 hd_h_niceng130er.apph.tab1_1_1_1_8" id="hd_b_niceng130er.apph.tab1_1_1_7_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 2 weeks follow-up – (higher values favour topical aminosalicylates)</th><th headers="hd_h_niceng130er.apph.tab1_1_1_1_9" id="hd_b_niceng130er.apph.tab1_1_1_7_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_b_niceng130er.apph.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref5" rid="niceng130er.appe.s1.1.ref5">Campieri 1991</a>)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_2 hd_b_niceng130er.apph.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_3 hd_b_niceng130er.apph.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_4 hd_b_niceng130er.apph.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 13.71 (1.77, 106.21)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_5 hd_b_niceng130er.apph.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_6 hd_b_niceng130er.apph.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_7 hd_b_niceng130er.apph.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_8 hd_b_niceng130er.apph.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_9 hd_b_niceng130er.apph.tab1_1_1_7_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td></tr><tr><th headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_h_niceng130er.apph.tab1_1_1_1_2 hd_h_niceng130er.apph.tab1_1_1_1_3 hd_h_niceng130er.apph.tab1_1_1_1_4 hd_h_niceng130er.apph.tab1_1_1_1_5 hd_h_niceng130er.apph.tab1_1_1_1_6 hd_h_niceng130er.apph.tab1_1_1_1_7 hd_h_niceng130er.apph.tab1_1_1_1_8 hd_h_niceng130er.apph.tab1_1_1_1_9" id="hd_b_niceng130er.apph.tab1_1_1_9_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 3 to 4 weeks follow-up – (higher values favour topical aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref5" rid="niceng130er.appe.s1.1.ref5">Campieri 1991</a>)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_2 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_3 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">115</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_4 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 50.27 (6.50, 388.66)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_5 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_6 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_7 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_8 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_9 hd_b_niceng130er.apph.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td></tr><tr><th headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_h_niceng130er.apph.tab1_1_1_1_2 hd_h_niceng130er.apph.tab1_1_1_1_3 hd_h_niceng130er.apph.tab1_1_1_1_4 hd_h_niceng130er.apph.tab1_1_1_1_5 hd_h_niceng130er.apph.tab1_1_1_1_6 hd_h_niceng130er.apph.tab1_1_1_1_7 hd_h_niceng130er.apph.tab1_1_1_1_8 hd_h_niceng130er.apph.tab1_1_1_1_9" id="hd_b_niceng130er.apph.tab1_1_1_11_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour topical aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab1_1_1_1_1 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (<a class="bibr" href="#niceng130er.appe.s1.1.ref15" rid="niceng130er.appe.s1.1.ref15">Hanauer 1998</a>; Pokrotneiks 2000)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_2 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_3 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">292</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_4 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 3.92 (2.22, 6.92)</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_5 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_6 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_7 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_8 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab1_1_1_1_9 hd_b_niceng130er.apph.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab1_1"><p class="no_margin">Greater than 33.3% of the weight in a meta-analysis came from studies at moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab1_2"><p class="no_margin">2 I<sup>2</sup> value was greater than 33.3% and less than 66.7%.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab1_3"><p class="no_margin">Inconsistency not applicable as effect size is from a single study</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="niceng130er.apph.tab1_4"><p class="no_margin">95% confidence intervals crossed two MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab2"><div id="niceng130er.apph.tab2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab2_1_1_1_1 hd_h_niceng130er.apph.tab2_1_1_1_2 hd_h_niceng130er.apph.tab2_1_1_1_3 hd_h_niceng130er.apph.tab2_1_1_1_4 hd_h_niceng130er.apph.tab2_1_1_1_5 hd_h_niceng130er.apph.tab2_1_1_1_6 hd_h_niceng130er.apph.tab2_1_1_1_7 hd_h_niceng130er.apph.tab2_1_1_1_8" id="hd_b_niceng130er.apph.tab2_1_1_1_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 3 to 4 weeks follow-up – (lower values favour topical prednisolone)</th><th headers="hd_h_niceng130er.apph.tab2_1_1_1_9" id="hd_b_niceng130er.apph.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng130er.apph.tab2_1_1_1_1 hd_b_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref22" rid="niceng130er.appe.s1.1.ref22">Lauritsen 1986</a>)</td><td headers="hd_h_niceng130er.apph.tab2_1_1_1_2 hd_b_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab2_1_1_1_3 hd_b_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_niceng130er.apph.tab2_1_1_1_4 hd_b_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.26 (0.04, 1.70)</td><td headers="hd_h_niceng130er.apph.tab2_1_1_1_5 hd_b_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab2_1_1_1_6 hd_b_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab2_1_1_1_7 hd_b_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab2_1_1_1_8 hd_b_niceng130er.apph.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab2_1_1_1_9 hd_b_niceng130er.apph.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab2_1"><p class="no_margin">Moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab2_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab2_3"><p class="no_margin">95% confidence intervals crossed two MIDs</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab3"><div id="niceng130er.apph.tab3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab3_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab3_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab3_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab3_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab3_1_1_1_1 hd_h_niceng130er.apph.tab3_1_1_1_2 hd_h_niceng130er.apph.tab3_1_1_1_3 hd_h_niceng130er.apph.tab3_1_1_1_4 hd_h_niceng130er.apph.tab3_1_1_1_5 hd_h_niceng130er.apph.tab3_1_1_1_6 hd_h_niceng130er.apph.tab3_1_1_1_7 hd_h_niceng130er.apph.tab3_1_1_1_8" id="hd_b_niceng130er.apph.tab3_1_1_1_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctitis at 5 to 8 weeks follow-up – (higher values favour tacrolimus ointment)</th><th headers="hd_h_niceng130er.apph.tab3_1_1_1_9" id="hd_b_niceng130er.apph.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng130er.apph.tab3_1_1_1_1 hd_b_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.2.ref4" rid="niceng130er.appe.s1.2.ref4">Lawrance 2017</a>)</td><td headers="hd_h_niceng130er.apph.tab3_1_1_1_2 hd_b_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab3_1_1_1_3 hd_b_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21</td><td headers="hd_h_niceng130er.apph.tab3_1_1_1_4 hd_b_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 17.77 (0.84, 377.40)</td><td headers="hd_h_niceng130er.apph.tab3_1_1_1_5 hd_b_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab3_1_1_1_6 hd_b_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab3_1_1_1_7 hd_b_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A</td><td headers="hd_h_niceng130er.apph.tab3_1_1_1_8 hd_b_niceng130er.apph.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab3_1_1_1_9 hd_b_niceng130er.apph.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab3_1"><p class="no_margin">Indirect treatment preparation as ointment form of tacrolimus not used for proctitis in clinical practice.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab3_2"><p class="no_margin">95% confidence intervals crossed one MID.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab4"><div id="niceng130er.apph.tab4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab4_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab4_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab4_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab4_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab4_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab4_1_1_1_1 hd_h_niceng130er.apph.tab4_1_1_1_2 hd_h_niceng130er.apph.tab4_1_1_1_3 hd_h_niceng130er.apph.tab4_1_1_1_4 hd_h_niceng130er.apph.tab4_1_1_1_5 hd_h_niceng130er.apph.tab4_1_1_1_6 hd_h_niceng130er.apph.tab4_1_1_1_7 hd_h_niceng130er.apph.tab4_1_1_1_8" id="hd_b_niceng130er.apph.tab4_1_1_1_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 2 weeks follow-up – (higher values favour topical prednisolone)</th><th headers="hd_h_niceng130er.apph.tab4_1_1_1_9" id="hd_b_niceng130er.apph.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng130er.apph.tab4_1_1_1_1 hd_b_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref2" rid="niceng130er.appe.s1.1.ref2">Binder 1987</a>)</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_2 hd_b_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_3 hd_b_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">117</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_4 hd_b_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.49 (0.23, 1.03)</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_5 hd_b_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_6 hd_b_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_7 hd_b_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_8 hd_b_niceng130er.apph.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_9 hd_b_niceng130er.apph.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab4_1_1_1_1 hd_h_niceng130er.apph.tab4_1_1_1_2 hd_h_niceng130er.apph.tab4_1_1_1_3 hd_h_niceng130er.apph.tab4_1_1_1_4 hd_h_niceng130er.apph.tab4_1_1_1_5 hd_h_niceng130er.apph.tab4_1_1_1_6 hd_h_niceng130er.apph.tab4_1_1_1_7 hd_h_niceng130er.apph.tab4_1_1_1_8 hd_h_niceng130er.apph.tab4_1_1_1_9" id="hd_b_niceng130er.apph.tab4_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour topical budesonide)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab4_1_1_1_1 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (<a class="bibr" href="#niceng130er.appe.s1.2.ref5" rid="niceng130er.appe.s1.2.ref5">Naganuma 2016</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref6" rid="niceng130er.appe.s1.2.ref6">Naganuma 2017</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref11" rid="niceng130er.appe.s1.2.ref11">Sandborn 2015</a>)</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_2 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_3 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">837</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_4 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.61 (1.92, 3.54)</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_5 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_6 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_7 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_8 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_9 hd_b_niceng130er.apph.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td></tr><tr><th headers="hd_h_niceng130er.apph.tab4_1_1_1_1 hd_h_niceng130er.apph.tab4_1_1_1_2 hd_h_niceng130er.apph.tab4_1_1_1_3 hd_h_niceng130er.apph.tab4_1_1_1_4 hd_h_niceng130er.apph.tab4_1_1_1_5 hd_h_niceng130er.apph.tab4_1_1_1_6 hd_h_niceng130er.apph.tab4_1_1_1_7 hd_h_niceng130er.apph.tab4_1_1_1_8 hd_h_niceng130er.apph.tab4_1_1_1_9" id="hd_b_niceng130er.apph.tab4_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events (all extents of disease) up to 10 weeks follow-up - (lower values favour topical budesonide)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab4_1_1_1_1 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (<a class="bibr" href="#niceng130er.appe.s1.2.ref5" rid="niceng130er.appe.s1.2.ref5">Naganuma 2016</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref6" rid="niceng130er.appe.s1.2.ref6">Naganuma 2017</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref11" rid="niceng130er.appe.s1.2.ref11">Sandborn 2015</a>)</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_2 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_3 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">837</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_4 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.00 (1.08, 3.70)</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_5 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_6 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_7 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_8 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab4_1_1_1_9 hd_b_niceng130er.apph.tab4_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab4_1"><p class="no_margin">Moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab4_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab4_3"><p class="no_margin">95% confidence intervals crossed one MID.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="niceng130er.apph.tab4_4"><p class="no_margin">Greater than 33.3% of the weight in a meta-analysis came from studies at moderate risk of bias.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab5"><div id="niceng130er.apph.tab5" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab5_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab5_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab5_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab5_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab5_1_1_1_1 hd_h_niceng130er.apph.tab5_1_1_1_2 hd_h_niceng130er.apph.tab5_1_1_1_3 hd_h_niceng130er.apph.tab5_1_1_1_4 hd_h_niceng130er.apph.tab5_1_1_1_5 hd_h_niceng130er.apph.tab5_1_1_1_6 hd_h_niceng130er.apph.tab5_1_1_1_7 hd_h_niceng130er.apph.tab5_1_1_1_8 hd_h_niceng130er.apph.tab5_1_1_1_9" id="hd_b_niceng130er.apph.tab5_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 3 to 4 weeks follow-up – (higher values favour foam budesonide)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab5_1_1_1_1 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref12" rid="niceng130er.appe.s1.1.ref12">Gross 2006</a>)</td><td headers="hd_h_niceng130er.apph.tab5_1_1_1_2 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab5_1_1_1_3 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">524</td><td headers="hd_h_niceng130er.apph.tab5_1_1_1_4 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.61 (0.43, 0.87)</td><td headers="hd_h_niceng130er.apph.tab5_1_1_1_5 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab5_1_1_1_6 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab5_1_1_1_7 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab5_1_1_1_8 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab5_1_1_1_9 hd_b_niceng130er.apph.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab5_1"><p class="no_margin">Moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab5_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab5_3"><p class="no_margin">95% confidence intervals crossed one MID</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab6"><div id="niceng130er.apph.tab6" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab6_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab6_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab6_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab6_1_1_1_1 hd_h_niceng130er.apph.tab6_1_1_1_2 hd_h_niceng130er.apph.tab6_1_1_1_3 hd_h_niceng130er.apph.tab6_1_1_1_4 hd_h_niceng130er.apph.tab6_1_1_1_5 hd_h_niceng130er.apph.tab6_1_1_1_6 hd_h_niceng130er.apph.tab6_1_1_1_7 hd_h_niceng130er.apph.tab6_1_1_1_8 hd_h_niceng130er.apph.tab6_1_1_1_9" id="hd_b_niceng130er.apph.tab6_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour foam budesonide)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab6_1_1_1_1 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref1" rid="niceng130er.appe.s1.1.ref1">Bar-Mieir 2003</a>)</td><td headers="hd_h_niceng130er.apph.tab6_1_1_1_2 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab6_1_1_1_3 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">248</td><td headers="hd_h_niceng130er.apph.tab6_1_1_1_4 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.04 (0.63, 1.71)</td><td headers="hd_h_niceng130er.apph.tab6_1_1_1_5 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab6_1_1_1_6 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab6_1_1_1_7 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab6_1_1_1_8 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab6_1_1_1_9 hd_b_niceng130er.apph.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab6_1"><p class="no_margin">High risk of bias (open-label trial).</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab6_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab6_3"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab7"><div id="niceng130er.apph.tab7" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th id="hd_h_niceng130er.apph.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab7_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab7_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab7_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab7_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab7_1_1_1_1 hd_h_niceng130er.apph.tab7_1_1_1_2 hd_h_niceng130er.apph.tab7_1_1_1_3 hd_h_niceng130er.apph.tab7_1_1_1_4 hd_h_niceng130er.apph.tab7_1_1_1_5 hd_h_niceng130er.apph.tab7_1_1_1_6 hd_h_niceng130er.apph.tab7_1_1_1_7 hd_h_niceng130er.apph.tab7_1_1_1_8 hd_h_niceng130er.apph.tab7_1_1_1_9" id="hd_b_niceng130er.apph.tab7_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctitis at 5 to 8 weeks follow-up – (higher values favour low-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab7_1_1_1_1 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref19" rid="niceng130er.appe.s1.1.ref19">Ito 2010</a>)</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_2 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_3 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">225</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_4 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 5.14 (1.51, 17.50)</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_5 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_6 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_7 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_8 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_9 hd_b_niceng130er.apph.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab7_1_1_1_1 hd_h_niceng130er.apph.tab7_1_1_1_2 hd_h_niceng130er.apph.tab7_1_1_1_3 hd_h_niceng130er.apph.tab7_1_1_1_4 hd_h_niceng130er.apph.tab7_1_1_1_5 hd_h_niceng130er.apph.tab7_1_1_1_6 hd_h_niceng130er.apph.tab7_1_1_1_7 hd_h_niceng130er.apph.tab7_1_1_1_8 hd_h_niceng130er.apph.tab7_1_1_1_9" id="hd_b_niceng130er.apph.tab7_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 3 to 4 weeks follow-up – (higher values favour low-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab7_1_1_1_1 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (<a class="bibr" href="#niceng130er.appe.s1.2.ref8" rid="niceng130er.appe.s1.2.ref8">Pontes 2014</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref33" rid="niceng130er.appe.s1.1.ref33">Sninsky 1991</a>)</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_2 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_3 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">179</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_4 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.23 (0.19, 8.08)</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_5 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_6 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_7 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_8 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_9 hd_b_niceng130er.apph.tab7_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab7_1_1_1_1 hd_h_niceng130er.apph.tab7_1_1_1_2 hd_h_niceng130er.apph.tab7_1_1_1_3 hd_h_niceng130er.apph.tab7_1_1_1_4 hd_h_niceng130er.apph.tab7_1_1_1_5 hd_h_niceng130er.apph.tab7_1_1_1_6 hd_h_niceng130er.apph.tab7_1_1_1_7 hd_h_niceng130er.apph.tab7_1_1_1_8 hd_h_niceng130er.apph.tab7_1_1_1_9" id="hd_b_niceng130er.apph.tab7_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour low-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab7_1_1_1_1 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (<a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer 1993</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref25" rid="niceng130er.appe.s1.1.ref25">Lichtenstein 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref33" rid="niceng130er.appe.s1.1.ref33">Sninsky 1991</a>)</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_2 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_3 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">866</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_4 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.38 (1.64, 3.45)</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_5 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_6 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_7 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_8 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_9 hd_b_niceng130er.apph.tab7_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td></tr><tr><th headers="hd_h_niceng130er.apph.tab7_1_1_1_1 hd_h_niceng130er.apph.tab7_1_1_1_2 hd_h_niceng130er.apph.tab7_1_1_1_3 hd_h_niceng130er.apph.tab7_1_1_1_4 hd_h_niceng130er.apph.tab7_1_1_1_5 hd_h_niceng130er.apph.tab7_1_1_1_6 hd_h_niceng130er.apph.tab7_1_1_1_7 hd_h_niceng130er.apph.tab7_1_1_1_8" id="hd_b_niceng130er.apph.tab7_1_1_7_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events (all extents of disease) up to 10 weeks follow-up - (lower values favour low-dose oral aminosalicylates)</th><th headers="hd_h_niceng130er.apph.tab7_1_1_1_9" id="hd_b_niceng130er.apph.tab7_1_1_7_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng130er.apph.tab7_1_1_1_1 hd_b_niceng130er.apph.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 (<a class="bibr" href="#niceng130er.appe.s1.1.ref9" rid="niceng130er.appe.s1.1.ref9">Dick 1964</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref10" rid="niceng130er.appe.s1.1.ref10">Feurle 1989</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer 1993</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref17" rid="niceng130er.appe.s1.1.ref17">Hetzel 1986</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref19" rid="niceng130er.appe.s1.1.ref19">Ito 2010</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref25" rid="niceng130er.appe.s1.1.ref25">Lichtenstein 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref31" rid="niceng130er.appe.s1.1.ref31">Sandborn 2012</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref33" rid="niceng130er.appe.s1.1.ref33">Sninsky 1991</a>)</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_2 hd_b_niceng130er.apph.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_3 hd_b_niceng130er.apph.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1156</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_4 hd_b_niceng130er.apph.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.72 (0.42, 1.24)</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_5 hd_b_niceng130er.apph.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_6 hd_b_niceng130er.apph.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_7 hd_b_niceng130er.apph.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_8 hd_b_niceng130er.apph.tab7_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>5</sup></td><td headers="hd_h_niceng130er.apph.tab7_1_1_1_9 hd_b_niceng130er.apph.tab7_1_1_7_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab7_1"><p class="no_margin">Moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab7_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab7_3"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="niceng130er.apph.tab7_4"><p class="no_margin">Greater than 33% of the studies were at moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="niceng130er.apph.tab7_5"><p class="no_margin">95% confidence intervals crossed one MID.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab8"><div id="niceng130er.apph.tab8" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab8_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab8_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab8_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab8_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab8_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab8_1_1_1_1 hd_h_niceng130er.apph.tab8_1_1_1_2 hd_h_niceng130er.apph.tab8_1_1_1_3 hd_h_niceng130er.apph.tab8_1_1_1_4 hd_h_niceng130er.apph.tab8_1_1_1_5 hd_h_niceng130er.apph.tab8_1_1_1_6 hd_h_niceng130er.apph.tab8_1_1_1_7 hd_h_niceng130er.apph.tab8_1_1_1_8" id="hd_b_niceng130er.apph.tab8_1_1_1_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctitis at 2 weeks follow-up – (higher values favour standard-dose oral aminosalicylates)</th><th headers="hd_h_niceng130er.apph.tab8_1_1_1_9" id="hd_b_niceng130er.apph.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng130er.apph.tab8_1_1_1_1 hd_b_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref11" rid="niceng130er.appe.s1.1.ref11">Gionchetti 1998</a>)</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_2 hd_b_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_3 hd_b_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_4 hd_b_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.16 (0.05, 0.51)</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_5 hd_b_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_6 hd_b_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_7 hd_b_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_8 hd_b_niceng130er.apph.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_9 hd_b_niceng130er.apph.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab8_1_1_1_1 hd_h_niceng130er.apph.tab8_1_1_1_2 hd_h_niceng130er.apph.tab8_1_1_1_3 hd_h_niceng130er.apph.tab8_1_1_1_4 hd_h_niceng130er.apph.tab8_1_1_1_5 hd_h_niceng130er.apph.tab8_1_1_1_6 hd_h_niceng130er.apph.tab8_1_1_1_7 hd_h_niceng130er.apph.tab8_1_1_1_8 hd_h_niceng130er.apph.tab8_1_1_1_9" id="hd_b_niceng130er.apph.tab8_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctitis at 3 to 4 weeks follow-up – (higher values favour standard-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab8_1_1_1_1 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref11" rid="niceng130er.appe.s1.1.ref11">Gionchetti 1998</a>)</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_2 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_3 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_4 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.08 (0.02, 0.33)</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_5 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_6 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_7 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_8 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab8_1_1_1_9 hd_b_niceng130er.apph.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab8_1"><p class="no_margin">Moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab8_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab9"><div id="niceng130er.apph.tab9" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab9_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab9_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab9_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab9_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab9_1_1_1_1 hd_h_niceng130er.apph.tab9_1_1_1_2 hd_h_niceng130er.apph.tab9_1_1_1_3 hd_h_niceng130er.apph.tab9_1_1_1_4 hd_h_niceng130er.apph.tab9_1_1_1_5 hd_h_niceng130er.apph.tab9_1_1_1_6 hd_h_niceng130er.apph.tab9_1_1_1_7 hd_h_niceng130er.apph.tab9_1_1_1_8" id="hd_b_niceng130er.apph.tab9_1_1_1_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour standard-dose oral aminosalicylates)</th><th headers="hd_h_niceng130er.apph.tab9_1_1_1_9" id="hd_b_niceng130er.apph.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng130er.apph.tab9_1_1_1_1 hd_b_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref34" rid="niceng130er.appe.s1.1.ref34">Vecchi 2001</a>)</td><td headers="hd_h_niceng130er.apph.tab9_1_1_1_2 hd_b_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab9_1_1_1_3 hd_b_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">130</td><td headers="hd_h_niceng130er.apph.tab9_1_1_1_4 hd_b_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.67 (0.25, 1.76)</td><td headers="hd_h_niceng130er.apph.tab9_1_1_1_5 hd_b_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab9_1_1_1_6 hd_b_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab9_1_1_1_7 hd_b_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab9_1_1_1_8 hd_b_niceng130er.apph.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab9_1_1_1_9 hd_b_niceng130er.apph.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab9_1"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab9_2"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab10"><div id="niceng130er.apph.tab10" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab10_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab10_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab10_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab10_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_h_niceng130er.apph.tab10_1_1_1_2 hd_h_niceng130er.apph.tab10_1_1_1_3 hd_h_niceng130er.apph.tab10_1_1_1_4 hd_h_niceng130er.apph.tab10_1_1_1_5 hd_h_niceng130er.apph.tab10_1_1_1_6 hd_h_niceng130er.apph.tab10_1_1_1_7 hd_h_niceng130er.apph.tab10_1_1_1_8" id="hd_b_niceng130er.apph.tab10_1_1_1_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 3 to 4 weeks follow-up – (higher values favour standard-dose oral aminosalicylates)</th><th headers="hd_h_niceng130er.apph.tab10_1_1_1_9" id="hd_b_niceng130er.apph.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_b_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref30" rid="niceng130er.appe.s1.1.ref30">Sandborn 2009</a>)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_2 hd_b_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_3 hd_b_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">724</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_4 hd_b_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.67 (0.47, 0.95)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_5 hd_b_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_6 hd_b_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_7 hd_b_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_8 hd_b_niceng130er.apph.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_9 hd_b_niceng130er.apph.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_h_niceng130er.apph.tab10_1_1_1_2 hd_h_niceng130er.apph.tab10_1_1_1_3 hd_h_niceng130er.apph.tab10_1_1_1_4 hd_h_niceng130er.apph.tab10_1_1_1_5 hd_h_niceng130er.apph.tab10_1_1_1_6 hd_h_niceng130er.apph.tab10_1_1_1_7 hd_h_niceng130er.apph.tab10_1_1_1_8 hd_h_niceng130er.apph.tab10_1_1_1_9" id="hd_b_niceng130er.apph.tab10_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour standard-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10 (Dhaens 2006; <a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer 1993</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref16" rid="niceng130er.appe.s1.1.ref16">Hanauer 2005</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref21" rid="niceng130er.appe.s1.1.ref21">Kruis 2003</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref24" rid="niceng130er.appe.s1.1.ref24">Levine 2002</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref7" rid="niceng130er.appe.s1.2.ref7">Ogata 2017</a>; <a class="bibr" href="#niceng130er.appe.s1.3.ref1" rid="niceng130er.appe.s1.3.ref1">Ogata 2018</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref28" rid="niceng130er.appe.s1.1.ref28">Pruitt 2002</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref30" rid="niceng130er.appe.s1.1.ref30">Sandborn 2009</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref12" rid="niceng130er.appe.s1.2.ref12">Suzuki 2016</a>)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_2 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_3 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2643</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_4 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.73 (0.62, 0.86)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_5 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_6 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_7 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_8 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_9 hd_b_niceng130er.apph.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_h_niceng130er.apph.tab10_1_1_1_2 hd_h_niceng130er.apph.tab10_1_1_1_3 hd_h_niceng130er.apph.tab10_1_1_1_4 hd_h_niceng130er.apph.tab10_1_1_1_5 hd_h_niceng130er.apph.tab10_1_1_1_6 hd_h_niceng130er.apph.tab10_1_1_1_7 hd_h_niceng130er.apph.tab10_1_1_1_8 hd_h_niceng130er.apph.tab10_1_1_1_9" id="hd_b_niceng130er.apph.tab10_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in children with extensive ulcerative colitis 6 weeks follow-up – (higher values favour standard-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.2.ref15" rid="niceng130er.appe.s1.2.ref15">Winter 2014</a>)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_2 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_3 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_4 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.17 (0.49, 2.81)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_5 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_6 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_7 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_8 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_9 hd_b_niceng130er.apph.tab10_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_h_niceng130er.apph.tab10_1_1_1_2 hd_h_niceng130er.apph.tab10_1_1_1_3 hd_h_niceng130er.apph.tab10_1_1_1_4 hd_h_niceng130er.apph.tab10_1_1_1_5 hd_h_niceng130er.apph.tab10_1_1_1_6 hd_h_niceng130er.apph.tab10_1_1_1_7 hd_h_niceng130er.apph.tab10_1_1_1_8 hd_h_niceng130er.apph.tab10_1_1_1_9" id="hd_b_niceng130er.apph.tab10_1_1_7_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events (all extents of disease) up to 10 weeks follow-up - (lower values favour standard-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 (<a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer 1993</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref16" rid="niceng130er.appe.s1.1.ref16">Hanauer 2005</a>; Hanauer 2007; <a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref24" rid="niceng130er.appe.s1.1.ref24">Levine 2002</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref25" rid="niceng130er.appe.s1.1.ref25">Lichtenstein 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref7" rid="niceng130er.appe.s1.2.ref7">Ogata 2017</a>; <a class="bibr" href="#niceng130er.appe.s1.3.ref1" rid="niceng130er.appe.s1.3.ref1">Ogata 2018</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref28" rid="niceng130er.appe.s1.1.ref28">Pruitt 2002</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref30" rid="niceng130er.appe.s1.1.ref30">Sandborn 2009</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref12" rid="niceng130er.appe.s1.2.ref12">Suzuki 2016</a>)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_2 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_3 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_4 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.07 (0.76, 1.51)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_5 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_6 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_7 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_8 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_9 hd_b_niceng130er.apph.tab10_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_h_niceng130er.apph.tab10_1_1_1_2 hd_h_niceng130er.apph.tab10_1_1_1_3 hd_h_niceng130er.apph.tab10_1_1_1_4 hd_h_niceng130er.apph.tab10_1_1_1_5 hd_h_niceng130er.apph.tab10_1_1_1_6 hd_h_niceng130er.apph.tab10_1_1_1_7 hd_h_niceng130er.apph.tab10_1_1_1_8 hd_h_niceng130er.apph.tab10_1_1_1_9" id="hd_b_niceng130er.apph.tab10_1_1_9_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events in children with extensive ulcerative colitis at 6 weeks follow-up - (lower values favour standard-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.2.ref15" rid="niceng130er.appe.s1.2.ref15">Winter 2014</a>)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_2 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_3 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_4 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.71 (0.49, 14.84)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_5 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_6 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_7 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_8 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_9 hd_b_niceng130er.apph.tab10_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_h_niceng130er.apph.tab10_1_1_1_2 hd_h_niceng130er.apph.tab10_1_1_1_3 hd_h_niceng130er.apph.tab10_1_1_1_4 hd_h_niceng130er.apph.tab10_1_1_1_5 hd_h_niceng130er.apph.tab10_1_1_1_6 hd_h_niceng130er.apph.tab10_1_1_1_7 hd_h_niceng130er.apph.tab10_1_1_1_8 hd_h_niceng130er.apph.tab10_1_1_1_9" id="hd_b_niceng130er.apph.tab10_1_1_11_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Quality of life using inflammatory bowel disease questionnaire (IBDQ) in adults (extent of disease not reported) - change from baseline to 6 weeks follow-up – (higher values favour standard-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab10_1_1_1_1 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (<a class="bibr" href="#niceng130er.appe.s1.1.ref18" rid="niceng130er.appe.s1.1.ref18">Irvine 2008</a> ASCEND I; <a class="bibr" href="#niceng130er.appe.s1.1.ref18" rid="niceng130er.appe.s1.1.ref18">Irvine 2008</a> ASCEND II)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_2 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_3 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">687</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_4 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −3.62 (−12.44, 5.19)</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_5 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_6 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_7 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_8 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab10_1_1_1_9 hd_b_niceng130er.apph.tab10_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab10_1"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab10_2"><p class="no_margin">95% confidence intervals crossed one MID.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab10_3"><p class="no_margin">Moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="niceng130er.apph.tab10_4"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab11"><div id="niceng130er.apph.tab11" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab11_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab11_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab11_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab11_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab11_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab11_1_1_1_1 hd_h_niceng130er.apph.tab11_1_1_1_2 hd_h_niceng130er.apph.tab11_1_1_1_3 hd_h_niceng130er.apph.tab11_1_1_1_4 hd_h_niceng130er.apph.tab11_1_1_1_5 hd_h_niceng130er.apph.tab11_1_1_1_6 hd_h_niceng130er.apph.tab11_1_1_1_7 hd_h_niceng130er.apph.tab11_1_1_1_8 hd_h_niceng130er.apph.tab11_1_1_1_9" id="hd_b_niceng130er.apph.tab11_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 3 to 4 weeks follow-up – (lower values favour beclometasone)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab11_1_1_1_1 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref6" rid="niceng130er.appe.s1.1.ref6">Campieri 2003</a>)</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_2 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_3 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">109</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_4 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.45 (0.66, 3.16)</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_5 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_6 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_7 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_8 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_9 hd_b_niceng130er.apph.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab11_1_1_1_1 hd_h_niceng130er.apph.tab11_1_1_1_2 hd_h_niceng130er.apph.tab11_1_1_1_3 hd_h_niceng130er.apph.tab11_1_1_1_4 hd_h_niceng130er.apph.tab11_1_1_1_5 hd_h_niceng130er.apph.tab11_1_1_1_6 hd_h_niceng130er.apph.tab11_1_1_1_7 hd_h_niceng130er.apph.tab11_1_1_1_8 hd_h_niceng130er.apph.tab11_1_1_1_9" id="hd_b_niceng130er.apph.tab11_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with extensive ulcerative colitis at 3 to 4 weeks follow-up – (lower values favour beclometasone)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab11_1_1_1_1 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref6" rid="niceng130er.appe.s1.1.ref6">Campieri 2003</a>)</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_2 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_3 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_4 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.37 (0.10, 1.31)</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_5 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_6 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_7 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_8 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_9 hd_b_niceng130er.apph.tab11_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab11_1_1_1_1 hd_h_niceng130er.apph.tab11_1_1_1_2 hd_h_niceng130er.apph.tab11_1_1_1_3 hd_h_niceng130er.apph.tab11_1_1_1_4 hd_h_niceng130er.apph.tab11_1_1_1_5 hd_h_niceng130er.apph.tab11_1_1_1_6 hd_h_niceng130er.apph.tab11_1_1_1_7 hd_h_niceng130er.apph.tab11_1_1_1_8 hd_h_niceng130er.apph.tab11_1_1_1_9" id="hd_b_niceng130er.apph.tab11_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with extensive ulcerative colitis at 3 to 4 weeks follow-up – (lower values favour prednisolone)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab11_1_1_1_1 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (Lennard-Jones 1960)</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_2 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_3 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_4 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.83 (0.52, 6.43)</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_5 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_6 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_7 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_8 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_9 hd_b_niceng130er.apph.tab11_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab11_1_1_1_1 hd_h_niceng130er.apph.tab11_1_1_1_2 hd_h_niceng130er.apph.tab11_1_1_1_3 hd_h_niceng130er.apph.tab11_1_1_1_4 hd_h_niceng130er.apph.tab11_1_1_1_5 hd_h_niceng130er.apph.tab11_1_1_1_6 hd_h_niceng130er.apph.tab11_1_1_1_7 hd_h_niceng130er.apph.tab11_1_1_1_8 hd_h_niceng130er.apph.tab11_1_1_1_9" id="hd_b_niceng130er.apph.tab11_1_1_7_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events (all extents of disease) up to 10 weeks follow-up - (higher values favour beclometasone)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab11_1_1_1_1 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref6" rid="niceng130er.appe.s1.1.ref6">Campieri 2003</a>)</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_2 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_3 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">177</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_4 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.34 (0.01, 8.48)</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_5 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_6 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_7 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_8 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab11_1_1_1_9 hd_b_niceng130er.apph.tab11_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab11_1"><p class="no_margin">High risk of bias for clinical remission.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab11_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab11_3"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="niceng130er.apph.tab11_4"><p class="no_margin">Moderate risk of bias for withdrawal due to adverse events.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab12"><div id="niceng130er.apph.tab12" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab12_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab12_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab12_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab12_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab12_1_1_1_1 hd_h_niceng130er.apph.tab12_1_1_1_2 hd_h_niceng130er.apph.tab12_1_1_1_3 hd_h_niceng130er.apph.tab12_1_1_1_4 hd_h_niceng130er.apph.tab12_1_1_1_5 hd_h_niceng130er.apph.tab12_1_1_1_6 hd_h_niceng130er.apph.tab12_1_1_1_7 hd_h_niceng130er.apph.tab12_1_1_1_8 hd_h_niceng130er.apph.tab12_1_1_1_9" id="hd_b_niceng130er.apph.tab12_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 3 to 4 weeks follow-up – (lower values favour oral mesalazine combined with oral beclometasone)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab12_1_1_1_1 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref29" rid="niceng130er.appe.s1.1.ref29">Rizzello 2002</a>)</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_2 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_3 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">119</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_4 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.37 (0.18, 0.78)</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_5 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_6 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_7 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_8 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_9 hd_b_niceng130er.apph.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab12_1_1_1_1 hd_h_niceng130er.apph.tab12_1_1_1_2 hd_h_niceng130er.apph.tab12_1_1_1_3 hd_h_niceng130er.apph.tab12_1_1_1_4 hd_h_niceng130er.apph.tab12_1_1_1_5 hd_h_niceng130er.apph.tab12_1_1_1_6 hd_h_niceng130er.apph.tab12_1_1_1_7 hd_h_niceng130er.apph.tab12_1_1_1_8 hd_h_niceng130er.apph.tab12_1_1_1_9" id="hd_b_niceng130er.apph.tab12_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to AE (all extents of disease) up to 10 weeks follow-up – (lower values favour oral mesalazine combined with oral beclometasone)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab12_1_1_1_1 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref29" rid="niceng130er.appe.s1.1.ref29">Rizzello 2002</a>)</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_2 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_3 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">119</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_4 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.95 (0.30, 29.19)</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_5 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_6 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_7 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_8 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab12_1_1_1_9 hd_b_niceng130er.apph.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab12_1"><p class="no_margin">Moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab12_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab12_3"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab13"><div id="niceng130er.apph.tab13" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab13/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab13_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab13_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab13_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab13_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab13_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab13_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab13_1_1_1_1 hd_h_niceng130er.apph.tab13_1_1_1_2 hd_h_niceng130er.apph.tab13_1_1_1_3 hd_h_niceng130er.apph.tab13_1_1_1_4 hd_h_niceng130er.apph.tab13_1_1_1_5 hd_h_niceng130er.apph.tab13_1_1_1_6 hd_h_niceng130er.apph.tab13_1_1_1_7 hd_h_niceng130er.apph.tab13_1_1_1_8 hd_h_niceng130er.apph.tab13_1_1_1_9" id="hd_b_niceng130er.apph.tab13_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour high-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab13_1_1_1_1 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 (<a class="bibr" href="#niceng130er.appe.s1.2.ref3" rid="niceng130er.appe.s1.2.ref3">Feagan 2013</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer 1993</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref25" rid="niceng130er.appe.s1.1.ref25">Lichtenstein 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref32" rid="niceng130er.appe.s1.1.ref32">Scherl 2009</a>)</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_2 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_3 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1060</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_4 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.14 (1.60, 2.84)</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_5 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_6 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_7 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_8 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_9 hd_b_niceng130er.apph.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab13_1_1_1_1 hd_h_niceng130er.apph.tab13_1_1_1_2 hd_h_niceng130er.apph.tab13_1_1_1_3 hd_h_niceng130er.apph.tab13_1_1_1_4 hd_h_niceng130er.apph.tab13_1_1_1_5 hd_h_niceng130er.apph.tab13_1_1_1_6 hd_h_niceng130er.apph.tab13_1_1_1_7 hd_h_niceng130er.apph.tab13_1_1_1_8 hd_h_niceng130er.apph.tab13_1_1_1_9" id="hd_b_niceng130er.apph.tab13_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to AE (all extents of disease) up to 10 weeks follow-up – (lower values favour high-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab13_1_1_1_1 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (<a class="bibr" href="#niceng130er.appe.s1.2.ref3" rid="niceng130er.appe.s1.2.ref3">Feagan 2013</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer 1993</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref25" rid="niceng130er.appe.s1.1.ref25">Lichtenstein 2007</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref32" rid="niceng130er.appe.s1.1.ref32">Scherl 2009</a>; <a class="bibr" href="#niceng130er.appe.s4.1.ref50" rid="niceng130er.appe.s4.1.ref50">Schroeder 1987</a>)</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_2 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_3 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1112</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_4 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.48 (0.31, 0.74)</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_5 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_6 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_7 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_8 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab13_1_1_1_9 hd_b_niceng130er.apph.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab13_1"><p class="no_margin">Greater than 33% of the studies were at moderate risk of bias.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab14"><div id="niceng130er.apph.tab14" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab14/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab14_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab14_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab14_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab14_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab14_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab14_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab14_1_1_1_1 hd_h_niceng130er.apph.tab14_1_1_1_2 hd_h_niceng130er.apph.tab14_1_1_1_3 hd_h_niceng130er.apph.tab14_1_1_1_4 hd_h_niceng130er.apph.tab14_1_1_1_5 hd_h_niceng130er.apph.tab14_1_1_1_6 hd_h_niceng130er.apph.tab14_1_1_1_7 hd_h_niceng130er.apph.tab14_1_1_1_8 hd_h_niceng130er.apph.tab14_1_1_1_9" id="hd_b_niceng130er.apph.tab14_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour high-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab14_1_1_1_1 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref13" rid="niceng130er.appe.s1.1.ref13">Gross 2011</a>)</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_2 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_3 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">274</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_4 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.74 (1.08, 2.81)</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_5 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_6 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_7 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_8 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_9 hd_b_niceng130er.apph.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab14_1_1_1_1 hd_h_niceng130er.apph.tab14_1_1_1_2 hd_h_niceng130er.apph.tab14_1_1_1_3 hd_h_niceng130er.apph.tab14_1_1_1_4 hd_h_niceng130er.apph.tab14_1_1_1_5 hd_h_niceng130er.apph.tab14_1_1_1_6 hd_h_niceng130er.apph.tab14_1_1_1_7 hd_h_niceng130er.apph.tab14_1_1_1_8 hd_h_niceng130er.apph.tab14_1_1_1_9" id="hd_b_niceng130er.apph.tab14_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with extensive ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour high-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab14_1_1_1_1 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref13" rid="niceng130er.appe.s1.1.ref13">Gross 2011</a>)</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_2 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_3 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_4 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.40 (0.91, 6.33)</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_5 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_6 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_7 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_8 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab14_1_1_1_9 hd_b_niceng130er.apph.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab14_1"><p class="no_margin">Study at moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab14_2"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab14_3"><p class="no_margin">95% confidence intervals crossed one MID.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab15"><div id="niceng130er.apph.tab15" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab15/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab15_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab15_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab15_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab15_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab15_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab15_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab15_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab15_1_1_1_1 hd_h_niceng130er.apph.tab15_1_1_1_2 hd_h_niceng130er.apph.tab15_1_1_1_3 hd_h_niceng130er.apph.tab15_1_1_1_4 hd_h_niceng130er.apph.tab15_1_1_1_5 hd_h_niceng130er.apph.tab15_1_1_1_6 hd_h_niceng130er.apph.tab15_1_1_1_7 hd_h_niceng130er.apph.tab15_1_1_1_8 hd_h_niceng130er.apph.tab15_1_1_1_9" id="hd_b_niceng130er.apph.tab15_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with extensive ulcerative colitis at 3 to 4 weeks follow-up – (higher values favour high-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab15_1_1_1_1 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref26" rid="niceng130er.appe.s1.1.ref26">Marteau 2005</a>)</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_2 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_3 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">104</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_4 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.66 (0.30, 1.47)</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_5 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_6 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_7 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_8 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_9 hd_b_niceng130er.apph.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab15_1_1_1_1 hd_h_niceng130er.apph.tab15_1_1_1_2 hd_h_niceng130er.apph.tab15_1_1_1_3 hd_h_niceng130er.apph.tab15_1_1_1_4 hd_h_niceng130er.apph.tab15_1_1_1_5 hd_h_niceng130er.apph.tab15_1_1_1_6 hd_h_niceng130er.apph.tab15_1_1_1_7 hd_h_niceng130er.apph.tab15_1_1_1_8 hd_h_niceng130er.apph.tab15_1_1_1_9" id="hd_b_niceng130er.apph.tab15_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with extensive ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour high-dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab15_1_1_1_1 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref26" rid="niceng130er.appe.s1.1.ref26">Marteau 2005</a>)</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_2 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_3 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">115</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_4 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 0.44 (0.21, 0.94)</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_5 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_6 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_7 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_8 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_9 hd_b_niceng130er.apph.tab15_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab15_1_1_1_1 hd_h_niceng130er.apph.tab15_1_1_1_2 hd_h_niceng130er.apph.tab15_1_1_1_3 hd_h_niceng130er.apph.tab15_1_1_1_4 hd_h_niceng130er.apph.tab15_1_1_1_5 hd_h_niceng130er.apph.tab15_1_1_1_6 hd_h_niceng130er.apph.tab15_1_1_1_7 hd_h_niceng130er.apph.tab15_1_1_1_8 hd_h_niceng130er.apph.tab15_1_1_1_9" id="hd_b_niceng130er.apph.tab15_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Quality of life (EQ-5D) in adults with extensive ulcerative colitis - change from baseline to 8 weeks follow-up – (higher values favour high -dose oral aminosalicylates)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab15_1_1_1_1 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.1.ref26" rid="niceng130er.appe.s1.1.ref26">Marteau 2005</a></td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_2 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_3 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">127</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_4 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.04 (−0.10, 0.03)</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_5 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_6 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_7 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_8 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab15_1_1_1_9 hd_b_niceng130er.apph.tab15_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab15_1"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab15_2"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab15_3"><p class="no_margin">95% confidence intervals crossed one MID.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab16"><div id="niceng130er.apph.tab16" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab16/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab16_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab16_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab16_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab16_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab16_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab16_1_1_1_1 hd_h_niceng130er.apph.tab16_1_1_1_2 hd_h_niceng130er.apph.tab16_1_1_1_3 hd_h_niceng130er.apph.tab16_1_1_1_4 hd_h_niceng130er.apph.tab16_1_1_1_5 hd_h_niceng130er.apph.tab16_1_1_1_6 hd_h_niceng130er.apph.tab16_1_1_1_7 hd_h_niceng130er.apph.tab16_1_1_1_8 hd_h_niceng130er.apph.tab16_1_1_1_9" id="hd_b_niceng130er.apph.tab16_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with proctosigmoiditis and left-sided ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour budesonide)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab16_1_1_1_1 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (<a class="bibr" href="#niceng130er.appe.s1.2.ref10" rid="niceng130er.appe.s1.2.ref10">Rubin 2017</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref31" rid="niceng130er.appe.s1.1.ref31">Sandborn 2012</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref1" rid="niceng130er.appe.s1.2.ref1">Travis 2013</a>)</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_2 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_3 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">802</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_4 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.26 (0.89, 5.75)</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_5 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_6 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_7 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_8 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_9 hd_b_niceng130er.apph.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab16_1_1_1_1 hd_h_niceng130er.apph.tab16_1_1_1_2 hd_h_niceng130er.apph.tab16_1_1_1_3 hd_h_niceng130er.apph.tab16_1_1_1_4 hd_h_niceng130er.apph.tab16_1_1_1_5 hd_h_niceng130er.apph.tab16_1_1_1_6 hd_h_niceng130er.apph.tab16_1_1_1_7 hd_h_niceng130er.apph.tab16_1_1_1_8 hd_h_niceng130er.apph.tab16_1_1_1_9" id="hd_b_niceng130er.apph.tab16_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with extensive ulcerative colitis at 5 to 8 weeks follow-up – (higher values favour budesonide)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab16_1_1_1_1 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (<a class="bibr" href="#niceng130er.appe.s1.1.ref31" rid="niceng130er.appe.s1.1.ref31">Sandborn 2012</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref1" rid="niceng130er.appe.s1.2.ref1">Travis 2013</a>)</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_2 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_3 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">167</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_4 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 2.02 (0.58, 7.00)</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_5 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_6 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_7 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_8 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_9 hd_b_niceng130er.apph.tab16_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab16_1_1_1_1 hd_h_niceng130er.apph.tab16_1_1_1_2 hd_h_niceng130er.apph.tab16_1_1_1_3 hd_h_niceng130er.apph.tab16_1_1_1_4 hd_h_niceng130er.apph.tab16_1_1_1_5 hd_h_niceng130er.apph.tab16_1_1_1_6 hd_h_niceng130er.apph.tab16_1_1_1_7 hd_h_niceng130er.apph.tab16_1_1_1_8 hd_h_niceng130er.apph.tab16_1_1_1_9" id="hd_b_niceng130er.apph.tab16_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events (all extents of disease) up to 10 weeks follow-up – (lower values favour budesonide)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab16_1_1_1_1 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (<a class="bibr" href="#niceng130er.appe.s1.2.ref10" rid="niceng130er.appe.s1.2.ref10">Rubin 2017</a>; <a class="bibr" href="#niceng130er.appe.s1.1.ref31" rid="niceng130er.appe.s1.1.ref31">Sandborn 2012</a>; <a class="bibr" href="#niceng130er.appe.s1.2.ref1" rid="niceng130er.appe.s1.2.ref1">Travis 2013</a>)</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_2 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_3 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1147</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_4 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 1.06 (0.57, 1.97)</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_5 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_6 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_7 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_8 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>4</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_9 hd_b_niceng130er.apph.tab16_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab16_1_1_1_1 hd_h_niceng130er.apph.tab16_1_1_1_2 hd_h_niceng130er.apph.tab16_1_1_1_3 hd_h_niceng130er.apph.tab16_1_1_1_4 hd_h_niceng130er.apph.tab16_1_1_1_5 hd_h_niceng130er.apph.tab16_1_1_1_6 hd_h_niceng130er.apph.tab16_1_1_1_7 hd_h_niceng130er.apph.tab16_1_1_1_8 hd_h_niceng130er.apph.tab16_1_1_1_9" id="hd_b_niceng130er.apph.tab16_1_1_7_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Quality of life using Inflammatory Bowel Disease Quality of Life Questionnaire (IBD-QoL) in adults with proctosigmoiditis and left-sided ulcerative colitis - change from baseline to 8 weeks follow-up – (higher values favour budesonide)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab16_1_1_1_1 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.2.ref10" rid="niceng130er.appe.s1.2.ref10">Rubin 2017</a>)</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_2 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_3 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">458</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_4 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MD −0.60 (−7.10, 5.90)</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_5 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>5</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_6 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_7 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>6</sup></td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_8 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab16_1_1_1_9 hd_b_niceng130er.apph.tab16_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab16_1"><p class="no_margin">Greater than 33% of the studies were at moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab16_2"><p class="no_margin">I2 value greater than 66.7%.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab16_3"><p class="no_margin">95% confidence intervals crossed one MID.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="niceng130er.apph.tab16_4"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="niceng130er.apph.tab16_5"><p class="no_margin">Moderate risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>6</dt><dd><div id="niceng130er.apph.tab16_6"><p class="no_margin">Inconsistency not applicable as effect size is from a single study.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab17"><div id="niceng130er.apph.tab17" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab17/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab17_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No. of studies</th><th id="hd_h_niceng130er.apph.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study design</th><th id="hd_h_niceng130er.apph.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Sample size</th><th id="hd_h_niceng130er.apph.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab17_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab17_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab17_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab17_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab17_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab17_1_1_1_1 hd_h_niceng130er.apph.tab17_1_1_1_2 hd_h_niceng130er.apph.tab17_1_1_1_3 hd_h_niceng130er.apph.tab17_1_1_1_4 hd_h_niceng130er.apph.tab17_1_1_1_5 hd_h_niceng130er.apph.tab17_1_1_1_6 hd_h_niceng130er.apph.tab17_1_1_1_7 hd_h_niceng130er.apph.tab17_1_1_1_8 hd_h_niceng130er.apph.tab17_1_1_1_9" id="hd_b_niceng130er.apph.tab17_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults with adults with extensive ulcerative colitis at 12 weeks follow-up – (higher values favour methotrexate)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab17_1_1_1_1 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.2.ref2" rid="niceng130er.appe.s1.2.ref2">Carbonnel 2016</a>)</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_2 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_3 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_4 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR 3.40 (0.76, 15.30)</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_5 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_6 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_7 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_8 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_9 hd_b_niceng130er.apph.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab17_1_1_1_1 hd_h_niceng130er.apph.tab17_1_1_1_2 hd_h_niceng130er.apph.tab17_1_1_1_3 hd_h_niceng130er.apph.tab17_1_1_1_4 hd_h_niceng130er.apph.tab17_1_1_1_5 hd_h_niceng130er.apph.tab17_1_1_1_6 hd_h_niceng130er.apph.tab17_1_1_1_7 hd_h_niceng130er.apph.tab17_1_1_1_8 hd_h_niceng130er.apph.tab17_1_1_1_9" id="hd_b_niceng130er.apph.tab17_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events with extensive ulcerative colitis at 12 weeks follow-up – (lower values favour methotrexate)</th></tr><tr><td headers="hd_h_niceng130er.apph.tab17_1_1_1_1 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (<a class="bibr" href="#niceng130er.appe.s1.2.ref2" rid="niceng130er.appe.s1.2.ref2">Carbonnel 2016</a>)</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_2 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_3 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_4 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OR (2.60 (0.10, 65.14)</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_5 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_6 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_7 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A</td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_8 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab17_1_1_1_9 hd_b_niceng130er.apph.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab17_1"><p class="no_margin">95% confidence intervals crossed two MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab17_2"><p class="no_margin">Indirect treatment: only subcutaneous considered in evidence review.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab18"><div id="niceng130er.apph.tab18" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab18/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab18_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th id="hd_h_niceng130er.apph.tab18_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Design</th><th id="hd_h_niceng130er.apph.tab18_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab18_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab18_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab18_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab18_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of participants</th><th id="hd_h_niceng130er.apph.tab18_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab18_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab18_1_1_1_1 hd_h_niceng130er.apph.tab18_1_1_1_2 hd_h_niceng130er.apph.tab18_1_1_1_3 hd_h_niceng130er.apph.tab18_1_1_1_4 hd_h_niceng130er.apph.tab18_1_1_1_5 hd_h_niceng130er.apph.tab18_1_1_1_6 hd_h_niceng130er.apph.tab18_1_1_1_7 hd_h_niceng130er.apph.tab18_1_1_1_8 hd_h_niceng130er.apph.tab18_1_1_1_9" id="hd_b_niceng130er.apph.tab18_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults: 0 to 2 weeks</th></tr><tr><td headers="hd_h_niceng130er.apph.tab18_1_1_1_1 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_2 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_3 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_4 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_5 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_6 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_7 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">214</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_8 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_9 hd_b_niceng130er.apph.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab18_1_1_1_1 hd_h_niceng130er.apph.tab18_1_1_1_2 hd_h_niceng130er.apph.tab18_1_1_1_3 hd_h_niceng130er.apph.tab18_1_1_1_4 hd_h_niceng130er.apph.tab18_1_1_1_5 hd_h_niceng130er.apph.tab18_1_1_1_6 hd_h_niceng130er.apph.tab18_1_1_1_7 hd_h_niceng130er.apph.tab18_1_1_1_8 hd_h_niceng130er.apph.tab18_1_1_1_9" id="hd_b_niceng130er.apph.tab18_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults: 0 to 4 weeks</th></tr><tr><td headers="hd_h_niceng130er.apph.tab18_1_1_1_1 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_2 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_3 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_4 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_5 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_6 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_7 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">343</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_8 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_9 hd_b_niceng130er.apph.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab18_1_1_1_1 hd_h_niceng130er.apph.tab18_1_1_1_2 hd_h_niceng130er.apph.tab18_1_1_1_3 hd_h_niceng130er.apph.tab18_1_1_1_4 hd_h_niceng130er.apph.tab18_1_1_1_5 hd_h_niceng130er.apph.tab18_1_1_1_6 hd_h_niceng130er.apph.tab18_1_1_1_7 hd_h_niceng130er.apph.tab18_1_1_1_8 hd_h_niceng130er.apph.tab18_1_1_1_9" id="hd_b_niceng130er.apph.tab18_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults: 5 to 8 weeks</th></tr><tr><td headers="hd_h_niceng130er.apph.tab18_1_1_1_1 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_2 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_3 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_4 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_5 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_6 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>3</sup></td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_7 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">279</td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_8 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab18_1_1_1_9 hd_b_niceng130er.apph.tab18_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab18_1"><p class="no_margin">Greater than 33% of the studies were at moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab18_2"><p class="no_margin">DIC statistic is lower in random effects model.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng130er.apph.tab18_3"><p class="no_margin">Analysis could not differentiate any clinically meaningful differences.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab19"><div id="niceng130er.apph.tab19" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab19/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab19_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th id="hd_h_niceng130er.apph.tab19_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Design</th><th id="hd_h_niceng130er.apph.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab19_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab19_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab19_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of participants</th><th id="hd_h_niceng130er.apph.tab19_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab19_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab19_1_1_1_1 hd_h_niceng130er.apph.tab19_1_1_1_2 hd_h_niceng130er.apph.tab19_1_1_1_3 hd_h_niceng130er.apph.tab19_1_1_1_4 hd_h_niceng130er.apph.tab19_1_1_1_5 hd_h_niceng130er.apph.tab19_1_1_1_6 hd_h_niceng130er.apph.tab19_1_1_1_7 hd_h_niceng130er.apph.tab19_1_1_1_8 hd_h_niceng130er.apph.tab19_1_1_1_9" id="hd_b_niceng130er.apph.tab19_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults: 0 to 2 weeks</th></tr><tr><td headers="hd_h_niceng130er.apph.tab19_1_1_1_1 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_2 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_3 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_4 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_5 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_6 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_7 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">201</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_8 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_9 hd_b_niceng130er.apph.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr><tr><th headers="hd_h_niceng130er.apph.tab19_1_1_1_1 hd_h_niceng130er.apph.tab19_1_1_1_2 hd_h_niceng130er.apph.tab19_1_1_1_3 hd_h_niceng130er.apph.tab19_1_1_1_4 hd_h_niceng130er.apph.tab19_1_1_1_5 hd_h_niceng130er.apph.tab19_1_1_1_6 hd_h_niceng130er.apph.tab19_1_1_1_7 hd_h_niceng130er.apph.tab19_1_1_1_8 hd_h_niceng130er.apph.tab19_1_1_1_9" id="hd_b_niceng130er.apph.tab19_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults: 0 to 4 weeks</th></tr><tr><td headers="hd_h_niceng130er.apph.tab19_1_1_1_1 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_2 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_3 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_4 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_5 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_6 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_7 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1356</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_8 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_9 hd_b_niceng130er.apph.tab19_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">High</td></tr><tr><th headers="hd_h_niceng130er.apph.tab19_1_1_1_1 hd_h_niceng130er.apph.tab19_1_1_1_2 hd_h_niceng130er.apph.tab19_1_1_1_3 hd_h_niceng130er.apph.tab19_1_1_1_4 hd_h_niceng130er.apph.tab19_1_1_1_5 hd_h_niceng130er.apph.tab19_1_1_1_6 hd_h_niceng130er.apph.tab19_1_1_1_7 hd_h_niceng130er.apph.tab19_1_1_1_8 hd_h_niceng130er.apph.tab19_1_1_1_9" id="hd_b_niceng130er.apph.tab19_1_1_5_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults: 5 to 8 weeks</th></tr><tr><td headers="hd_h_niceng130er.apph.tab19_1_1_1_1 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_2 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_3 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_4 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_5 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_6 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_7 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6352</td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_8 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab19_1_1_1_9 hd_b_niceng130er.apph.tab19_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab19_1"><p class="no_margin">Greater than 33% of the studies were at moderate risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab19_2"><p class="no_margin">DIC statistic is lower in random effects model.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab20"><div id="niceng130er.apph.tab20" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab20/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab20_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th id="hd_h_niceng130er.apph.tab20_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Design</th><th id="hd_h_niceng130er.apph.tab20_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab20_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab20_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of participants</th><th id="hd_h_niceng130er.apph.tab20_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab20_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab20_1_1_1_1 hd_h_niceng130er.apph.tab20_1_1_1_2 hd_h_niceng130er.apph.tab20_1_1_1_3 hd_h_niceng130er.apph.tab20_1_1_1_4 hd_h_niceng130er.apph.tab20_1_1_1_5 hd_h_niceng130er.apph.tab20_1_1_1_6 hd_h_niceng130er.apph.tab20_1_1_1_7 hd_h_niceng130er.apph.tab20_1_1_1_8 hd_h_niceng130er.apph.tab20_1_1_1_9" id="hd_b_niceng130er.apph.tab20_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults: 0 to 4 weeks</th></tr><tr><td headers="hd_h_niceng130er.apph.tab20_1_1_1_1 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_2 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_3 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_4 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_5 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>2</sup></td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_6 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_7 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">188</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_8 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_9 hd_b_niceng130er.apph.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Low</td></tr><tr><th headers="hd_h_niceng130er.apph.tab20_1_1_1_1 hd_h_niceng130er.apph.tab20_1_1_1_2 hd_h_niceng130er.apph.tab20_1_1_1_3 hd_h_niceng130er.apph.tab20_1_1_1_4 hd_h_niceng130er.apph.tab20_1_1_1_5 hd_h_niceng130er.apph.tab20_1_1_1_6 hd_h_niceng130er.apph.tab20_1_1_1_7 hd_h_niceng130er.apph.tab20_1_1_1_8 hd_h_niceng130er.apph.tab20_1_1_1_9" id="hd_b_niceng130er.apph.tab20_1_1_3_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Clinical remission in adults: 5 to 8 weeks</th></tr><tr><td headers="hd_h_niceng130er.apph.tab20_1_1_1_1 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_2 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_3 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_4 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_5 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_6 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_7 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">331</td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_8 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab20_1_1_1_9 hd_b_niceng130er.apph.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Moderate</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab20_1"><p class="no_margin">Greater than 33% of the studies were at high risk of bias.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng130er.apph.tab20_2"><p class="no_margin">Serious indirectness as the network meta-analysis was connected by using evidence (high-dose oral aminosalicylates versus standard dose oral aminosalicylates) from proctosigmoiditis and left-sided disease</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erapphtab21"><div id="niceng130er.apph.tab21" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.apph.tab21/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.apph.tab21_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of studies</th><th id="hd_h_niceng130er.apph.tab21_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Design</th><th id="hd_h_niceng130er.apph.tab21_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk of bias</th><th id="hd_h_niceng130er.apph.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Inconsistency</th><th id="hd_h_niceng130er.apph.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Indirectness</th><th id="hd_h_niceng130er.apph.tab21_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Imprecision</th><th id="hd_h_niceng130er.apph.tab21_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">No of participants</th><th id="hd_h_niceng130er.apph.tab21_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Effect size (95% CI)</th><th id="hd_h_niceng130er.apph.tab21_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Quality</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.apph.tab21_1_1_1_1 hd_h_niceng130er.apph.tab21_1_1_1_2 hd_h_niceng130er.apph.tab21_1_1_1_3 hd_h_niceng130er.apph.tab21_1_1_1_4 hd_h_niceng130er.apph.tab21_1_1_1_5 hd_h_niceng130er.apph.tab21_1_1_1_6 hd_h_niceng130er.apph.tab21_1_1_1_7 hd_h_niceng130er.apph.tab21_1_1_1_8 hd_h_niceng130er.apph.tab21_1_1_1_9" id="hd_b_niceng130er.apph.tab21_1_1_1_1" colspan="9" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events</th></tr><tr><td headers="hd_h_niceng130er.apph.tab21_1_1_1_1 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28</td><td headers="hd_h_niceng130er.apph.tab21_1_1_1_2 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT</td><td headers="hd_h_niceng130er.apph.tab21_1_1_1_3 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very serious<sup>1</sup></td><td headers="hd_h_niceng130er.apph.tab21_1_1_1_4 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab21_1_1_1_5 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab21_1_1_1_6 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No serious</td><td headers="hd_h_niceng130er.apph.tab21_1_1_1_7 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6594</td><td headers="hd_h_niceng130er.apph.tab21_1_1_1_8 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">See <a href="#niceng130er.appi">Appendix I</a></td><td headers="hd_h_niceng130er.apph.tab21_1_1_1_9 hd_b_niceng130er.apph.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Very low</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng130er.apph.tab21_1"><p class="no_margin">Greater than 33% of the studies were at moderate risk of bias.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab1"><div id="niceng130er.appi.tab1" class="table"><h3><span class="label">Table 11</span><span class="title">Model selection for network meta-analysis</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Outcome</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Number of studies</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Participants</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Datapoints</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Model</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Number of unique options</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">FE/RE</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Total residual deviance</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">DIC</th><th id="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Standard deviation of random effects distribution (95%CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_1" rowspan="24" colspan="1" style="text-align:center;vertical-align:middle;">Clinical remission: 5–8 weeks</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_2" rowspan="24" colspan="1" style="text-align:center;vertical-align:middle;">23</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_3" rowspan="24" colspan="1" style="text-align:center;vertical-align:middle;">5,863</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_4" rowspan="24" colspan="1" style="text-align:center;vertical-align:middle;">57</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">01. Class</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">77.46</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">360.8</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">56.95</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">352.3</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.28 (0.11, 0.47)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">02. Drug</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">5</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">78.39</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">362.6</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57.01</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">353.6</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.29 (0.12, 0.49)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">03. Dose_class</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">5</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">69.51</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">353.7</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">59.29</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">352.1</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.20 (0.01, 0.42)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">04. Dose_drug</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">7</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">70.69</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">357.0</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">59.11</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">354.3</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.23 (0.04, 0.44)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">05. Mode_class</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">7</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">68.05</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">354.3</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57.02</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">351.7</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.21 (0.04, 0.42)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">06. Mode_drug</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">68.82</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">356.1</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57.78</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">353.6</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.22 (0.04, 0.43)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">07. Mode_dose_class</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">58.18</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">345.4</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">55.91</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">346.7</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.10 (0.00, 0.31)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">08. Mode_dose_drug</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">10</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">59.89</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">349.1</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57.00</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">350.6</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.13 (0.01, 0.35)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">09. Mode2_class</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">67.35</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">354.7</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57.39</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">352.7</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.20 (0.02, 0.41)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">10. Mode2_drug</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">9</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">68.20</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">356.6</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57.25</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">353.6</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.22 (0.03, 0.43)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">11. Mode2_dose_class</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">9</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57.49</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">345.8</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">55.82</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">347.6</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.09 (0.00, 0.31)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">12. Mode2_dose_drug</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_6" rowspan="2" colspan="1" style="text-align:center;vertical-align:top;">11</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">59.15</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">349.4</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab1_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">57.09</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">351.1</td><td headers="hd_h_niceng130er.appi.tab1_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.11 (0.00, 0.33)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab2"><div id="niceng130er.appi.tab2" class="table"><h3><span class="label">Table 12</span><span class="title">Clinical remission for proctosigmoiditis and left-sided at 5–8 weeks’ follow-up: expanded mode, dose and drug model (FE)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">low-dose mesalazine - oral</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">budesonide - oral</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">budesonide - topical (foam)</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">high-dose balsalazide - oral</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">high-dose mesalazine - oral</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">hydrocortisone - topical (foam)</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">mesalazine - topical (foam)</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">mesalazine - topical (liquid enema)</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">low-dose balsalazide - oral</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">low-dose mesalazine - oral + mesalazine - topical (liquid enema)</th><th id="hd_h_niceng130er.appi.tab2_1_1_1_12" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose mesalazine - oral</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.58</p>
|
|
<p>(0.78, 3.22)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.14</p>
|
|
<p>(0.65, 1.99)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.36</p>
|
|
<p>(1.13, 1.63)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="background-color:#ffff00;text-align:center;vertical-align:top;">
|
|
<p>1.04</p>
|
|
<p>(0.32, 3.33)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.50</p>
|
|
<p>(0.57, 3.96)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.46</p>
|
|
<p>(0.31, 0.68)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - oral</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.82</p>
|
|
<p>(0.58, 1.15)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.74</p>
|
|
<p>(1.08, 2.81)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.74</p>
|
|
<p>(0.51, 1.08)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.53</p>
|
|
<p>(1.02, 2.32)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.87</p>
|
|
<p>(1.19, 2.92)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.94</p>
|
|
<p>(0.62, 1.42)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.39</p>
|
|
<p>(0.28, 0.53)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose balsalazide - oral</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.19</p>
|
|
<p>(0.78, 1.83)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.44</p>
|
|
<p>(0.87, 2.41)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.77</p>
|
|
<p>(0.46, 1.33)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.84</p>
|
|
<p>(0.27, 2.65)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.47</p>
|
|
<p>(0.26, 0.86)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose mesalazine - oral</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.34</p>
|
|
<p>(1.13, 1.60)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.64</p>
|
|
<p>(1.17, 2.27)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.88</p>
|
|
<p>(0.58, 1.32)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="background-color:#ffff00;text-align:center;vertical-align:top;">
|
|
<p>1.13</p>
|
|
<p>(0.72, 1.77)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.46</p>
|
|
<p>(0.32, 0.67)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hydrocortisone - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.54</p>
|
|
<p>(0.89, 2.66)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.87</p>
|
|
<p>(1.06, 3.32)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="background-color:#ffff00;text-align:center;vertical-align:top;">
|
|
<p>1.00</p>
|
|
<p>(0.67, 1.50)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.30</p>
|
|
<p>(0.68, 2.47)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.15</p>
|
|
<p>(0.66, 1.97)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.27</p>
|
|
<p>(0.12, 0.64)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">mesalazine - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.40</p>
|
|
<p>(0.54, 3.69)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.71</p>
|
|
<p>(0.65, 4.58)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.91</p>
|
|
<p>(0.35, 2.45)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.18</p>
|
|
<p>(0.43, 3.31)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.04</p>
|
|
<p>(0.40, 2.73)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.91</p>
|
|
<p>(0.32, 2.60)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.40</p>
|
|
<p>(0.35, 5.99)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.42</p>
|
|
<p>(0.17, 1.06)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">mesalazine - topical (liquid enema)</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>3.16</p>
|
|
<p>(1.45, 7.26)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>3.86</p>
|
|
<p>(1.74, 9.07)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>2.07</p>
|
|
<p>(0.94, 4.87)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>2.67</p>
|
|
<p>(1.15, 6.58)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>2.35</p>
|
|
<p>(1.08, 5.40)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>2.06</p>
|
|
<p>(0.87, 5.20)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="background-color:#00ffff;text-align:center;vertical-align:top;">
|
|
<p>2.27</p>
|
|
<p>(0.69, 7.61)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>3.17</p>
|
|
<p>(0.89, 12.45)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.19</p>
|
|
<p>(0.09, 0.40)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose balsalazide - oral</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="background-color:#ffff00;text-align:center;vertical-align:top;">
|
|
<p>1.01</p>
|
|
<p>(0.33, 2.75)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.22</p>
|
|
<p>(0.39, 3.52)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.65</p>
|
|
<p>(0.20, 1.91)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.85</p>
|
|
<p>(0.28, 2.34)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.75</p>
|
|
<p>(0.24, 2.07)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.65</p>
|
|
<p>(0.19, 2.03)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose mesalazine - oral + topical (liquid enema)</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.52</p>
|
|
<p>(0.56, 4.19)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.85</p>
|
|
<p>(0.65, 5.38)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.99</p>
|
|
<p>(0.34, 2.97)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.28</p>
|
|
<p>(0.44, 3.87)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.13</p>
|
|
<p>(0.41, 3.16)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.99</p>
|
|
<p>(0.32, 3.16)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.08</p>
|
|
<p>(0.28, 4.31)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.48</p>
|
|
<p>(0.13, 1.75)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>1.52</p>
|
|
<p>(0.36, 6.82)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab2_1_1_1_1" id="hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab2_1_1_1_2 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.59</p>
|
|
<p>(0.45, 0.77)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_3 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.71</p>
|
|
<p>(0.52, 0.98)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_4 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.38</p>
|
|
<p>(0.28, 0.52)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_5 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.49</p>
|
|
<p>(0.32, 0.75)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_6 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.44</p>
|
|
<p>(0.33, 0.57)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_7 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.38</p>
|
|
<p>(0.24, 0.61)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_8 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.42</p>
|
|
<p>(0.17, 1.04)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_9 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.19</p>
|
|
<p>(0.08, 0.38)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_10 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.59</p>
|
|
<p>(0.21, 1.81)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_11 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>0.39</p>
|
|
<p>(0.13, 1.07)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab2_1_1_1_12 hd_b_niceng130er.appi.tab2_1_1_11_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% Cis derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. . ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs higher than 1 favour the column defining treatment.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Comparisons of different agents within the same class are highlighted in yellow. Comparisons of different modes of topical delivery are highlighted in blue</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab3"><div id="niceng130er.appi.tab3" class="table"><h3><span class="label">Table 13</span><span class="title">Model selection based on fixed- and random-effects for each model</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Outcome</th><th id="hd_h_niceng130er.appi.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Model</th><th id="hd_h_niceng130er.appi.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Number of Studies</th><th id="hd_h_niceng130er.appi.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Participants</th><th id="hd_h_niceng130er.appi.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Datapoints</th><th id="hd_h_niceng130er.appi.tab3_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Total residual deviance</th><th id="hd_h_niceng130er.appi.tab3_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">DIC</th><th id="hd_h_niceng130er.appi.tab3_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">Tau -Standard deviation of random effects distribution (95%CrI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_h_niceng130er.appi.tab3_1_1_1_2 hd_h_niceng130er.appi.tab3_1_1_1_3 hd_h_niceng130er.appi.tab3_1_1_1_4 hd_h_niceng130er.appi.tab3_1_1_1_5 hd_h_niceng130er.appi.tab3_1_1_1_6 hd_h_niceng130er.appi.tab3_1_1_1_7 hd_h_niceng130er.appi.tab3_1_1_1_8" id="hd_b_niceng130er.appi.tab3_1_1_1_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Proctitis</th></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">0-2wks</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">214</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6.69</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">35.91</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">N/A</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">214</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6.67</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">36.94</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.634 (0.035, 1.869)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">0-4 wks</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">343</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9.56</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">48.65</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">N/A</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">343</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8.89</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">49.69</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.539 (0.020, 1.807)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:top;">5-8 wks</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">279</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11.13</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">44.23</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">N/A</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">279</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8.57</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">43.42</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.697 (0.058, 1.864)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_h_niceng130er.appi.tab3_1_1_1_2 hd_h_niceng130er.appi.tab3_1_1_1_3 hd_h_niceng130er.appi.tab3_1_1_1_4 hd_h_niceng130er.appi.tab3_1_1_1_5 hd_h_niceng130er.appi.tab3_1_1_1_6 hd_h_niceng130er.appi.tab3_1_1_1_7 hd_h_niceng130er.appi.tab3_1_1_1_8" id="hd_b_niceng130er.appi.tab3_1_1_8_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Proctosigmoiditis and left-sided</th></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-2wks</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">201</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.23</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">26.44</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">N/A</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_8_1 hd_h_niceng130er.appi.tab3_1_1_1_4 hd_h_niceng130er.appi.tab3_1_1_1_5 hd_h_niceng130er.appi.tab3_1_1_1_6 hd_h_niceng130er.appi.tab3_1_1_1_7 hd_h_niceng130er.appi.tab3_1_1_1_8" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">Random effects model not possible<sup>a</sup>.</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 wks</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1356</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19.02</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">96.99</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">N/A</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1356</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17.49</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">97.40</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.737 (0.033, 1.872)</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 wks</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">23</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5675</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">58</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">62.31</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">351.8</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">N/A</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">23</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5675</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">58</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">59.06</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">353.3</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.121 (0.005, 0.354)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_h_niceng130er.appi.tab3_1_1_1_2 hd_h_niceng130er.appi.tab3_1_1_1_3 hd_h_niceng130er.appi.tab3_1_1_1_4 hd_h_niceng130er.appi.tab3_1_1_1_5 hd_h_niceng130er.appi.tab3_1_1_1_6 hd_h_niceng130er.appi.tab3_1_1_1_7 hd_h_niceng130er.appi.tab3_1_1_1_8" id="hd_b_niceng130er.appi.tab3_1_1_15_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Extensive</th></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4wks</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">188</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6.108</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">34.66</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">N/A</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_15_1 hd_h_niceng130er.appi.tab3_1_1_1_4 hd_h_niceng130er.appi.tab3_1_1_1_5 hd_h_niceng130er.appi.tab3_1_1_1_6 hd_h_niceng130er.appi.tab3_1_1_1_7 hd_h_niceng130er.appi.tab3_1_1_1_8" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">Random effects model not possible<sup>b</sup>.</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 wks</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">331</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">331</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_h_niceng130er.appi.tab3_1_1_1_2 hd_h_niceng130er.appi.tab3_1_1_1_3 hd_h_niceng130er.appi.tab3_1_1_1_4 hd_h_niceng130er.appi.tab3_1_1_1_5 hd_h_niceng130er.appi.tab3_1_1_1_6 hd_h_niceng130er.appi.tab3_1_1_1_7 hd_h_niceng130er.appi.tab3_1_1_1_8" id="hd_b_niceng130er.appi.tab3_1_1_20_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal due to adverse events – all extents of disease</th></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All follow-up</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">FE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">28</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6594</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">67</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">68.99</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">303.98</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">n/a</td></tr><tr><td headers="hd_h_niceng130er.appi.tab3_1_1_1_1 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All follow-up</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_2 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RE</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_3 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">28</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_4 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6594</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_5 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">67</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_6 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">64.96</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_7 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">303.26</td><td headers="hd_h_niceng130er.appi.tab3_1_1_1_8 hd_b_niceng130er.appi.tab3_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.213 (0.007, 0.638)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng130er.appi.tab3_1"><p class="no_margin">Random effects model not possible as there are no loops in the network and no links with more than 2 studies.</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng130er.appi.tab3_2"><p class="no_margin">Random effects model not possible as there are no loops in the network and no links with more than 2 studies. Additionaly, in order to connect the network, the network borrows evidence from proctosigmoiditis and left-sided extent of disease at 0-4 weeks follow-up.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig1"><div id="niceng130er.appi.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%208.%20Proctitis%3B%20clinical%20remission%20at%202%20weeks%3B%20mode%2C%20dose%20and%20class%20%02013%20evidence%20network.&p=BOOKS&id=576848_niceng130erappif1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif1.jpg" alt="Figure 8. Proctitis; clinical remission at 2 weeks; mode, dose and class – evidence network." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 8</span><span class="title">Proctitis; clinical remission at 2 weeks; mode, dose and class – evidence network</span></h3><div class="caption"><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Arrowheads indicate direction of effect in pairwise data (a > b denotes a is more effective than b) – filled arrowheads show comparisons where one option is significantly superior (p<0.05); outlined arrowheads show direction of trend where effect does not reach statistical significance.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab4"><div id="niceng130er.appi.tab4" class="table"><h3><span class="label">Table 14</span><span class="title">Proctitis; clinical remission at 2 weeks; mode, dose and class – input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab4_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab4_1_1_1_1" id="hd_b_niceng130er.appi.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref3" rid="niceng130er.appe.s1.1.ref3">Campieri et al. (1990)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab4_1_1_1_2 hd_b_niceng130er.appi.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab4_1_1_1_3 hd_b_niceng130er.appi.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">27/63</td><td headers="hd_h_niceng130er.appi.tab4_1_1_1_4 hd_b_niceng130er.appi.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7/31</td></tr><tr><th headers="hd_h_niceng130er.appi.tab4_1_1_1_1" id="hd_b_niceng130er.appi.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref11" rid="niceng130er.appe.s1.1.ref11">Gionchetti et al. (1998)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab4_1_1_1_2 hd_b_niceng130er.appi.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6/29</td><td headers="hd_h_niceng130er.appi.tab4_1_1_1_3 hd_b_niceng130er.appi.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18/29</td><td headers="hd_h_niceng130er.appi.tab4_1_1_1_4 hd_b_niceng130er.appi.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab4_1_1_1_1" id="hd_b_niceng130er.appi.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref4" rid="niceng130er.appe.s1.1.ref4">Campieri et al. (1990a)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab4_1_1_1_2 hd_b_niceng130er.appi.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab4_1_1_1_3 hd_b_niceng130er.appi.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8/32</td><td headers="hd_h_niceng130er.appi.tab4_1_1_1_4 hd_b_niceng130er.appi.tab4_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/30</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab5"><div id="niceng130er.appi.tab5" class="table"><h3><span class="label">Table 15</span><span class="title">Proctitis; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab5_1_1_1_1" id="hd_b_niceng130er.appi.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab5_1_1_1_2 hd_b_niceng130er.appi.tab5_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab5_1_1_1_3 hd_b_niceng130er.appi.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>6.27</p>
|
|
<p>(1.95, 20.22)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab5_1_1_1_4 hd_b_niceng130er.appi.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab5_1_1_1_1" id="hd_b_niceng130er.appi.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab5_1_1_1_2 hd_b_niceng130er.appi.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>6.62</p>
|
|
<p>(2.11, 23.38)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab5_1_1_1_3 hd_b_niceng130er.appi.tab5_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab5_1_1_1_4 hd_b_niceng130er.appi.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.29</p>
|
|
<p>(0.12, 0.69)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab5_1_1_1_1" id="hd_b_niceng130er.appi.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab5_1_1_1_2 hd_b_niceng130er.appi.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.81</p>
|
|
<p>(0.42, 8.35)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab5_1_1_1_3 hd_b_niceng130er.appi.tab5_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.27</p>
|
|
<p>(0.11, 0.64)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab5_1_1_1_4 hd_b_niceng130er.appi.tab5_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs lower than 1 favour the row defining treatment, ORs higher than 1 favour the column defining treatment</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig2"><div id="niceng130er.appi.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%209.%20Proctitis%3B%20clinical%20remission%20at%202%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20relative%20effect%20of%20all%20options%20versus%20reference%20option.&p=BOOKS&id=576848_niceng130erappif2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif2.jpg" alt="Figure 9. Proctitis; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 9</span><span class="title">Proctitis; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3><div class="caption"><p>Values less than 1 favour low-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Solid error bars are 95% credible intervals; dashed error bars are 95% confidence intervals.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab6"><div id="niceng130er.appi.tab6" class="table"><h3><span class="label">Table 16</span><span class="title">Proctitis mode, dose and class fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab6_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probability best</th><th id="hd_h_niceng130er.appi.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab6_1_1_1_1" id="hd_b_niceng130er.appi.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab6_1_1_1_2 hd_b_niceng130er.appi.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab6_1_1_1_3 hd_b_niceng130er.appi.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (2, 3)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab6_1_1_1_1" id="hd_b_niceng130er.appi.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab6_1_1_1_2 hd_b_niceng130er.appi.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.999</td><td headers="hd_h_niceng130er.appi.tab6_1_1_1_3 hd_b_niceng130er.appi.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (1, 1)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab6_1_1_1_1" id="hd_b_niceng130er.appi.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab6_1_1_1_2 hd_b_niceng130er.appi.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.001</td><td headers="hd_h_niceng130er.appi.tab6_1_1_1_3 hd_b_niceng130er.appi.tab6_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (2, 3)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig3"><div id="niceng130er.appi.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2010&p=BOOKS&id=576848_niceng130erappif3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif3.jpg" alt="Figure 10" class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 10</span></h3><div class="caption"><p>Proctitis; clinical remission at 2 weeks; mode, dose and drug/class; fixed-effect – rank probability histograms</p><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab7"><div id="niceng130er.appi.tab7" class="table"><h3><span class="label">Table 17</span><span class="title">Proctitis mode, dose and class fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab7_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dbar</th><th id="hd_h_niceng130er.appi.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dhat</th><th id="hd_h_niceng130er.appi.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">pD</th><th id="hd_h_niceng130er.appi.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>6.675</p>
|
|
<p>(compared to 7 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.842</td><td headers="hd_h_niceng130er.appi.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.803</td><td headers="hd_h_niceng130er.appi.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.038</td><td headers="hd_h_niceng130er.appi.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.88</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig4"><div id="niceng130er.appi.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2011&p=BOOKS&id=576848_niceng130erappif4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif4.jpg" alt="Figure 11" class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 11</span></h3><div class="caption"><p>Proctitis; clinical remission at 0–4 weeks; mode, dose and class – evidence network</p><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Arrowheads indicate direction of effect in pairwise data (a > b denotes a is more effective than b) – filled arrowheads show comparisons where one option is significantly superior (p<0.05); outlined arrowheads show direction of trend where effect does not reach statistical significance.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab8"><div id="niceng130er.appi.tab8" class="table"><h3><span class="label">Table 18</span><span class="title">Proctitis; clinical remission at 0–4 weeks; mode, dose and class – input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab8_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th id="hd_h_niceng130er.appi.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab8_1_1_1_1" id="hd_b_niceng130er.appi.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref3" rid="niceng130er.appe.s1.1.ref3">Campieri et al. (1990)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab8_1_1_1_2 hd_b_niceng130er.appi.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab8_1_1_1_3 hd_b_niceng130er.appi.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">45/63</td><td headers="hd_h_niceng130er.appi.tab8_1_1_1_4 hd_b_niceng130er.appi.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12/31</td></tr><tr><th headers="hd_h_niceng130er.appi.tab8_1_1_1_1" id="hd_b_niceng130er.appi.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref11" rid="niceng130er.appe.s1.1.ref11">Gionchetti et al. (1998)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab8_1_1_1_2 hd_b_niceng130er.appi.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12/29</td><td headers="hd_h_niceng130er.appi.tab8_1_1_1_3 hd_b_niceng130er.appi.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">26/29</td><td headers="hd_h_niceng130er.appi.tab8_1_1_1_4 hd_b_niceng130er.appi.tab8_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab8_1_1_1_1" id="hd_b_niceng130er.appi.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref14" rid="niceng130er.appe.s1.2.ref14">Watanabe et al. (2013)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab8_1_1_1_2 hd_b_niceng130er.appi.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab8_1_1_1_3 hd_b_niceng130er.appi.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">41/65</td><td headers="hd_h_niceng130er.appi.tab8_1_1_1_4 hd_b_niceng130er.appi.tab8_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11/64</td></tr><tr><th headers="hd_h_niceng130er.appi.tab8_1_1_1_1" id="hd_b_niceng130er.appi.tab8_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref3" rid="niceng130er.appe.s1.1.ref3">Campieri et al. (1990)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab8_1_1_1_2 hd_b_niceng130er.appi.tab8_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab8_1_1_1_3 hd_b_niceng130er.appi.tab8_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18/32</td><td headers="hd_h_niceng130er.appi.tab8_1_1_1_4 hd_b_niceng130er.appi.tab8_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/30</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab9"><div id="niceng130er.appi.tab9" class="table"><h3><span class="label">Table 19</span><span class="title">Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th id="hd_h_niceng130er.appi.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab9_1_1_1_1" id="hd_b_niceng130er.appi.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab9_1_1_1_2 hd_b_niceng130er.appi.tab9_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab9_1_1_1_3 hd_b_niceng130er.appi.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>12.28</p>
|
|
<p>(3.01, 50.04)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab9_1_1_1_4 hd_b_niceng130er.appi.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab9_1_1_1_1" id="hd_b_niceng130er.appi.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab9_1_1_1_2 hd_b_niceng130er.appi.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>13.99</p>
|
|
<p>(3.68, 75.81)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab9_1_1_1_3 hd_b_niceng130er.appi.tab9_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab9_1_1_1_4 hd_b_niceng130er.appi.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.14</p>
|
|
<p>(0.08, 0.25)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab9_1_1_1_1" id="hd_b_niceng130er.appi.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th><td headers="hd_h_niceng130er.appi.tab9_1_1_1_2 hd_b_niceng130er.appi.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.91</p>
|
|
<p>(0.44, 11.35)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab9_1_1_1_3 hd_b_niceng130er.appi.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.14</p>
|
|
<p>(0.08, 0.23)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab9_1_1_1_4 hd_b_niceng130er.appi.tab9_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs lower than 1 favour the row defining treatment, ORs higher than 1 favour the column defining treatment.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig5"><div id="niceng130er.appi.fig5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2012&p=BOOKS&id=576848_niceng130erappif5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif5.jpg" alt="Figure 12" class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 12</span></h3><div class="caption"><p>Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</p><p>Values less than 1 favour low-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Solid error bars are 95% credible intervals; dashed error bars are 95% confidence intervals.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab10"><div id="niceng130er.appi.tab10" class="table"><h3><span class="label">Table 20</span><span class="title">Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab10_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probability best</th><th id="hd_h_niceng130er.appi.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab10_1_1_1_1" id="hd_b_niceng130er.appi.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab10_1_1_1_2 hd_b_niceng130er.appi.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab10_1_1_1_3 hd_b_niceng130er.appi.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (2, 3)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab10_1_1_1_1" id="hd_b_niceng130er.appi.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab10_1_1_1_2 hd_b_niceng130er.appi.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.000</td><td headers="hd_h_niceng130er.appi.tab10_1_1_1_3 hd_b_niceng130er.appi.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (1, 1)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab10_1_1_1_1" id="hd_b_niceng130er.appi.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab10_1_1_1_2 hd_b_niceng130er.appi.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab10_1_1_1_3 hd_b_niceng130er.appi.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (2, 3)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig6"><div id="niceng130er.appi.fig6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2013.%20Proctitis%3B%20clinical%20remission%20at%200%020134%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20rank%20probability%20histograms.&p=BOOKS&id=576848_niceng130erappif6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif6.jpg" alt="Figure 13. Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 13</span><span class="title">Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms</span></h3><div class="caption"><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab11"><div id="niceng130er.appi.tab11" class="table"><h3><span class="label">Table 21</span><span class="title">Proctitis; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab11_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dbar</th><th id="hd_h_niceng130er.appi.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dhat</th><th id="hd_h_niceng130er.appi.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">pD</th><th id="hd_h_niceng130er.appi.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9.581</p>
|
|
<p>(compared to 9 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.637</td><td headers="hd_h_niceng130er.appi.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.585</td><td headers="hd_h_niceng130er.appi.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.052</td><td headers="hd_h_niceng130er.appi.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.689</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig7"><div id="niceng130er.appi.fig7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2014.%20Proctitis%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%20%02013%20evidence%20network.&p=BOOKS&id=576848_niceng130erappif7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif7.jpg" alt="Figure 14. Proctitis; clinical remission at 5–8 weeks; mode, dose and class – evidence network." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 14</span><span class="title">Proctitis; clinical remission at 5–8 weeks; mode, dose and class – evidence network</span></h3><div class="caption"><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Arrowheads indicate direction of effect in pairwise data (a > b denotes a is more effective than b) – filled arrowheads show comparisons where one option is significantly superior (p<0.05); outlined arrowheads show direction of trend where effect does not reach statistical significance.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab12"><div id="niceng130er.appi.tab12" class="table"><h3><span class="label">Table 22</span><span class="title">Proctitis; clinical remission at 5–8 weeks; mode, dose and class – input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab12_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab12_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">immunomodulator - topical</th><th id="hd_h_niceng130er.appi.tab12_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab12_1_1_1_1" id="hd_b_niceng130er.appi.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref19" rid="niceng130er.appe.s1.1.ref19">Ito et al. (2010)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab12_1_1_1_2 hd_b_niceng130er.appi.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">67/193</td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_3 hd_b_niceng130er.appi.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_4 hd_b_niceng130er.appi.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_5 hd_b_niceng130er.appi.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3/32</td></tr><tr><th headers="hd_h_niceng130er.appi.tab12_1_1_1_1" id="hd_b_niceng130er.appi.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref27" rid="niceng130er.appe.s1.1.ref27">Pokrotnieks et al. (2000)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab12_1_1_1_2 hd_b_niceng130er.appi.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_3 hd_b_niceng130er.appi.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7/13</td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_4 hd_b_niceng130er.appi.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_5 hd_b_niceng130er.appi.tab12_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8/20</td></tr><tr><th headers="hd_h_niceng130er.appi.tab12_1_1_1_1" id="hd_b_niceng130er.appi.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref4" rid="niceng130er.appe.s1.2.ref4">Lawrance et al. (2017)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab12_1_1_1_2 hd_b_niceng130er.appi.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_3 hd_b_niceng130er.appi.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_4 hd_b_niceng130er.appi.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5/11</td><td headers="hd_h_niceng130er.appi.tab12_1_1_1_5 hd_b_niceng130er.appi.tab12_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/10</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab13"><div id="niceng130er.appi.tab13" class="table"><h3><span class="label">Table 23</span><span class="title">Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab13/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab13_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">immunomodulator - topical</th><th id="hd_h_niceng130er.appi.tab13_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab13_1_1_1_1" id="hd_b_niceng130er.appi.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab13_1_1_1_2 hd_b_niceng130er.appi.tab13_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_3 hd_b_niceng130er.appi.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_4 hd_b_niceng130er.appi.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_5 hd_b_niceng130er.appi.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.19</p>
|
|
<p>(0.06, 0.66)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab13_1_1_1_1" id="hd_b_niceng130er.appi.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab13_1_1_1_2 hd_b_niceng130er.appi.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.31</p>
|
|
<p>(0.04, 2.05)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_3 hd_b_niceng130er.appi.tab13_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_4 hd_b_niceng130er.appi.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_5 hd_b_niceng130er.appi.tab13_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.57</p>
|
|
<p>(0.14, 2.34)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab13_1_1_1_1" id="hd_b_niceng130er.appi.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">immunomodulator - topical</th><td headers="hd_h_niceng130er.appi.tab13_1_1_1_2 hd_b_niceng130er.appi.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>6.59</p>
|
|
<p>(0.27, 3661.00)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_3 hd_b_niceng130er.appi.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>21.90</p>
|
|
<p>(0.80, 12000.00)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_4 hd_b_niceng130er.appi.tab13_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_5 hd_b_niceng130er.appi.tab13_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.06</p>
|
|
<p>(0.00, 1.20)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab13_1_1_1_1" id="hd_b_niceng130er.appi.tab13_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab13_1_1_1_2 hd_b_niceng130er.appi.tab13_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.18</p>
|
|
<p>(0.04, 0.54)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_3 hd_b_niceng130er.appi.tab13_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.55</p>
|
|
<p>(0.13, 2.34)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_4 hd_b_niceng130er.appi.tab13_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.03</p>
|
|
<p>(0.00, 0.45)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab13_1_1_1_5 hd_b_niceng130er.appi.tab13_1_1_4_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs lower than 1 favour the row defining treatment, ORs higher than 1 favour the column defining treatment</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig8"><div id="niceng130er.appi.fig8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2015.%20Proctitis%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20relative%20effect%20of%20all%20options%20versus%20reference%20option.&p=BOOKS&id=576848_niceng130erappif8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif8.jpg" alt="Figure 15. Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 15</span><span class="title">Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3><div class="caption"><p>Values less than 1 favour low-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Solid error bars are 95% credible intervals; dashed error bars are 95% confidence intervals.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab14"><div id="niceng130er.appi.tab14" class="table"><h3><span class="label">Table 24</span><span class="title">Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab14/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab14_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probability best</th><th id="hd_h_niceng130er.appi.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab14_1_1_1_1" id="hd_b_niceng130er.appi.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab14_1_1_1_2 hd_b_niceng130er.appi.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.134</td><td headers="hd_h_niceng130er.appi.tab14_1_1_1_3 hd_b_niceng130er.appi.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (1, 3)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab14_1_1_1_1" id="hd_b_niceng130er.appi.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab14_1_1_1_2 hd_b_niceng130er.appi.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.014</td><td headers="hd_h_niceng130er.appi.tab14_1_1_1_3 hd_b_niceng130er.appi.tab14_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (2, 4)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab14_1_1_1_1" id="hd_b_niceng130er.appi.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">immunomodulator - topical</th><td headers="hd_h_niceng130er.appi.tab14_1_1_1_2 hd_b_niceng130er.appi.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.852</td><td headers="hd_h_niceng130er.appi.tab14_1_1_1_3 hd_b_niceng130er.appi.tab14_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (1, 3)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab14_1_1_1_1" id="hd_b_niceng130er.appi.tab14_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab14_1_1_1_2 hd_b_niceng130er.appi.tab14_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab14_1_1_1_3 hd_b_niceng130er.appi.tab14_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (3, 4)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig9"><div id="niceng130er.appi.fig9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2016.%20Proctitis%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20rank%20probability%20histograms.&p=BOOKS&id=576848_niceng130erappif9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif9.jpg" alt="Figure 16. Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 16</span><span class="title">Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms</span></h3><div class="caption"><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab15"><div id="niceng130er.appi.tab15" class="table"><h3><span class="label">Table 25</span><span class="title">Proctitis; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab15/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab15_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dbar</th><th id="hd_h_niceng130er.appi.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dhat</th><th id="hd_h_niceng130er.appi.tab15_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">pD</th><th id="hd_h_niceng130er.appi.tab15_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>11.13</p>
|
|
<p>(compared to 8 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">38.381</td><td headers="hd_h_niceng130er.appi.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">32.525</td><td headers="hd_h_niceng130er.appi.tab15_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.856</td><td headers="hd_h_niceng130er.appi.tab15_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44.237</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig10"><div id="niceng130er.appi.fig10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2017.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%202%20weeks%3B%20mode%2C%20dose%20and%20class%20%02013%20evidence%20network.&p=BOOKS&id=576848_niceng130erappif10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif10.jpg" alt="Figure 17. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class – evidence network." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 17</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class – evidence network</span></h3><div class="caption"><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Arrowheads indicate direction of effect in pairwise data (a > b denotes a is more effective than b) – filled arrowheads show comparisons where one option is significantly superior (p<0.05); outlined arrowheads show direction of trend where effect does not reach statistical significance.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab16"><div id="niceng130er.appi.tab16" class="table"><h3><span class="label">Table 26</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class – input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab16/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab16_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><th id="hd_h_niceng130er.appi.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">prednisolone - topical</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab16_1_1_1_1" id="hd_b_niceng130er.appi.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref2" rid="niceng130er.appe.s1.1.ref2">Binder et al. (1987)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab16_1_1_1_2 hd_b_niceng130er.appi.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab16_1_1_1_3 hd_b_niceng130er.appi.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">27/56</td><td headers="hd_h_niceng130er.appi.tab16_1_1_1_4 hd_b_niceng130er.appi.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19/61</td></tr><tr><th headers="hd_h_niceng130er.appi.tab16_1_1_1_1" id="hd_b_niceng130er.appi.tab16_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref5" rid="niceng130er.appe.s1.1.ref5">Campieri et al. (1991)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab16_1_1_1_2 hd_b_niceng130er.appi.tab16_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/27</td><td headers="hd_h_niceng130er.appi.tab16_1_1_1_3 hd_b_niceng130er.appi.tab16_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20/57</td><td headers="hd_h_niceng130er.appi.tab16_1_1_1_4 hd_b_niceng130er.appi.tab16_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab17"><div id="niceng130er.appi.tab17" class="table"><h3><span class="label">Table 27</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab17/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab17_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_niceng130er.appi.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th><th id="hd_h_niceng130er.appi.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">prednisolone - topical</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab17_1_1_1_1" id="hd_b_niceng130er.appi.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th><td headers="hd_h_niceng130er.appi.tab17_1_1_1_2 hd_b_niceng130er.appi.tab17_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab17_1_1_1_3 hd_b_niceng130er.appi.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>14.05</p>
|
|
<p>(1.77, 111.38)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab17_1_1_1_4 hd_b_niceng130er.appi.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab17_1_1_1_1" id="hd_b_niceng130er.appi.tab17_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab17_1_1_1_2 hd_b_niceng130er.appi.tab17_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>21.04</p>
|
|
<p>(3.20, 492.60)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab17_1_1_1_3 hd_b_niceng130er.appi.tab17_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab17_1_1_1_4 hd_b_niceng130er.appi.tab17_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.49</p>
|
|
<p>(0.23, 1.03)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab17_1_1_1_1" id="hd_b_niceng130er.appi.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">prednisolone - topical</th><td headers="hd_h_niceng130er.appi.tab17_1_1_1_2 hd_b_niceng130er.appi.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>10.30</p>
|
|
<p>(1.29, 260.90)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab17_1_1_1_3 hd_b_niceng130er.appi.tab17_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.48</p>
|
|
<p>(0.22, 1.03)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab17_1_1_1_4 hd_b_niceng130er.appi.tab17_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs lower than 1 favour the row defining treatment, ORs higher than 1 favour the column defining treatment.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig11"><div id="niceng130er.appi.fig11" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2018.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%202%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20relative%20effect%20of%20all%20options%20versus%20reference%20option.&p=BOOKS&id=576848_niceng130erappif11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif11.jpg" alt="Figure 18. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 18</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3><div class="caption"><p>Values less than 1 favour low-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Solid error bars are 95% credible intervals; dashed error bars are 95% confidence intervals.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab18"><div id="niceng130er.appi.tab18" class="table"><h3><span class="label">Table 28</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab18/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab18_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab18_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probability best</th><th id="hd_h_niceng130er.appi.tab18_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab18_1_1_1_1" id="hd_b_niceng130er.appi.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab18_1_1_1_2 hd_b_niceng130er.appi.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab18_1_1_1_3 hd_b_niceng130er.appi.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (3, 3)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab18_1_1_1_1" id="hd_b_niceng130er.appi.tab18_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab18_1_1_1_2 hd_b_niceng130er.appi.tab18_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.971</td><td headers="hd_h_niceng130er.appi.tab18_1_1_1_3 hd_b_niceng130er.appi.tab18_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (1, 2)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab18_1_1_1_1" id="hd_b_niceng130er.appi.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">prednisolone - topical</th><td headers="hd_h_niceng130er.appi.tab18_1_1_1_2 hd_b_niceng130er.appi.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.029</td><td headers="hd_h_niceng130er.appi.tab18_1_1_1_3 hd_b_niceng130er.appi.tab18_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (1, 2)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig12"><div id="niceng130er.appi.fig12" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2019.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%202%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20rank%20probability%20histograms.&p=BOOKS&id=576848_niceng130erappif12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif12.jpg" alt="Figure 19. Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – rank probability histograms." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 19</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – rank probability histograms</span></h3><div class="caption"><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab19"><div id="niceng130er.appi.tab19" class="table"><h3><span class="label">Table 29</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 2 weeks; mode, dose and class; fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab19/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab19_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab19_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dbar</th><th id="hd_h_niceng130er.appi.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dhat</th><th id="hd_h_niceng130er.appi.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">pD</th><th id="hd_h_niceng130er.appi.tab19_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>4.228</p>
|
|
<p>(compared to 5 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab19_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">22.543</td><td headers="hd_h_niceng130er.appi.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18.647</td><td headers="hd_h_niceng130er.appi.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.896</td><td headers="hd_h_niceng130er.appi.tab19_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">26.439</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig13"><div id="niceng130er.appi.fig13" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2020.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%200%020134%20weeks%3B%20mode%2C%20dose%20and%20class%20%02013%20evidence%20network.&p=BOOKS&id=576848_niceng130erappif13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif13.jpg" alt="Figure 20. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class – evidence network." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 20</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class – evidence network</span></h3><div class="caption"><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Arrowheads indicate direction of effect in pairwise data (a > b denotes a is more effective than b) – filled arrowheads show comparisons where one option is significantly superior (p<0.05); outlined arrowheads show direction of trend where effect does not reach statistical significance.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab20"><div id="niceng130er.appi.tab20" class="table"><h3><span class="label">Table 30</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class - input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab20/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab20_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab20_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab20_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">beclomethasone - oral</th><th id="hd_h_niceng130er.appi.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab20_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">low-dose oral aminosalicylate + oral</th><th id="hd_h_niceng130er.appi.tab20_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">placebo</th><th id="hd_h_niceng130er.appi.tab20_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:bottom;">prednisolone - topical</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab20_1_1_1_1" id="hd_b_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref2" rid="niceng130er.appe.s1.1.ref2">Binder et al. (1987)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab20_1_1_1_2 hd_b_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_3 hd_b_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">27/56</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_4 hd_b_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_5 hd_b_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_6 hd_b_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_7 hd_b_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_8 hd_b_niceng130er.appi.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19/61</td></tr><tr><th headers="hd_h_niceng130er.appi.tab20_1_1_1_1" id="hd_b_niceng130er.appi.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref5" rid="niceng130er.appe.s1.1.ref5">Campieri et al. (1991)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab20_1_1_1_2 hd_b_niceng130er.appi.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_3 hd_b_niceng130er.appi.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">37/57</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_4 hd_b_niceng130er.appi.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_5 hd_b_niceng130er.appi.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_6 hd_b_niceng130er.appi.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_7 hd_b_niceng130er.appi.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3/27</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_8 hd_b_niceng130er.appi.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab20_1_1_1_1" id="hd_b_niceng130er.appi.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref22" rid="niceng130er.appe.s1.1.ref22">Lauritsen et al. (1986)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab20_1_1_1_2 hd_b_niceng130er.appi.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_3 hd_b_niceng130er.appi.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7/13</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_4 hd_b_niceng130er.appi.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_5 hd_b_niceng130er.appi.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_6 hd_b_niceng130er.appi.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_7 hd_b_niceng130er.appi.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_8 hd_b_niceng130er.appi.tab20_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9/11</td></tr><tr><th headers="hd_h_niceng130er.appi.tab20_1_1_1_1" id="hd_b_niceng130er.appi.tab20_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref30" rid="niceng130er.appe.s1.1.ref30">Sandborn et al. (2009)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab20_1_1_1_2 hd_b_niceng130er.appi.tab20_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">65/359</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_3 hd_b_niceng130er.appi.tab20_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_4 hd_b_niceng130er.appi.tab20_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_5 hd_b_niceng130er.appi.tab20_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">91/365</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_6 hd_b_niceng130er.appi.tab20_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_7 hd_b_niceng130er.appi.tab20_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_8 hd_b_niceng130er.appi.tab20_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab20_1_1_1_1" id="hd_b_niceng130er.appi.tab20_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref33" rid="niceng130er.appe.s1.1.ref33">Sninsky et al. (1991)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab20_1_1_1_2 hd_b_niceng130er.appi.tab20_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/106</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_3 hd_b_niceng130er.appi.tab20_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_4 hd_b_niceng130er.appi.tab20_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_5 hd_b_niceng130er.appi.tab20_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_6 hd_b_niceng130er.appi.tab20_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_7 hd_b_niceng130er.appi.tab20_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/52</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_8 hd_b_niceng130er.appi.tab20_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab20_1_1_1_1" id="hd_b_niceng130er.appi.tab20_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref6" rid="niceng130er.appe.s1.1.ref6">Campieri et al. (2003)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab20_1_1_1_2 hd_b_niceng130er.appi.tab20_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">41/62</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_3 hd_b_niceng130er.appi.tab20_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_4 hd_b_niceng130er.appi.tab20_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">27/47</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_5 hd_b_niceng130er.appi.tab20_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_6 hd_b_niceng130er.appi.tab20_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_7 hd_b_niceng130er.appi.tab20_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_8 hd_b_niceng130er.appi.tab20_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab20_1_1_1_1" id="hd_b_niceng130er.appi.tab20_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref8" rid="niceng130er.appe.s1.2.ref8">Pontes et al. (2014)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab20_1_1_1_2 hd_b_niceng130er.appi.tab20_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/8</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_3 hd_b_niceng130er.appi.tab20_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_4 hd_b_niceng130er.appi.tab20_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_5 hd_b_niceng130er.appi.tab20_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_6 hd_b_niceng130er.appi.tab20_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_7 hd_b_niceng130er.appi.tab20_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/13</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_8 hd_b_niceng130er.appi.tab20_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab20_1_1_1_1" id="hd_b_niceng130er.appi.tab20_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref29" rid="niceng130er.appe.s1.1.ref29">Rizzello et al. (2002)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab20_1_1_1_2 hd_b_niceng130er.appi.tab20_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">21/61</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_3 hd_b_niceng130er.appi.tab20_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_4 hd_b_niceng130er.appi.tab20_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_5 hd_b_niceng130er.appi.tab20_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_6 hd_b_niceng130er.appi.tab20_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">34/58</td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_7 hd_b_niceng130er.appi.tab20_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab20_1_1_1_8 hd_b_niceng130er.appi.tab20_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab21"><div id="niceng130er.appi.tab21" class="table"><h3><span class="label">Table 31</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab21/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab21_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_niceng130er.appi.tab21_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab21_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">beclomethasone - oral</th><th id="hd_h_niceng130er.appi.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab21_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose oral aminosalicylate + oral beclomethasone</th><th id="hd_h_niceng130er.appi.tab21_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th><th id="hd_h_niceng130er.appi.tab21_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">prednisolone - topical</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab21_1_1_1_1" id="hd_b_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab21_1_1_1_2 hd_b_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_3 hd_b_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_4 hd_b_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.69</p>
|
|
<p>(0.32, 1.51)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_5 hd_b_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.50</p>
|
|
<p>(1.05, 2.15)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_6 hd_b_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.70</p>
|
|
<p>(1.28, 5.67)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_7 hd_b_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.81</p>
|
|
<p>(0.12, 5.36)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_8 hd_b_niceng130er.appi.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab21_1_1_1_1" id="hd_b_niceng130er.appi.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab21_1_1_1_2 hd_b_niceng130er.appi.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>13.21</p>
|
|
<p>(0.95, 163.50)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_3 hd_b_niceng130er.appi.tab21_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_4 hd_b_niceng130er.appi.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_5 hd_b_niceng130er.appi.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_6 hd_b_niceng130er.appi.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_7 hd_b_niceng130er.appi.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.07</p>
|
|
<p>(0.02, 0.25)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_8 hd_b_niceng130er.appi.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.68</p>
|
|
<p>(0.35, 1.33)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab21_1_1_1_1" id="hd_b_niceng130er.appi.tab21_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">beclomethasone - oral</th><td headers="hd_h_niceng130er.appi.tab21_1_1_1_2 hd_b_niceng130er.appi.tab21_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.69</p>
|
|
<p>(0.31, 1.52)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_3 hd_b_niceng130er.appi.tab21_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.05</p>
|
|
<p>(0.00, 0.81)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_4 hd_b_niceng130er.appi.tab21_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_5 hd_b_niceng130er.appi.tab21_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_6 hd_b_niceng130er.appi.tab21_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_7 hd_b_niceng130er.appi.tab21_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_8 hd_b_niceng130er.appi.tab21_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab21_1_1_1_1" id="hd_b_niceng130er.appi.tab21_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab21_1_1_1_2 hd_b_niceng130er.appi.tab21_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.50</p>
|
|
<p>(1.06, 2.16)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_3 hd_b_niceng130er.appi.tab21_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.11</p>
|
|
<p>(0.01, 1.62)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_4 hd_b_niceng130er.appi.tab21_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.19</p>
|
|
<p>(0.92, 5.22)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_5 hd_b_niceng130er.appi.tab21_1_1_4_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_6 hd_b_niceng130er.appi.tab21_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_7 hd_b_niceng130er.appi.tab21_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_8 hd_b_niceng130er.appi.tab21_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab21_1_1_1_1" id="hd_b_niceng130er.appi.tab21_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose oral aminosalicylate + oral beclomethasone</th><td headers="hd_h_niceng130er.appi.tab21_1_1_1_2 hd_b_niceng130er.appi.tab21_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.75</p>
|
|
<p>(1.30, 5.89)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_3 hd_b_niceng130er.appi.tab21_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.21</p>
|
|
<p>(0.01, 3.26)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_4 hd_b_niceng130er.appi.tab21_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>4.01</p>
|
|
<p>(1.33, 12.00)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_5 hd_b_niceng130er.appi.tab21_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.83</p>
|
|
<p>(0.79, 4.23)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_6 hd_b_niceng130er.appi.tab21_1_1_5_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_7 hd_b_niceng130er.appi.tab21_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_8 hd_b_niceng130er.appi.tab21_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab21_1_1_1_1" id="hd_b_niceng130er.appi.tab21_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th><td headers="hd_h_niceng130er.appi.tab21_1_1_1_2 hd_b_niceng130er.appi.tab21_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.77</p>
|
|
<p>(0.08, 5.80)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_3 hd_b_niceng130er.appi.tab21_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.06</p>
|
|
<p>(0.01, 0.20)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_4 hd_b_niceng130er.appi.tab21_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.12</p>
|
|
<p>(0.10, 9.49)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_5 hd_b_niceng130er.appi.tab21_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.51</p>
|
|
<p>(0.05, 3.87)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_6 hd_b_niceng130er.appi.tab21_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.28</p>
|
|
<p>(0.03, 2.36)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_7 hd_b_niceng130er.appi.tab21_1_1_6_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_8 hd_b_niceng130er.appi.tab21_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab21_1_1_1_1" id="hd_b_niceng130er.appi.tab21_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">prednisolone - topical</th><td headers="hd_h_niceng130er.appi.tab21_1_1_1_2 hd_b_niceng130er.appi.tab21_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>8.88</p>
|
|
<p>(0.58, 122.00)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_3 hd_b_niceng130er.appi.tab21_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.67</p>
|
|
<p>(0.33, 1.34)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_4 hd_b_niceng130er.appi.tab21_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>12.95</p>
|
|
<p>(0.77, 200.10)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_5 hd_b_niceng130er.appi.tab21_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>5.90</p>
|
|
<p>(0.37, 82.59)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_6 hd_b_niceng130er.appi.tab21_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>3.24</p>
|
|
<p>(0.19, 49.52)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_7 hd_b_niceng130er.appi.tab21_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>11.50</p>
|
|
<p>(2.72, 63.97)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab21_1_1_1_8 hd_b_niceng130er.appi.tab21_1_1_7_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs lower than 1 favour the row defining treatment, ORs higher than 1 favour the column defining treatment.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig14"><div id="niceng130er.appi.fig14" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2021.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%200%020134%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20relative%20effect%20of%20all%20options%20versus%20reference%20option.&p=BOOKS&id=576848_niceng130erappif14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif14.jpg" alt="Figure 21. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 21</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3><div class="caption"><p>Values less than 1 favour low-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Solid error bars are 95% credible intervals; dashed error bars are 95% confidence intervals.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab22"><div id="niceng130er.appi.tab22" class="table"><h3><span class="label">Table 32</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab22/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab22_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab22_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probability best</th><th id="hd_h_niceng130er.appi.tab22_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab22_1_1_1_1" id="hd_b_niceng130er.appi.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab22_1_1_1_2 hd_b_niceng130er.appi.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab22_1_1_1_3 hd_b_niceng130er.appi.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 (4, 7)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab22_1_1_1_1" id="hd_b_niceng130er.appi.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab22_1_1_1_2 hd_b_niceng130er.appi.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.764</td><td headers="hd_h_niceng130er.appi.tab22_1_1_1_3 hd_b_niceng130er.appi.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (1, 4)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab22_1_1_1_1" id="hd_b_niceng130er.appi.tab22_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">beclomethasone - oral</th><td headers="hd_h_niceng130er.appi.tab22_1_1_1_2 hd_b_niceng130er.appi.tab22_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab22_1_1_1_3 hd_b_niceng130er.appi.tab22_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (4, 7)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab22_1_1_1_1" id="hd_b_niceng130er.appi.tab22_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab22_1_1_1_2 hd_b_niceng130er.appi.tab22_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.004</td><td headers="hd_h_niceng130er.appi.tab22_1_1_1_3 hd_b_niceng130er.appi.tab22_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (2, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab22_1_1_1_1" id="hd_b_niceng130er.appi.tab22_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose oral aminosalicylate + oral beclomethasone</th><td headers="hd_h_niceng130er.appi.tab22_1_1_1_2 hd_b_niceng130er.appi.tab22_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.117</td><td headers="hd_h_niceng130er.appi.tab22_1_1_1_3 hd_b_niceng130er.appi.tab22_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (1, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab22_1_1_1_1" id="hd_b_niceng130er.appi.tab22_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab22_1_1_1_2 hd_b_niceng130er.appi.tab22_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab22_1_1_1_3 hd_b_niceng130er.appi.tab22_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (3, 7)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab22_1_1_1_1" id="hd_b_niceng130er.appi.tab22_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">prednisolone - topical</th><td headers="hd_h_niceng130er.appi.tab22_1_1_1_2 hd_b_niceng130er.appi.tab22_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.115</td><td headers="hd_h_niceng130er.appi.tab22_1_1_1_3 hd_b_niceng130er.appi.tab22_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (1, 6)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig15"><div id="niceng130er.appi.fig15" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2022.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%200%020134%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20rank%20probability%20histograms.&p=BOOKS&id=576848_niceng130erappif15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif15.jpg" alt="Figure 22. Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 22</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms</span></h3><div class="caption"><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab23"><div id="niceng130er.appi.tab23" class="table"><h3><span class="label">Table 33</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab23/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab23_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab23_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dbar</th><th id="hd_h_niceng130er.appi.tab23_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dhat</th><th id="hd_h_niceng130er.appi.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">pD</th><th id="hd_h_niceng130er.appi.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>19.02</p>
|
|
<p>(compared to 18 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab23_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">83.053</td><td headers="hd_h_niceng130er.appi.tab23_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">69.116</td><td headers="hd_h_niceng130er.appi.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13.937</td><td headers="hd_h_niceng130er.appi.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96.991</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig16"><div id="niceng130er.appi.fig16" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2023.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%20%02013%20evidence%20network.&p=BOOKS&id=576848_niceng130erappif16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif16.jpg" alt="Figure 23. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class – evidence network." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 23</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class – evidence network</span></h3><div class="caption"><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Arrowheads indicate direction of effect in pairwise data (a > b denotes a is more effective than b) – filled arrowheads show comparisons where one option is significantly superior (p<0.05); outlined arrowheads show direction of trend where effect does not reach statistical significance.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab24"><div id="niceng130er.appi.tab24" class="table"><h3><span class="label">Table 34</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class – input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab24/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab24_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab24_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab24_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - oral</th><th id="hd_h_niceng130er.appi.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - topical (foam)</th><th id="hd_h_niceng130er.appi.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab24_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hydrocortisone - topical (foam)</th><th id="hd_h_niceng130er.appi.tab24_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral asa and topical asa</th><th id="hd_h_niceng130er.appi.tab24_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab24_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref1" rid="niceng130er.appe.s1.1.ref1">Bar-Meir et al. (2003)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64/120</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67/128</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref8" rid="niceng130er.appe.s1.1.ref8">D’Haens et al. (2006)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4/27</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2/11</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer et al. (1993)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47/189</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28/95</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11/90</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref15" rid="niceng130er.appe.s1.1.ref15">Hanauer (1998)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67/144</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10/70</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref16" rid="niceng130er.appe.s1.1.ref16">Hanauer et al. (2005)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23/77</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25/89</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm et al. (2007)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64/170</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35/85</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19/86</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref21" rid="niceng130er.appe.s1.1.ref21">Kruis et al. (2003)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52/103</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">129/213</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref24" rid="niceng130er.appe.s1.1.ref24">Levine et al. (2002)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14/71</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8/35</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref27" rid="niceng130er.appe.s1.1.ref27">Pokrotnieks et al. (2000)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23/41</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13/37</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref28" rid="niceng130er.appe.s1.1.ref28">Pruitt et al. (2002)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38/77</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38/73</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref30" rid="niceng130er.appe.s1.1.ref30">Sandborn et al. (2009)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">121/347</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">152/353</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref31" rid="niceng130er.appe.s1.1.ref31">Sandborn et al. (2012)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18/66</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7/75</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref32" rid="niceng130er.appe.s1.1.ref32">Scherl et al. (2009)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64/166</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19/83</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref33" rid="niceng130er.appe.s1.1.ref33">Sninsky et al. (1991)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12/106</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2/52</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref34" rid="niceng130er.appe.s1.1.ref34">Vecchi et al. (2001)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55/67</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55/3</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref1" rid="niceng130er.appe.s1.2.ref1">Travis S et al. (2013)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17/95</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6/108</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref3" rid="niceng130er.appe.s1.2.ref3">Feagan et al. (2013)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42/140</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29/141</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref11" rid="niceng130er.appe.s1.2.ref11">Sandborn et al. (2015)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110/267</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67/279</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref5" rid="niceng130er.appe.s1.2.ref5">Naganuma et al. (2016)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55/111</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11/54</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref12" rid="niceng130er.appe.s1.2.ref12">Suzuki et al. (2016)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10/55</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14/55</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref6" rid="niceng130er.appe.s1.2.ref6">Naganuma et al. (2017)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26/64</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10/62</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref10" rid="niceng130er.appe.s1.2.ref10">Rubin David et al. (2017)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56/230</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52/228</td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref13" rid="niceng130er.appe.s1.1.ref13">Gross et al. (2011)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56/140</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72/134</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab24_1_1_1_1" id="hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref7" rid="niceng130er.appe.s1.2.ref7">Ogata et al. (2017)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab24_1_1_1_2 hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40/131</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_3 hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_4 hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_5 hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56/136</td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_6 hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_7 hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_8 hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab24_1_1_1_9 hd_b_niceng130er.appi.tab24_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab25"><div id="niceng130er.appi.tab25" class="table"><h3><span class="label">Table 35</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab25/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab25_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_niceng130er.appi.tab25_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">budesonide - oral</th><th id="hd_h_niceng130er.appi.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">budesonide - topical (foam)</th><th id="hd_h_niceng130er.appi.tab25_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab25_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">hydrocortisone - topical (foam)</th><th id="hd_h_niceng130er.appi.tab25_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">low-dose aminosalicylate - oral asa and topical asa</th><th id="hd_h_niceng130er.appi.tab25_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">low-dose aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab25_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab25_1_1_1_1" id="hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab25_1_1_1_2 hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_3 hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_4 hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_5 hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.33</p>
|
|
<p>(1.12, 1.58)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_6 hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_7 hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.50</p>
|
|
<p>(0.57, 3.96)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_8 hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_9 hd_b_niceng130er.appi.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.43</p>
|
|
<p>(0.28, 0.67)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab25_1_1_1_1" id="hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">budesonide - oral</th><td headers="hd_h_niceng130er.appi.tab25_1_1_1_2 hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.82</p>
|
|
<p>(0.57, 1.17)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_3 hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_4 hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_5 hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.74</p>
|
|
<p>(1.08, 2.81)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_6 hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_7 hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_8 hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_9 hd_b_niceng130er.appi.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.63</p>
|
|
<p>(0.44, 0.90)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab25_1_1_1_1" id="hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">budesonide - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab25_1_1_1_2 hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.41</p>
|
|
<p>(0.93, 2.15)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_3 hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.73</p>
|
|
<p>(1.13, 2.66)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_4 hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_5 hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_6 hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.96</p>
|
|
<p>(0.58, 1.58)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_7 hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_8 hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_9 hd_b_niceng130er.appi.tab25_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.38</p>
|
|
<p>(0.28, 0.52)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab25_1_1_1_1" id="hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab25_1_1_1_2 hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.30</p>
|
|
<p>(1.10, 1.54)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_3 hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.59</p>
|
|
<p>(1.14, 2.22)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_4 hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.92</p>
|
|
<p>(0.62, 1.38)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_5 hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_6 hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_7 hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_8 hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_9 hd_b_niceng130er.appi.tab25_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.47</p>
|
|
<p>(0.34, 0.64)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab25_1_1_1_1" id="hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">hydrocortisone - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab25_1_1_1_2 hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.36</p>
|
|
<p>(0.71, 2.61)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_3 hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.66</p>
|
|
<p>(0.87, 3.20)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_4 hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.96</p>
|
|
<p>(0.58, 1.58)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_5 hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.04</p>
|
|
<p>(0.55, 1.99)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_6 hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_7 hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_8 hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_9 hd_b_niceng130er.appi.tab25_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab25_1_1_1_1" id="hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral asa and topical asa</th><td headers="hd_h_niceng130er.appi.tab25_1_1_1_2 hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.52</p>
|
|
<p>(0.57, 4.22)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_3 hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.87</p>
|
|
<p>(0.66, 5.54)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_4 hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.08</p>
|
|
<p>(0.38, 3.25)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_5 hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.17</p>
|
|
<p>(0.44, 3.32)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_6 hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.13</p>
|
|
<p>(0.35, 3.75)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_7 hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_8 hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_9 hd_b_niceng130er.appi.tab25_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab25_1_1_1_1" id="hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab25_1_1_1_2 hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.13</p>
|
|
<p>(1.15, 4.08)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_3 hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.60</p>
|
|
<p>(1.39, 5.02)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_4 hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.51</p>
|
|
<p>(0.80, 2.94)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_5 hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.64</p>
|
|
<p>(0.89, 3.14)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_6 hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.57</p>
|
|
<p>(0.70, 3.61)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_7 hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.40</p>
|
|
<p>(0.42, 4.51)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_8 hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_9 hd_b_niceng130er.appi.tab25_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.26</p>
|
|
<p>(0.14, 0.45)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab25_1_1_1_1" id="hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th><td headers="hd_h_niceng130er.appi.tab25_1_1_1_2 hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.54</p>
|
|
<p>(0.40, 0.72)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_3 hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.66</p>
|
|
<p>(0.49, 0.89)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_4 hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.38</p>
|
|
<p>(0.28, 0.52)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_5 hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.42</p>
|
|
<p>(0.32, 0.54)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_6 hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.40</p>
|
|
<p>(0.22, 0.71)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_7 hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.35</p>
|
|
<p>(0.12, 0.97)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_8 hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.25</p>
|
|
<p>(0.14, 0.44)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab25_1_1_1_9 hd_b_niceng130er.appi.tab25_1_1_8_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs lower than 1 favour the row defining treatment, ORs higher than 1 favour the column defining treatment.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig17"><div id="niceng130er.appi.fig17" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2024.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20relative%20effect%20of%20all%20options%20versus%20reference%20option.&p=BOOKS&id=576848_niceng130erappif17.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif17.jpg" alt="Figure 24. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 24</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3><div class="caption"><p>Values less than 1 favour low-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Solid error bars are 95% credible intervals; dashed error bars are 95% confidence intervals.</p></div></div></article><article data-type="fig" id="figobniceng130erappifig18"><div id="niceng130er.appi.fig18" class="figure bk_fig"><h3><span class="label">Figure 25</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappitab26"><div id="niceng130er.appi.tab26" class="table"><h3><span class="label">Table 36</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab26/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab26_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab26_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probability best</th><th id="hd_h_niceng130er.appi.tab26_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab26_1_1_1_1" id="hd_b_niceng130er.appi.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab26_1_1_1_2 hd_b_niceng130er.appi.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab26_1_1_1_3 hd_b_niceng130er.appi.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (4, 7)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab26_1_1_1_1" id="hd_b_niceng130er.appi.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - oral</th><td headers="hd_h_niceng130er.appi.tab26_1_1_1_2 hd_b_niceng130er.appi.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab26_1_1_1_3 hd_b_niceng130er.appi.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 (5, 7)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab26_1_1_1_1" id="hd_b_niceng130er.appi.tab26_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab26_1_1_1_2 hd_b_niceng130er.appi.tab26_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.028</td><td headers="hd_h_niceng130er.appi.tab26_1_1_1_3 hd_b_niceng130er.appi.tab26_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (1, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab26_1_1_1_1" id="hd_b_niceng130er.appi.tab26_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab26_1_1_1_2 hd_b_niceng130er.appi.tab26_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.010</td><td headers="hd_h_niceng130er.appi.tab26_1_1_1_3 hd_b_niceng130er.appi.tab26_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (2, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab26_1_1_1_1" id="hd_b_niceng130er.appi.tab26_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hydrocortisone - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab26_1_1_1_2 hd_b_niceng130er.appi.tab26_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.079</td><td headers="hd_h_niceng130er.appi.tab26_1_1_1_3 hd_b_niceng130er.appi.tab26_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (1, 7)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab26_1_1_1_1" id="hd_b_niceng130er.appi.tab26_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral asa and topical asa</th><td headers="hd_h_niceng130er.appi.tab26_1_1_1_2 hd_b_niceng130er.appi.tab26_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.260</td><td headers="hd_h_niceng130er.appi.tab26_1_1_1_3 hd_b_niceng130er.appi.tab26_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (1, 7)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab26_1_1_1_1" id="hd_b_niceng130er.appi.tab26_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab26_1_1_1_2 hd_b_niceng130er.appi.tab26_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.622</td><td headers="hd_h_niceng130er.appi.tab26_1_1_1_3 hd_b_niceng130er.appi.tab26_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (1, 4)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab26_1_1_1_1" id="hd_b_niceng130er.appi.tab26_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab26_1_1_1_2 hd_b_niceng130er.appi.tab26_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab26_1_1_1_3 hd_b_niceng130er.appi.tab26_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 (7, 8)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig19"><div id="niceng130er.appi.fig19" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2026.%20Proctosigmoiditis%20and%20left-sided%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20rank%20probability%20histograms.&p=BOOKS&id=576848_niceng130erappif18.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif18.jpg" alt="Figure 26. Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 26</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms</span></h3><div class="caption"><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab27"><div id="niceng130er.appi.tab27" class="table"><h3><span class="label">Table 37</span><span class="title">Proctosigmoiditis and left-sided; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab27/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab27_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab27_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dbar</th><th id="hd_h_niceng130er.appi.tab27_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dhat</th><th id="hd_h_niceng130er.appi.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">pD</th><th id="hd_h_niceng130er.appi.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>62.98</p>
|
|
<p>(compared to 58 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab27_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">323.252</td><td headers="hd_h_niceng130er.appi.tab27_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">292.229</td><td headers="hd_h_niceng130er.appi.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">31.023</td><td headers="hd_h_niceng130er.appi.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">354.276</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig20"><div id="niceng130er.appi.fig20" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2027.%20Extensive%20disease%20in%20adults%3B%20clinical%20remission%20at%200%020134%20weeks%3B%20mode%2C%20dose%20and%20class%20%02013%20evidence%20network.&p=BOOKS&id=576848_niceng130erappif19.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif19.jpg" alt="Figure 27. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class – evidence network." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 27</span><span class="title">Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class – evidence network</span></h3><div class="caption"><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Arrowheads indicate direction of effect in pairwise data (a > b denotes a is more effective than b) – filled arrowheads show comparisons where one option is significantly superior (p<0.05); outlined arrowheads show direction of trend where effect does not reach statistical significance.</p><p>The dashed blue line shows where evidence from proctosigmoiditis/left-sided disease has been used in order to form a connected network.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab28"><div id="niceng130er.appi.tab28" class="table"><h3><span class="label">Table 38</span><span class="title">Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class – input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab28/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab28_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab28_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab28_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">beclometasone - oral</th><th id="hd_h_niceng130er.appi.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral asa and topical asa</th><th id="hd_h_niceng130er.appi.tab28_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">prednisolone - oral</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab28_1_1_1_1" id="hd_b_niceng130er.appi.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref23" rid="niceng130er.appe.s1.1.ref23">Lennard Jones et al. (1960)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab28_1_1_1_2 hd_b_niceng130er.appi.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8/20</td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_3 hd_b_niceng130er.appi.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_4 hd_b_niceng130er.appi.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_5 hd_b_niceng130er.appi.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_6 hd_b_niceng130er.appi.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11/20</td></tr><tr><th headers="hd_h_niceng130er.appi.tab28_1_1_1_1" id="hd_b_niceng130er.appi.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref6" rid="niceng130er.appe.s1.1.ref6">Campieri et al. (2003)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab28_1_1_1_2 hd_b_niceng130er.appi.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9/18</td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_3 hd_b_niceng130er.appi.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19/26</td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_4 hd_b_niceng130er.appi.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_5 hd_b_niceng130er.appi.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_6 hd_b_niceng130er.appi.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab28_1_1_1_1" id="hd_b_niceng130er.appi.tab28_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref9" rid="niceng130er.appe.s1.2.ref9">Probert et al. (2014)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab28_1_1_1_2 hd_b_niceng130er.appi.tab28_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_3 hd_b_niceng130er.appi.tab28_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_4 hd_b_niceng130er.appi.tab28_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16/47</td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_5 hd_b_niceng130er.appi.tab28_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25/57</td><td headers="hd_h_niceng130er.appi.tab28_1_1_1_6 hd_b_niceng130er.appi.tab28_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab29"><div id="niceng130er.appi.tab29" class="table"><h3><span class="label">Table 39</span><span class="title">Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab29/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab29_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_niceng130er.appi.tab29_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab29_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">beclometasone - oral</th><th id="hd_h_niceng130er.appi.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">high-dose aminosalicylate - oral and topical asa</th><th id="hd_h_niceng130er.appi.tab29_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">prednisolone - oral</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab29_1_1_1_1" id="hd_b_niceng130er.appi.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab29_1_1_1_2 hd_b_niceng130er.appi.tab29_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_3 hd_b_niceng130er.appi.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.71</p>
|
|
<p>(0.76, 9.63)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_4 hd_b_niceng130er.appi.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>
|
|
<i>1.50</i>
|
|
</p>
|
|
<p>
|
|
<i>(1.05, 2.15)</i>
|
|
</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_5 hd_b_niceng130er.appi.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_6 hd_b_niceng130er.appi.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.83</p>
|
|
<p>(0.52, 6.43)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab29_1_1_1_1" id="hd_b_niceng130er.appi.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">beclomethasone - oral</th><td headers="hd_h_niceng130er.appi.tab29_1_1_1_2 hd_b_niceng130er.appi.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.83</p>
|
|
<p>(0.79, 10.86)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_3 hd_b_niceng130er.appi.tab29_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_4 hd_b_niceng130er.appi.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_5 hd_b_niceng130er.appi.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_6 hd_b_niceng130er.appi.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab29_1_1_1_1" id="hd_b_niceng130er.appi.tab29_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab29_1_1_1_2 hd_b_niceng130er.appi.tab29_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>
|
|
<i>1.51</i>
|
|
</p>
|
|
<p>
|
|
<i>(1.06, 2.16)</i>
|
|
</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_3 hd_b_niceng130er.appi.tab29_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.53</p>
|
|
<p>(0.13, 2.01)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_4 hd_b_niceng130er.appi.tab29_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_5 hd_b_niceng130er.appi.tab29_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.51</p>
|
|
<p>(0.68, 3.36)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_6 hd_b_niceng130er.appi.tab29_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab29_1_1_1_1" id="hd_b_niceng130er.appi.tab29_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>high-dose aminosalicylate - oral and topical</p>
|
|
<p>(liquid enema) asa</p>
|
|
</th><td headers="hd_h_niceng130er.appi.tab29_1_1_1_2 hd_b_niceng130er.appi.tab29_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.31</p>
|
|
<p>(0.95, 5.57)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_3 hd_b_niceng130er.appi.tab29_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.81</p>
|
|
<p>(0.16, 3.86)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_4 hd_b_niceng130er.appi.tab29_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.53</p>
|
|
<p>(0.69, 3.43)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_5 hd_b_niceng130er.appi.tab29_1_1_4_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_6 hd_b_niceng130er.appi.tab29_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab29_1_1_1_1" id="hd_b_niceng130er.appi.tab29_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">prednisolone - oral</th><td headers="hd_h_niceng130er.appi.tab29_1_1_1_2 hd_b_niceng130er.appi.tab29_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.89</p>
|
|
<p>(0.53, 6.92)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_3 hd_b_niceng130er.appi.tab29_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.66</p>
|
|
<p>(0.10, 4.09)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_4 hd_b_niceng130er.appi.tab29_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.26</p>
|
|
<p>(0.33, 4.78)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_5 hd_b_niceng130er.appi.tab29_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.82</p>
|
|
<p>(0.18, 3.92)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab29_1_1_1_6 hd_b_niceng130er.appi.tab29_1_1_5_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs lower than 1 favour the row defining treatment, ORs higher than 1 favour the column defining treatment. Estimates shown in italics are not estimated in this model; rather they are assumed identical to observed effect in the analogous NMA for proctosigmoiditis and left-sided disease, in order to join what would otherwise be a disconnected network.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig21"><div id="niceng130er.appi.fig21" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2028.%20Extensive%20disease%20in%20adults%3B%20clinical%20remission%20at%200%020134%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20relative%20effect%20of%20all%20options%20versus%20reference%20option.&p=BOOKS&id=576848_niceng130erappif20.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif20.jpg" alt="Figure 28. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 28</span><span class="title">Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3><div class="caption"><p>Values less than 1 favour low-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Solid error bars are 95% credible intervals; dashed error bars are 95% confidence intervals.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab30"><div id="niceng130er.appi.tab30" class="table"><h3><span class="label">Table 40</span><span class="title">Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab30/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab30_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_niceng130er.appi.tab30_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Probability best</th><th id="hd_h_niceng130er.appi.tab30_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab30_1_1_1_1" id="hd_b_niceng130er.appi.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab30_1_1_1_2 hd_b_niceng130er.appi.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.000</td><td headers="hd_h_niceng130er.appi.tab30_1_1_1_3 hd_b_niceng130er.appi.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5 (4, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab30_1_1_1_1" id="hd_b_niceng130er.appi.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">beclometasone - oral</th><td headers="hd_h_niceng130er.appi.tab30_1_1_1_2 hd_b_niceng130er.appi.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.491</td><td headers="hd_h_niceng130er.appi.tab30_1_1_1_3 hd_b_niceng130er.appi.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 (1, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab30_1_1_1_1" id="hd_b_niceng130er.appi.tab30_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab30_1_1_1_2 hd_b_niceng130er.appi.tab30_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.011</td><td headers="hd_h_niceng130er.appi.tab30_1_1_1_3 hd_b_niceng130er.appi.tab30_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3 (2, 4)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab30_1_1_1_1" id="hd_b_niceng130er.appi.tab30_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral asa and topical (liquid enema) asa</th><td headers="hd_h_niceng130er.appi.tab30_1_1_1_2 hd_b_niceng130er.appi.tab30_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.280</td><td headers="hd_h_niceng130er.appi.tab30_1_1_1_3 hd_b_niceng130er.appi.tab30_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 (1, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab30_1_1_1_1" id="hd_b_niceng130er.appi.tab30_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">prednisolone - oral</th><td headers="hd_h_niceng130er.appi.tab30_1_1_1_2 hd_b_niceng130er.appi.tab30_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.218</td><td headers="hd_h_niceng130er.appi.tab30_1_1_1_3 hd_b_niceng130er.appi.tab30_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3 (1, 5)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig22"><div id="niceng130er.appi.fig22" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2029.%20Extensive%20disease%20in%20adults%3B%20clinical%20remission%20at%200%020134%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20rank%20probability%20histograms.&p=BOOKS&id=576848_niceng130erappif21.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif21.jpg" alt="Figure 29. Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 29</span><span class="title">Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – rank probability histograms</span></h3><div class="caption"><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab31"><div id="niceng130er.appi.tab31" class="table"><h3><span class="label">Table 41</span><span class="title">Extensive disease in adults; clinical remission at 0–4 weeks; mode, dose and class; fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab31/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab31_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab31_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dbar</th><th id="hd_h_niceng130er.appi.tab31_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dhat</th><th id="hd_h_niceng130er.appi.tab31_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">pD</th><th id="hd_h_niceng130er.appi.tab31_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>6.108</p>
|
|
<p>(compared to 6 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab31_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28.565</td><td headers="hd_h_niceng130er.appi.tab31_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">22.474</td><td headers="hd_h_niceng130er.appi.tab31_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.091</td><td headers="hd_h_niceng130er.appi.tab31_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">34.655</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig23"><div id="niceng130er.appi.fig23" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2030.%20Extensive%20disease%20in%20adults%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%20%02013%20evidence%20network.&p=BOOKS&id=576848_niceng130erappif22.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif22.jpg" alt="Figure 30. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class – evidence network." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 30</span><span class="title">Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class – evidence network</span></h3><div class="caption"><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Arrowheads indicate direction of effect in pairwise data (a > b denotes a is more effective than b) – filled arrowheads show comparisons where one option is significantly superior (p<0.05); outlined arrowheads show direction of trend where effect does not reach statistical significance.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab32"><div id="niceng130er.appi.tab32" class="table"><h3><span class="label">Table 42</span><span class="title">Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class – input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab32/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab32_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab32_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab32_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - oral</th><th id="hd_h_niceng130er.appi.tab32_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral asa and topical asa</th><th id="hd_h_niceng130er.appi.tab32_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab32_1_1_1_1" id="hd_b_niceng130er.appi.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref31" rid="niceng130er.appe.s1.1.ref31">Sandborn et al. (2012)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab32_1_1_1_2 hd_b_niceng130er.appi.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_3 hd_b_niceng130er.appi.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4/56</td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_4 hd_b_niceng130er.appi.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_5 hd_b_niceng130er.appi.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/40</td></tr><tr><th headers="hd_h_niceng130er.appi.tab32_1_1_1_1" id="hd_b_niceng130er.appi.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref1" rid="niceng130er.appe.s1.2.ref1">Travis S et al. (2013)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab32_1_1_1_2 hd_b_niceng130er.appi.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_3 hd_b_niceng130er.appi.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4/31</td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_4 hd_b_niceng130er.appi.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_5 hd_b_niceng130er.appi.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/20</td></tr><tr><th headers="hd_h_niceng130er.appi.tab32_1_1_1_1" id="hd_b_niceng130er.appi.tab32_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.2.ref9" rid="niceng130er.appe.s1.2.ref9">Probert et al. (2014)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab32_1_1_1_2 hd_b_niceng130er.appi.tab32_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25/57</td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_3 hd_b_niceng130er.appi.tab32_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_4 hd_b_niceng130er.appi.tab32_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">37/58</td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_5 hd_b_niceng130er.appi.tab32_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab32_1_1_1_1" id="hd_b_niceng130er.appi.tab32_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref13" rid="niceng130er.appe.s1.1.ref13">Gross et al. (2011)</a>
|
|
</th><td headers="hd_h_niceng130er.appi.tab32_1_1_1_2 hd_b_niceng130er.appi.tab32_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19/32</td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_3 hd_b_niceng130er.appi.tab32_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14/37</td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_4 hd_b_niceng130er.appi.tab32_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab32_1_1_1_5 hd_b_niceng130er.appi.tab32_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab33"><div id="niceng130er.appi.tab33" class="table"><h3><span class="label">Table 43</span><span class="title">Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab33/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab33_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_niceng130er.appi.tab33_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab33_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">budesonide - oral</th><th id="hd_h_niceng130er.appi.tab33_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">high-dose aminosalicylate - oral asa and topical asa</th><th id="hd_h_niceng130er.appi.tab33_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab33_1_1_1_1" id="hd_b_niceng130er.appi.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab33_1_1_1_2 hd_b_niceng130er.appi.tab33_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_3 hd_b_niceng130er.appi.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.42</p>
|
|
<p>(0.16, 1.10)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_4 hd_b_niceng130er.appi.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.26</p>
|
|
<p>(1.07, 4.77)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_5 hd_b_niceng130er.appi.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab33_1_1_1_1" id="hd_b_niceng130er.appi.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">budesonide - oral</th><td headers="hd_h_niceng130er.appi.tab33_1_1_1_2 hd_b_niceng130er.appi.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.41</p>
|
|
<p>(0.15, 1.09)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_3 hd_b_niceng130er.appi.tab33_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_4 hd_b_niceng130er.appi.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_5 hd_b_niceng130er.appi.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.40</p>
|
|
<p>(0.09, 1.70)</p>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appi.tab33_1_1_1_1" id="hd_b_niceng130er.appi.tab33_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral asa and topical asa</th><td headers="hd_h_niceng130er.appi.tab33_1_1_1_2 hd_b_niceng130er.appi.tab33_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.29</p>
|
|
<p>(1.10, 4.95)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_3 hd_b_niceng130er.appi.tab33_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>5.66</p>
|
|
<p>(1.65, 19.91)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_4 hd_b_niceng130er.appi.tab33_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_5 hd_b_niceng130er.appi.tab33_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">-</td></tr><tr><th headers="hd_h_niceng130er.appi.tab33_1_1_1_1" id="hd_b_niceng130er.appi.tab33_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th><td headers="hd_h_niceng130er.appi.tab33_1_1_1_2 hd_b_niceng130er.appi.tab33_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.12</p>
|
|
<p>(0.01, 0.72)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_3 hd_b_niceng130er.appi.tab33_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.29</p>
|
|
<p>(0.04, 1.32)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_4 hd_b_niceng130er.appi.tab33_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.05</p>
|
|
<p>(0.00, 0.37)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab33_1_1_1_5 hd_b_niceng130er.appi.tab33_1_1_4_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are odds ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells gives pooled direct evidence from fixed-effect pairwise meta-analysis, where available (column versus row). Numbers in parentheses are 95% confidence intervals. ORs lower than 1 favour the row defining treatment, ORs higher than 1 favour the column defining treatment.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig24"><div id="niceng130er.appi.fig24" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2031.%20Extensive%20disease%20in%20adults%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20relative%20effect%20of%20all%20options%20versus%20reference%20option.&p=BOOKS&id=576848_niceng130erappif23.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif23.jpg" alt="Figure 31. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 31</span><span class="title">Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3><div class="caption"><p>Values less than 1 favour high-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Solid error bars are 95% credible intervals; dashed error bars are 95% confidence intervals.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab34"><div id="niceng130er.appi.tab34" class="table"><h3><span class="label">Table 44</span><span class="title">Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab34/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab34_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab34_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab34_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probability best</th><th id="hd_h_niceng130er.appi.tab34_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab34_1_1_1_1" id="hd_b_niceng130er.appi.tab34_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab34_1_1_1_2 hd_b_niceng130er.appi.tab34_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.013</td><td headers="hd_h_niceng130er.appi.tab34_1_1_1_3 hd_b_niceng130er.appi.tab34_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (2, 3)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab34_1_1_1_1" id="hd_b_niceng130er.appi.tab34_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - oral</th><td headers="hd_h_niceng130er.appi.tab34_1_1_1_2 hd_b_niceng130er.appi.tab34_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002</td><td headers="hd_h_niceng130er.appi.tab34_1_1_1_3 hd_b_niceng130er.appi.tab34_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (2, 4)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab34_1_1_1_1" id="hd_b_niceng130er.appi.tab34_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral asa and topical asa</th><td headers="hd_h_niceng130er.appi.tab34_1_1_1_2 hd_b_niceng130er.appi.tab34_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.983</td><td headers="hd_h_niceng130er.appi.tab34_1_1_1_3 hd_b_niceng130er.appi.tab34_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 (1, 1)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab34_1_1_1_1" id="hd_b_niceng130er.appi.tab34_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab34_1_1_1_2 hd_b_niceng130er.appi.tab34_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.001</td><td headers="hd_h_niceng130er.appi.tab34_1_1_1_3 hd_b_niceng130er.appi.tab34_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 (3, 4)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig25"><div id="niceng130er.appi.fig25" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2032.%20Extensive%20disease%20in%20adults%3B%20clinical%20remission%20at%205%020138%20weeks%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20rank%20probability%20histograms.&p=BOOKS&id=576848_niceng130erappif24.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif24.jpg" alt="Figure 32. Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 32</span><span class="title">Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – rank probability histograms</span></h3><div class="caption"><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab35"><div id="niceng130er.appi.tab35" class="table"><h3><span class="label">Table 45</span><span class="title">Extensive disease in adults; clinical remission at 5–8 weeks; mode, dose and class; fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab35/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab35_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab35_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab35_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dbar</th><th id="hd_h_niceng130er.appi.tab35_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dhat</th><th id="hd_h_niceng130er.appi.tab35_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">pD</th><th id="hd_h_niceng130er.appi.tab35_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab35_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>9.486</p>
|
|
<p>(compared to 8 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab35_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35.214</td><td headers="hd_h_niceng130er.appi.tab35_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">28.303</td><td headers="hd_h_niceng130er.appi.tab35_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6.911</td><td headers="hd_h_niceng130er.appi.tab35_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">42.125</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig26"><div id="niceng130er.appi.fig26" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2033.%20All%20extents%3A%20rate%20of%20withdrawal%20due%20to%20adverse%20events%3B%20mode%2C%20dose%20and%20class%20%02013%20evidence%20network.&p=BOOKS&id=576848_niceng130erappif25.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif25.jpg" alt="Figure 33. All extents: rate of withdrawal due to adverse events; mode, dose and class – evidence network." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 33</span><span class="title">All extents: rate of withdrawal due to adverse events; mode, dose and class – evidence network</span></h3><div class="caption"><p>Size of nodes is proportional to total number of participants randomised to receive the treatment in question across the evidence-base. Width of connecting lines is proportional to number of trial-level comparisons available. Direction and strength of effect in pairwise data is not depicted, as there is no simple way to provide a pairwise frequentist estimate of effect for this (complementary log–log) model.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab36"><div id="niceng130er.appi.tab36" class="table"><h3><span class="label">Table 46</span><span class="title">All extents: rate of withdrawal due to adverse events; mode, dose and class – input data</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab36/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab36_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab36_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab36_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">beclometasone - oral</th><th id="hd_h_niceng130er.appi.tab36_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - oral</th><th id="hd_h_niceng130er.appi.tab36_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - topical</th><th id="hd_h_niceng130er.appi.tab36_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab36_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral asa and topical asa</th><th id="hd_h_niceng130er.appi.tab36_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab36_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose oral aminosalicylate + oral corticosteroid</th><th id="hd_h_niceng130er.appi.tab36_1_1_1_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref6" rid="niceng130er.appe.s1.1.ref6">Campieri et al. (2003)</a> - 0.08yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/80</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/90</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref7" rid="niceng130er.appe.s1.1.ref7">Connolly et al. (2009)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11/56</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9/71</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref9" rid="niceng130er.appe.s1.1.ref9">DICK A et al. (1964)</a> - 0.08yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/21</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/23</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref3" rid="niceng130er.appe.s1.2.ref3">Feagan et al. (2013)</a> - 0.19yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12/140</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_4_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">30/141</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref10" rid="niceng130er.appe.s1.1.ref10">Feurle et al. (1989)</a> - 0.08yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3/52</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/53</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref14" rid="niceng130er.appe.s1.1.ref14">Hanauer et al. (1993)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14/189</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7/95</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_6_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11/90</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref16" rid="niceng130er.appe.s1.1.ref16">Hanauer et al. (2005)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4/139</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4/129</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s4.1.ref22" rid="niceng130er.appe.s4.1.ref22">Hanauer et al. (2007)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8/154</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5/147</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_8_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref17" rid="niceng130er.appe.s1.1.ref17">Hetzel et al. (1986)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/15</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4/15</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref19" rid="niceng130er.appe.s1.1.ref19">Ito et al. (2010)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10/196</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_10_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/33</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref20" rid="niceng130er.appe.s1.1.ref20">Kamm et al. (2007)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/170</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/85</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/86</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref24" rid="niceng130er.appe.s1.1.ref24">Levine et al. (2002)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10/101</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/53</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_12_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref5" rid="niceng130er.appe.s1.2.ref5">Naganuma et al. (2016)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/111</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/54</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref6" rid="niceng130er.appe.s1.2.ref6">Naganuma et al. (2017)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4/64</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_14_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/62</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref7" rid="niceng130er.appe.s1.2.ref7">Ogata et al. (2017)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">17/140</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8/140</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref27" rid="niceng130er.appe.s1.1.ref27">Pokrotnieks et al. (2000)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/54</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_16_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/57</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref28" rid="niceng130er.appe.s1.1.ref28">Pruitt et al. (2002)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6/89</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3/84</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref29" rid="niceng130er.appe.s1.1.ref29">Rizzello et al. (2002)</a> - 0.08yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3/61</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/58</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_18_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref10" rid="niceng130er.appe.s1.2.ref10">Rubin David et al. (2017)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12/255</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9/255</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref30" rid="niceng130er.appe.s1.1.ref30">Sandborn et al. (2009)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15/383</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15/389</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_20_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref31" rid="niceng130er.appe.s1.1.ref31">Sandborn et al. (2012)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7/124</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6/127</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10/129</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref11" rid="niceng130er.appe.s1.2.ref11">Sandborn et al. (2015)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">26/268</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_22_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12/278</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref32" rid="niceng130er.appe.s1.1.ref32">Scherl et al. (2009)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15/166</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10/83</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s4.1.ref50" rid="niceng130er.appe.s4.1.ref50">Schroeder et al. (1987)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/11</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/38</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_24_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/38</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.1.ref33" rid="niceng130er.appe.s1.1.ref33">Sninsky et al. (1991)</a> - 0.11yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/106</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/52</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref12" rid="niceng130er.appe.s1.2.ref12">Suzuki et al. (2016)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/55</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/55</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_26_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref1" rid="niceng130er.appe.s1.2.ref1">Travis S et al. (2013)</a> - 0.15yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/127</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1/128</td></tr><tr><th headers="hd_h_niceng130er.appi.tab36_1_1_1_1" id="hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="bibr" href="#niceng130er.appe.s1.2.ref14" rid="niceng130er.appe.s1.2.ref14">Watanabe et al. (2013)</a> - 0.08yr</th><td headers="hd_h_niceng130er.appi.tab36_1_1_1_2 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_3 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_4 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_5 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_6 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_7 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_8 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0/65</td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_9 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"></td><td headers="hd_h_niceng130er.appi.tab36_1_1_1_10 hd_b_niceng130er.appi.tab36_1_1_28_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2/64</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab37"><div id="niceng130er.appi.tab37" class="table"><h3><span class="label">Table 47</span><span class="title">All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – relative effectiveness of all pairwise combinations</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab37/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab37_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_niceng130er.appi.tab37_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">low-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab37_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">beclometasone - oral</th><th id="hd_h_niceng130er.appi.tab37_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">budesonide - oral</th><th id="hd_h_niceng130er.appi.tab37_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">budesonide - topical</th><th id="hd_h_niceng130er.appi.tab37_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">high-dose aminosalicylate - oral</th><th id="hd_h_niceng130er.appi.tab37_1_1_1_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">high-dose aminosalicylate - oral asa and topical asa</th><th id="hd_h_niceng130er.appi.tab37_1_1_1_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">aminosalicylate - topical</th><th id="hd_h_niceng130er.appi.tab37_1_1_1_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">low-dose oral aminosalicylate + oral corticosteroid</th><th id="hd_h_niceng130er.appi.tab37_1_1_1_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">placebo</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">beclometasone - oral</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>4.58</p>
|
|
<p>(0.15, 2590.00)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">budesonide - oral</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.11</p>
|
|
<p>(0.57, 2.16)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.24</p>
|
|
<p>(0.00, 7.92)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">budesonide - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.22</p>
|
|
<p>(1.10, 4.57)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.48</p>
|
|
<p>(0.00, 15.95)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.99</p>
|
|
<p>(0.86, 4.73)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.62</p>
|
|
<p>(0.44, 0.86)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.13</p>
|
|
<p>(0.00, 4.28)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.55</p>
|
|
<p>(0.28, 1.09)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.28</p>
|
|
<p>(0.14, 0.56)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">high-dose aminosalicylate - oral asa and topical asa</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.38</p>
|
|
<p>(0.14, 0.98)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.08</p>
|
|
<p>(0.00, 2.95)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.34</p>
|
|
<p>(0.11, 1.04)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.17</p>
|
|
<p>(0.05, 0.53)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.62</p>
|
|
<p>(0.24, 1.50)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.41</p>
|
|
<p>(0.03, 2.91)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.08</p>
|
|
<p>(0.00, 4.78)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.37</p>
|
|
<p>(0.03, 2.85)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.19</p>
|
|
<p>(0.01, 1.39)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.67</p>
|
|
<p>(0.05, 4.74)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.08</p>
|
|
<p>(0.07, 9.61)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">low-dose oral aminosalicylate + oral corticosteroid</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.27</p>
|
|
<p>(0.01, 2.52)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.05</p>
|
|
<p>(0.00, 3.56)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.24</p>
|
|
<p>(0.01, 2.58)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.12</p>
|
|
<p>(0.00, 1.29)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.43</p>
|
|
<p>(0.01, 4.22)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.70</p>
|
|
<p>(0.02, 8.01)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.64</p>
|
|
<p>(0.01, 19.13)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><th headers="hd_h_niceng130er.appi.tab37_1_1_1_1" id="hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">placebo</th><td headers="hd_h_niceng130er.appi.tab37_1_1_1_2 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.12</p>
|
|
<p>(0.77, 1.64)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_3 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.24</p>
|
|
<p>(0.00, 7.71)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_4 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.00</p>
|
|
<p>(0.56, 1.85)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_5 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>0.51</p>
|
|
<p>(0.27, 0.91)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_6 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>1.81</p>
|
|
<p>(1.26, 2.63)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_7 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.96</p>
|
|
<p>(1.12, 8.10)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_8 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>2.69</p>
|
|
<p>(0.40, 34.80)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_9 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>4.21</p>
|
|
<p>(0.43, 136.10)<sup>*</sup></p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab37_1_1_1_10 hd_b_niceng130er.appi.tab37_1_1_9_1" rowspan="1" colspan="1" style="background-color:#cccccc;text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Values given are hazard ratios.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">The segment below and to the left of the shaded cells are posterior median odds ratios and 95% CIs derived from the network meta-analysis, reflecting direct and indirect evidence of treatment effects (row versus column). The point estimate reflects the median odds ratios of the posterior distribution, and numbers in parentheses are 95% credible intervals. ORs lower than 1 favour the column defining treatment, ORs higher than 1 favour the row defining treatment. The segment above and to the right of the shaded cells is blank, as there is no simple way to provide a pairwise frequentist estimate of effect for this (complementary log–log) model.</p></div></dd></dl><dl class="bkr_refwrap"><dt>*</dt><dd><div id="niceng130er.appi.tab37_1"><p class="no_margin">One trial (<a class="bibr" href="#niceng130er.appe.s1.1.ref29" rid="niceng130er.appe.s1.1.ref29">Rizzello 2002</a>) contributed to wide credible intervals as it was the only trial contributing data for low-dose oral ASA + oral corticosteroid and due to its small sample and low event rate.</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erappifig27"><div id="niceng130er.appi.fig27" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2034.%20All%20extents%3A%20rate%20of%20withdrawal%20due%20to%20adverse%20events%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effect%20%02013%20relative%20effect%20of%20all%20options%20versus%20reference%20option.&p=BOOKS&id=576848_niceng130erappif26.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif26.jpg" alt="Figure 34. All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – relative effect of all options versus reference option." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 34</span><span class="title">All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – relative effect of all options versus reference option</span></h3><div class="caption"><p>Values less than 1 favour low-dose oral aminosalicylates; values greater than 1 favour the comparator treatment. Error bars are 95% credible intervals.</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab38"><div id="niceng130er.appi.tab38" class="table"><h3><span class="label">Table 48</span><span class="title">All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – rankings for each comparator</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab38/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab38_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab38_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng130er.appi.tab38_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Probability best</th><th id="hd_h_niceng130er.appi.tab38_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Median rank (95%CI)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 (4, 8)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">beclometasone - oral</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.036</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 (1, 9)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - oral</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.001</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (3, 8)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budesonide - topical (foam)</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 (7, 9)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.011</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 (2, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">high-dose aminosalicylate - oral asa and topical asa</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.208</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (1, 5)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aminosalicylate - topical</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.279</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (1, 8)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">low-dose oral aminosalicylate + oral corticosteroid</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.465</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 (1, 8)</td></tr><tr><th headers="hd_h_niceng130er.appi.tab38_1_1_1_1" id="hd_b_niceng130er.appi.tab38_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo</th><td headers="hd_h_niceng130er.appi.tab38_1_1_1_2 hd_b_niceng130er.appi.tab38_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.000</td><td headers="hd_h_niceng130er.appi.tab38_1_1_1_3 hd_b_niceng130er.appi.tab38_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 (4, 8)</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappifig28"><div id="niceng130er.appi.fig28" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2035.%20All%20extents%3A%20rate%20of%20withdrawal%20due%20to%20adverse%20events%3B%20mode%2C%20dose%20and%20class%3B%20fixed-effectfixed-effect%20%02013%20rank%20probability%20histograms.&p=BOOKS&id=576848_niceng130erappif27.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappif27.jpg" alt="Figure 35. All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effectfixed-effect – rank probability histograms." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 35</span><span class="title">All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effectfixed-effect – rank probability histograms</span></h3><div class="caption"><p>Histograms show probability that each treatment is ranked in each position relative to the other treatments in the network. Rank 1 always refects whatever is desirable (a high probability of good outcomes or a low probability of bad outcomes).</p></div></div></article><article data-type="table-wrap" id="figobniceng130erappitab39"><div id="niceng130er.appi.tab39" class="table"><h3><span class="label">Table 49</span><span class="title">All extents: rate of withdrawal due to adverse events; mode, dose and class; fixed-effect – model fit statistics</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appi.tab39/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appi.tab39_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appi.tab39_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Residual deviance</th><th id="hd_h_niceng130er.appi.tab39_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dbar</th><th id="hd_h_niceng130er.appi.tab39_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dhat</th><th id="hd_h_niceng130er.appi.tab39_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">pD</th><th id="hd_h_niceng130er.appi.tab39_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DIC</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appi.tab39_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>68.99</p>
|
|
<p>(compared to 67 datapoints)</p>
|
|
</td><td headers="hd_h_niceng130er.appi.tab39_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">269.107</td><td headers="hd_h_niceng130er.appi.tab39_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">234.236</td><td headers="hd_h_niceng130er.appi.tab39_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">34.87</td><td headers="hd_h_niceng130er.appi.tab39_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">303.977</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erappjfig1"><div id="niceng130er.appj.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=*The%20de%20novo%20economic%20model%20conducted%20in%20the%202013%20guideline%20was%20reviewed%20in%20addition%20to%20the%20studies%20identified%20through%20the%20search%20of%20the%20published%20literature&p=BOOKS&id=576848_niceng130erappjf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erappjf1.jpg" alt="*The de novo economic model conducted in the 2013 guideline was reviewed in addition to the studies identified through the search of the published literature" class="tileshop" title="Click on image to zoom" /></a></div><div class="caption"><p>*The de novo economic model conducted in the 2013 guideline was reviewed in addition to the studies identified through the search of the published literature.</p></div></div></article><article data-type="fig" id="figobniceng130erapplfig1"><div id="niceng130er.appl.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2036.%20Structure%20of%20the%20decision%20tree%20for%20a%20single%20sequence%20of%20treatments.&p=BOOKS&id=576848_niceng130erapplf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf1.jpg" alt="Figure 36. Structure of the decision tree for a single sequence of treatments." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 36</span><span class="title">Structure of the decision tree for a single sequence of treatments</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab1"><div id="niceng130er.appl.tab1" class="table"><h3><span class="label">Table 50</span><span class="title">Treatment sequences for proctitis</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab1_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab1_1_1_1_1" style="text-align:left;vertical-align:bottom;">Strategy</th><th id="hd_h_niceng130er.appl.tab1_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab1_1_1_1_2" style="text-align:left;vertical-align:bottom;">1st line</th><th id="hd_h_niceng130er.appl.tab1_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Following non-remission</th><th id="hd_h_niceng130er.appl.tab1_1_1_1_4" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Following withdrawal</th></tr><tr><th headers="hd_h_niceng130er.appl.tab1_1_1_1_3" id="hd_h_niceng130er.appl.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab1_1_1_1_3" id="hd_h_niceng130er.appl.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th><th headers="hd_h_niceng130er.appl.tab1_1_1_1_3" id="hd_h_niceng130er.appl.tab1_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4th line</th><th headers="hd_h_niceng130er.appl.tab1_1_1_1_4" id="hd_h_niceng130er.appl.tab1_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab1_1_1_1_4" id="hd_h_niceng130er.appl.tab1_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th><th headers="hd_h_niceng130er.appl.tab1_1_1_1_4" id="hd_h_niceng130er.appl.tab1_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4th line</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_h_niceng130er.appl.tab1_1_1_1_2 hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_h_niceng130er.appl.tab1_1_1_2_6" id="hd_b_niceng130er.appl.tab1_1_1_1_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">PRC1 – PRC4: Start with topical ASA, add low-dose oral ASA, keep low-dose oral ASA and add topical or oral corticosteroid, topical tacrolimus</th></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC1</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC2</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC3</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC4</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><th headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_h_niceng130er.appl.tab1_1_1_1_2 hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_h_niceng130er.appl.tab1_1_1_2_6" id="hd_b_niceng130er.appl.tab1_1_1_6_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">PRC5 – PRC8: Start with low-dose oral ASA, add topical ASA, keep low-dose oral ASA and add topical or oral corticosteroid, topical tacrolimus</th></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC5</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC6</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC7</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC8</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><th headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_h_niceng130er.appl.tab1_1_1_1_2 hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_h_niceng130er.appl.tab1_1_1_2_6" id="hd_b_niceng130er.appl.tab1_1_1_11_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">PRC9 – PRC16: Start with combination low-dose oral and topical ASA, keep low-dose oral ASA and add topical or oral corticosteroid, topical tacrolimus</th></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC9</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC10</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC11</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC12</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC13</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC14</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC15</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC16</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tTAC</td></tr><tr><th headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_h_niceng130er.appl.tab1_1_1_1_2 hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_h_niceng130er.appl.tab1_1_1_2_6" id="hd_b_niceng130er.appl.tab1_1_1_20_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">PRC17 – PRC20: Start with topical ASA, add low-dose oral ASA, keep low-dose oral ASA and add topical or oral corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC17</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC18</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC19</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC20</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><th headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_h_niceng130er.appl.tab1_1_1_1_2 hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_h_niceng130er.appl.tab1_1_1_2_6" id="hd_b_niceng130er.appl.tab1_1_1_25_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">PRC21 – PRC24: Start with low-dose oral ASA, add topical ASA, keep low-dose oral ASA and add topical or oral corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC21</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC22</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC23</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC24</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><th headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_h_niceng130er.appl.tab1_1_1_1_2 hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_h_niceng130er.appl.tab1_1_1_2_6" id="hd_b_niceng130er.appl.tab1_1_1_30_1" colspan="8" rowspan="1" style="text-align:left;vertical-align:top;">PRC25 – PRC32: Start with combination low-dose oral and topical ASA, keep low-dose oral ASA and add topical or oral corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC25</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC26</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC27</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC28</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC29</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC30</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC31</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab1_1_1_1_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC32</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_1 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_2 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_3 hd_h_niceng130er.appl.tab1_1_1_2_3 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_4 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_5 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab1_1_1_1_4 hd_h_niceng130er.appl.tab1_1_1_2_6 hd_b_niceng130er.appl.tab1_1_1_30_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PRC = proctitis; LD = low-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; tTAC = topical tacrolimus</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab2"><div id="niceng130er.appl.tab2" class="table"><h3><span class="label">Table 51</span><span class="title">Treatment sequences for proctosigmoiditis and left-sided disease</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab2_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab2_1_1_1_1" style="text-align:left;vertical-align:bottom;">Strategy</th><th id="hd_h_niceng130er.appl.tab2_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab2_1_1_1_2" style="text-align:left;vertical-align:bottom;">1st line</th><th id="hd_h_niceng130er.appl.tab2_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Following non-remission</th><th id="hd_h_niceng130er.appl.tab2_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Following withdrawal</th></tr><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_3" id="hd_h_niceng130er.appl.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab2_1_1_1_3" id="hd_h_niceng130er.appl.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th><th headers="hd_h_niceng130er.appl.tab2_1_1_1_4" id="hd_h_niceng130er.appl.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab2_1_1_1_4" id="hd_h_niceng130er.appl.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_h_niceng130er.appl.tab2_1_1_1_2 hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_h_niceng130er.appl.tab2_1_1_2_4" id="hd_b_niceng130er.appl.tab2_1_1_1_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">PLS1 – PLS12: Start with low-dose oral ASA, increase to high-dose oral ASA, keep low-dose oral ASA and add oral or topical corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS1</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS2</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS3</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS4</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS5</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS6</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS7</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS8</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS9</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS10</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS11</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS12</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_h_niceng130er.appl.tab2_1_1_1_2 hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_h_niceng130er.appl.tab2_1_1_2_4" id="hd_b_niceng130er.appl.tab2_1_1_14_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">PLS13 – PLS24: Start with low-dose oral ASA, add topical ASA, keep low-dose oral ASA and add oral or topical corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS13</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS14</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS15</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS16</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS17</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS18</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS19</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS20</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS21</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS22</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS23</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS24</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_h_niceng130er.appl.tab2_1_1_1_2 hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_h_niceng130er.appl.tab2_1_1_2_4" id="hd_b_niceng130er.appl.tab2_1_1_27_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">PLS25 – PLS30: Start with high-dose oral ASA, add topical ASA, keep low-dose oral ASA and add oral or topical corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS25</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS26</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS27</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS28</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS29</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS30</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_h_niceng130er.appl.tab2_1_1_1_2 hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_h_niceng130er.appl.tab2_1_1_2_4" id="hd_b_niceng130er.appl.tab2_1_1_34_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">PLS31 – PLS36: Start with topical ASA, add low-dose oral ASA, keep low-dose oral ASA and add oral or topical corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS31</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS32</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS33</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS34</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS35</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS36</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_34_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_h_niceng130er.appl.tab2_1_1_1_2 hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_h_niceng130er.appl.tab2_1_1_2_4" id="hd_b_niceng130er.appl.tab2_1_1_41_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">PLS37 – PLS48: Start with combination low-dose oral and topical ASA, keep low-dose oral ASA and add oral or topical corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS37</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS38</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS39</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS40</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS41</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS42</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS43</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS44</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS45</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS46</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS47</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS48</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_h_niceng130er.appl.tab2_1_1_1_2 hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_h_niceng130er.appl.tab2_1_1_2_4" id="hd_b_niceng130er.appl.tab2_1_1_54_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">PLS49 – PLS57: Start with topical corticosteroid, switch to low-dose oral ASA, keep low-dose oral ASA and add oral corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS49</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS50</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS51</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS52</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS53</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS54</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS55</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS56</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS57</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_h_niceng130er.appl.tab2_1_1_1_2 hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_h_niceng130er.appl.tab2_1_1_2_4" id="hd_b_niceng130er.appl.tab2_1_1_64_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">PLS58 – PLS66: Start with topical corticosteroid, switch to high-dose oral ASA, keep low-dose oral ASA and add oral corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS58</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS59</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS60</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS61</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS62</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS63</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS64</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS65</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS66</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_64_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_h_niceng130er.appl.tab2_1_1_1_2 hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_h_niceng130er.appl.tab2_1_1_2_4" id="hd_b_niceng130er.appl.tab2_1_1_74_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">PLS67 – PLS75: Start with topical corticosteroid, switch to combination low-dose oral and topical ASA, keep low-dose oral ASA and add oral corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS67</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS68</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS69</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS70</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS71</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS72</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS73</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS74</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab2_1_1_1_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS75</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_1 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_3 hd_h_niceng130er.appl.tab2_1_1_2_2 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_3 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab2_1_1_1_4 hd_h_niceng130er.appl.tab2_1_1_2_4 hd_b_niceng130er.appl.tab2_1_1_74_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PLS = proctosigmoiditis and left-sided disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; hydro = hydrocortisone</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab3"><div id="niceng130er.appl.tab3" class="table"><h3><span class="label">Table 52</span><span class="title">Treatment sequences for extensive disease</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab3_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab3_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab3_1_1_1_1" style="text-align:left;vertical-align:bottom;">Strategy</th><th id="hd_h_niceng130er.appl.tab3_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab3_1_1_1_2" style="text-align:left;vertical-align:bottom;">1st line</th><th id="hd_h_niceng130er.appl.tab3_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Following non-remission</th><th id="hd_h_niceng130er.appl.tab3_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Following withdrawal</th></tr><tr><th headers="hd_h_niceng130er.appl.tab3_1_1_1_3" id="hd_h_niceng130er.appl.tab3_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab3_1_1_1_3" id="hd_h_niceng130er.appl.tab3_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th><th headers="hd_h_niceng130er.appl.tab3_1_1_1_4" id="hd_h_niceng130er.appl.tab3_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab3_1_1_1_4" id="hd_h_niceng130er.appl.tab3_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appl.tab3_1_1_1_1 hd_h_niceng130er.appl.tab3_1_1_1_2 hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_1 hd_h_niceng130er.appl.tab3_1_1_2_2 hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_3 hd_h_niceng130er.appl.tab3_1_1_2_4" id="hd_b_niceng130er.appl.tab3_1_1_1_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">EXT1 – EXT3: Start with high-dose oral ASA, add topical ASA, keep low-dose oral ASA and add oral corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab3_1_1_1_1 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT1</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_2 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_1 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_2 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_3 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_4 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab3_1_1_1_1 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT2</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_2 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_1 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_2 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_3 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_4 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab3_1_1_1_1 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT3</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_2 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_1 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_2 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_3 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_4 hd_b_niceng130er.appl.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab3_1_1_1_1 hd_h_niceng130er.appl.tab3_1_1_1_2 hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_1 hd_h_niceng130er.appl.tab3_1_1_2_2 hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_3 hd_h_niceng130er.appl.tab3_1_1_2_4" id="hd_b_niceng130er.appl.tab3_1_1_5_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">EXT4 – EXT6: Start with combination high-dose oral and topical ASA, keep low-dose oral ASA and add oral corticosteroid</th></tr><tr><td headers="hd_h_niceng130er.appl.tab3_1_1_1_1 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT4</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_2 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_1 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_2 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_3 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_4 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab3_1_1_1_1 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT5</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_2 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_1 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_2 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_3 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_4 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr><tr><td headers="hd_h_niceng130er.appl.tab3_1_1_1_1 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT6</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_2 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_1 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_3 hd_h_niceng130er.appl.tab3_1_1_2_2 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_3 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab3_1_1_1_4 hd_h_niceng130er.appl.tab3_1_1_2_4 hd_b_niceng130er.appl.tab3_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">EXT = extensive disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; hydro = hydrocortisone</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab4"><div id="niceng130er.appl.tab4" class="table"><h3><span class="label">Table 53</span><span class="title">Treatment duration assumptions in the base-case cost-effectiveness analyses</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab4_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment</th><th id="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab4_1_1_1_2" style="text-align:left;vertical-align:bottom;">Duration of follow-up in RCTs (weeks)</th><th id="hd_h_niceng130er.appl.tab4_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Treatment duration assumed in model (base case)</th></tr><tr><th headers="hd_h_niceng130er.appl.tab4_1_1_1_3" id="hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Remission</th><th headers="hd_h_niceng130er.appl.tab4_1_1_1_3" id="hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Non-remission</th><th headers="hd_h_niceng130er.appl.tab4_1_1_1_3" id="hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Withdrawal</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4-8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8-10</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2-6</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (beclo) + LD oASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2-4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude) ± LD oASA<sup>(a)</sup></td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6-8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro) ± LD oASA<sup>(a)</sup></td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td></tr><tr><td headers="hd_h_niceng130er.appl.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Topical tacrolimus</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng130er.appl.tab4_1_1_1_3 hd_h_niceng130er.appl.tab4_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; hydro = hydrocortisone</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab4_1"><p class="no_margin">Omitted from base-case analysis in proctosigmoiditis and left-sided disease because treatment duration in RCTs exceeded committee assumption about treatment duration in clinical practice</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab5"><div id="niceng130er.appl.tab5" class="table"><h3><span class="label">Table 54</span><span class="title">Baseline log-rate for withdrawal and log-odds of remission</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Reference treatment</th><th id="hd_h_niceng130er.appl.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Network</th><th id="hd_h_niceng130er.appl.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ln(rate) (SE)</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Withdrawal all extents and time points</td><td headers="hd_h_niceng130er.appl.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.806 (0.104)</td></tr></tbody></table><table><thead><tr><th id="hd_h_niceng130er.appl.tab5_1_2_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Reference treatment</th><th id="hd_h_niceng130er.appl.tab5_1_2_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Network</th><th id="hd_h_niceng130er.appl.tab5_1_2_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ln(odds) (SE)</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab5_1_2_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remission proctitis (0-4 weeks)</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.348 (0.377)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab5_1_2_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remission proctitis (5-8 weeks)</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.635 (0.151)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab5_1_2_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remission proctosigmoiditis and left-sided (0-4 weeks)</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−1.169 (0.100)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab5_1_2_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remission proctosigmoiditis and left-sided (5-8 weeks)</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.592 (0.057)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab5_1_2_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remission extensive (0-4 weeks)</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.220 (0.325)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab5_1_2_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remission extensive (5-8 weeks)</td><td headers="hd_h_niceng130er.appl.tab5_1_2_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.019 (0.208)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab6"><div id="niceng130er.appl.tab6" class="table"><h3><span class="label">Table 55</span><span class="title">Absolute probabilities of withdrawal due to adverse events and remission and non-remission conditional on non-withdrawal</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Treatment</th><th id="hd_h_niceng130er.appl.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Probability withdrawal</th><th id="hd_h_niceng130er.appl.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Probability remission</th><th id="hd_h_niceng130er.appl.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Probability nonremission</th><th id="hd_h_niceng130er.appl.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Evidence network (remission relative effect)</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_h_niceng130er.appl.tab6_1_1_1_2 hd_h_niceng130er.appl.tab6_1_1_1_3 hd_h_niceng130er.appl.tab6_1_1_1_4 hd_h_niceng130er.appl.tab6_1_1_1_5" id="hd_b_niceng130er.appl.tab6_1_1_1_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Extensive disease</th></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.1%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.5%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.3%<sup>(a)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.1%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.5%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%<sup>(b)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.8%<sup>(c)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.5%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (beclo) + LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.9%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><th headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_h_niceng130er.appl.tab6_1_1_1_2 hd_h_niceng130er.appl.tab6_1_1_1_3 hd_h_niceng130er.appl.tab6_1_1_1_4 hd_h_niceng130er.appl.tab6_1_1_1_5" id="hd_b_niceng130er.appl.tab6_1_1_8_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Proctosigmoiditis and left-sided disease</th></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.7%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.0%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.2%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.1%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.7%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.2%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%<sup>(b)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.5%<sup>(c</sup><sup>,</sup><sup>d)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.7%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (beclo) + LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.9%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.7%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.7%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.5%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%<sup>(e)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.0%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude) ± LD oASA<sup>(f)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.1%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.5%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro) ± LD oASA<sup>(f)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.4%<sup>(e)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.1%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.5%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><th headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_h_niceng130er.appl.tab6_1_1_1_2 hd_h_niceng130er.appl.tab6_1_1_1_3 hd_h_niceng130er.appl.tab6_1_1_1_4 hd_h_niceng130er.appl.tab6_1_1_1_5" id="hd_b_niceng130er.appl.tab6_1_1_19_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Proctitis</th></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.7%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.8%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.6%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Topical tacrolimus</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.3%<sup>(g)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85.8%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.9%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.2%<sup>(h)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.5%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (pred) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%<sup>(b)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.2%<sup>(c</sup><sup>,</sup><sup>d)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.0%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (beclo) + LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.8%<sup>(h)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.8%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">oCS (bude) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.9%<sup>(h)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.3%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-8 weeks</td></tr><tr><td headers="hd_h_niceng130er.appl.tab6_1_1_1_1 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred) ± LD oASA</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_2 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%<sup>(e)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_3 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83.3%<sup>(h)</sup></td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_4 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.9%</td><td headers="hd_h_niceng130er.appl.tab6_1_1_1_5 hd_b_niceng130er.appl.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0-4 weeks</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; hydro = hydrocortisone</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab6_1"><p class="no_margin">In the absence of withdrawal data, assumed equivalent to LD oASA + tASA</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng130er.appl.tab6_2"><p class="no_margin">In the absence of withdrawal data, assumed equivalent to oCS (bude) ± LD oASA</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng130er.appl.tab6_3"><p class="no_margin">Relative effectiveness derived from earlier time point than specified duration in clinical practice</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng130er.appl.tab6_4"><p class="no_margin">Relative effectiveness derived from extensive disease (same timepoint, greater extent)</p></div></dd></dl><dl class="bkr_refwrap"><dt>(e)</dt><dd><div id="niceng130er.appl.tab6_5"><p class="no_margin">In the absence of withdrawal data, assumed equivalent to tCS (bude) ± LD oASA</p></div></dd></dl><dl class="bkr_refwrap"><dt>(f)</dt><dd><div id="niceng130er.appl.tab6_6"><p class="no_margin">Not included in base case analysis; only modelled in sensitivity analysis where duration of treatment is set to maximum duration across RCTs</p></div></dd></dl><dl class="bkr_refwrap"><dt>(g)</dt><dd><div id="niceng130er.appl.tab6_7"><p class="no_margin">In the absence of withdrawal data, assumed equivalent to tASA</p></div></dd></dl><dl class="bkr_refwrap"><dt>(h)</dt><dd><div id="niceng130er.appl.tab6_8"><p class="no_margin">Relative effectiveness derived from proctosigmoiditis and left-sided disease (same timepoint, greater extent)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab7"><div id="niceng130er.appl.tab7" class="table"><h3><span class="label">Table 56</span><span class="title">Health state utility values used in the cost-effectiveness model</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab7_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Health state</th><th id="hd_h_niceng130er.appl.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Source</th><th id="hd_h_niceng130er.appl.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Value</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mild to moderate disease</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole 2010</a>
|
|
</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.775</td></tr><tr><td headers="hd_h_niceng130er.appl.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remission</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole 2010</a>
|
|
</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.940</td></tr><tr><td headers="hd_h_niceng130er.appl.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severe relapse</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole 2010</a>
|
|
</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.660</td></tr><tr><td headers="hd_h_niceng130er.appl.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Disutility adverse events on oral ASAs</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s3.ref8" rid="niceng130er.appe.s3.ref8">Modi 2017</a>
|
|
</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.040</td></tr><tr><td headers="hd_h_niceng130er.appl.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Disutility adverse events on corticosteroids</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sullivan 2016</td><td headers="hd_h_niceng130er.appl.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.047</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab8"><div id="niceng130er.appl.tab8" class="table"><h3><span class="label">Table 57</span><span class="title">Weighted average cost per week for low-dose oral mesalazine</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab8_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Drug</th><th id="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Dose</th><th id="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost per week</th><th id="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Weighting</th><th id="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Weighted cost</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Asacol_MR Tab E/C 400mg</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.4g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£13.73</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.5%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2.96</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine_Tab E/C 400mg</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.4g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7.74</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.7%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.44</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mezavant XL_Tab G/R 1.2g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.4g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10.02</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.6%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.76</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Octasa_MR Tab E/C 400mg</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.4g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7.74</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.4%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.81</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa SR_Tab 500mg</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8.61</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.6%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2.21</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa_Gran Sach 1g M/R</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8.61</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.1%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.35</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa_Gran Sach 2g M/R</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8.61</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.9%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.25</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa_Tab 1g M/R</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8.61</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.6%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.48</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk_Gran Sach G/R 500mg M/R</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.5g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.04</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.7%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.04</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk_Gran Sach G/R 1.5g M/R</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.5g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5.70</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.9%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.11</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk_Tab G/R 500mg</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.5g</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.80</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.9%</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.06</td></tr><tr><td headers="hd_h_niceng130er.appl.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Weighted average cost per week</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab8_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£9.47</b>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab9"><div id="niceng130er.appl.tab9" class="table"><h3><span class="label">Table 58</span><span class="title">Weighted average cost per week for high-dose oral mesalazine</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab9_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Drug</th><th id="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dose</th><th id="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per week</th><th id="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Weighting</th><th id="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Weighted cost</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Asacol_MR Tab E/C 800mg</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£27.45</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.0%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7.68</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine_Tab E/C 800mg</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£18.84</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.7%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.89</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mezavant XL_Tab G/R 1.2g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£20.04</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.8%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2.76</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Octasa_MR Tab E/C 800mg</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£18.84</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.5%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5.75</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa_Gran Sach 2g M/R</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£17.22</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.3%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.92</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa_Gran Sach 4g M/R</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£17.22</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.8%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.14</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa_Tab 1g M/R</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£17.22</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.1%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.74</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk_Gran Sach G/R 1g M/R</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£12.07</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.1%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.37</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk_Gran Sach G/R 3g M/R</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3g</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£11.40</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.7%</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.42</td></tr><tr><td headers="hd_h_niceng130er.appl.tab9_1_1_1_1 hd_h_niceng130er.appl.tab9_1_1_1_2 hd_h_niceng130er.appl.tab9_1_1_1_3 hd_h_niceng130er.appl.tab9_1_1_1_4" colspan="4" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Weighted average cost per week</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab9_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£20.67</b>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab10"><div id="niceng130er.appl.tab10" class="table"><h3><span class="label">Table 59</span><span class="title">Weighted average cost per week for topical mesalazine (proctitis)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab10_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Drug</th><th id="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dose</th><th id="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per week</th><th id="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Weighting</th><th id="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Weighted cost</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Asacol Foam Aero Enem 1g/D</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£15.09</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.4%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.20</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Asacol Suppos 250mg</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.75</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.7%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.12</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Asacol Suppos 500mg</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.75</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.8%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.53</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine Enem 2g In 59ml</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£29.92</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.1%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.23</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine Foam Aero Enem 1g/D</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£15.09</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.1%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.22</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine Suppos 250mg</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.75</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.4%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.16</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine Suppos 500mg</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.75</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.8%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.73</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa Enem 1g In 100ml</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£17.73</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.5%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.97</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa Suppos 1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10.00</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.6%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3.57</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk Enem (2g/59ml)</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£29.92</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.0%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.81</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk Foam Aero Enem 1g/D</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£15.09</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.9%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.58</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk Suppos 1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10.00</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.6%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.16</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk Suppos 500mg</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.75</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.1%</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.07</td></tr><tr><td headers="hd_h_niceng130er.appl.tab10_1_1_1_1 hd_h_niceng130er.appl.tab10_1_1_1_2 hd_h_niceng130er.appl.tab10_1_1_1_3 hd_h_niceng130er.appl.tab10_1_1_1_4" colspan="4" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Weighted average cost per week</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab10_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£12.35</b>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab11"><div id="niceng130er.appl.tab11" class="table"><h3><span class="label">Table 60</span><span class="title">Weighted average cost per week for topical mesalazine (proctosigmoiditis, left-sided and extensive disease)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab11/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab11_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Drug</th><th id="hd_h_niceng130er.appl.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dose</th><th id="hd_h_niceng130er.appl.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per week</th><th id="hd_h_niceng130er.appl.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Weighting</th><th id="hd_h_niceng130er.appl.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Weighted cost</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Asacol Foam Aero Enem 1g/D</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£30.17</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.7%</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1.41</td></tr><tr><td headers="hd_h_niceng130er.appl.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine Enem 2g In 59ml</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£29.92</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.2%</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.25</td></tr><tr><td headers="hd_h_niceng130er.appl.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine Foam Aero Enem 1g/D</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£30.17</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.9%</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8.43</td></tr><tr><td headers="hd_h_niceng130er.appl.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa Enem 1g In 100ml</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1g</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£17.73</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.9%</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3.35</td></tr><tr><td headers="hd_h_niceng130er.appl.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk Enem (2g/59ml)</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£29.92</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.9%</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6.26</td></tr><tr><td headers="hd_h_niceng130er.appl.tab11_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Salofalk Foam Aero Enem 1g/D</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£30.17</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.4%</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.04</td></tr><tr><td headers="hd_h_niceng130er.appl.tab11_1_1_1_1 hd_h_niceng130er.appl.tab11_1_1_1_2 hd_h_niceng130er.appl.tab11_1_1_1_3 hd_h_niceng130er.appl.tab11_1_1_1_4" colspan="4" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Weighted average cost per week</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab11_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£27.73</b>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab12"><div id="niceng130er.appl.tab12" class="table"><h3><span class="label">Table 61</span><span class="title">Cost per week for other drugs for the induction of remission</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab12/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab12_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Drug</th><th id="hd_h_niceng130er.appl.tab12_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dose</th><th id="hd_h_niceng130er.appl.tab12_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per week</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_h_niceng130er.appl.tab12_1_1_1_2 hd_h_niceng130er.appl.tab12_1_1_1_3" id="hd_b_niceng130er.appl.tab12_1_1_1_1" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">Oral aminosalicylates</th></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Balsalazide 750mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.75g</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£14.74</td></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Olsalazine 250mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2g</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£75.13</td></tr><tr><th headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_h_niceng130er.appl.tab12_1_1_1_2 hd_h_niceng130er.appl.tab12_1_1_1_3" id="hd_b_niceng130er.appl.tab12_1_1_4_1" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">Oral corticosteroids</th></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Beclometasone 5mg M/R</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£13.20</td></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Budesonide 9mg M/R</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£17.50</td></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Prednisolone 5 mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40mg tapering over 8 weeks</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.88</td></tr><tr><th headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_h_niceng130er.appl.tab12_1_1_1_2 hd_h_niceng130er.appl.tab12_1_1_1_3" id="hd_b_niceng130er.appl.tab12_1_1_8_1" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">Topical corticosteroids</th></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Budesonide foam enema 2mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£28.56</td></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Hydrocortisone foam enema 10%</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.67</td></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Prednisolone foam enema 20mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£93.50</td></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Prednisolone liquid enema 20mg/100ml</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7.50</td></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Prednisolone suppository 5mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_8_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£77.06</td></tr><tr><th headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_h_niceng130er.appl.tab12_1_1_1_2 hd_h_niceng130er.appl.tab12_1_1_1_3" id="hd_b_niceng130er.appl.tab12_1_1_14_1" colspan="3" rowspan="1" style="text-align:left;vertical-align:top;">Immunomodulators</th></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Tacrolimus ointment 0.1%<sup>a</sup></td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£16.55</td></tr><tr><td headers="hd_h_niceng130er.appl.tab12_1_1_1_1 hd_b_niceng130er.appl.tab12_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Tacrolimus suppository 2mg<sup>b</sup></td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_2 hd_b_niceng130er.appl.tab12_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2mg</td><td headers="hd_h_niceng130er.appl.tab12_1_1_1_3 hd_b_niceng130er.appl.tab12_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£47.56</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab12_1"><p class="no_margin">As described in the trial by <a class="bibr" href="#niceng130er.appe.s1.2.ref4" rid="niceng130er.appe.s1.2.ref4">Lawrance 2017</a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng130er.appl.tab12_2"><p class="no_margin">Formulated on a case by case basis assuming 2mg suppository made from 2x1mg capsules requiring 20 minutes of Band 6 pharmacist time per 4-week supply (PSSRU 2017)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab13"><div id="niceng130er.appl.tab13" class="table"><h3><span class="label">Table 62</span><span class="title">Assumptions about the proportion of people receiving maintenance treatment and the weekly cost</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab13/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab13_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assumption</th><th id="hd_h_niceng130er.appl.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">%</th><th id="hd_h_niceng130er.appl.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dose</th><th id="hd_h_niceng130er.appl.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost per week</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">% of patients low-dose mesalazine</td><td headers="hd_h_niceng130er.appl.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41%</td><td headers="hd_h_niceng130er.appl.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.4g</td><td headers="hd_h_niceng130er.appl.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9.82</td></tr><tr><td headers="hd_h_niceng130er.appl.tab13_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">% of patients low-dose on azathioprine</td><td headers="hd_h_niceng130er.appl.tab13_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20%</td><td headers="hd_h_niceng130er.appl.tab13_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2mg/kg<sup>a</sup></td><td headers="hd_h_niceng130er.appl.tab13_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.84</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab13_1"><p class="no_margin">Average body weight 77kg</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab14"><div id="niceng130er.appl.tab14" class="table"><h3><span class="label">Table 63</span><span class="title">Other healthcare resource use assumptions</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab14/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab14_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Resource type</th><th id="hd_h_niceng130er.appl.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Active disease</th><th id="hd_h_niceng130er.appl.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remission</th><th id="hd_h_niceng130er.appl.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Unit cost</th><th id="hd_h_niceng130er.appl.tab14_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Source</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GP appointments (9.22 minutes each) per year-mean (SD)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.00 (2.10)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.80 (1.00)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£38.00</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSSRU 2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outpatient appointments per year – mean (SD)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.20 (1.40)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.00 (1.00)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£137.37</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [301]</td></tr><tr><td headers="hd_h_niceng130er.appl.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Specialist nurse appointments per year – mean (SD)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.00 (1.60)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.20 (0.60)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£68.00</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [N29AF]</td></tr><tr><td headers="hd_h_niceng130er.appl.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A&E attendance (%)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15%</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£148.36</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [180]</td></tr><tr><td headers="hd_h_niceng130er.appl.tab14_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outpatient procedure (%)</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26%</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7%</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£210.63</td><td headers="hd_h_niceng130er.appl.tab14_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [FE35Z, FE32Z]</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng130erapplfig2"><div id="niceng130er.appl.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2037.%20Structure%20of%20rescue%20therapy%20assumptions%20in%20the%20cost-effectiveness%20model.&p=BOOKS&id=576848_niceng130erapplf2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf2.jpg" alt="Figure 37. Structure of rescue therapy assumptions in the cost-effectiveness model." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 37</span><span class="title">Structure of rescue therapy assumptions in the cost-effectiveness model</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab15"><div id="niceng130er.appl.tab15" class="table"><h3><span class="label">Table 64</span><span class="title">Assumptions for response to rescue therapy</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab15/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab15_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment</th><th id="hd_h_niceng130er.appl.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Response</th><th id="hd_h_niceng130er.appl.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Source</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV hydrocortisone</td><td headers="hd_h_niceng130er.appl.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65%</td><td headers="hd_h_niceng130er.appl.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IBD national clinical audit of inpatient care 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV ciclosporin</td><td headers="hd_h_niceng130er.appl.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27%</td><td headers="hd_h_niceng130er.appl.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IBD national clinical audit of inpatient care 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Biological therapy</td><td headers="hd_h_niceng130er.appl.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85%</td><td headers="hd_h_niceng130er.appl.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IBD national clinical audit of inpatient care 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab15_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Surgery</td><td headers="hd_h_niceng130er.appl.tab15_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100%</td><td headers="hd_h_niceng130er.appl.tab15_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assumption</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab16"><div id="niceng130er.appl.tab16" class="table"><h3><span class="label">Table 65</span><span class="title">Dose and cost of biological therapies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab16/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab16_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Drug</th><th id="hd_h_niceng130er.appl.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost induction (6 weeks)<sup>(a)</sup></th><th id="hd_h_niceng130er.appl.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Maintenance dose</th><th id="hd_h_niceng130er.appl.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost per week maintenance (8 weeks)</th><th id="hd_h_niceng130er.appl.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Proportion on each drug<sup>(b)</sup></th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adalimumab 40mg/0.4mL</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4930</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40mg every 2 weeks</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£352</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20%</td></tr><tr><td headers="hd_h_niceng130er.appl.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Golimumab 50mg/0.5mL<sup>(c)</sup></td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3052</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50mg or 100mg every 4 weeks</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£191</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8%</td></tr><tr><td headers="hd_h_niceng130er.appl.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Infliximab 100mg (originator)</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5035</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5mg/kg every 8 weeks</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£227</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36%</td></tr><tr><td headers="hd_h_niceng130er.appl.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Infliximab 100mg (biosimilar)</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4524</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5mg/kg every 8 weeks</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£206</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28%</td></tr><tr><td headers="hd_h_niceng130er.appl.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vedolizumab 300mg<sup>(d)</sup></td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£6150</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">300mg every 8 weeks</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£256</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9%</td></tr><tr><td headers="hd_h_niceng130er.appl.tab16_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Weighted average cost across all biological agents</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£5084</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£246</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab16_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab16_1"><p class="no_margin">As per BNF, assuming average body weight 77kg</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng130er.appl.tab16_2"><p class="no_margin">IBD national clinical audit 2016</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng130er.appl.tab16_3"><p class="no_margin">As per NICE TA329, assumes 100 mg dose of golimumab provided at the same cost as the 50 mg dose under a patient acces scheme</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng130er.appl.tab16_4"><p class="no_margin">Patient access scheme discount not applied (commercial in confidence)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab17"><div id="niceng130er.appl.tab17" class="table"><h3><span class="label">Table 66</span><span class="title">Combined cost and durations for each branch of rescue therapy</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab17/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab17_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appl.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Time to remission (weeks)</th><th id="hd_h_niceng130er.appl.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost</th><th id="hd_h_niceng130er.appl.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Source</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV hydrocortisone</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.43</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1957</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [FD02E-H]</td></tr><tr><td headers="hd_h_niceng130er.appl.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV hydrocortisone followed by surgery</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3456</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [FD02C-D]</td></tr><tr><td headers="hd_h_niceng130er.appl.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV hydrocortisone followed by IV ciclosporin</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3456</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [FD02C-D]</td></tr><tr><td headers="hd_h_niceng130er.appl.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV hydrocortisone followed by IV ciclosporin and surgery</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7242</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [FD02A-B]</td></tr><tr><td headers="hd_h_niceng130er.appl.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV hydrocortisone followed by biological therapy (induction phase)</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.5</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7042</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [FD02E-H]; weighted average cost of biological therapies (<a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab6/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab6" rid-ob="figobniceng130erappitab6">Table 16</a>)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab17_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV hydrocortisone followed by biological therapy (induction phase) and surgery</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.5</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10,497</td><td headers="hd_h_niceng130er.appl.tab17_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017 [FD02C-H]; weighted average cost of biological therapies (<a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab6/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab6" rid-ob="figobniceng130erappitab6">Table 16</a>)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab18"><div id="niceng130er.appl.tab18" class="table"><h3><span class="label">Table 67</span><span class="title">Summary of assumptions for parameter uncertainty used in probabilistic sensitivity analyses</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab18/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab18_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab18_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Parameter</th><th id="hd_h_niceng130er.appl.tab18_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Point estimate</th><th id="hd_h_niceng130er.appl.tab18_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Distribution</th><th id="hd_h_niceng130er.appl.tab18_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Parameters</th><th id="hd_h_niceng130er.appl.tab18_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Source</th></tr></thead><tbody><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_1_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Withdrawal all extents of disease</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_2_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Baseline ln(rate)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.806</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −0.806</p>
|
|
<p>σ = 0.104</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baseline synthesis<sup>(a)</sup></td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_4_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>ln(HR) vs. LD oASA</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  HD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.481</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_4_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.940</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_4_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.966</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_4_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  oCS (beclo) + LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−1.469</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_4_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.116</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_4_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.805</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_4_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_11_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Remission proctitis 0-4 weeks</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_11_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_12_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Baseline probability</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_11_1 hd_b_niceng130er.appl.tab18_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_11_1 hd_b_niceng130er.appl.tab18_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.414</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_11_1 hd_b_niceng130er.appl.tab18_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_11_1 hd_b_niceng130er.appl.tab18_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 12</p>
|
|
<p>β = 17</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_11_1 hd_b_niceng130er.appl.tab18_1_1_12_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref11" rid="niceng130er.appe.s1.1.ref11">Gionchetti 1998</a>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_14_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>ln(OR) vs LD oASA</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tASA vs. LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.681</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_14_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Placebo vs. LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.686</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_14_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_14_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_17_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Remission proctitis 5-8 weeks</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_17_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_18_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Baseline ln(odds)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_17_1 hd_b_niceng130er.appl.tab18_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_17_1 hd_b_niceng130er.appl.tab18_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.635</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_17_1 hd_b_niceng130er.appl.tab18_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_17_1 hd_b_niceng130er.appl.tab18_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −0.635</p>
|
|
<p>σ = 0.151</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_17_1 hd_b_niceng130er.appl.tab18_1_1_18_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s1.1.ref19" rid="niceng130er.appe.s1.1.ref19">Ito 2010</a>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_20_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>ln(OR) vs. LD oASA</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−1.179</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_20_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Topical tacrolimus</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.246</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_20_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Placebo</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−1.782</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_20_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_20_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_24_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Remission: proctosigmoiditis and left-sided disease 0-4 weeks</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_24_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_25_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Baseline ln(odds)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_24_1 hd_b_niceng130er.appl.tab18_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_24_1 hd_b_niceng130er.appl.tab18_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−1.169</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_24_1 hd_b_niceng130er.appl.tab18_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_24_1 hd_b_niceng130er.appl.tab18_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −1.169</p>
|
|
<p>σ = 0.100</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_24_1 hd_b_niceng130er.appl.tab18_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baseline synthesis<sup>(b)</sup></td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_27_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>ln(OR) vs. LD oASA</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.379</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_27_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  HD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.409</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_27_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.610</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_27_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  oCS (beclo) + LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.012</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_27_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Placebo</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.280</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_27_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tCS (pred)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.211</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_27_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_34_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Remission: proctosigmoiditis and left-sided disease 5-8 weeks</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_34_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_35_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Baseline ln(odds)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_34_1 hd_b_niceng130er.appl.tab18_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_34_1 hd_b_niceng130er.appl.tab18_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.592</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_34_1 hd_b_niceng130er.appl.tab18_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_34_1 hd_b_niceng130er.appl.tab18_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −0.592</p>
|
|
<p>σ = 0.057</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_34_1 hd_b_niceng130er.appl.tab18_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baseline synthesis<sup>(c)</sup></td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_37_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>ln(OR) vs. LD oASA</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.216</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_37_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.324</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_37_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  HD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.254</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_37_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.280</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_37_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.427</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_37_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.740</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_37_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Placebo</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.638</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_37_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_45_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Remission: extensive disease 0-4 weeks</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_45_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_46_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Baseline ln(odds)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_45_1 hd_b_niceng130er.appl.tab18_1_1_46_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_45_1 hd_b_niceng130er.appl.tab18_1_1_46_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.220</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_45_1 hd_b_niceng130er.appl.tab18_1_1_46_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_45_1 hd_b_niceng130er.appl.tab18_1_1_46_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −0.220</p>
|
|
<p>σ = 0.325</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_45_1 hd_b_niceng130er.appl.tab18_1_1_46_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baseline synthesis<sup>(d)</sup></td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_48_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>ln(OR) vs. LD oASA</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.047</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_48_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  HD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.410</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_48_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.838</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_48_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.648</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_48_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_48_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_53_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Remission: extensive disease 5-8 weeks</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_53_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_54_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Baseline ln(odds)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_53_1 hd_b_niceng130er.appl.tab18_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  HD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_53_1 hd_b_niceng130er.appl.tab18_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.019</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_53_1 hd_b_niceng130er.appl.tab18_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_53_1 hd_b_niceng130er.appl.tab18_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −0.019</p>
|
|
<p>σ = 0.208</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_53_1 hd_b_niceng130er.appl.tab18_1_1_54_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baseline synthesis<sup>(e)</sup></td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_56_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>ln(OR) vs. HD oASA</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_56_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_56_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.907</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_56_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_56_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_56_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_56_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.830</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_56_1 hd_h_niceng130er.appl.tab18_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Multivariate normal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_56_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NMA</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_59_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Health state utilities</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Remission</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.940</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 22627.813</p>
|
|
<p>β = 1444.329</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole 2010</a>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Active disease</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.775</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 864.093</p>
|
|
<p>β = 250.866</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole 2010</a>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Severe relapse</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.660</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 133.999</p>
|
|
<p>β = 69.030</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_59_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s3.ref9" rid="niceng130er.appe.s3.ref9">Poole 2010</a>
|
|
</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_63_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Treatment-related adverse event disutilities</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Aminosalicylates</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.040</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Triangular</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Min = −0.08</p>
|
|
<p>Mode = −0.04</p>
|
|
<p>Max = 0</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s3.ref8" rid="niceng130er.appe.s3.ref8">Modi 2017</a>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Corticosteroids</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.047</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Triangular</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Min = −0.094</p>
|
|
<p>Mode = −0.047</p>
|
|
<p>Max = 0</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sullivan 2016</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Surgery</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">−0.100</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Triangular</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Min = −0.2</p>
|
|
<p>Mode = −0.1</p>
|
|
<p>Max = 0</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_63_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Argueda 2004</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_67_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Drug costs</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_68_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Proctitis</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9.47</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.00</p>
|
|
<p>β = 0.379</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£12.35</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.494</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.88</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.035</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£15.92</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 1.142</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> tCS (pred liquid enema)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7.50</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.300</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> tCS (pred suppository)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£64.85</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 2.594</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Topical tacrolimus (ointment)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£16.55</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.662</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Topical tacrolimus (suppository)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£47.56</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 1.902</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017), PSSRU 2017 (pharmacist cost)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£21.82</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.873</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10.28</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.411</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£22.67</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.907</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£25.39</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 1.016</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + tCS (pred liquid enema)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£16.97</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.679</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_67_1 hd_b_niceng130er.appl.tab18_1_1_68_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_82_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Proctosigmoiditis and left-sided / extensive disease</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9.47</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.00</p>
|
|
<p>β = 0.379</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> HD oASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£20.67</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.00</p>
|
|
<p>β = 0.827</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> HD oASA (balsalazide)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£14.74</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.00</p>
|
|
<p>β = 0.590</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> HD oASA (olsalazine)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£75.13</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.00</p>
|
|
<p>β = 3.005</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£27.73</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.00</p>
|
|
<p>β = 1.109</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£0.88</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.00</p>
|
|
<p>β = 0.035</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£15.92</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.00</p>
|
|
<p>β = 0.637</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> tCS (pred liquid enema)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£7.50</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.300</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> tCS (pred foam enema)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£93.50</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 3.740</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4.67</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.187</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£28.56</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 1.142</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£37.20</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 1.488</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> HD oASA + tASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£48.40</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 1.936</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£10.28</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.411</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£22.67</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.907</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£25.39</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 1.016</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + tCS (pred liquid enema)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£16.97</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.679</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + tCS (pred foam enema)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£102.97</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 4.119</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£14.14</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 0.566</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£38.03</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 25.000</p>
|
|
<p>β = 1.521</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_82_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BNF, NHS PCA data (Nov 2017)</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_103_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Maintenance treatment</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_104_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Proportion of people taking</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> ASA</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.414</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">Dirichlet</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SE = 0.059</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="3" colspan="1" style="text-align:left;vertical-align:top;">Alexakis 2016</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> Azathiorprine</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.200</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SE = 0.048</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"> None</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.386</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_103_1 hd_b_niceng130er.appl.tab18_1_1_104_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SE = 0.058</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_108_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Background healthcare resource use</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_109_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Remission (per year)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  GP appointment</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.80</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lognormal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −0.246</p>
|
|
<p>σ = 0.212</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Outpatient appointments</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.00</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lognormal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −0.014</p>
|
|
<p>σ = 0.170</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Nursing face-to-face</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.20</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lognormal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −1.727</p>
|
|
<p>σ = 0.485</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  A&E attendance (%)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.00</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Outpatient procedures (%)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.07</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 2</p>
|
|
<p>β = 32</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_108_1 hd_b_niceng130er.appl.tab18_1_1_109_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_115_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Active disease</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  GP appointment</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.00</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lognormal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = 0.685</p>
|
|
<p>σ = 0.125</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Outpatient appointments</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.20</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lognormal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = 1.162</p>
|
|
<p>σ = 0.052</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Nursing face-to-face</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.00</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lognormal</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>µ = −0.018</p>
|
|
<p>σ = 0.190</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  A&E attendance (%)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.15</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 11</p>
|
|
<p>β = 59</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Outpatient procedures (%)</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.26</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 18</p>
|
|
<p>β = 52</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_115_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bodger 2014</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_121_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Unit costs</th></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_122_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Outpatient appointments</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Consultant-led gastroenterology outpatient appt [301]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£141</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 1746.500</p>
|
|
<p>β = 0.081</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Non-consultant-led gastroenterology outpatient appt [301]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£107</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 585.645</p>
|
|
<p>β = 0.182</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_121_1 hd_b_niceng130er.appl.tab18_1_1_122_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_125_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Outpatient procedures</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Diagnostic Flexible Sigmoidoscopy, 19 years and over [FE35Z]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£175</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 70.795</p>
|
|
<p>β = 2.475</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  Diagnostic Colonoscopy, 19 years and over [FE32Z]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£277</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 37.980</p>
|
|
<p>β = 7.301</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nursing face-to-face [N29AF]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£68</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 282.247</p>
|
|
<p>β = 0.241</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A&E attendance [180]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£148</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blood test [DAPS03]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 143.315</p>
|
|
<p>β = 0.012</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GP appointment</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£38</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_125_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSSRU 2017</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_132_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">Rescue therapy</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_132_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion of people responding to IV hydrocortisone</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_132_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.652</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_132_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_132_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 2293</p>
|
|
<p>β = 1226</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_132_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UK IBD national clinical audit of inpatient care 2014</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_134_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Of people not responding to IV hydrocortisone:</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_134_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion receiving surgery</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_134_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.193</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_134_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_134_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 237</p>
|
|
<p>β = 989</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_134_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UK IBD national clinical audit of inpatient care 2014</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_136_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Of people not receiving surgery:</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion receiving ciclosporin</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.338</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 261</p>
|
|
<p>β = 512</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UK IBD national clinical audit of inpatient care 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion receiving aTNFs</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.662</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 512</p>
|
|
<p>β = 261</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_136_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UK IBD national clinical audit of inpatient care 2014</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_139_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Of people receiving ciclosporin:</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion achieving remission</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.736</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 184</p>
|
|
<p>β = 66</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UK IBD national clinical audit of inpatient care 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion requiring surgery</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.264</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_139_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Calculated</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_142_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Of people receiving biological therapy</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion achieving remission</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.848</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beta</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 425</p>
|
|
<p>β = 76</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UK IBD national clinical audit of inpatient care 2014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion requiring surgery</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.152</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_142_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Calculated</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_145_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Proportion of people taking each biological therapy</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adalimumab</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.199</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="5" colspan="1" style="text-align:left;vertical-align:top;">Dirichlet</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SE = 0.014</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="5" colspan="1" style="text-align:left;vertical-align:top;">UK IBD national clinical audit of biological therapies 2016</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Golimumab</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.076</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SE = 0.009</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Infliximab biosimilar</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.278</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SE = 0.016</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Infliximab originator</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.357</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SE = 0.017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vedolizumab</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.090</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_145_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SE = 0.010</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_151_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Cost inpatient admissions (elective)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Multiple Interventions, CC Score 3+ [FD02A]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£9,009</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 72.160</p>
|
|
<p>β = 124.849</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Multiple Interventions, CC Score 0-2 [FD02B]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4,848</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 152.626</p>
|
|
<p>β = 31.761</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Single Intervention, CC Score 4+ [FD02C]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4,529</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 94.620</p>
|
|
<p>β = 47.861</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Single Intervention, CC Score 0-3 [FD02D]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£3,393</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 1672.459</p>
|
|
<p>β = 2.029</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 5+ [FD02E]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,960</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 266.054</p>
|
|
<p>β = 11.125</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 3-4 [FD02F]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,700</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 300.944</p>
|
|
<p>β = 5.650</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 1-2 [FD02G]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,290</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 743.071</p>
|
|
<p>β = 1.736</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 0 [FD02H]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£828</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 508.533</p>
|
|
<p>β = 1.627</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_151_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_160_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Cost inpatient admissions (elective excess bed-days)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Multiple Interventions, CC Score 3+ [FD02A]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£435</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 4.896</p>
|
|
<p>β = 88.793</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Multiple Interventions, CC Score 0-2 [FD02B]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£409</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Single Intervention, CC Score 4+ [FD02C]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£269</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Single Intervention, CC Score 0-3 [FD02D]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£434</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 34.576</p>
|
|
<p>β = 12.552</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 5+ [FD02E]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£379</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 63.315</p>
|
|
<p>β = 5.983</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 3-4 [FD02F]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£371</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 1099.660</p>
|
|
<p>β = 0.337</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 1-2 [FD02G]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£309</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 483.196</p>
|
|
<p>β = 0.640</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 0 [FD02H]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£384</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 260.178</p>
|
|
<p>β = 1.476</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_160_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_169_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Cost inpatient admissions (non-elective)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Multiple Interventions, CC Score 3+ [FD02A]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£8,300</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 1252.396</p>
|
|
<p>β = 6.627</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Multiple Interventions, CC Score 0-2 [FD02B]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5,000</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 774.982</p>
|
|
<p>β = 6.452</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Single Intervention, CC Score 4+ [FD02C]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£5,050</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 5151.508</p>
|
|
<p>β = 0.980</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Single Intervention, CC Score 0-3 [FD02D]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,820</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 12501.295</p>
|
|
<p>β = 0.226</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 5+ [FD02E]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,641</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 15831.327</p>
|
|
<p>β = 0.167</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 3-4 [FD02F]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£2,134</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 15224.861</p>
|
|
<p>β = 0.140</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 1-2 [FD02G]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,806</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 31459.911</p>
|
|
<p>β = 0.057</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 0 [FD02H]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,648</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 28362.720</p>
|
|
<p>β = 0.058</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_169_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><th headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_h_niceng130er.appl.tab18_1_1_1_2 hd_h_niceng130er.appl.tab18_1_1_1_3 hd_h_niceng130er.appl.tab18_1_1_1_4 hd_h_niceng130er.appl.tab18_1_1_1_5" id="hd_b_niceng130er.appl.tab18_1_1_178_1" colspan="5" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<i>Cost inpatient admissions (non-elective excess bed-days)</i>
|
|
</th></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Multiple Interventions, CC Score 3+ [FD02A]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£353</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 261.341</p>
|
|
<p>β = 1.352</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Multiple Interventions, CC Score 0-2 [FD02B]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£396</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 196.123</p>
|
|
<p>β = 2.022</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Single Intervention, CC Score 4+ [FD02C]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£321</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 190.149</p>
|
|
<p>β = 1.689</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD Single Intervention, CC Score 0-3 [FD02D]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£329</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 1033.307</p>
|
|
<p>β = 0.318</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 5+ [FD02E]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£304</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 1545.016</p>
|
|
<p>β = 0.197</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 3-4 [FD02F]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£294</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 2571.506</p>
|
|
<p>β = 0.114</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 1-2 [FD02G]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£294</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 3172.810</p>
|
|
<p>β = 0.093</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab18_1_1_1_1 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">  IBD without Interventions, CC Score 0 [FD02H]</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_2 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£299</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_3 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gamma</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_4 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>α = 2813.486</p>
|
|
<p>β = 0.106</p>
|
|
</td><td headers="hd_h_niceng130er.appl.tab18_1_1_1_5 hd_b_niceng130er.appl.tab18_1_1_178_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NHS Ref Costs 2016/2017</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; hydro = hydrocortisone</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab18_1"><p class="no_margin">See <a href="#niceng130er.appi">Appendix I</a>, <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab36/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab36" rid-ob="figobniceng130erappitab36">Table 46</a> for list of studies that informed baseline synthesis</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng130er.appl.tab18_2"><p class="no_margin">See <a href="#niceng130er.appi">Appendix I</a>, <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab20/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab20" rid-ob="figobniceng130erappitab20">Table 30</a> for list of studies that informed baseline synthesis</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng130er.appl.tab18_3"><p class="no_margin">See <a href="#niceng130er.appi">Appendix I</a>, <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab24/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab24" rid-ob="figobniceng130erappitab24">Table 34</a> for list of studies that informed baseline synthesis</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng130er.appl.tab18_4"><p class="no_margin">See <a href="#niceng130er.appi">Appendix I</a>, <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab28/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab28" rid-ob="figobniceng130erappitab28">Table 38</a> for list of studies that informed baseline synthesis</p></div></dd></dl><dl class="bkr_refwrap"><dt>(e)</dt><dd><div id="niceng130er.appl.tab18_5"><p class="no_margin">See <a href="#niceng130er.appi">Appendix I</a>, <a class="figpopup" href="/books/NBK576848/table/niceng130er.appi.tab32/?report=objectonly" target="object" rid-figpopup="figniceng130erappitab32" rid-ob="figobniceng130erappitab32">Table 42</a> for list of studies that informed baseline synthesis</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab19"><div id="niceng130er.appl.tab19" class="table"><h3><span class="label">Table 68</span><span class="title">Proportion of people whose disease enters remission by line of treatment, average time spent in active disease vs. remission and breakdown of costs for each treatment sequence in the base-case analysis for proctosigmoiditis and left-sided disease (excludes sequences with topical budesonide and topical hydrocortisone)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab19/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab19_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab19_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab19_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab19_1_1_1_2" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Proportion entering remission</th><th id="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab19_1_1_1_3" style="text-align:left;vertical-align:bottom;">Weeks active</th><th id="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab19_1_1_1_4" style="text-align:left;vertical-align:bottom;">Weeks remission</th><th id="hd_h_niceng130er.appl.tab19_1_1_1_5" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th id="hd_h_niceng130er.appl.tab19_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th></tr><tr><th headers="hd_h_niceng130er.appl.tab19_1_1_1_2" id="hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1st line</th><th headers="hd_h_niceng130er.appl.tab19_1_1_1_2" id="hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab19_1_1_1_2" id="hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th><th headers="hd_h_niceng130er.appl.tab19_1_1_1_2" id="hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Rescue</th><th headers="hd_h_niceng130er.appl.tab19_1_1_1_5" id="hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Drug</th><th headers="hd_h_niceng130er.appl.tab19_1_1_1_5" id="hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Rescue</th><th headers="hd_h_niceng130er.appl.tab19_1_1_1_5" id="hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other healthcare</th><th headers="hd_h_niceng130er.appl.tab19_1_1_1_5" id="hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Maintenance</th><th headers="hd_h_niceng130er.appl.tab19_1_1_1_6" id="hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Total</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS01</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">17.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£159</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£549</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£364</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£110</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,182</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS02</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">18.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">20.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.7</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.3</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£160</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£660</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£367</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,304</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS03</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">27.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£185</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£867</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£378</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£111</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,542</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS04</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">17.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.3</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.7</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£148</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£546</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£364</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£110</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,168</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS05</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">18.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">20.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.7</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.3</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£149</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£657</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£366</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,290</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS06</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">27.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£174</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£863</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£378</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£111</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,526</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS07</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">27.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£157</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£356</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£354</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£984</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS10</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">27.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£147</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£354</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£353</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£970</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS13</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">20.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">16.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.2</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.8</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£219</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£509</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£359</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£110</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,197</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS14</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">16.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">19.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£220</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£612</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£361</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£116</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,310</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS15</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">10.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£244</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£805</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£371</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£112</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,531</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS16</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">20.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">16.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.2</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.8</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£209</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£506</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£358</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£110</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,183</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS17</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">16.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">19.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£210</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£609</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£360</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,295</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS18</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">10.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£233</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£800</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£371</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£112</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,515</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS19</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">10.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£218</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£330</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£348</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,013</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS22</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">10.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£207</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£328</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£348</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,000</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS25</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, <b><i>LD oASA+ oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">40.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.2</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.8</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£258</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£308</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£333</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£118</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,017</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS26</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">40.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">15.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">17.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.3</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.7</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£261</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£557</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£344</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£118</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,280</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS27</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">40.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.0</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.0</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£282</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£725</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£353</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£113</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,473</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS28</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">40.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.1</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.9</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£258</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£297</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£332</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£118</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,006</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS31</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">80.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.3</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.7</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£148</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£152</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£229</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£147</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£676</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS32</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">80.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.1</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.9</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£148</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£184</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£230</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£149</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£711</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS33</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">80.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.3</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.7</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£155</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£241</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£233</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£147</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£776</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS34</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">80.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.0</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">27.0</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£147</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£99</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£226</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£149</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£621</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS37</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">30.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.5</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£250</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£754</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£298</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£123</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,425</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS38</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">24.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£252</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£915</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£302</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,601</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS39</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">16.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">37.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.8</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.2</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£286</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,191</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£317</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£124</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,919</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS40</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">39.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">15.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.3</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">24.7</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£247</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£489</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£284</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,152</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS43</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">30.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">24.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£250</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£762</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£300</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£122</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,434</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS44</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">29.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">24.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£252</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£926</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£303</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,613</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS45</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">16.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">38.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.8</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.2</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£286</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,204</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£319</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£124</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,934</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS46</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">45.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">38.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">15.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">24.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£247</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£494</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£285</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,158</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS55</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">10.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.4%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.0</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.0</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£51</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£266</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£260</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£142</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£719</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS56</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">10.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.7</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.3</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£52</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£320</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£261</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£146</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£779</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS57</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">13.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.1</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.9</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£64</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£420</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£267</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£143</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£894</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS64</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.6%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.9</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.1</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£69</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£240</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£256</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£143</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£708</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS65</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.9%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£70</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£290</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£257</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£146</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£762</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS66</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">12.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.0</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.0</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£81</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£379</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£262</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£143</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£865</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS73</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">13.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.8%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.0%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.8</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.2</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£97</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£222</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£253</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£143</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£715</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS74</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">13.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.3%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.5%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.6</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.4</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£98</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£268</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£254</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£146</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£766</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS75</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">71.2%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">13.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.7%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.1%</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.9</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">26.1</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£108</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£350</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£259</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£143</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£860</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Minimum</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>34.4%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>8.8%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>0.1%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>3.1%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>3.0</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>21.5</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£51</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£99</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£226</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£110</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£621</b>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appl.tab19_1_1_1_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Maximum</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>80.3%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>39.1%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>27.8%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_2 hd_h_niceng130er.appl.tab19_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>38.2%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>8.5</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>27.0</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£286</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£1,204</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£378</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_5 hd_h_niceng130er.appl.tab19_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£149</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab19_1_1_1_6 hd_h_niceng130er.appl.tab19_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£1,934</b>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PLS = proctosigmoiditis and left-sided disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab20"><div id="niceng130er.appl.tab20" class="table"><h3><span class="label">Table 69</span><span class="title">Base-case mean probabilistic cost-effectiveness results for proctosigmoiditis and left-sided disease</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab20/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab20_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab20_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab20_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab20_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab20_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab20_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab20_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab20_1_1_1_2" id="hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab20_1_1_1_2" id="hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab20_1_1_1_3" id="hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab20_1_1_1_3" id="hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab20_1_1_1_3" id="hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS31</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, <i><b>LD oASA + oCS (pred)</b></i></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£749</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5286</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">13.9%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,823</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS34</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£769</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5294</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£20</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0008</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£24,396</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">55.5%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,819</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS64</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£775</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5266</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£6</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0028</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.6%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,757</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS73</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£779</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5269</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0025</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.6%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,759</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS32</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£788</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5293</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£19</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.6%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,799</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS55</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£789</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5263</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£20</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0031</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.9%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,737</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS74</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£830</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5279</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£61</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0015</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.5%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,727</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS65</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£830</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5277</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£61</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0017</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">2.8%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,723</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS56</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£850</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5274</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£81</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0020</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,699</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS33</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£874</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5283</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£104</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0011</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,692</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS75</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£942</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5265</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£173</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0029</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,588</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS66</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£953</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5262</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£184</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0032</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,570</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS57</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£987</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5258</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£218</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0036</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,529</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS10</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,034</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£265</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,287</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS07</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,048</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£279</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,273</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS28</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,055</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5174</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£285</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0120</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,294</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS22</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,055</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5164</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£285</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0130</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,273</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS25</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, <b><i>LD oASA+ oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,063</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5173</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£293</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0121</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,283</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS19</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,068</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5163</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£299</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0131</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,259</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS04</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,181</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£412</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.4%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,084</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS16</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,188</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5138</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£419</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0156</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.3%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,087</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS01</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,195</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£426</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,069</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS13</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,202</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5137</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£433</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0157</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,073</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS40</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,233</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5228</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£464</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0066</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,224</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS46</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,238</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5227</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£469</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0067</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,216</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS26</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,269</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5168</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£500</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0126</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.7%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,067</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS17</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,285</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£516</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0138</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,027</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS05</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,286</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5152</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£517</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0142</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.6%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,019</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS14</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,299</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£530</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0139</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,012</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS02</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,300</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5152</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£531</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0142</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,004</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS37</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,430</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5190</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£661</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0104</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,949</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS43</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,439</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5188</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£670</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0106</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,937</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS27</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,465</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5143</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£695</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0151</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,822</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS18</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,506</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5130</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£737</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0165</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,753</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS15</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,522</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5129</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£753</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0165</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,736</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS06</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,528</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5123</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£758</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0171</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,719</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS03</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,544</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5123</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£775</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0171</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,702</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS38</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,582</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5218</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£813</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0076</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,854</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS44</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,594</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5217</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£825</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0077</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,840</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS39</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,902</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5178</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,133</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0116</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,453</td></tr><tr><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS45</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,916</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_2 hd_h_niceng130er.appl.tab20_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5176</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,147</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0118</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_3 hd_h_niceng130er.appl.tab20_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab20_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,435</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PLS = proctosigmoiditis and left-sided disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab20_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig3"><div id="niceng130er.appl.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2038.%20Cost-effectiveness%20acceptability%20curve%20for%20proctosigmoiditis%20and%20left-sided%20disease%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erapplf3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf3.jpg" alt="Figure 38. Cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 38</span><span class="title">Cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease base-case analysis</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig4"><div id="niceng130er.appl.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2039.%20Cost-effectiveness%20acceptability%20frontier%20for%20proctosigmoiditis%20and%20left-sided%20disease%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erapplf4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf4.jpg" alt="Figure 39. Cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 39</span><span class="title">Cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease base-case analysis</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab21"><div id="niceng130er.appl.tab21" class="table"><h3><span class="label">Table 70</span><span class="title">SA1 cost-effectiveness results for proctosigmoiditis and left-sided disease with duration of treatment set to maximum of all RCTs for each drug</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab21/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab21_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab21_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab21_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab21_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab21_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab21_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab21_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab21_1_1_1_2" id="hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab21_1_1_1_2" id="hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab21_1_1_1_3" id="hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab21_1_1_1_3" id="hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab21_1_1_1_3" id="hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS64</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£829</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5277</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">22.8%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,724</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS73</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£836</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5278</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£7</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0001</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£48,396</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.4%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,720</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS65</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (becl)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£840</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5276</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£4</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0002</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">18.3%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,713</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS74</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (becl)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£847</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5278</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£11</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0000</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">18.2%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,709</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS55</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£849</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5274</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£13</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0004</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.1%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,700</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS56</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (becl)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£860</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5274</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£24</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0004</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.3%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,688</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS75</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£959</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5263</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£123</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0015</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,567</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS66</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£960</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5261</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£124</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0017</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,562</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS57</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£993</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5257</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£157</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0021</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,521</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS34</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£995</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5195</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£159</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0083</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,394</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS10</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,040</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£204</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0117</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,281</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS07</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,053</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5160</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£217</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0118</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,268</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS22</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,068</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5163</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£233</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0115</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,257</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS28</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,069</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5173</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£233</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0105</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,278</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS19</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,082</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5163</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£246</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0115</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,243</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS25</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, <b><i>LD oASA+ oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,083</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5173</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£247</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0105</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,263</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS31</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,152</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5190</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£317</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0088</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.1%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,227</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS32</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,171</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5190</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£336</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0088</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.8%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,208</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS58</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,188</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5165</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£353</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0113</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.4%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,141</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS67</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,196</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5167</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£361</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0111</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.8%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,138</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS59</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro), HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,212</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5164</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£376</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0114</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">2.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,116</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS68</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro), LD oASA + tASA, LD oASA + oCS (bec)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,219</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5167</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£384</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0111</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.8%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,114</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS49</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,222</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£387</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0117</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,099</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS35</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,230</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5172</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£395</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0106</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,114</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS50</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro), LD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,248</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5160</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£412</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0118</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,072</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS36</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,257</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5172</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£422</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0106</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,087</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS40</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,258</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5226</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£423</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0052</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,193</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS46</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,260</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5226</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£424</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0052</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,191</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS04</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,278</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5153</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£442</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0125</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.2%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,029</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS16</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,286</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£450</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0122</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,027</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS26</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,288</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5167</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£453</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0111</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.2%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,046</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS01</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,292</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5153</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£456</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0125</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,014</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS13</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,300</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£464</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0122</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,012</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS05</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,302</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5153</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£467</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0125</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,004</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS61</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bud), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,305</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5166</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£470</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0112</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,027</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS17</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,309</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£474</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0122</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,002</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS70</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bud), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,313</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5169</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£477</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0109</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,025</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS02</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,317</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5153</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£481</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0125</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,988</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS14</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,324</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£488</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0122</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,987</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS33</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,326</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5169</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£490</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0109</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,013</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS62</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bud), HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,328</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5166</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£493</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0112</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,003</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS71</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bud), LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,335</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5169</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£499</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0109</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,002</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS52</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bud), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,339</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5162</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£503</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0116</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,986</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS29</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,360</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5145</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£524</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,931</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS53</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bud), LD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,364</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5162</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£528</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0116</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,960</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS11</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,387</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5127</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£551</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0151</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,868</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS23</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,389</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£553</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,875</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS30</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,393</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5146</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£558</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0132</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,898</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS08</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,402</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5127</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£566</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0151</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,852</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS20</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,404</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£568</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,859</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS69</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,415</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5141</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£580</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0137</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,867</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS60</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS60: tCS (hydro), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,423</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5136</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£587</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0141</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,850</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS24</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,425</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£590</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,839</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS12</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,427</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5128</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£591</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0150</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,829</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS21</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (bud)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,441</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£605</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,823</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS09</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,442</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5127</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£606</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0151</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,812</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS27</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,480</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5142</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£644</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0136</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,804</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS51</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (hydro), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,481</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5130</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£645</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0148</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,778</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS18</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,521</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5128</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£685</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0150</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,735</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS06</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,529</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5123</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£693</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0155</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,718</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS72</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bud), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,529</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5143</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£693</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0135</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,758</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS63</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bud), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,537</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5139</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£701</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0139</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,740</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS15</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,537</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5128</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£701</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0150</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,718</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS03</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,545</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5123</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£709</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0155</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,701</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS37</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,583</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5216</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£747</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0062</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,850</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS43</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,586</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5216</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£750</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0062</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,845</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS54</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (bude), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,594</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£758</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,670</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS38</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,620</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5215</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£784</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0063</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,811</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS44</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,624</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5215</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£788</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0063</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,806</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS41</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,737</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£901</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0098</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,622</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS47</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,741</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5179</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£906</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0099</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,617</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS42</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,792</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£956</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0098</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,568</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS48</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (hydro)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,797</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£961</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0098</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,562</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS39</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,935</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5174</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,099</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0104</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,413</td></tr><tr><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS45</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,940</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_2 hd_h_niceng130er.appl.tab21_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5173</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,105</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0104</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_3 hd_h_niceng130er.appl.tab21_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab21_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,406</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PLS = proctosigmoiditis and left-sided disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab21_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig5"><div id="niceng130er.appl.fig5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2040.%20SA1%20cost-effectiveness%20acceptability%20curve%20for%20proctosigmoiditis%20and%20left-sided%20disease%20with%20duration%20of%20treatment%20set%20to%20maximum%20of%20all%20RCTs%20for%20each%20drug.&p=BOOKS&id=576848_niceng130erapplf5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf5.jpg" alt="Figure 40. SA1 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease with duration of treatment set to maximum of all RCTs for each drug." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 40</span><span class="title">SA1 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease with duration of treatment set to maximum of all RCTs for each drug</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig6"><div id="niceng130er.appl.fig6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2041.%20SA1%20cost-effectiveness%20acceptability%20frontier%20for%20proctosigmoiditis%20and%20left-sided%20disease%20with%20duration%20of%20treatment%20set%20to%20maximum%20of%20all%20RCTs%20for%20each%20drug.&p=BOOKS&id=576848_niceng130erapplf6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf6.jpg" alt="Figure 41. SA1 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease with duration of treatment set to maximum of all RCTs for each drug." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 41</span><span class="title">SA1 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease with duration of treatment set to maximum of all RCTs for each drug</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab22"><div id="niceng130er.appl.tab22" class="table"><h3><span class="label">Table 71</span><span class="title">SA2 cost-effectiveness results for proctosigmoiditis and left-sided disease with no early switching of treatments in the event of non-remission</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab22/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab22_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab22_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab22_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab22_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab22_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab22_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab22_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab22_1_1_1_2" id="hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab22_1_1_1_2" id="hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab22_1_1_1_3" id="hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab22_1_1_1_3" id="hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab22_1_1_1_3" id="hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS31</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£807</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5241</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">15.2%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,675</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS34</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£829</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5253</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£22</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0012</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£17,694</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">60.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,678</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS32</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£844</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5252</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£15</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0002</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.8%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,659</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS64</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£849</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5200</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£20</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0053</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.2%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,551</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS55</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£858</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5192</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£29</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0061</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,527</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS73</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£864</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5206</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£35</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0047</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.1%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,549</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS65</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£903</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5216</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£74</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0038</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">2.1%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,528</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS74</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£914</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5221</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£85</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0033</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">2.2%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,527</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS56</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£916</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5209</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£88</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0044</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,502</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS33</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£941</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5233</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£112</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0020</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,525</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS66</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,046</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5196</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£217</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0058</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,345</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS75</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,048</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5189</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£219</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0065</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,329</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS57</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,079</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£250</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0074</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,280</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS10</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,134</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5021</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£306</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0232</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,908</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS22</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,170</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5028</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£341</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0225</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,886</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS07</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,171</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5021</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£342</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0233</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,870</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS28</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,187</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5051</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£358</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0202</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,915</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS25</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, <b><i>LD oASA+ oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,202</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5046</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£373</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0207</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,890</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS19</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,207</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5027</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£378</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0226</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,847</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS04</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,275</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4979</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£447</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0275</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.2%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,682</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS16</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,302</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4988</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£473</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0265</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,674</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS01</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,313</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4977</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£485</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0276</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,641</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS13</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,340</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4987</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£512</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0266</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,633</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS40</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,362</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5147</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£533</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0106</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,933</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS05</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,369</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5006</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£540</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0247</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.7%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,643</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS46</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,373</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5143</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£544</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0111</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,912</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS17</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,388</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5013</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£559</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0240</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,639</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS26</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,394</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5040</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£565</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0213</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.2%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,686</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS02</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,407</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5005</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£578</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0249</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,603</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS14</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,426</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5012</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£597</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0241</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,598</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS37</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,548</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5091</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£719</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,634</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS43</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,568</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5085</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£739</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0169</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,602</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS27</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,613</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4997</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£785</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0256</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,381</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS06</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,639</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4958</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£810</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0296</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,276</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS18</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,639</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4969</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£811</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0285</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,298</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS03</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,681</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4956</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£852</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0297</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,231</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS15</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,681</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4967</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£853</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0286</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,253</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS38</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,683</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5131</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£855</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0123</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,578</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS44</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,708</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5126</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£879</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0128</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,544</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS39</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£2,029</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5063</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,200</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0190</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,098</td></tr><tr><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS45</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£2,059</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_2 hd_h_niceng130er.appl.tab22_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5056</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,230</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0197</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_3 hd_h_niceng130er.appl.tab22_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab22_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,054</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PLS = proctosigmoiditis and left-sided disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab22_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig7"><div id="niceng130er.appl.fig7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2042.%20SA2%20cost-effectiveness%20acceptability%20curve%20for%20proctosigmoiditis%20and%20left-sided%20disease%20with%20no%20early%20switching%20of%20treatments%20in%20the%20event%20of%20non-remission.&p=BOOKS&id=576848_niceng130erapplf7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf7.jpg" alt="Figure 42. SA2 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease with no early switching of treatments in the event of non-remission." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 42</span><span class="title">SA2 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease with no early switching of treatments in the event of non-remission</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig8"><div id="niceng130er.appl.fig8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2043.%20SA2%20cost-effectiveness%20acceptability%20frontier%20for%20proctosigmoiditis%20and%20left-sided%20disease%20with%20no%20early%20switching%20of%20treatments%20in%20the%20event%20of%20non-remission.&p=BOOKS&id=576848_niceng130erapplf8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf8.jpg" alt="Figure 43. SA2 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease with no early switching of treatments in the event of non-remission." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 43</span><span class="title">SA2 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease with no early switching of treatments in the event of non-remission</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab23"><div id="niceng130er.appl.tab23" class="table"><h3><span class="label">Table 72</span><span class="title">SA3 cost-effectiveness results for proctosigmoiditis and left-sided disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab23/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab23_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab23_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab23_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab23_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab23_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab23_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab23_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab23_1_1_1_2" id="hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab23_1_1_1_2" id="hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab23_1_1_1_3" id="hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab23_1_1_1_3" id="hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab23_1_1_1_3" id="hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS31</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£763</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5286</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">14.6%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,808</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS34</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£786</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5294</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£23</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0008</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£27,398</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">54.4%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,802</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS73</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£800</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5268</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£14</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0026</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.1%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,737</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS64</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£802</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5265</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£16</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0029</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7.5%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,728</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS32</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£806</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5293</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£21</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,780</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS55</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£817</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5262</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£32</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0032</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.8%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,706</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS65</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£858</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5278</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£72</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0016</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.3%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,699</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS74</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£865</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5276</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£79</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0018</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.5%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,686</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS56</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£887</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5273</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£101</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0021</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,660</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS33</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£889</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5282</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£103</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0011</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,676</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS75</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£965</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5264</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£179</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0030</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,563</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS66</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£985</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5260</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£200</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0033</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,536</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS57</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,020</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5257</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£235</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0037</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,493</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS10</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,062</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£276</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,259</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS28</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,074</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5174</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£288</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0120</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,274</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS22</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,074</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5164</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£288</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0130</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,253</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS07</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,076</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5160</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£290</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,245</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS25</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, <b><i>LD oASA+ oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,083</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5172</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£297</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0122</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,262</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS19</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,088</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5163</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£302</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0130</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,239</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS04</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,208</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£422</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.8%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,056</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS16</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,212</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5137</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£426</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0157</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.8%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,062</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS01</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,222</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5132</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£436</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,041</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS13</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,226</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5137</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£441</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0157</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,048</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS40</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,286</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5228</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£500</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0066</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,171</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS46</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,291</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5227</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£505</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0067</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,163</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS26</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,302</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5168</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£516</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0126</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,034</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS17</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,318</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£533</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0138</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.2%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,993</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS05</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,325</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5152</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£540</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0142</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,979</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS14</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,333</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5155</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£547</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0139</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,978</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS02</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,340</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5152</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£554</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0142</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,964</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS27</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,486</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5143</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£700</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0151</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,800</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS37</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,497</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5189</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£711</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0105</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,881</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS43</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,507</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5187</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£721</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0107</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,868</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS18</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,527</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5129</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£741</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0165</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,732</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS15</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,543</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5129</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£758</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0165</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,715</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS06</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,553</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5123</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£767</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0171</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,694</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS03</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,569</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5123</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£783</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0171</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,677</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS38</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,669</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5218</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£884</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0076</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,767</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS44</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,682</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5217</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£896</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0077</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,751</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS39</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,981</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5177</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,195</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0116</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,374</td></tr><tr><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS45</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,996</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_2 hd_h_niceng130er.appl.tab23_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5175</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,210</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0118</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_3 hd_h_niceng130er.appl.tab23_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab23_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,355</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PLS = proctosigmoiditis and left-sided disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab23_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig9"><div id="niceng130er.appl.fig9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2044.%20SA3%20cost-effectiveness%20acceptability%20curve%20for%20proctosigmoiditis%20and%20left-sided%20disease%20assuming%20people%20whose%20disease%20is%20responding%20to%20biological%20drugs%20as%20part%20of%20rescue%20therapy%20continue%20to%20receive%20treatment%20for%20the%20remaining%20time%20horizon%20of%20the%20model.&p=BOOKS&id=576848_niceng130erapplf9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf9.jpg" alt="Figure 44. SA3 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 44</span><span class="title">SA3 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig10"><div id="niceng130er.appl.fig10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2045.%20SA3%20cost-effectiveness%20acceptability%20frontier%20for%20proctosigmoiditis%20and%20left-sided%20disease%20assuming%20people%20whose%20disease%20is%20responding%20to%20biological%20drugs%20as%20part%20of%20rescue%20therapy%20continue%20to%20receive%20treatment%20for%20the%20remaining%20time%20horizon%20of%20the%20model.&p=BOOKS&id=576848_niceng130erapplf10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf10.jpg" alt="Figure 45. SA3 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 45</span><span class="title">SA3 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab24"><div id="niceng130er.appl.tab24" class="table"><h3><span class="label">Table 73</span><span class="title">SA4 cost-effectiveness results for proctosigmoiditis and left-sided disease varying the cost of topical prednisolone</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab24/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab24_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab24_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab24_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab24_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab24_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab24_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab24_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab24_1_1_1_2" id="hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab24_1_1_1_2" id="hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab24_1_1_1_3" id="hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab24_1_1_1_3" id="hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab24_1_1_1_3" id="hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS31</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£757</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5285</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">24.8%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,812</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS32</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£801</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5292</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£44</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0008</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£57,870</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.5%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,783</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS34</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£825</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5293</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£25</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0001</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£378,492</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">59.3%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,760</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS33</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£890</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5281</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£65</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0012</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,672</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS64</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,061</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5265</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£235</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0028</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,469</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS73</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,068</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5267</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£243</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0025</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,467</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS55</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,074</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5261</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£249</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0031</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,449</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS65</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,121</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5275</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£295</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0017</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,430</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS74</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,124</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5277</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£299</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0015</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,430</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS56</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,140</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5273</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£315</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0020</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,406</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS10</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,152</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£326</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0131</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,171</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS28</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,155</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5175</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£330</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0118</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,194</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS25</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, <b><i>LD oASA+ oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,157</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5173</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£332</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0120</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,189</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS22</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,166</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5164</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£340</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0129</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,162</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS07</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,166</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£341</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0132</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,156</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS19</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,180</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5164</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£355</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0129</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,147</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS04</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,181</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5133</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£355</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0159</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">2.3%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,086</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS16</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,191</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5138</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£366</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0155</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,085</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS01</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,195</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5133</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£370</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0160</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,071</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS13</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,206</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5138</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£380</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0155</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,070</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS75</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,239</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5263</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£414</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0030</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,287</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS66</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,247</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5260</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£421</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0033</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,273</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS26</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,275</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5169</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£450</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0124</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.8%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,062</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS57</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tCS (pred liq enema), LD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,281</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5256</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£455</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0037</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,232</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS05</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,291</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5153</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£465</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0140</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.4%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,016</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS17</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,293</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£467</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0136</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,020</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS02</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,305</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5153</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£480</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0140</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,000</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS14</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,307</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£482</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0137</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,005</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS40</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,400</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5228</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£574</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0065</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,057</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS46</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + tCS (pred liq enema)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,406</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5227</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£581</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0066</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,047</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS37</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,436</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5190</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£610</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0103</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.2%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,944</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS43</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, <b><i>LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,445</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5188</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£620</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0105</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,931</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS27</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, LD oASA + tASA, LD oASA+ oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,466</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5144</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£640</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0149</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,822</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS18</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,509</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5130</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£683</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0163</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,752</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS15</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,525</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5130</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£700</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0163</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,734</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS06</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,525</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5124</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£700</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0168</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,724</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS03</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, HD oASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,541</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5124</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£716</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0169</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,707</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS38</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,594</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5218</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£769</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0075</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,842</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS44</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,606</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5217</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£781</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0076</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,827</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS39</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,907</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5178</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,081</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0115</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,449</td></tr><tr><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLS45</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,921</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_2 hd_h_niceng130er.appl.tab24_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5176</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,096</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0117</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_3 hd_h_niceng130er.appl.tab24_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab24_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,430</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PLS = proctosigmoiditis and left-sided disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab24_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig11"><div id="niceng130er.appl.fig11" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2046.%20SA4%20cost-effectiveness%20acceptability%20curve%20for%20proctosigmoiditis%20and%20left-sided%20disease%20varying%20the%20cost%20of%20topical%20prednisolone.&p=BOOKS&id=576848_niceng130erapplf11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf11.jpg" alt="Figure 46. SA4 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease varying the cost of topical prednisolone." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 46</span><span class="title">SA4 cost-effectiveness acceptability curve for proctosigmoiditis and left-sided disease varying the cost of topical prednisolone</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig12"><div id="niceng130er.appl.fig12" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2047.%20SA4%20cost-effectiveness%20acceptability%20frontier%20for%20proctosigmoiditis%20and%20left-sided%20disease%20varying%20the%20cost%20of%20topical%20prednisolone.&p=BOOKS&id=576848_niceng130erapplf12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf12.jpg" alt="Figure 47. SA4 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease varying the cost of topical prednisolone." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 47</span><span class="title">SA4 cost-effectiveness acceptability frontier for proctosigmoiditis and left-sided disease varying the cost of topical prednisolone</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab25"><div id="niceng130er.appl.tab25" class="table"><h3><span class="label">Table 74</span><span class="title">Proportion of people whose disease enters remission by line of treatment, average time spent in active disease vs. remission and breakdown of costs for each treatment sequence in base case analysis for proctitis</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab25/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab25_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab25_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab25_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab25_1_1_1_2" colspan="5" rowspan="1" style="text-align:left;vertical-align:bottom;">Proportion entering remission</th><th id="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab25_1_1_1_3" style="text-align:left;vertical-align:bottom;">Weeks active</th><th id="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab25_1_1_1_4" style="text-align:left;vertical-align:bottom;">Weeks remiss</th><th id="hd_h_niceng130er.appl.tab25_1_1_1_5" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th id="hd_h_niceng130er.appl.tab25_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th></tr><tr><th headers="hd_h_niceng130er.appl.tab25_1_1_1_2" id="hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1st line</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_2" id="hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_2" id="hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_2" id="hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">4th line</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_2" id="hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Rescue</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_5" id="hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Drug</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_5" id="hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Rescue</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_5" id="hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other HC</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_5" id="hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Main</th><th headers="hd_h_niceng130er.appl.tab25_1_1_1_6" id="hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Tottal</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC01</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£63</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£3</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£199</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£152</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£417</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC02</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.6</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.4</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£64</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£202</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£151</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£426</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC03</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.2%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£64</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£7</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£200</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£152</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£424</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC04</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.7</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.3</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£69</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£14</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£203</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£151</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£436</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC05</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.0</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.0</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£151</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£21</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£322</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£611</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC06</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.9</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.1</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£161</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£56</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£337</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£109</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£663</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC07</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.2</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.8</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£161</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£43</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£330</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£115</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£649</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC08</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.1</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.9</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£188</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£81</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£346</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£108</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£724</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC09</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.3</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.7</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£171</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£36</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£267</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£129</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£603</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC10</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.8</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.2</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£188</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£95</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£293</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£116</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£692</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC11</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.2%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.6</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.4</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£188</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£73</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£281</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£126</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£668</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC12</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.2</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.8</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£234</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£139</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£309</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£114</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£796</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC13</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.4</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.6</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£171</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£36</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£268</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£129</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£605</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC14</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.8</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.2</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£189</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£96</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£295</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£116</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£695</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC15</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.7</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.3</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£188</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£74</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£283</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£126</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£671</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC16</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.2</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.8</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£235</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£140</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£311</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£113</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£800</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC17</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.9%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£62</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£25</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£199</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£152</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£437</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC18</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.6</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.4</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£62</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£66</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£201</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£152</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£480</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC19</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£62</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£51</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£200</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£152</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£466</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC20</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.8%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.6</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.4</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£65</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£96</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£202</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£152</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£515</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC21</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.9</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.1</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£146</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£147</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£320</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£119</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£731</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC22</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.5%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.6</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.4</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£146</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£394</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£332</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£114</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£986</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC23</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.0</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.0</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£149</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£303</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£327</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£119</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£897</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC24</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.2%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.7</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.3</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£166</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£573</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£340</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£115</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,194</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC25</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.1</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.9</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£161</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£250</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£264</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£808</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC26</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.2</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.8</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£162</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£671</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£286</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£124</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,242</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC27</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.2%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.2</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.8</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£168</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£514</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£276</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,090</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC28</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.4</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.6</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£196</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£976</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£299</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£125</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,596</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC29</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.1</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.9</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£162</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£254</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£266</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£813</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC30</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.3</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.7</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£162</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£680</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£287</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£123</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,252</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC31</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.6%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.7%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.3</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.7</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£168</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£523</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£277</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,100</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC32</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.1%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.4%</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.5</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£197</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£990</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£300</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£125</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,612</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Minimum</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>40.0%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>4.8%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>0.0%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>0.0%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>0.1%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>2.5</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>21.9</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£62</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£3</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£199</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£108</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£417</b>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appl.tab25_1_1_1_1" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Maximum</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>90.5%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>39.6%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>26.8%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>15.6%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_2 hd_h_niceng130er.appl.tab25_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>31.4%</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>8.1</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>27.5</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£235</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£990</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£346</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_5 hd_h_niceng130er.appl.tab25_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£152</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab25_1_1_1_6 hd_h_niceng130er.appl.tab25_1_1_2_10" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>£1,612</b>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PRC = proctitis; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; tTAC = topical tacrolimus; pred = prednisolone; beclo = beclometasone; bude = budesonide; remiss = remission; HC = healthcare; Main = maintenance</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab26"><div id="niceng130er.appl.tab26" class="table"><h3><span class="label">Table 75</span><span class="title">Base-case cost-effectiveness results for proctitis</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab26/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab26_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab26_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab26_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab26_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab26_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab26_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab26_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab26_1_1_1_2" id="hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab26_1_1_1_2" id="hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab26_1_1_1_3" id="hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab26_1_1_1_3" id="hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab26_1_1_1_3" id="hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC01</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£437</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5320</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">72.9%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,202</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC03</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£448</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5318</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">18.9%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,189</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC02</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£451</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5314</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£14</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0006</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">2.4%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,177</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC04</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£470</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5312</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£33</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0008</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,154</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC17</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£472</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5321</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£34</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0001</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£359,175</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.3%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,169</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC19</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£500</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5320</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£28</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.9%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,139</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC18</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£512</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5316</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£40</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0005</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,119</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC20</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£558</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5314</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£86</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0006</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,071</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC05</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£651</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£180</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0141</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,709</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC09</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£675</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5232</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£203</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0089</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,788</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC13</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£678</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5230</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£206</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0091</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,782</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC07</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£694</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5174</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£222</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,655</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC06</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£714</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5154</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£242</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0166</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,595</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC11</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£744</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5222</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£272</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0098</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,701</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC15</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£748</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5220</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£276</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0100</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,692</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC10</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£779</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5188</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£307</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,597</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC14</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£783</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5186</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£311</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0135</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,588</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC08</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£793</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5146</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£322</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0174</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,499</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC21</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£797</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5184</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£325</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0137</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,571</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC12</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£913</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5175</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£442</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,436</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC25</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£917</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5238</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£446</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0082</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,559</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC23</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£918</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£446</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0140</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,443</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC16</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£920</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5172</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£448</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0148</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,425</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC29</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£924</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5237</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£452</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0084</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,549</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC22</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£985</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5162</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£514</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0159</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,338</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC27</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,116</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5232</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£644</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0088</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,349</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC31</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,127</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5230</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£655</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0090</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,334</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC24</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,179</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5157</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£707</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0164</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,135</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC26</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,234</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5200</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£762</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0120</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,166</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC30</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,245</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5198</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£773</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0122</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,151</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC28</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,563</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5192</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,091</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0128</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,821</td></tr><tr><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC32</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,579</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_2 hd_h_niceng130er.appl.tab26_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5190</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,107</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0131</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_3 hd_h_niceng130er.appl.tab26_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab26_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,801</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PRC = proctitis; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; tTAC = topical tacrolimus; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab26_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig13"><div id="niceng130er.appl.fig13" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2048.%20Cost-effectiveness%20acceptability%20curve%20for%20proctitis%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erapplf13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf13.jpg" alt="Figure 48. Cost-effectiveness acceptability curve for proctitis base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 48</span><span class="title">Cost-effectiveness acceptability curve for proctitis base-case analysis</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig14"><div id="niceng130er.appl.fig14" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2049.%20Cost-effectiveness%20acceptability%20frontier%20for%20proctitis%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erapplf14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf14.jpg" alt="Figure 49. Cost-effectiveness acceptability frontier for proctitis base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 49</span><span class="title">Cost-effectiveness acceptability frontier for proctitis base-case analysis</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab27"><div id="niceng130er.appl.tab27" class="table"><h3><span class="label">Table 76</span><span class="title">SA2 cost-effectiveness results for proctitis with no early switching of treatments in the event of non-remission</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab27/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab27_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab27_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab27_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab27_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab27_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab27_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab27_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab27_1_1_1_2" id="hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab27_1_1_1_2" id="hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab27_1_1_1_3" id="hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab27_1_1_1_3" id="hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab27_1_1_1_3" id="hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC01</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£457</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5300</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">74.5%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,143</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC03</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£467</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5298</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0003</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">16.2%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,128</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC02</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£474</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5290</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£18</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0010</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.7%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,106</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC17</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£496</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5302</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£39</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0002</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£205,150</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.8%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,108</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC04</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£498</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5286</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£3</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0016</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,074</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC19</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£523</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5300</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£27</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0002</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.3%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,077</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC18</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£543</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5293</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£47</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0008</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.4%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,044</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC20</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£593</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5291</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£98</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0011</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,988</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC05</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£699</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5072</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£203</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0229</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,446</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC09</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£734</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£238</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0141</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,588</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC07</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£740</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5063</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£244</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0239</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,387</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC13</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£741</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£245</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0146</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,571</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC06</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£768</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5034</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£273</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0268</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,299</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC11</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£801</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5147</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£305</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0155</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,494</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC15</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£810</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5140</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£315</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,470</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC21</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£846</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5079</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£351</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0223</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,312</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC10</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£850</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5096</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£354</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0206</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,342</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC14</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£859</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5089</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£364</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0213</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,318</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC08</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£860</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5018</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£364</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0284</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,177</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC23</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£954</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5073</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£458</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0229</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,192</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC25</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£981</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5173</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£486</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0129</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,364</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC29</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£995</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5168</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£500</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0134</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,340</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC12</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,004</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5070</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£508</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0232</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,136</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC16</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,018</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5062</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£522</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0240</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,106</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC22</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,039</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5046</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£544</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0256</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,053</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC27</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,155</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5163</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£659</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0139</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,172</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC31</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,178</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5157</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£682</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0145</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,136</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC24</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,234</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5035</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£738</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0267</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,836</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC26</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,304</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5116</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£808</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0186</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,929</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC30</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,327</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5110</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£831</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0192</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,893</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC28</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,634</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5098</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,139</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0204</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,562</td></tr><tr><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC32</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,667</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_2 hd_h_niceng130er.appl.tab27_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5091</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,171</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0211</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_3 hd_h_niceng130er.appl.tab27_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab27_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,515</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PRC = proctitis; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; tTAC = topical tacrolimus; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab27_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig15"><div id="niceng130er.appl.fig15" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2050.%20SA2%20cost-effectveness%20acceptability%20curve%20for%20proctitis%20with%20no%20early%20switching%20of%20treatments%20in%20the%20event%20of%20non-remission.&p=BOOKS&id=576848_niceng130erapplf15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf15.jpg" alt="Figure 50. SA2 cost-effectveness acceptability curve for proctitis with no early switching of treatments in the event of non-remission." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 50</span><span class="title">SA2 cost-effectveness acceptability curve for proctitis with no early switching of treatments in the event of non-remission</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig16"><div id="niceng130er.appl.fig16" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2051.%20SA2%20cost-effectveness%20acceptability%20frontier%20for%20proctitis%20with%20no%20early%20switching%20of%20treatments%20in%20the%20event%20of%20non-remission.&p=BOOKS&id=576848_niceng130erapplf16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf16.jpg" alt="Figure 51. SA2 cost-effectveness acceptability frontier for proctitis with no early switching of treatments in the event of non-remission." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 51</span><span class="title">SA2 cost-effectveness acceptability frontier for proctitis with no early switching of treatments in the event of non-remission</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab28"><div id="niceng130er.appl.tab28" class="table"><h3><span class="label">Table 77</span><span class="title">SA3 cost-effectiveness results for proctitis assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab28/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab28_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab28_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab28_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab28_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab28_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab28_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab28_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab28_1_1_1_2" id="hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab28_1_1_1_2" id="hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab28_1_1_1_3" id="hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab28_1_1_1_3" id="hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab28_1_1_1_3" id="hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC01</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£444</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5320</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">74.6%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,195</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC03</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£455</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5318</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£11</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">16.8%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,181</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC02</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£459</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5314</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£15</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0006</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.4%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,168</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC04</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£479</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5312</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£35</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0008</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,144</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC17</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£483</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5321</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£39</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0001</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£369,405</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">3.8%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,158</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC19</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£514</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5320</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£31</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1.1%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,126</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC18</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£528</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5315</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£44</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0005</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.3%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,103</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC20</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£575</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5314</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£92</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0006</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,053</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC05</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£659</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£176</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0141</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,700</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC09</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£690</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5231</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£207</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0090</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,772</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC13</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£693</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5229</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£210</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0091</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,766</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC07</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£708</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5174</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£224</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0147</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,640</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC06</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£725</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5153</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£242</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0167</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,581</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC11</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£771</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5221</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£288</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0099</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,672</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC15</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£776</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5219</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£292</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0101</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,663</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC10</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£804</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5186</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£321</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0134</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,569</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC14</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£808</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5184</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£325</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0137</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,560</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC08</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£809</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5145</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£326</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0176</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,481</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC21</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£818</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5184</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£335</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0137</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,550</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC23</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA<b><i>, LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£947</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£464</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0140</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,414</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC12</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£949</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5173</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£465</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0148</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,397</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC16</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£955</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5170</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£472</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0151</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,386</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC25</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£968</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5238</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£484</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0083</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,508</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC29</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£974</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5237</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£491</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0084</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,499</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC22</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,013</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5161</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£529</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0160</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,310</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC27</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,186</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5232</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£703</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0088</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,279</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC31</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,197</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5230</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£714</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0090</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,263</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC24</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,215</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5156</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£732</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0164</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,098</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC26</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,307</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5199</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£824</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0121</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,092</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC30</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,318</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5197</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£835</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0123</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,077</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC28</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,661</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5191</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,178</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0130</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,722</td></tr><tr><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC32</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,677</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_2 hd_h_niceng130er.appl.tab28_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5189</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,194</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0132</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_3 hd_h_niceng130er.appl.tab28_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab28_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,701</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PRC = proctitis; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; tTAC = topical tacrolimus; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab28_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig17"><div id="niceng130er.appl.fig17" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2052.%20SA3%20cost-effectiveness%20acceptability%20curve%20for%20proctitis%20assuming%20people%20whose%20disease%20is%20responding%20to%20biological%20drugs%20as%20part%20of%20rescue%20therapy%20continue%20to%20receive%20treatment%20for%20the%20remaining%20time%20horizon%20of%20the%20model.&p=BOOKS&id=576848_niceng130erapplf17.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf17.jpg" alt="Figure 52. SA3 cost-effectiveness acceptability curve for proctitis assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 52</span><span class="title">SA3 cost-effectiveness acceptability curve for proctitis assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig18"><div id="niceng130er.appl.fig18" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2053.%20SA3%20cost-effectiveness%20acceptability%20frontier%20for%20proctitis%20assuming%20people%20whose%20disease%20is%20responding%20to%20biological%20drugs%20as%20part%20of%20rescue%20therapy%20continue%20to%20receive%20treatment%20for%20the%20remaining%20time%20horizon%20of%20the%20model.&p=BOOKS&id=576848_niceng130erapplf18.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf18.jpg" alt="Figure 53. SA3 cost-effectiveness acceptability frontier for proctitis assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 53</span><span class="title">SA3 cost-effectiveness acceptability frontier for proctitis assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab29"><div id="niceng130er.appl.tab29" class="table"><h3><span class="label">Table 78</span><span class="title">SA4 cost-effectiveness results for proctitis varying the cost of topical prednisolone and topical tacrolimus</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab29/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab29_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab29_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab29_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab29_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab29_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab29_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab29_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab29_1_1_1_2" id="hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab29_1_1_1_2" id="hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab29_1_1_1_3" id="hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab29_1_1_1_3" id="hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab29_1_1_1_3" id="hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC03</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£459</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5317</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">49%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,175</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC01</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£459</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5319</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0002</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£3,768</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,178</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC02</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£464</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5312</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£5</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0006</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,161</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC04</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£488</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5310</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£28</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0008</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,133</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC17</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£491</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5320</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£32</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0001</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£312,216</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">7%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,148</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC19</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£507</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5319</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£15</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0001</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">2%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,130</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC18</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£520</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5314</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£29</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0005</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">1%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,108</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC20</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">tASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£568</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5313</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£77</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0007</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£10,058</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC07</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£721</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5175</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£229</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0145</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,629</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC05</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£730</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5181</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£238</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0139</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,632</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC06</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£741</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5155</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£250</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0164</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,569</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC11</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£790</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5222</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£299</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0097</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,655</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC15</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£795</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5220</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£304</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0099</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,646</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC09</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£810</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5232</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£319</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0088</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,654</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC13</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£815</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5230</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£323</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0089</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,646</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC10</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£826</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5189</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£335</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0131</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,552</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC14</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£831</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5187</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£339</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0133</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,543</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC08</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£838</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5147</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£347</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0173</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,456</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC21</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i></b></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£856</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5185</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£365</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0135</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,513</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC23</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (beclo)</i></b></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£912</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5181</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£421</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0138</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,450</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC22</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (pred)</i></b></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£973</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5163</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£482</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0157</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,352</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC12</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£989</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5175</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£498</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0145</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,361</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC16</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b>, tTAC</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£996</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5172</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£505</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0147</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,349</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC25</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,023</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5239</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£531</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0081</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,455</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC29</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + tCS (pred liq enema)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,030</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5237</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£539</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0082</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,444</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC27</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,110</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5233</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£619</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0087</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,356</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC31</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (beclo)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,121</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5231</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£629</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0089</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,341</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC24</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LD oASA, <b><i>LD oASA + tASA, LD oASA + oCS (bude)</i></b></td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,172</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5158</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£680</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0162</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,144</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC26</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,217</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5201</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£725</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0118</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,186</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC30</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (pred)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,227</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5199</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£736</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0120</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,172</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC28</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,553</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5193</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,061</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0127</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,833</td></tr><tr><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PRC32</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>
|
|
<i>LD oASA + tASA, LD oASA + oCS (bude)</i>
|
|
</b>
|
|
</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,568</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_2 hd_h_niceng130er.appl.tab29_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5191</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,077</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0129</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_3 hd_h_niceng130er.appl.tab29_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0%</td><td headers="hd_h_niceng130er.appl.tab29_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,814</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">PRC = proctitis; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; tCS = topical corticosteroid; tTAC = topical tacrolimus; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Treatments in bold italics indicate information on relative effectiveness was derived from the same timepoint in a greater extent of disease</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab29_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig19"><div id="niceng130er.appl.fig19" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2054.%20SA4%20cost-effectiveness%20acceptability%20curve%20for%20proctitis%20varying%20the%20cost%20of%20topical%20prednisolone%20and%20topical%20tacrolimus.&p=BOOKS&id=576848_niceng130erapplf19.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf19.jpg" alt="Figure 54. SA4 cost-effectiveness acceptability curve for proctitis varying the cost of topical prednisolone and topical tacrolimus." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 54</span><span class="title">SA4 cost-effectiveness acceptability curve for proctitis varying the cost of topical prednisolone and topical tacrolimus</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig20"><div id="niceng130er.appl.fig20" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2055.%20SA4%20cost-effectiveness%20acceptability%20frontier%20for%20proctitis%20varying%20the%20cost%20of%20topical%20prednisolone%20and%20topical%20tacrolimus.&p=BOOKS&id=576848_niceng130erapplf20.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf20.jpg" alt="Figure 55. SA4 cost-effectiveness acceptability frontier for proctitis varying the cost of topical prednisolone and topical tacrolimus." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 55</span><span class="title">SA4 cost-effectiveness acceptability frontier for proctitis varying the cost of topical prednisolone and topical tacrolimus</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab30"><div id="niceng130er.appl.tab30" class="table"><h3><span class="label">Table 79</span><span class="title">Proportion of people whose disease enters remission by line of treatment, average time spent in active disease vs. remission and breakdown of costs for each treatment sequence in base-case analysis for extensive disease</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab30/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab30_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab30_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab30_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab30_1_1_1_2" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Proportion entering remission</th><th id="hd_h_niceng130er.appl.tab30_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab30_1_1_1_3" style="text-align:left;vertical-align:bottom;">Weeks active</th><th id="hd_h_niceng130er.appl.tab30_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab30_1_1_1_4" style="text-align:left;vertical-align:bottom;">Weeks remission</th><th id="hd_h_niceng130er.appl.tab30_1_1_1_5" colspan="4" rowspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th id="hd_h_niceng130er.appl.tab30_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th></tr><tr><th headers="hd_h_niceng130er.appl.tab30_1_1_1_2" id="hd_h_niceng130er.appl.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">1st line</th><th headers="hd_h_niceng130er.appl.tab30_1_1_1_2" id="hd_h_niceng130er.appl.tab30_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">2nd line</th><th headers="hd_h_niceng130er.appl.tab30_1_1_1_2" id="hd_h_niceng130er.appl.tab30_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">3rd line</th><th headers="hd_h_niceng130er.appl.tab30_1_1_1_2" id="hd_h_niceng130er.appl.tab30_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Rescue</th><th headers="hd_h_niceng130er.appl.tab30_1_1_1_5" id="hd_h_niceng130er.appl.tab30_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Drug</th><th headers="hd_h_niceng130er.appl.tab30_1_1_1_5" id="hd_h_niceng130er.appl.tab30_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Rescue</th><th headers="hd_h_niceng130er.appl.tab30_1_1_1_5" id="hd_h_niceng130er.appl.tab30_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other healthcare</th><th headers="hd_h_niceng130er.appl.tab30_1_1_1_5" id="hd_h_niceng130er.appl.tab30_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Maintenance</th><th headers="hd_h_niceng130er.appl.tab30_1_1_1_6" id="hd_h_niceng130er.appl.tab30_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Total</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT01</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">48.5%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.6%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.6%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">12.3%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.9</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.1</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£305</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£389</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£303</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_6 hd_h_niceng130er.appl.tab30_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,114</td></tr><tr><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT02</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">48.5%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.6%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.7%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.2%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.4</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.6</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£296</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£164</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£292</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£120</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_6 hd_h_niceng130er.appl.tab30_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£873</td></tr><tr><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT03</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">48.5%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">34.6%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">10.6%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.3%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">6.8</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.2</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£295</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£199</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£295</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£117</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_6 hd_h_niceng130er.appl.tab30_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£905</td></tr><tr><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT04</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">68.3%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">8.6%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">23.0%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.6</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">24.4</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£365</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£726</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£262</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£128</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_6 hd_h_niceng130er.appl.tab30_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,481</td></tr><tr><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT05</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">68.3%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">21.9%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">9.7%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">4.8</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.2</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£349</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£307</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£242</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£132</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_6 hd_h_niceng130er.appl.tab30_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,030</td></tr><tr><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT06</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">68.3%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">19.9%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_2 hd_h_niceng130er.appl.tab30_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">11.8%</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.4</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">24.6</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£346</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_6" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£372</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_7" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£247</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_5 hd_h_niceng130er.appl.tab30_1_1_2_8" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£126</td><td headers="hd_h_niceng130er.appl.tab30_1_1_1_6 hd_h_niceng130er.appl.tab30_1_1_2_9" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,091</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">EXT = extensive disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng130erappltab31"><div id="niceng130er.appl.tab31" class="table"><h3><span class="label">Table 80</span><span class="title">Base-case cost-effectiveness results for extensive disease</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab31/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab31_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab31_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab31_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab31_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab31_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab31_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab31_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab31_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab31_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab31_1_1_1_2" id="hd_h_niceng130er.appl.tab31_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab31_1_1_1_2" id="hd_h_niceng130er.appl.tab31_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab31_1_1_1_3" id="hd_h_niceng130er.appl.tab31_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab31_1_1_1_3" id="hd_h_niceng130er.appl.tab31_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab31_1_1_1_3" id="hd_h_niceng130er.appl.tab31_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT02</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£895</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5197</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">41.8%</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,500</td></tr><tr><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT03</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£929</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5185</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£34</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0012</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">27.6%</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,442</td></tr><tr><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT05</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,069</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5248</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£174</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0050</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£34,460</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">25.1%</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,427</td></tr><tr><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT06</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,128</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5225</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£59</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0022</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.4%</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,323</td></tr><tr><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT01</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,132</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5180</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£63</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0068</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,227</td></tr><tr><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT04</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,505</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_2 hd_h_niceng130er.appl.tab31_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5216</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£436</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0032</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_3 hd_h_niceng130er.appl.tab31_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab31_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,926</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">EXT = extensive disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab31_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig21"><div id="niceng130er.appl.fig21" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2056.%20Cost-effectiveness%20acceptability%20curve%20for%20extensive%20disease%20case-case%20analysis.&p=BOOKS&id=576848_niceng130erapplf21.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf21.jpg" alt="Figure 56. Cost-effectiveness acceptability curve for extensive disease case-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 56</span><span class="title">Cost-effectiveness acceptability curve for extensive disease case-case analysis</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig22"><div id="niceng130er.appl.fig22" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2057.%20Cost-effectiveness%20acceptability%20frontier%20for%20extensive%20disease%20base-case%20analysis.&p=BOOKS&id=576848_niceng130erapplf22.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf22.jpg" alt="Figure 57. Cost-effectiveness acceptability frontier for extensive disease base-case analysis." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 57</span><span class="title">Cost-effectiveness acceptability frontier for extensive disease base-case analysis</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab32"><div id="niceng130er.appl.tab32" class="table"><h3><span class="label">Table 81</span><span class="title">SA2 cost-effectiveness results for extensive disease with no early switching of treatments in the event of non-remission</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab32/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab32_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab32_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab32_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab32_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab32_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab32_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab32_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab32_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab32_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab32_1_1_1_2" id="hd_h_niceng130er.appl.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab32_1_1_1_2" id="hd_h_niceng130er.appl.tab32_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab32_1_1_1_3" id="hd_h_niceng130er.appl.tab32_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab32_1_1_1_3" id="hd_h_niceng130er.appl.tab32_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab32_1_1_1_3" id="hd_h_niceng130er.appl.tab32_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT02</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£985</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5103</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">20.8%</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,221</td></tr><tr><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT03</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,030</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5084</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£45</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0018</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">12.6%</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,138</td></tr><tr><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT05</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,148</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5198</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£163</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0095</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£17,087</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">51.9%</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,248</td></tr><tr><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT06</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,225</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5166</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£77</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0032</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">14.7%</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,107</td></tr><tr><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT01</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,246</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5071</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£98</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0127</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,897</td></tr><tr><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT04</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,605</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_2 hd_h_niceng130er.appl.tab32_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5143</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£457</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0055</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_3 hd_h_niceng130er.appl.tab32_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab32_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,682</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">EXT = extensive disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab32_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig23"><div id="niceng130er.appl.fig23" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2058.%20SA2%20cost-effectiveness%20acceptability%20curve%20for%20extensive%20disease%20with%20no%20early%20switching%20of%20treatments%20in%20the%20event%20of%20non-remission.&p=BOOKS&id=576848_niceng130erapplf23.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf23.jpg" alt="Figure 58. SA2 cost-effectiveness acceptability curve for extensive disease with no early switching of treatments in the event of non-remission." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 58</span><span class="title">SA2 cost-effectiveness acceptability curve for extensive disease with no early switching of treatments in the event of non-remission</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig24"><div id="niceng130er.appl.fig24" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2059.%20SA2%20cost-effectiveness%20acceptability%20frontier%20for%20extensive%20disease%20with%20no%20early%20switching%20of%20treatments%20in%20the%20event%20of%20non-remission.&p=BOOKS&id=576848_niceng130erapplf24.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf24.jpg" alt="Figure 59. SA2 cost-effectiveness acceptability frontier for extensive disease with no early switching of treatments in the event of non-remission." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 59</span><span class="title">SA2 cost-effectiveness acceptability frontier for extensive disease with no early switching of treatments in the event of non-remission</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappltab33"><div id="niceng130er.appl.tab33" class="table"><h3><span class="label">Table 82</span><span class="title">SA3 deterministic cost-effectiveness results for extensive assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appl.tab33/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appl.tab33_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng130er.appl.tab33_1_1_1_1" colspan="2" rowspan="2" headers="hd_h_niceng130er.appl.tab33_1_1_1_1" style="text-align:left;vertical-align:bottom;">Treatment sequence</th><th id="hd_h_niceng130er.appl.tab33_1_1_1_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Total</th><th id="hd_h_niceng130er.appl.tab33_1_1_1_3" colspan="3" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental</th><th id="hd_h_niceng130er.appl.tab33_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab33_1_1_1_4" style="text-align:left;vertical-align:bottom;">Prob CE at £20K/ QALY</th><th id="hd_h_niceng130er.appl.tab33_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng130er.appl.tab33_1_1_1_5" style="text-align:left;vertical-align:bottom;">NMB at £20K/ QALY</th></tr><tr><th headers="hd_h_niceng130er.appl.tab33_1_1_1_2" id="hd_h_niceng130er.appl.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab33_1_1_1_2" id="hd_h_niceng130er.appl.tab33_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab33_1_1_1_3" id="hd_h_niceng130er.appl.tab33_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Costs</th><th headers="hd_h_niceng130er.appl.tab33_1_1_1_3" id="hd_h_niceng130er.appl.tab33_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">QALYs</th><th headers="hd_h_niceng130er.appl.tab33_1_1_1_3" id="hd_h_niceng130er.appl.tab33_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">ICER</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT02</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£905</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5198</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;"></td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">43.0%</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,492</td></tr><tr><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT03</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£927</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5187</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£22</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0011</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">31.8%</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,446</td></tr><tr><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT05</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (beclo)</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,100</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5249</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£195</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0051</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£38,630</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">19.7%</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,398</td></tr><tr><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT06</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (pred)</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,130</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5182</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£30</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0067</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.1%</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,233</td></tr><tr><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT01</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA, HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,142</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5228</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£42</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0021</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">5.4%</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£9,314</td></tr><tr><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EXT04</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HD oASA + tASA, LD oASA + oCS (bude)</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£1,531</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_2 hd_h_niceng130er.appl.tab33_1_1_2_2" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.5218</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_3" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£431</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">−0.0031</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_3 hd_h_niceng130er.appl.tab33_1_1_2_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">dominated</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_4" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">0.0%</td><td headers="hd_h_niceng130er.appl.tab33_1_1_1_5" rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">£8,905</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">EXT = extensive disease; LD = low-dose; HD = high-dose; oASA = oral aminosalicylate; tASA = topical aminosalicylate; oCS = oral corticosteroid; pred = prednisolone; beclo = beclometasone; bude = budesonide; CE = cost effective; ICER = incremental cost-effectiveness ratio; NMB = net monetary benefit; QALY = quality-adjusted life year</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng130er.appl.tab33_1"><p class="no_margin">Treatment strategies that are dominated are more costly and produce fewer QALYs than one or more of the alternative treatment strategies in the decision space</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng130erapplfig25"><div id="niceng130er.appl.fig25" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2060.%20SA3%20cost-effectiveness%20acceptability%20curve%20for%20extensive%20disease%20assuming%20people%20whose%20disease%20is%20responding%20to%20biological%20drugs%20as%20part%20of%20rescue%20therapy%20continue%20to%20receive%20treatment%20for%20the%20remaining%20time%20horizon%20of%20the%20model.&p=BOOKS&id=576848_niceng130erapplf25.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf25.jpg" alt="Figure 60. SA3 cost-effectiveness acceptability curve for extensive disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 60</span><span class="title">SA3 cost-effectiveness acceptability curve for extensive disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3></div></article><article data-type="fig" id="figobniceng130erapplfig26"><div id="niceng130er.appl.fig26" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2061.%20SA3%20cost-effectiveness%20acceptability%20frontier%20for%20extensive%20disease%20assuming%20people%20whose%20disease%20is%20responding%20to%20biological%20drugs%20as%20part%20of%20rescue%20therapy%20continue%20to%20receive%20treatment%20for%20the%20remaining%20time%20horizon%20of%20the%20model.&p=BOOKS&id=576848_niceng130erapplf26.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK576848/bin/niceng130erapplf26.jpg" alt="Figure 61. SA3 cost-effectiveness acceptability frontier for extensive disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 61</span><span class="title">SA3 cost-effectiveness acceptability frontier for extensive disease assuming people whose disease is responding to biological drugs as part of rescue therapy continue to receive treatment for the remaining time horizon of the model</span></h3></div></article><article data-type="table-wrap" id="figobniceng130erappmtab1"><div id="niceng130er.appm.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appm.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appm.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Short Title</th><th id="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Title</th><th id="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reasons for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref1" rid="niceng130er.appe.s4.1.ref1">Andus (2008)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A novel high-dose 1g mesalamine suppository (Salofalk) is as efficacious as a 500-mg TID suppositories in mild to moderate active ulcerative proctitis: A multicenter, randomized trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref2" rid="niceng130er.appe.s4.1.ref2">Andus (2010)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref3" rid="niceng130er.appe.s4.1.ref3">Ardizzone (1999)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine foam (Salofalk (R) foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk (R) enema</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Article unavailable: journal out of print or could not be sourced.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref4" rid="niceng130er.appe.s4.1.ref4">BARON (1962)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref5" rid="niceng130er.appe.s4.1.ref5">Baumgart (2008)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref6" rid="niceng130er.appe.s4.1.ref6">Biancone (2007)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes in protocol reported.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref7" rid="niceng130er.appe.s4.1.ref7">Cai (2001)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine versus sulfasalazine in the treatment of ulcerative colitis: Randomized controlled Clinical trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref8" rid="niceng130er.appe.s4.1.ref8">Campieri (1988)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-Aminosalicylic Acid As Enemas Or Suppositories in Distal Ulcerative-Colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as both arms were categorised as a topical aminosalicylate.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref9" rid="niceng130er.appe.s4.1.ref9">Campieri (1991)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sucralfate, 5-Aminosalicylic Acid and Placebo Enemas in the Treatment of Distal Ulcerative-Colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Article unavailable: journal out of print or could not be sourced.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref10" rid="niceng130er.appe.s4.1.ref10">Campieri (1993)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Better Quality of Therapy with 5-Asa Colonic Foam in Active Ulcerative-Colitis – A Multicenter Comparative Trial with 5-Asa Enema</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref11" rid="niceng130er.appe.s4.1.ref11">Cortot (2008)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalamine Foam Enema Versus Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as both arms were categorised as a topical aminosalicylate.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref12" rid="niceng130er.appe.s4.1.ref12">Danielsson (1987)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref13" rid="niceng130er.appe.s4.1.ref13">Farup (1995)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine Suppositories Versus Hydrocortisone Foam in Patients with Distal Ulcerative-Colitis - A Comparison of the Efficacy and Practicality of 2 Topical Treatment Regimens</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref14" rid="niceng130er.appe.s4.1.ref14">Farup (2001)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included. Info: Comparison of different oral preparations of mesalazine.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref15" rid="niceng130er.appe.s4.1.ref15">Ferry (1993)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as both arms were categorised as standard-dose oral aminosalicylates.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref16" rid="niceng130er.appe.s4.1.ref16">Forbes (2005)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref17" rid="niceng130er.appe.s4.1.ref17">Friedman (1986)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-Aminosalicylic Acid Enemas in Refractory Distal Ulcerative-Colitis - A Randomized, Controlled Trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref18" rid="niceng130er.appe.s4.1.ref18">Gibson (2006)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as both arms were categorised as standard-dose oral aminosalicylates.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref19" rid="niceng130er.appe.s4.1.ref19">Green (1998)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>10% of study population had severe ulcerative colitis.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref20" rid="niceng130er.appe.s4.1.ref20">Hanauer (1996)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref21" rid="niceng130er.appe.s4.1.ref21">Hanauer (1998)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study.</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes in protocol reported.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref22" rid="niceng130er.appe.s4.1.ref22">Hanauer (2007)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome could not be extracted from the study as remission with response was reported, but not remission alone. Info: ‘Remission’ could not be extracted from ‘clinical remission or response’.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref23" rid="niceng130er.appe.s4.1.ref23">Hartmann (2010)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref24" rid="niceng130er.appe.s4.1.ref24">Hiwatashi (2011)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as both arms were categorised as standard-dose oral aminosalicylates.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref25" rid="niceng130er.appe.s4.1.ref25">Jewell (1974)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Azathioprine in Ulcerative-Colitis - Final Report on Controlled Therapeutic Trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population not included in evidence review: population had severe relapse requiring intravenous therapy.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref26" rid="niceng130er.appe.s4.1.ref26">Jiang (2004)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Different therapy for different types of ulcerative colitis in China</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as both arms were categorised as standard-dose oral aminosalicylates.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref27" rid="niceng130er.appe.s4.1.ref27">Kruis (2009)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as both arms were categorised as standard-dose oral aminosalicylates.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref28" rid="niceng130er.appe.s4.1.ref28">Lamet (2005)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included. Info Both arms of trial compared same dose of topical mesalazine, but different prescription (1g versus 500mg twice a day).</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref29" rid="niceng130er.appe.s4.1.ref29">Lamet (2011)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included. Info: Both arms of trial compared same dose of topical mesalazine, but different prescription (1g versus 500mg twice a day).</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref30" rid="niceng130er.appe.s4.1.ref30">Lee (1996)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity of the population included was not described.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref31" rid="niceng130er.appe.s4.1.ref31">Lemann (1995)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison of Budesonide and 5-Aminosalicylic Acid Enemas in Active Distal Ulcerative-Colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity of the population included was not described.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref32" rid="niceng130er.appe.s4.1.ref32">Lindgren (2002)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as both arms were categorised as topical (liquid enema) budesonide.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref33" rid="niceng130er.appe.s4.1.ref33">Lofberg (1994)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.[Erratum appears in Aliment Pharmacol Ther 1995 Apr;9(2):213]</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes in protocol reported. Preparation not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref34" rid="niceng130er.appe.s4.1.ref34">Marakhouski (2005)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.[Erratum appears in Aliment Pharmacol Ther. 2005 Mar 15;21(6):793]</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included. Info: Comparison of different preparations (pellets versus tablets) of same dose of oral mesalazine.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref35" rid="niceng130er.appe.s4.1.ref35">Meyers (1987)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes in protocol reported.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref36" rid="niceng130er.appe.s4.1.ref36">Miglioli (1989)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral 5-ASA (Asacol) in mild ulcerative colitis. A randomized double blind dose ranging trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref37" rid="niceng130er.appe.s4.1.ref37">Mulder (1988)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulcerative colitis in remission phase.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref38" rid="niceng130er.appe.s4.1.ref38">Ogata (2006)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.[Erratum appears in Gut. 2006 Nov;55(11):1684 Note: Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text]</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">>10% of study population had severe ulcerative colitis.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref39" rid="niceng130er.appe.s4.1.ref39">Ogata (2012)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroidrefractory ulcerative colitis.</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proportion with severe UC not reported.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref40" rid="niceng130er.appe.s4.1.ref40">Oren (1996)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chronic active ulcerative colitis.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref41" rid="niceng130er.appe.s4.1.ref41">Porro (1994)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome (remission) could not be included as it was not defined.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref42" rid="niceng130er.appe.s4.1.ref42">Powell-Tuck (1978)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref43" rid="niceng130er.appe.s4.1.ref43">Powell-Tuck (1986)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A Defense of the Small Clinical-Trial - Evaluation of 3 Gastroenterological Studies</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref44" rid="niceng130er.appe.s4.1.ref44">Prantera (2005)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A new oral delivery system for 5-ASA: Preliminary clinical findings for MMx</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref45" rid="niceng130er.appe.s4.1.ref45">Raedler (2004)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included. Info: Comparison of same dose of ASA, different preparations.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref46" rid="niceng130er.appe.s4.1.ref46">Rijk (1991)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref47" rid="niceng130er.appe.s4.1.ref47">Rizzello (2001)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study.</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RCT that did not contain a relevant comparison, as beclomethasone doses above 5mg was not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref48" rid="niceng130er.appe.s4.1.ref48">Robinson (1988)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine in the treatment of mild to moderate ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref49" rid="niceng130er.appe.s4.1.ref49">Romano (2010)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Beclometasone excluded in paediatric population.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref50" rid="niceng130er.appe.s4.1.ref50">Schroeder (1987)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative-Colitis - A Randomized Study</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Extent of disease was not reported.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref51" rid="niceng130er.appe.s4.1.ref51">Selby (1985)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine in active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcome(s) could not be analysed (no events were reported).</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref52" rid="niceng130er.appe.s4.1.ref52">Shivananda (1996)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD).</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref53" rid="niceng130er.appe.s4.1.ref53">Sood (2002)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulcerative colitis in remission phase.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref54" rid="niceng130er.appe.s4.1.ref54">Sood (2002)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methylprednisolone acetate versus oral prednisolone in moderately active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Route of administration (intramuscular/intravenous) not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref55" rid="niceng130er.appe.s4.1.ref55">Tarpila (1994)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Budesonide enema in active haemorrhagic proctitis--a controlled trial against hydrocortisone foam enema</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref56" rid="niceng130er.appe.s4.1.ref56">van Bodegraven (1996)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Distribution of mesalazine enemas in active and quiescent ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes in protocol reported.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref57" rid="niceng130er.appe.s4.1.ref57">Williams (1987)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Double-Blind, Placebo-Controlled Evaluation of 5-Asa Suppositories in Active Distal Proctitis and Measurement of Extent of Spread Using Tc-99M-Labeled 5-Asa Suppositories</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes in protocol reported.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref58" rid="niceng130er.appe.s4.1.ref58">Willoughby (1986)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-Aminosalicylic acid (Pentasa) in enema form for the treatment of active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes in protocol reported.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.1.ref59" rid="niceng130er.appe.s4.1.ref59">Zinberg (1990)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Double-Blind Placebo-Controlled Study of Olsalazine in the Treatment of Ulcerative-Colitis</td><td headers="hd_h_niceng130er.appm.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No outcomes in protocol reported. Info: It is unclear if the discontinuations reported are attributed to disease worsening or drug adverse effects.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappmtab2"><div id="niceng130er.appm.tab2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appm.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appm.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Short Title</th><th id="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Title</th><th id="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">New column</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref1" rid="niceng130er.appe.s4.2.ref1">Akobeng (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulcerative colitis in remission phase.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref2" rid="niceng130er.appe.s4.2.ref2">Assche (2015)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Erratum: oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study (American Journal of Gastroenterology (2015) 110 (708-715) DOI: 10.1038/ajg.2015.114)</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref3" rid="niceng130er.appe.s4.2.ref3">Assche (2015)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Preparation not available in the UK. Info: Comparator ‘Deltacortene’ tablets not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref4" rid="niceng130er.appe.s4.2.ref4">Balzola (2013)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised clinical trial: Once- Vs. twice-daily prolonged-release mesalazine for active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref5" rid="niceng130er.appe.s4.2.ref5">Chande (2014)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methotrexate for induction of remission in ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref6" rid="niceng130er.appe.s4.2.ref6">Chen (2015)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pentasa enema may be superior to salofalk or glucocorticoid in patients with left-sided active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref7" rid="niceng130er.appe.s4.2.ref7">Crispino (2015)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy of mesalazine or beclomethasone dipropionate enema or their combination in patients with distal active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention not available in the UK.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref8" rid="niceng130er.appe.s4.2.ref8">Cuffari (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pharmacokinetic study.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref9" rid="niceng130er.appe.s4.2.ref9">D’Haens (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref10" rid="niceng130er.appe.s4.2.ref10">Dhaka (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomized controlled trial comparing the efficacy of measalamine and oral steroids in patients with moderately active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref11" rid="niceng130er.appe.s4.2.ref11">Flourié (2013)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref12" rid="niceng130er.appe.s4.2.ref12">Ford (2012)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis (Structured abstract)</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref13" rid="niceng130er.appe.s4.2.ref13">Hindryckx (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Biologic drugs for induction and maintenance of remission in Crohn’s disease: a network meta-analysis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref14" rid="niceng130er.appe.s4.2.ref14">Kawakami (2015)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Observational study design.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref15" rid="niceng130er.appe.s4.2.ref15">Komaki (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref16" rid="niceng130er.appe.s4.2.ref16">Kruis (1998)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention not available in the UK. Info: Mesalamine ‘Claversal’.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref17" rid="niceng130er.appe.s4.2.ref17">Lasa (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy of Tacrolimus for Induction of Remission in Patients with Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref18" rid="niceng130er.appe.s4.2.ref18">Lie (2014)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Drug therapies for ulcerative proctitis: systematic review and meta-analysis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref19" rid="niceng130er.appe.s4.2.ref19">Manguso (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref20" rid="niceng130er.appe.s4.2.ref20">Mate-Jimenez (2000)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included. Trial duration longer than 12 weeks, no results reported for up to 12 weeks.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref21" rid="niceng130er.appe.s4.2.ref21">Nguyen (2013)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Erratum: 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: A meta-analysis of non-referral populations (American Journal of Gastroenterology (2012) 107 (1298-1304) DOI:10.1038/ajg.2012.198)</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref22" rid="niceng130er.appe.s4.2.ref22">Pica (2013)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral beclomethasone dipropionate vs 5-ASA enema in active UC: lower efficacy but better compliance</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref23" rid="niceng130er.appe.s4.2.ref23">Pica (2015)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulcerative colitis in remission phase.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref24" rid="niceng130er.appe.s4.2.ref24">Raskin (2014)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref25" rid="niceng130er.appe.s4.2.ref25">Rubin (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulcerative colitis in remission phase.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref26" rid="niceng130er.appe.s4.2.ref26">Sun (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ulcerative colitis in remission phase.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref27" rid="niceng130er.appe.s4.2.ref27">Turner (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Once versus twice daily mesalazine to induce remission in pediatric ulcerative colitis: an investigator-initiated randomized controlled trial</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref28" rid="niceng130er.appe.s4.2.ref28">Turner (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref29" rid="niceng130er.appe.s4.2.ref29">Van Assche (2015)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Corrigendum: Oral Prolonged Release Beclomethasone Dipropionate and Prednisone in the Treatment of Active Ulcerative Colitis: Results From a Double-Blind, Randomized, Parallel Group Study.[Erratum for Am J Gastroenterol. 2015 May;110(5):708-15; PMID: 25869389]</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract; protocol; conference proceeding or non-peer reviewed publication.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref30" rid="niceng130er.appe.s4.2.ref30">Wang (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref31" rid="niceng130er.appe.s4.2.ref31">Wang (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy of single vs multiple doses of 5-aminosalicylic acid (5-ASA) in the treatment of mild-moderate ulcerative colitis: An open randomized clinical trial</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref32" rid="niceng130er.appe.s4.2.ref32">Zeng (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref33" rid="niceng130er.appe.s4.2.ref33">Zhao (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref34" rid="niceng130er.appe.s4.2.ref34">Zhao (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic or narrative review: used to identify relevant references.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.2.ref35" rid="niceng130er.appe.s4.2.ref35">Zhu (2012)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials</td><td headers="hd_h_niceng130er.appm.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappmtab3"><div id="niceng130er.appm.tab3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appm.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appm.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Short Title</th><th id="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Title</th><th id="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusion reason</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref1" rid="niceng130er.appe.s4.3.ref1">Chande (2014)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methotrexate for induction of remission in ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review/meta-analysis which does not meet criteria of protocol. Relevant references were checked.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref2" rid="niceng130er.appe.s4.3.ref2">D’Haens (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included in evidence review.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref3" rid="niceng130er.appe.s4.3.ref3">Dignass (2018)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included in evidence review.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref4" rid="niceng130er.appe.s4.3.ref4">Kato (2018)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: a prospective randomised clinical trial (CORRECT study)</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref5" rid="niceng130er.appe.s4.3.ref5">Kokkinidis (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Emerging treatments for ulcerative colitis: a systematic review</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review/meta-analysis which does not meet criteria of protocol. Relevant references were checked.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref6" rid="niceng130er.appe.s4.3.ref6">Komaki (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population not included - severe ulcerative colitis.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref7" rid="niceng130er.appe.s4.3.ref7">Kreijne (2018)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trial</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref8" rid="niceng130er.appe.s4.3.ref8">Lasa (2018)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy and safety of anti-integrin antibodies in inflammatory bowel disease: Systematic review and meta-analysis</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review/meta-analysis which does not meet criteria of protocol. Relevant references were checked.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref9" rid="niceng130er.appe.s4.3.ref9">Lawrance (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in evidence review.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref10" rid="niceng130er.appe.s4.3.ref10">Loftus (2018)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: a post hoc analysis of GEMINI 1</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref11" rid="niceng130er.appe.s4.3.ref11">Fang (2018)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mesalazine combined with golden bifid for treatment of patients with ulcerative colitis: effect on inflammatory response and anorectal motility</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not in English.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref12" rid="niceng130er.appe.s4.3.ref12">Perez-Calle (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulce-rative colitis</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in evidence review. Secondary publication of included study.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref13" rid="niceng130er.appe.s4.3.ref13">Roblin (2018)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interest in the addition of azathioprine (AZA) to the switch of anti-TNF in IBD patients in loss of response with undetectable anti-TNF trough levels and anti-drug antibodies: a prospective randomised trial</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract, Indirect population - not post-surgery.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref14" rid="niceng130er.appe.s4.3.ref14">Rubin (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in evidence review.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref15" rid="niceng130er.appe.s4.3.ref15">Sherlock (2015)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oral budesonide for induction of remission in ulcerative colitis</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review/meta-analysis which does not meet criteria of protocol. Relevant references were checked.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref16" rid="niceng130er.appe.s4.3.ref16">Simadibrata (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: an Evidence-based Clinical Review</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention not included in evidence review.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref17" rid="niceng130er.appe.s4.3.ref17">Turner (2016)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison not included in evidence review.</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref18" rid="niceng130er.appe.s4.3.ref18">Turner (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract</td></tr><tr><td headers="hd_h_niceng130er.appm.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a class="bibr" href="#niceng130er.appe.s4.3.ref19" rid="niceng130er.appe.s4.3.ref19">van Gennep (2017)</a>
|
|
</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice</td><td headers="hd_h_niceng130er.appm.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review/meta-analysis which does not meet criteria of protocol. Relevant references were checked.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappntab1"><div id="niceng130er.appn.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appn.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appn.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appn.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Question</th><th id="hd_h_niceng130er.appn.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">In mild-to-moderate first presentation or inflammatory exacerbation of proctitis that is resistant to standard treatment, what is the effectiveness of topical immunomodulators, such as tacrolimus, in achieving clinical remission and what is the most effective formulation (suppository/ointment)?</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">People with first presentation, or exacerbation, of chronic proctitis who have received standard treatment but still have active disease.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Topical immunomodulator (ointment or suppository).</td></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Placebo, other treatment, other formulation/dose.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Clinical remission</div></li><li class="half_rhythm"><div>Endoscopic remission</div></li><li class="half_rhythm"><div>Adverse outcomes</div></li><li class="half_rhythm"><div>Withdrawal due to adverse events</div></li><li class="half_rhythm"><div>Quality of life</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised Controlled Trial</td></tr><tr><th headers="hd_h_niceng130er.appn.tab1_1_1_1_1" id="hd_b_niceng130er.appn.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potential criterion</th><th headers="hd_h_niceng130er.appn.tab1_1_1_1_2" id="hd_b_niceng130er.appn.tab1_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Explanation</th></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1 hd_b_niceng130er.appn.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients, service users or the population</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2 hd_b_niceng130er.appn.tab1_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">If shown to be effective and cost-effective, immunomodulators could provide another treatment option when standard treatments have failed to induce remission. This would improve outcomes and quality of life for people whose proctitis did not respond to standard treatments.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1 hd_b_niceng130er.appn.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2 hd_b_niceng130er.appn.tab1_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The committee agreed not to recommend topical tacrolimus or other topical immunomodulators since the evidence was unclear about their effectiveness in achieving clinical remission in first presentation or inflammatory exacerbation of proctitis that is resistant to standard treatment. Additionally, the committee noted that it is unclear which formulation of topical immunomodulator (suppository or ointment) is more clinically effective in practice – it was sceptical that ointment would ever be used.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1 hd_b_niceng130er.appn.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2 hd_b_niceng130er.appn.tab1_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The evidence considered for tacrolimus came from one small RCT of 20 participants which compared tacrolimus and placebo. It was of low quality and may not be directly appropriate to a UK population. No evidence was included for other immunomodulators.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1 hd_b_niceng130er.appn.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2 hd_b_niceng130er.appn.tab1_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No additional equality issues are envisaged relating to this study over and above those applying generally to vulnerable groups of people.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab1_1_1_1_1 hd_b_niceng130er.appn.tab1_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</td><td headers="hd_h_niceng130er.appn.tab1_1_1_1_2 hd_b_niceng130er.appn.tab1_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There is a large enough population of people with resistant proctitis that this study is feasible.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappntab2"><div id="niceng130er.appn.tab2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appn.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appn.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appn.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Question</th><th id="hd_h_niceng130er.appn.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">What is the effectiveness of oral tacrolimus and systemic (intramuscular/subcutaneous/oral) methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates?</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">People with first presentation, or exacerbation, of mild-moderate ulcerative colitis who have been unresponsive to aminosalicylate treatment and still have active disease.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tacrolimus (oral) or methotrexate (oral, intramuscular or subcutaneous).</td></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Placebo, other treatment, other formulation/dose.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Clinical remission</div></li><li class="half_rhythm"><div>Endoscopic remission</div></li><li class="half_rhythm"><div>Adverse outcomes</div></li><li class="half_rhythm"><div>Withdrawal due to adverse events</div></li><li class="half_rhythm"><div>Quality of life</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised Controlled Trial</td></tr><tr><th headers="hd_h_niceng130er.appn.tab2_1_1_1_1" id="hd_b_niceng130er.appn.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potential criterion</th><th headers="hd_h_niceng130er.appn.tab2_1_1_1_2" id="hd_b_niceng130er.appn.tab2_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Explanation</th></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1 hd_b_niceng130er.appn.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients, service users or the population</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2 hd_b_niceng130er.appn.tab2_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">If shown to be effective and cost-effective, immunomodulators could provide another treatment option when standard aminosalicylate treatment has failed to induce remission. This would improve outcomes and quality of life for people whose ulcerative colitis did not respond to aminosalicylates.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1 hd_b_niceng130er.appn.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2 hd_b_niceng130er.appn.tab2_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The committee agreed not to recommend topical tacrolimus or methotrexate since the evidence was unclear about their effectiveness in achieving clinical remission in first presentation or inflammatory exacerbation of ulcerative colitis that is resistant to aminosalicylate treatment. Additionally, the committee noted that it is unclear which formulation of methotrexate (oral or injection) is more clinically effective in practice.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1 hd_b_niceng130er.appn.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2 hd_b_niceng130er.appn.tab2_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The evidence considered for tacrolimus came from one small RCT of 20 participants which compared topical tacrolimus and placebo. It was of low quality and may not be directly appropriate to a UK population. No evidence was seen for methotrexate</td></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1 hd_b_niceng130er.appn.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2 hd_b_niceng130er.appn.tab2_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No additional equality issues are envisaged relating to this study over and above those applying generally to vulnerable groups of people.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab2_1_1_1_1 hd_b_niceng130er.appn.tab2_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</td><td headers="hd_h_niceng130er.appn.tab2_1_1_1_2 hd_b_niceng130er.appn.tab2_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There is a large enough population of people with resistant ulcerative colitis that this study is feasible.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng130erappntab3"><div id="niceng130er.appn.tab3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK576848/table/niceng130er.appn.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng130er.appn.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_niceng130er.appn.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Question</th><th id="hd_h_niceng130er.appn.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">What is the clinical and cost effectiveness of oral prednisolone, budesonide, beclometasone in addition to aminosalicylates compared with each other and with aminosalicylate monotherapy for the induction of remission for people with mild-to-moderate ulcerative colitis?</th></tr></thead><tbody><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">People with first presentation or acute exacerbation of mild-moderate ulcerative colitis</td></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aminosalicylate plus oral corticosteroid (prednisolone, budesonide or beclometasone)</td></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparator</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aminosalicylate alone or in combination with other corticosteroid/dose</td></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Clinical remission</div></li><li class="half_rhythm"><div>Endoscopic remission</div></li><li class="half_rhythm"><div>Adverse events</div></li><li class="half_rhythm"><div>Withdrawal due to adverse events</div></li><li class="half_rhythm"><div>Quality of life</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Randomised Controlled Trial</td></tr><tr><th headers="hd_h_niceng130er.appn.tab3_1_1_1_1" id="hd_b_niceng130er.appn.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potential criterion</th><th headers="hd_h_niceng130er.appn.tab3_1_1_1_2" id="hd_b_niceng130er.appn.tab3_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Explanation</th></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1 hd_b_niceng130er.appn.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Importance to patients, service users or the population</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2 hd_b_niceng130er.appn.tab3_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">It is unclear from the evidence whether all corticosteroids are equally useful in combination with aminosalicylate therapy for inducing remission in mild-moderate ulcerative colitis. It is important to know what corticosteroids are effective (if any) so that patients can receive the best treatment with the least side-effects.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1 hd_b_niceng130er.appn.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Relevance to NICE guidance</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2 hd_b_niceng130er.appn.tab3_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The committee recognised the limited evidence base for oral corticosteroids and noted the uncertainty about which oral corticosteroid is most clinically and cost effective in all extents of disease, but in particular in proctosigmoiditis, left-sided and extensive disease.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1 hd_b_niceng130er.appn.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Current evidence base</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2 hd_b_niceng130er.appn.tab3_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Only one study allowed direct comparison of different corticosteroids (both topical).</td></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1 hd_b_niceng130er.appn.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Equality</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2 hd_b_niceng130er.appn.tab3_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No additional equality issues are envisaged relating to this study over and above those applying generally to vulnerable groups of people.</td></tr><tr><td headers="hd_h_niceng130er.appn.tab3_1_1_1_1 hd_b_niceng130er.appn.tab3_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Feasibility</td><td headers="hd_h_niceng130er.appn.tab3_1_1_1_2 hd_b_niceng130er.appn.tab3_1_1_6_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">There is a large enough population of people</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript" src="/core/mathjax/2.7.9/MathJax.js?config=TeX-AMS-MML_SVG"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|